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"It seems to me that the natural world is the greatest source of excitement; the greatest source 
of visual beauty; the greatest source of intellectual interest. It is the greatest source of so much 
in life that makes life worth living."    
– Sir David Attenborough 
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Abstract 
Gitelman & Gordon: Mirror image syndromes reveal the roles of WNKs in 
blood pressure homeostasis and novel anti-hypertensive targets 
Abstract for a dissertation submitted for the degree of Doctor of Philosophy by  
Keith Siew 
 
Study of Gordon (PHAII) and Gitelman (GS) syndromes revealed the importance of the WNK pathway 
and thiazide-sensitive Na-Cl Cotransporter (NCC) in the renal control of blood pressure. PHAII 
mutations lead to WNK accumulation resulting in the hyperphosphorylation of the downstream effector, 
SPAK, which overactivates NCC causing salt retention and hypertension. Mutations causing deletion 
of exon-9 in Cullin-3, which normally ubiquitylates WNKs for degradation, were recently discovered 
to cause the severest subtype of PHAII (PHA2E) with early onset salt-sensitive hypertension and 
hyperkalaemia. The reasons for this severity have remained elusive, however clues came from SPAK 
knock-out mice which recapitulate GS, the phenotypic mirror image of PHAII, typically caused by 
activation-inhibiting NCC phosphorylation site mutations resulting in salt-wasting and hypotension. As 
these mice were also discovered to have reduced vascular tone, it suggests the WNK pathway may have 
extra-renal roles in vascular smooth muscle function and highlights inhibition of SPAK function as a 
promising anti-hypertensive strategy with multiple sites of action. To address these possibilities the 
work aimed to phenotype: (1) heterozygous CUL3WT/Δ403-459 mice to investigate a possible vascular 
contribution to PHAII pathophysiology, (2) homozygous knock-out mice of MO25, a master regulator 
known to increase SPAK activity up to 100-fold independent of WNKs, and (3) homozygous 
SPAKL502A/L502A knock-ins, predicted to have disrupted SPAK binding to WNK/NCC, in order to 
validate SPAK signalling inhibition as a viable anti-hypertensive strategy. In mice, the CUL3Δ403-459 
proteins are hyperflexible, hypermodified and ultimately have reduced WNK ubiquitylation. This lead 
to hypertension, hyperkalaemia, hyperchloraemia with compensated metabolic acidosis and growth 
retardation, which closely recapitulates human PHA2E. The discovery of increased vascular tone 
suggests an explanation for the severity of CUL3Δex9 PHAII. In mice, homozygous MO25α knock-out 
proved embryonically lethal, while homozygous MO25β knock-out did not meaningfully alter blood 
pressure or electrolyte homeostasis. However, the SPAKL502A protein had a decreased ability to bind 
WNKs and cation-chloride cotransporters NCC and NKCC1/2, serving to reduce their activation. 
SPAKL502A/L502A mice showed typical features of GS with mild hypokalaemia, hypomagnesaemia, 
hypocalciuria and salt-wasting hypotension. The mice also presented with decreased markers of 
vascular tone potentially due to effects on cardiovascular and neuronal NKCC1. These results show that 
SPAK binding is crucial for blood pressure control and pharmacological inhibition of this binding is an 
attractive anti-hypertensive strategy. 
3 
 
Thesis at a Glance 
Study I                Constitutive CUL3WT/Δ403-459 Knock-in Mouse Model 
 Aim: Determine how CUL3 mutations causes PHA2E, a severe form of Gordon syndrome.  
 
Methods: Structural modelling, mass 
spectrometry and biochemical analysis of 
CUL3Δ403-459. In vivo pulse wave analysis, 
vasopressor responses and electrolytes. 
Fluorescent and electron microscopy. 
 
Results: CUL3Δ403-459 enhances structural 
flexibility, promoting auto-ubiquitylation 
and its own degradation.  CUL3WT/Δ403-459 
mice are hyperkalaemic, hypertensive 
with enhanced vascular contractility. 
Renal WNK accumulation and pathway 
overactivation leads to puncta formation.  
 
Conclusion: The previously unreported vascular contribution to hypertension explains 
PHA2E severity, suggesting concomitant thiazide/vasodilator treatment for PHA2E.  
Study II               Constitutive MO25β-/- Knock-out Mouse Model 
Aim: Explore role of MO25β in blood pressure control. 
 
Methods: In vivo blood pressure, dietary manipulations 
and electrolytes. Microscopy and immunoblotting. 
 
Results: No differences in blood pressure or electrolyte 
homeostasis were observed between MO25β-/- and WT 
mice, with the exception of [Mg2+]U on a NNa diet. 
 
Conclusion: MO25β has a no significant role in blood 
pressure control, or its loss is compensated by MO25α, 
the physiologically dominant isoform. 
Study III              Constitutive SPAKL502A/L502A Knock-in Mouse Model 
Aim: Investigate if in vivo SPAK binding inhibition 
produces a Gitelman syndrome-like phenotype. 
 
Methods: In vivo pulse wave analysis, vasopressor 
responses, diet manipulations and electrolytes. 
Microscopy, immunoblotting and in vitro SPAK-
WNK binding assays and biochemical analyses.  
 
Results: Gitelman syndrome is recapitulated by 
SPAKL502A/L502A mice, with lower vascular tone, 
hypotension and decreased phosphorylation of 
SPAK, NCC and NKCC1/2 in multiple tissues. 
 
Conclusion: SPAK binding is an attractive druggable 
target for a new class of thiazide-like anti-
hypertensives without unwanted off-target effects. 
WT = wild-type; SBP = systolic blood pressure; DBP = diastolic blood pressure; τ = DBP decay time constant; 
AN = anacrotic notch; DN = dicrotic notch; NNa = Normal Na+ diet; HNa = High Na+ diet; LNa = Low Na+ diet 
MO25β is most abundant in the distal 
nephron segments of the renal cortex. 
CUL3WT/Δ403-459 mice have elevated markers of artery 
stiffening and increased peripheral vascular resistance. 
SPAKL502A/L502A urinary Na+ wasting 
during acute HNa to LNa diet-switch 
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Chapter 1 : Introduction  
[This chapter is written principally as a contemporaneous overview of the state of knowledge 
prior to these studies. In-depth reviews of the recent literature appears in subsequent chapters] 
1.1 Hypertension 
1.1.1  The problem and therapies 
According to the World Health Organisation, systemic high blood pressure, or hypertension 
remains one of the largest risk factors to health globally, affecting approximately 1 in 4 over 
the age of 25 years. It is estimated that an astonishing 12.8% of global death can be attributed 
to hypertension; causing 51% of deaths from stroke and 45% from coronary heart disease 
(World Health Organisation, 2012).  
Although the strict definition of what constitutes hypertension can vary, given the 
normal Gaussian distribution amongst the normal population, it is most commonly defined by 
learned bodies as a blood pressure of ≥140/90 mmHg (but has recently been redefined in the 
USA as ≥130/80mmHg). Broadly speaking hypertension can be classified into two categories: 
Secondary hypertension which accounts for the minority of cases, in which there is a known 
cause of hypertension that results secondary to disease of other organs or systems, drugs or 
genetic syndromes; or essential hypertension which is estimated to account for as many as 
~90% of cases, in which the exact cause of hypertension is unknown (Carretero & Oparil, 2000; 
Messerli et al., 2007; Bolívar, 2013). In the latter, genetic influence is reported to account for 
anywhere between 34-67% of blood pressure variation between persons in the population 
(Vinck WJ Loos R, Vlietinck R., 2001; Hottenga et al., 2005); additionally numerous 
environmental risk factors such as poor diet, lack of exercise, obesity, sodium intake, smoking 
and excess alcohol consumption are documented to contribute significantly to onset of the 
condition (World Health Organisation, 2007). Due to this immense complexity progress has 
been quite slow in the identification of gene candidates that may be causative or contribute to 
hypertension onset. Thus, although rare, monogenetic diseases have been a great resource in 
the discovery of hypertension aetiology. 
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Blood pressure is primarily controlled by the cardiovascular and renal systems working 
in concert with one another; the heart capable of modulating heartbeat rate and stroke volume 
to alter cardiac output, while blood vessels dilate or constrict to provide vascular resistance and 
alter the circulatory volume capacity, and finally the renal system can regulate the volume of 
plasma in the cardiovascular system. It is at the level of the kidney that numerous 
pharmacological therapies have emerged to treat and ameliorate the cardiovascular impact of 
hypertension. Diuretics are a key part of these therapies with thiazide drugs still considered to 
be first-line agents in many hypertension guidelines. They act to reduce blood pressure, in part, 
by inhibition of thiazide-sensitive Na+-Cl- cotransporter (NCC) activity in the distal convoluted 
tubule of the kidney. Subsequently resulting in a reduction of circulating plasma volume and 
extracellular fluid via salt and water loss. However, reductions in circulating volume only last 
up to 4 – 6 weeks of chronic treatment, and the long-term maintenance of reduced blood 
pressure is purported to involve a concomitant decrease in total peripheral vascular resistance 
via thiazide action on the vascular smooth muscle cell (VSMC) or endothelial cell function 
(Duarte & Cooper-DeHoff, 2010).   
The physiological processes that regulate NCC activity in vivo have only been recently 
under investigation for the past decade or so, and the elucidation of such could perhaps lead to 
better understanding of thiazides’ mechanisms of action and discovery of novel therapeutic 
targets. 
 
1.1.2   Genetic disorders 
Until recently, understanding of the mechanisms that regulate renal sodium reabsorption on a 
molecular physiology level have been extremely limited. However breakthroughs in the 
profiling of rare genetic diseases such as Bartter syndrome, Gitelman syndrome and Gordon 
syndrome have permitted dissection of the signalling pathways involved in the 
pathophysiology of these conditions. This has not only improved treatment of these conditions 
but allowed exploration of new therapeutic targets for treating hypertension generally (Figure 
1.1). 
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Figure 1.1: Diagram illustrating the sites at which Bartter, Gitelman and Gordon 
syndrome exert their effects in the nephron. 
Bartter syndrome results from impaired electroneutral influx of a Na+, K+, and two Cl- ions from thick 
ascending limb (TAL) tubule fluid. This can occur via loss-of-function mutations in the NKCC2 
cotransporter which directly impairs this influx, or indirectly via mutations in proteins like ROMK, 
Barttin or CLC-Kb which impair the efflux of K+ or Cl- from the cell that NKCC2 activity is dependent 
on. Gitelman syndrome and Gordon syndrome (PHAII) result from the impaired or enhanced 
electroneutral influx of Na+ and Cl- form distal convoluted tubule (DCT) fluid, respectively. For 
Gitelman syndrome this is due to loss-of-function mutations to NCC, while Gordon syndrome mutations 
lead to increased WNK activity which stimulates Na+-Cl- influx via NCC. With all of these activities 
ultimately dependent on the basolateral sodium-potassium pump (3Na+/2K+-ATPase). [Taken from 
(Hebert et al., 2004) with a typo in “SLC12A1” corrected]. 
1.1.2.1  Bartter Syndrome 
Patients often present early in childhood and the syndrome manifests with hypotension, renal 
salt wasting, hypokalaemia, hypercalciuria with normal serum magnesium and calcium levels, 
and an activated renin-angiotensin system. The phenotype of these patient mimics that of 
someone on long-term chronic administration of loop diuretics (Amirlak & Dawson, 2000; 
Unwin & Capasso, 2006; Seyberth & Schlingmann, 2011). The genetic mutations that present 
in Bartter’s syndrome are heterogeneous with at least five known genes: SLC12A1 (encodes 
NKCC2); KCNJ1 (encodes ROMK1); BSND (encodes Barttin); CLCNKA (encodes CLC-K1 
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or CLC-Ka); CLCNKB (encodes CLC-K2 or CLC-Kb) (Figure 1.1) (Seyberth & Schlingmann, 
2011). Nonetheless they all relate to either a direct loss of bumetanide-sensitive Na+-K+-2Cl- 
cotransporter (NKCC) activity, specifically NKCC2 function (Bartter syndrome type 1), and/or 
mutations that effect the channel indirectly, for example, loss of inward-rectifier renal outer 
medullar potassium channel (ROMK) activity (Bartter syndrome type 2) on which NKCC2 
activity is dependent (Figure 1.1) (O’Shaughnessy & Karet, 2004). This is supported not only 
by the mimicry of chronic loop diuretic administration which inhibits NKCC2 (Amirlak & 
Dawson, 2000; Unwin & Capasso, 2006; Seyberth & Schlingmann, 2011), but also by animal 
models in which NKCC2 has been mutated (Kemter et al., 2010), NKCC2 activity suppressed 
indirectly by loss of ROMK activity (Cantone et al., 2008; Wagner et al., 2008) or the absence 
of a positive regulator such as oxidative stress-response kinase 1 (OSR1) (Lin et al., 2011). For 
more details on the gene-phenotype relationship and clinical features see OMIM: #241200, 
#300971, #601678, #602522, #607364, #613090. 
 
1.1.2.2   Gitelman Syndrome 
At one point Bartter and Gitelman syndromes were thought to be variations of the same disease 
(Simon et al., 1996); although recent advances have distinguished Gitelman as separate from 
Bartter syndrome (Unwin & Capasso, 2006; Seyberth & Schlingmann, 2011). Gitelman 
patients can often be asymptomatic with evidence of the syndrome not present until late 
childhood or in some cases adulthood; reporting joint problems, lethargy, growth retardation 
and usually a preference for salty foods. The phenotype of Gitelman syndrome mimics Bartter 
syndrome in many respects, with hypotension, salt wasting, hypokalaemia and an activated 
renin-angiotensin system. Although the other biochemical characteristics of the syndrome 
better emulate chronic thiazide administration, as patients also have hypocalciuria, 
hypomagnaesemia and renal magnesium wasting (Unwin & Capasso, 2006; Seyberth & 
Schlingmann, 2011). All reported cases of Gitelman syndrome with a genetic diagnosis have 
resulted from mutations in NCC which either reduce or abolish activity (O’Shaughnessy & 
Karet, 2004). Unsurprisingly, knock-out (KO) and knock-in (KI) animal models which exhibit 
a Gitelman syndrome phenotype include NCC-KO and loss-of-function NCC-KI mice (Loffing 
et al., 2004; Yang et al., 2010b) and those deficient in positive upstream regulators such as 
STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) activity (see section 1.3.2) 
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(Rafiqi et al., 2010; Yang et al., 2010c). For more details on the gene-phenotype relationship 
and clinical features see OMIM: #263800. 
1.1.2.3  Gordon Syndrome 
Gordon syndrome, also known as pseudohypoaldosteronism type II (PHAII) or familial 
hyperkalaemia and hypertension (FHHt), is the mirror image of Gitelman syndrome in terms 
of clinical presentation. Patients present with hypertension, salt retention and elevated serum 
potassium with a metabolic acidosis. Despite the genetic heterogeneity of the syndrome, the 
pathophysiological endpoint remains the same, resulting in elevated NCC activity via either 
increased apical membrane expression and/or increased intrinsic cotransporter activity (Cope 
et al., 2005; Boyden et al., 2012; Louis-Dit-Picard et al., 2012; Osawa et al., 2013). Mutations 
in the With-No-Lysine kinases (WNK) have traditionally been associated with the syndrome, 
namely exonic mutations in WNK4 and or intronic mutations in WNK1 which result in the 
overexpression of WNK1 that inhibits WNK4 activity, thus indirectly increasing apical 
membrane expression (Cope et al., 2005). The most recently reported kelch-like 3 (KLHL3) 
and cullin-3 (CUL3) proteins, which are known to negatively regulate NCC membrane 
abundance, have also been identified as causative sites of genetic mutation (Boyden et al., 
2012; Louis-Dit-Picard et al., 2012). Additionally it was found that transplant patients on long-
term chronic administration of protein phosphatase 3 inhibitors, Tacrolimus and Cyclosporine 
exhibited many of the hallmarks of Gordon syndrome. These drugs act to remove a negative 
regulator of NCC activity (see section 1.3.5), and it was found that the clinical features resulting 
from this increase in NCC activity were reversible with thiazide administration (Hoorn et al., 
2011; Melnikov et al., 2011). Furthermore, animal models mimicking these mutations have 
allowed  exploration of the regulation of NCC in vivo and given insight into new potential 
therapeutic strategies (Yang et al., 2007b; Chowdhury et al., 2013; Vidal-petiot et al., 2013). 
For more details on the gene-phenotype relationship and clinical features see OMIM: #145260, 
#614491, #614492, #614495, #614496. 
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1.2  Renal Salt Handling 
1.2.1  Nephron segments 
The average daily intake of sodium is approximately 9-12g (World Health Organisation, 2016), 
the vast majority of which is subsequently lost in the urine, with some minor loss also via the 
faeces  and sweat. Within a day an average human will filter 170-180L of plasma, which 
equates to approximately 25 moles of sodium. Thus to maintain salt homeostasis the kidneys 
must reabsorb sodium; which is done at all segments of the nephron except the descending thin 
limb of the loop of Henle (Figure 1.2) (O’Shaughnessy & Karet, 2006).  
Figure 1.2: Schematic of the major sites of Na+ reabsorption along the mammalian 
nephron. 
The kidneys are capable of reabsorbing ~99% of filtered sodium in the nephron. The vast majority of 
sodium reabsorption occurs in the proximal tubule (PT) through the Na+/H+ exchanger (NHE3), with 
the second largest bulk of sodium uptake in the thick ascending limb (TAL) of the loop of Henle by the 
electroneutral NKCC2 cotransporter; a process dependent on TAL K+ and Cl- efflux by ROMK, CLC-
Kb and Barttin. Fine tuning of the final sodium excretion is determined by the distal convoluted tubule 
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(DCT) via electroneutral NCC cotransporter activity and in the collecting duct (CD) through 
electrogenic reabsorption mediated by epithelial sodium channel (ENaC). Additionally sodium 
reabsorption can be modulated by the renin-angiotensin-aldosterone system (RAAS) in the aldosterone-
sensitive segments of the distal tubule expressing the mineralocorticoid receptor (MR). [Adapted from 
(Cope et al., 2005) with changes to labels]. 
The majority of sodium is reabsorbed in the proximal convoluted tubule (PCT) with 
approximately 60% via primary active transport of the Na+/H+ exchanger (NHE3). A further 
25% is then reabsorbed by the thick ascending limb of the loop of Henle (TAL) via the 
electroneutral NKCC2; the function of which is dependent on recycling of potassium into the 
tubular fluid via ROMK. In the distal convoluted tubule (DCT), up to 10% of total sodium 
reabsorption is regulated by the electroneutral NCC. Finally amiloride-sensitive epithelial 
sodium channels (ENaC) reabsorb the remaining 2-3% of sodium in the collecting ducts (CD) 
(Figure 1.2) (O’Shaughnessy & Karet, 2006). 
1.2.2  NCC and the SLC12 gene family 
The solute carrier family 12  (SLC12) genes which encode for electroneutral cation-coupled 
chloride cotransporters (CCC) and can be divided into two divergent groups: a K+-Cl- 
cotransporter (KCC) group which has four members, KCC1 – 4 encoded by SLC12A4 – 7 
respectively, and the other group containing a thiazide-sensitive Na+-Cl- cotransporter (NCC) 
encoded by the SLC12A3 gene and two bumetanide-sensitive Na+-K+-2Cl- cotransporters 
(NKCC) encoded by SLC12A2 (NKCC1) and SLC12A1 (NKCC2) (Figure 1.3). Two more 
orphan members of the SLC12  family exist, namely SLC12A8 (CCC8) which has been linked 
with psoriasis and SCL12A9 (CCC9; also known as CCC interacting protein, CIP) which has 
been shown to inhibit the functional expression of NKCC1, however both of these await further 
characterisation (Hebert et al., 2004; Gagnon & Delpire, 2013). 
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Figure 1.3: Cluster dendrogram of the SLC12 family members. 
The cluster dendrogram shows a visual representation of the evolutionary relationships of the human 
SLC12 gene family. Length of tree branches can be compared with the reference bar, which represents 
0.1 amino acid substitutions per site. The closely related K+-Cl- cotransporters (KCC) 1 – 4 are 
responsible for cellular efflux of these ions, while Na+-K+-2Cl- (NKCC) 1 – 2 and Na+-Cl- (NCC) 
cotransporters control cellular influx of these ions. The exact transporter substrates of cation-coupled 
cotransporter (CCC) 8 – 9 are not known, although the evolutionary older CCC8 is more closely related 
to the Na+-independent branch of the family while CC9 branched off early from Na+-dependent 
cotransporters. [Taken from (Gagnon & Delpire, 2013)]. 
The SLC12A3 gene located on chromosome 16q13, was originally characterised in the 
urinary bladder of the winter flounder, Pseudopleuronectes americanus (Gamba et al., 1993). 
The expression of its product, NCC, is restricted to the DCT of the kidney where it plays an 
important role in water and salt homeostasis. Regulation of NCC activity is controlled by two 
mechanisms: membrane trafficking of the protein to govern levels of apical membrane 
expression, and the phosphorylation status of highly conserved serine (S)/threonine (T) 
residues (Hebert et al., 2004) that control the  level of intrinsic channel activity . It was once 
thought that NCC expression was relatively static in the apical membrane of the DCT, but in 
the last decade or so it has become apparent that a highly complex, multi-level system of 
upstream regulators exists (Dimke, 2011). In particular these upstream regulators 
phosphorylate or dephosphorylate at key residues T46, T55 and T60 in humans (T53, T58 and 
S71 in mice) to increase or decrease activity (Figure 1.4), respectively (Rafiqi et al., 2010); the 
most functionally important of which has been shown to be T60 (equivalent to T58 in mice) 
which likely induces conformational change (Richardson et al., 2008). 
This figure was redacted for copyright reasons. 
The Copyright holder is The American 
Physiological Society.
The original can be found as Figure 1A in
DOI: 10.1152/ajpcell.00350.2012
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Figure 1.4: NCC and NKCC1 conserved phosphorylation sites 
N-terminal sequence alignment of human and mouse NCC, NKCC1 and NKCC2 residues showing the 
highly conserved nature of a region known to increase cotransporter activity when phosphorylated. 
Characterised phosphorylation sites are shown in red boxes, identical residues are shown in black and 
similar residues are in grey. [Adapted from (Richardson et al., 2008) with changes to sequence order 
and labelling]. 
Due to the high degree of homology between the SLC12 family members the S/T 
residues are conserved in the NKCCs, and the upstream regulators which act on these residues 
often solicit responses similar to those seen in NCC. Hence in NKCC1, the more ubiquitously 
expressed of the two, expression tends to be localised to the basolateral membrane in epithelia 
and it is activated by phosphorylation of T203, T212 and T217 (Figure 1.4) (Richardson et al., 
2008; Thastrup et al., 2012). While NKCC2, whose expression is confined to apical membrane 
expression in the TAL of the kidney, has phosphorylation sites at T91, T100 and T105 (Figure 
1.4) (Hebert et al., 2004). Also of note is that NCC and the NKCCs share a conserved docking 
site, the [S/V/G]RFx[V/I]xx[T/I/S/V]xx motif (abbreviated to RFxV), that is integral for 
binding to the conserved C-Terminal (CCT) of their upstream regulators, SPAK and OSR1 to 
enable phosphorylation (Figure 1.5) (Richardson et al., 2008). 
1.3  The Role and Regulation of the WNK Pathway in the kidney 
1.3.1  WNK: The original regulators of NCC 
Four novel members of the MEK kinase family, the so called With-No-Lysine kinases (WNK) 
were the first proteins to be investigated for a role in the regulation of CCC activity. The 
members of the WNK family also share a conserved RFxV binding motif, present in the CCC 
substrates. This facilitates binding to and phosphorylation of SPAK/OSR1 which are the 
downstream effectors of the WNKs (Figure 1.5). 
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The best profiled of these to date is WNK4. Tissue expression of WNK4 in humans and 
mice is localised to many polarised epithelial cell types such as the pancreas, liver, epididymis, 
colon, kidney, in addition to blood-brain barrier endothelia (Kahle et al., 2004). In renal tissue, 
WNK4 expression is highest in the DCT, predominantly associated with tight junctions 
(evidenced by colocalisation with zona-occludens-1 tight junction protein), and the cortical CD 
(CCD), in which expression is cytosolic with some intercellular junction localisation (Wilson 
et al., 2001). Amphibian oocyte and mammalian cell line experiments have demonstrated that 
WNK4 can act indirectly to positively regulate CCCs; WNK4 phosphorylates its downstream 
effectors SPAK/OSR1, which in turn mediate its action by phosphorylating CCCs at key 
residues to stimulate transporter activity (Figure 1.5) (see section 1.3.2) (Vitari et al., 2005; 
Ahlstrom & Yu, 2009). Mutation of the WNK4 kinase domain in most cases was capable of 
abolishing this effect, as were experiments utilising kinase-dead forms of SPAK/OSR1, thus 
demonstrating the necessity for these downstream effectors to mediate WNK4 positive 
regulation of CCCs (Vitari et al., 2005; Ahlstrom & Yu, 2009). However in contrast to this, 
native/wildtype WNK4 acting in isolation is known to have a direct negative regulatory effect 
on CCCs, via inhibition of anterograde trafficking of proteins resulting in a reduction of 
membrane expression (Yang et al., 2003). In vitro experiments demonstrate that co-expression 
of WNK4 with NCC or NKCC1 will inhibit the transporter activity by dramatically reducing 
surface membrane levels of CCCs which can be reversed by introduction of Gordon syndrome-
causing mutations into WNK4. This mechanism acts independent of dynamin-dependent 
endocytosis to inhibit anterograde trafficking of NCC from the trans-Golgi network (Yang et 
al., 2003; Golbang et al., 2006); instead channels are diverted to lysosomes for degradation via 
a mechanism reliant on the MAPK ERK1/2 signalling pathway (Zhou et al., 2012) and 
stimulation of AP-3 interaction with NCC (Subramanya et al., 2009). WNK4 reduction of 
surface membrane NCC can be inhibited through serum/glucocorticoid-induced kinase 1 
(SGK1), an aldosterone effector, directly phosphorylating human WNK4 at S1190, the same 
site targeted by full length WNK1 (L-WNK1) to halt the process and encourage NCC 
membrane anterograde trafficking (Figure 1.5) (Rozansky et al., 2009). 
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Figure 1.5: Schematic diagram of NCC regulation by WNK 1 and WNK4. 
Serum/glucocorticoid-induced kinase 1 (SGK1) is transcriptionally induced by aldosterone and 
phosphorylated (P) by phosphoinositide 3-kinase (PI3K) and phosphoinositide-dependent kinase (PDK) 
1 – 2 signalling, which activates SGK1 and incidentally promotes its degradation. Both SGK1 and full 
length WNK1 (L-WNK1) can phosphorylate WNK4 to inhibit its negative regulation of NCC activity, 
which WNK4 normally achieves through disruption of anterograde trafficking of NCC from the trans-
Golgi network to the plasma membrane. WNK4 and L-WNK1 can also positively regulate NCC activity 
through phosphorylation of SPAK/OSR1 which in turn phosphorylate NCC to increase transporter 
activity. However, the actions of L-WNK1 can also be inhibited by a kidney-specific WNK1 (KS-
WNK1) shorter splice variant. [Taken from (Rozansky et al., 2009)]. 
Similar to SGK1 inhibition of WNK4, WNK1 the first of the WNKs to be discovered 
and the oldest phylogenetically (Xu et al., 2000), is also capable of interacting with WNK4 to 
inhibit its negative effect on NCC anterograde trafficking (Yang et al., 2003, 2005). WNK1 
phosphorylates WNK4 at the same site as SGK1 to disable its inhibitory effect on NCC activity 
(Rozansky et al., 2009), and it is also worth noting that WNK1 has been shown to interact with 
and activate SGK1 to regulate ENaC activity and a similar process may occur in the DCT to 
further suppress WNK4 (Xu et al., 2005). WNK1 has a broad tissue expression profile and 
numerous isoforms with putatively different functional roles. In the renal tissue WNK1 
colocalises with WNK4 in the DCT and CCD with a diffuse cytosolic distribution (Wilson et 
al., 2001). In fact a kidney-specific shortened sequence of WNK1 (KS-WNK1) which is kinase 
inactive and confined to the distal nephron accounts for 90% of WNK1 in this area. The other 
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10%  is made up of L-WNK1, whose tissue distribution is ubiquitous (Yu, 2006; Lee et al., 
2009; Rozansky et al., 2009). KS-WNK1 exerts an inhibitory effect on L-WNK1by removing 
L-WNK1 inhibition of WNK4, which increases inhibition of NCC anterograde trafficking and 
thus NCC activity (Subramanya et al., 2006; Rozansky et al., 2009). Evidence from KS-
WNK1-KO mice have demonstrated this effect in vivo with mice demonstrating elevated 
diastolic blood pressure due to increased NCC expression and phosphorylation (Hadchouel et 
al., 2010). In vitro data also shows L-WNK1 is also capable of increasing NCC activity by 
phosphorylating SPAK/OSR1 (Moriguchi et al., 2005; Vitari et al., 2005), although given the 
high ratio of KS-WNK1 to L-WNK1 in the kidney it is likely this effect is typically suppressed 
in vivo (Figure 1.5). 
A third member of the WNK family, WNK3, is known to present in at least two 
isoforms, renal and brain, which exhibit opposite regulatory effects on NCC (Glover et al., 
2009). The renal form of WNK3 is expressed along the entire length of the nephron, with the 
highest levels in PCT and TAL; exhibiting a subcellular localisation to intercellular junctions 
(zona-occludens-1, tight junction marker protein) (Rinehart et al., 2005). WNK3 has been 
shown to promote surface membrane expression of NCC by up to 3-fold in amphibian oocyte 
experiments. Unexpectedly when WNK3 is mutated to remove its activity it gains WNK4-like 
attributes reducing NCC membrane surface expression (Rinehart et al., 2005). WNK3 is also 
involved in a chloride sensing mechanism, and like WNK1 and WNK4, SPAK activity is 
essential to mediate the actions of WNK3 on the downstream substrate NKCC2 (Ponce-Coria 
et al., 2008). It was the study of WNK3 that provided further confirmation of the two distinct 
methods of modulating CCC activity; first by control of surface membrane protein abundance 
and secondly, by altering channel phosphorylation status to increase or decrease the intrinsic 
activity of the individual transporters inserted into the membrane (Glover et al., 2009). 
1.3.2  SPAK/OSR1: The recent focus of NCC regulation 
STE20/SPS1-related proline-alanine-rich protein kinase (SPAK) encoded by the STK39 gene 
and oxidative stress-response kinase-1 (OSR1) encoded by the OXSR1 gene, belong to the 
germinal centre kinase (GCK) subgroup of the STE kinase group (Figure 1.6) (Filippi et al., 
2011). Originally discovered for the their ability to stimulate NKCC1 activity, these two closely 
related kinases sterile-20 (STE20) kinases (Figure 1.7) share 68% sequence identity with one 
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another, as well as 79% conserved C-terminal (CCT) domain and 96% N-terminal catalytic 
domain sequence homology (Delpire & Gagnon, 2008). 
Figure 1.6: STE kinase group classification and relationships. 
Neighbour-joining distance tree illustrating the evolutionary relationships of the human sterile (STE) 
serine/threonine kinase family members. Kinases with all four putative MO25α binding sites are in blue 
with either a conserved tryptophan-glutamic acid-phenylalanine/tryptophan (WEF/WEW) motifs at 
their C-terminal flanking tail (CFT) of the kinase domain, STRADα/β are in red and those with three 
of the putative sites are in green; the majority of these belong to the germinal centre kinase (GCK) 
subgroup. [Adapted from (Filippi et al., 2011)]. 
Of the two, OSR1 is more ubiquitously expressed and present in the tissues of the brain, 
heart, kidney, lung, spleen, testis, liver and skeletal muscle; likely indicative of the more global 
regulatory actions of OSR1, evidenced by the embryonic lethality of constitutive OSR1-KO 
(Delpire & Gagnon, 2008; Rafiqi et al., 2010). While SPAK, which has most likely evolved to 
perform more specialised function has a more restricted expression profile limited to specific 
areas in the brain, heart, testis, spleen, lung and kidneys, where expression is confined to the 
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TAL and DCT portions of the mouse nephron (Rafiqi et al., 2010) and TAL, DCT and CCD 
of human kidneys (Wang et al., 2009). This tissue specific expression correlates well with the 
expression patterns of the known substrates of OSR1 and SPAK, namely NCC, NKCC1 and 
NKCC2 which they directly phosphorylate at conserved key S/T residues to positively regulate 
transporter activity (Moriguchi et al., 2005).  
Figure 1.7: SPAK and OSR1 evolutionary relationship. 
Phylogenetic cluster dendrogram of SPAK and OSR1 in the animal kingdom. Length of tree branches 
can be compared with the reference bar, which represents 0.1 amino acid substitutions per site. SPAK 
branched from OSR1 in avian and mammalian species. Notably, due to the close relationship between 
mouse, rat and human OSR1/SPAK these animals have proved useful models for studying OSR1/SPAK 
in human physiology. [Taken from (Delpire & Gagnon, 2008)]. 
The CCTs of both SPAK and OSR1 are capable of binding with a conserved motif of 
both substrates (CCCs) and upstream regulators (WNKs), [S/V/G]RFx[V/I]xx[T/I/S/V]xx, 
more commonly referred to as RFxV (Delpire & Gagnon, 2008), and an example of this binding 
complex, OSR1-WNK4 has been confirmed by x-ray crystallography (Villa et al., 2007). In 
order to activate SPAK or OSR1, key T and/or S residues must be phosphorylated; SPAK at 
S373 (mouse S383) and T233 (mouse T243), and OSR1 at S325 and T185 (Rafiqi et al., 2010; 
Gagnon et al., 2011). These residues are typically phosphorylated by upstream regulators 
WNK1, WNK3 and WNK4. This has been verified in vitro with experiments employing 
mutated kinase-dead WNKs and SPAK/OSR1 with key S/T residues mutated such that CCCs 
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cannot be activated (Vitari et al., 2006; Delpire & Gagnon, 2008; Ponce-Coria et al., 2008). 
The WNK-SPAK/OSR1-NCC signalling cascade has circadian rhythm, with phosphorylated 
levels of NCC, SPAK and OSR1 increased at the start of the active period (night in mice/rats) 
and decreased at the start of the rest period (day in mice/rats) in the nocturnal mouse (Susa et 
al., 2012). It has also been shown that OSR1 and SPAK, can form functional homodimers and 
heterodimers with one another that may be capable of activation by trans-autophosphorylation, 
bypassing normal upstream WNK activation and utilising a stabilising regulator Mouse 
protein-25 (MO25) (see section 1.3.3) (Lee et al., 2009; Ponce-Coria et al., 2012). 
Independently generated SPAK-KO (Geng et al., 2009; Yang et al., 2010c) and kinase 
inactive SPAK-KI mouse models (Rafiqi et al., 2010) have provided viable animals exhibiting 
sodium-wasting hypotensive phenotypes similar to Gitelman’s syndrome or chronic thiazide 
use. These mice have significantly reduced expression of total and phospho-NCC (pNCC), thus 
verifying the dominant role of SPAK in DCT regulation of NCC activity in vivo (Geng et al., 
2009; Rafiqi et al., 2010; Yang et al., 2010c). Notably SPAK-KO mice also exhibit an increase 
in TAL phospho-NKCC2 (pNKCC2) which cannot be entirely attributed to an increase in 
phospho-OSR1 (pOSR1), but rather may be explained by the emergence of a novel theory 
supporting a role for shorter sequence SPAK isoforms that exert a negative regulatory effect 
on CCCs reminiscent of the KS-WNK1/L-WNK1 story (Mccormick et al., 2011; Grimm et al., 
2012).  
Two of these isoforms that have been discovered in the kidney differ from full length 
SPAK (~60kDa) in predicted molecular weight and kinase activity. The first isoform, SPAK2, 
(~49kDa) is missing part of the N-terminus of the kinase domain and presumed to be kinase 
impaired, while the second isoform, KS-SPAK (~34kDa), is kidney-specific and kinase 
inactive with loss of the entire kinase domain (Grimm et al., 2012). As the CCT domain is 
intact in these isoforms, it is presumed that they compete with full length SPAK and OSR1 for 
RFxV docking sites, thus inhibiting CCC activity. Another distinguishing factor is the 
differential expression of these isoforms along the nephron: of particular note in the TAL where 
SPAK2 and KS-SPAK are significantly higher than full length SPAK, and the DCT where the 
converse is true (Mccormick et al., 2011). It was noted in Xenopus oocyte and HEK-293 cell 
line experiments that SPAK2 significantly decreased NKCC1 activity and that KS-SPAK 
attenuates levels of pNCC. In vivo, the predominance of these truncated SPAK isoforms in the 
TAL would be expected to supress full-length SPAK activity and partially dampen down 
OSR1-dominated positive regulation of NKCC2 by competing for docking sites. However, in 
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the DCT full-length SPAK is the dominantly-expressed isoform allowing it to outcompete 
SPAK2 and KS-SPAK, overcoming their inhibitory effects. This is evidenced by in vitro co-
expression of full length SPAK, which serves to significantly diminish the inhibitory effects of 
SPAK2 on NKCC1 activity (Mccormick et al., 2011; Grimm et al., 2012). Perhaps the most 
intriguing report has been the presence of an isoform ratio switch in response to extracellular 
fluid depletion; in which a low sodium diet decreased the abundance of KS-SPAK while 
simultaneously increasing levels of full length SPAK to promote sodium retention (Figure 1.8) 
(Grimm et al., 2012). It is therefore likely that complete SPAK-KO wipes out all SPAK 
isoform-dependent competition, leaving OSR1 to increase NKCC2 activity uninhibited, thus 
accounting for increased pNKCC2 observed in these models (Geng et al., 2009; Yang et al., 
2010c). Furthermore, this may explain the absence of any change in NKCC2 activity in SPAK-
KI mice, as the ratios of full length SPAK (although mutated), SPAK2 and KS-SPAK are 
maintained with OSR1 operating in a relatively intact environment (Rafiqi et al., 2010).  
Figure 1.8: Model of SPAK isoform switch mechanism controlling NCC and NKCC2 
activity. 
In volume replete wildtype animals SPAK/OSR1 stimulates baseline NCC and NKCC2 activity, 
although full length SPAK/OSR1 activity is largely dampened by the high abundance of kinase-inactive 
kidney-specific SPAK (KS-SPAK) isoform in the TAL (“switched-off” = high KS-SPAK vs. low full 
length SPAK/OSR1 levels). During extracellular fluid (ECF) depletion the KS-SPAK is downregulated 
in the TAL while levels of full length SPAK and OSR1 are increased in DCT/TAL, thereby promoting 
phosphorylation of NCC and NKCC2 (“switched-on” = low KS-SPAK vs. high full length SPAK/OSR1 
levels). Whereas in SPAK-KO animals the absence of any SPAK isoforms leads to a decrease in 
phospho-NCC (pNCC) as full-length SPAK is the principal kinase in DCT, and an increase in phospho-
NKCC2 levels as OSR1 has no competition for binding sites in the TAL in the absence of KS-SPAK. 
The size of the oval and text is indicative of protein abundance. Red pointed arrows indicate a promotion 
41 
of indicated effect, while red flat-head arrows indicate inhibition of effect [Taken from McCormick et 
al, 2011 (42)]. 
While a homozygote constitutive OSR1-KO mouse model resulted in embryonic death 
(Delpire & Gagnon, 2008; Rafiqi et al., 2010), heterozygote constitutive OSR1-KO and 
homozygote kidney tubule-specific OSR1-KO produced viable animals that could be 
physiologically characterised (Lin et al., 2011). These mice present with a hypotensive 
phenotype accompanied by sodium/potassium/calcium-wasting, similar to Bartter’s syndrome 
or chronic use of loop diuretics. TAL expression of NKCC2 in these mice was relatively 
unaffected but levels of phospho-NKCC2 were dramatically decreased, thus supporting the 
role of OSR1 as the principal regulatory force in TAL NKCC2 activity. Interestingly, levels of 
SPAK, phospho-SPAK, total NCC and phospho-NCC were all markedly increased in the DCT 
(Lin et al., 2011), perhaps as a compensatory mechanism for Na+ handling or due to a yet 
unexplored mechanism involving previously identified but uncharacterised OSR1 lower 
molecular weight isoforms present in the kidney that may be operating in a similar fashion to 
the SPAK isoforms described above (Piechotta et al., 2003). 
Additionally, it was reported that SPAK-KO mice have a reduction in aortic 
contractility which contributes to hypotension, purportedly due to diminished NKCC1 
phosphorylation (Yang et al., 2010c); activation of NKCC1 in VSMCs causes a rise in 
intracellular Cl- which in turn stimulates the influx of Ca2+ via L-type calcium channels and 
subsequent vessel contraction (Akar et al., 2001; Anfinogenova et al., 2004; Orlov & Mongin, 
2007). Similarly heterozygote constitutive OSR1-KO mice exhibit significant reductions in 
aortic levels of phospho-NKCC1 (pNKCC1), pOSR1 and phospho-SPAK (pSPAK) without 
changes to the total levels of NKCC1 and SPAK, and thus likely exhibit reductions in aortic 
contractility similar to that observed in SPAK-KO mice (Yang et al., 2010c; Lin et al., 2011). 
Although, to account for the lack of compensation in these KO models by the other remaining 
kinases that may activate NKCC1, one may argue that evidence shows SPAK and OSR1 
interactions with one another stabilise the intracellular localisation of expression, which is 
required to facilitate their activation (Grimm et al., 2012). Therefore it is conceivable that the 
absence of one may destabilise and impair the function of the other in the vasculature.  
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1.3.3  MO25: The master regulator of SPAK/OSR1 
Mouse protein-25 (MO25), also known as calcium-binding protein 39 (CAB39), was first 
discovered to be a highly conserved protein expressed in the cleavage stage of mouse embryos 
(Miyamoto et al., 1993). Since then much progress has been made in the elucidation of its role 
as a scaffold protein in the binding to and stabilisation of STE20-related adaptor (STRAD) 
pseudo-kinase in an active conformation (Figure 1.9), so that it may stimulate liver kinase B1 
(LKB1) tumour suppressor protein kinase activity (Boudeau et al., 2003; Milburn et al., 2004; 
Zeqiraj et al., 2009b, 2009a). The Alessi group were the first to establish a role for MO25 as a 
potential master regulator of SPAK and OSR1; both of which are closely related to STRAD 
and possesses the same four key sites for MO25 interaction (Figure 1.6) (Filippi et al., 2011).  
Figure 1.9: STRAD-MO25 interaction sites 
Schematic representation of the STRAD–MO25 interaction based on the crystal structure (PDB: 3GNI). 
Highlighted are key interaction sites referred to as sites 1 and 2 (in red circles) on MO25α (shown in 
blue) and sites A, B, C and D (in purple circles) on STRADα (shown in green). 
There exists two isoforms of MO25 within mammals, namely MO25α and MO25β (also 
known as CAB39L), which share approximately 73% sequence homology and have similar 
biological actions on LKB1 (Boudeau et al., 2003). However, it was MO25α that was found in 
vitro to increase the activation of SPAK and OSR1 constitutively active mutants by up to 100-
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fold. This effect was found to be dose-dependent with an activity plateau reached around a 10-
fold molar excess of MO25α versus SPAK/OSR1; MO25β exhibited similar effects, although 
was not as potent. Additionally, siRNA-mediated ~70% knockdown of MO25α in a 
mammalian cell line was shown to decrease hypotonic low-chloride stimulated 
phosphorylation of NKCC1 by SPAK/OSR1 in a manner rescuable by re-expression of MO25α 
(Filippi et al., 2011).  
Immunofluorescent studies of mouse renal tissue have shown MO25α to specifically 
colocalise with SPAK and OSR1 at the apical membrane of the TAL and DCT, thus providing 
evidence to support a role for MO25α-SPAK/OSR1 signalling in vivo. Interestingly, in SPAK-
KO mice MO25α expression levels and localisation appear unaltered, while OSR1 in the DCT 
redistributes to punctate structures containing WNK1, but does not in the TAL. This suggests 
SPAK stabilises OSR1 apical localisation in the DCT and perhaps explains why OSR1 is 
incapable of compensating for the loss of positive SPAK regulation on NCC activity, as 
MO25α it is no longer in proximity to promote OSR1 activation (Grimm et al., 2012). 
Work by Delpire et al in Xenopus oocytes, has shown that SPAK and OSR1 are capable 
of forming functional homo- and heterodimers with one another; and while the functional unit 
of SPAK is the monomeric form, dimerisation can facilitate monomer activation. Importantly, 
this dimer-facilitated activation of monomeric kinase activity is mediated by MO25α, in a 
manner that bypasses the usual upstream phosphorylation requirement of SPAK/OSR1 by 
WNK (Figure 1.10). Also it was shown that MO25α is incapable of increasing NKCC1 
activation if SPAK is solely an unactivated monomer, although could significantly increase 
NKCC1 activity if the SPAK monomer was already in an active form (Ponce-Coria et al., 
2012). In another study MO25α was demonstrated to potentially stabilise and facilitate the 
active conformation of OSR1 kinase as either a monomer or dimers (Figure 1.11) (Gagnon et 
al., 2011). 
Of particular note is the ability of MO25α to facilitate the rescue of non-functional SPAK 
mutants by P+1 loop domain swapping with another non-functional SPAK mutant in a 
homodimer or  wildtype (WT) OSR1 in a heterodimer. This demonstrated an exciting new 
MO25α facilitated interplay between and within SPAK/OSR1 co-expressed in the TAL and 
DCT that had not previously been studied (Ponce-Coria et al., 2012). It should also be 
considered that due to the ability of MO25α to stimulate SPAK/OSR1 activity independent of 
the usual upstream WNK-mediated phosphorylation, caution should be exercised in 
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interpreting various phosphorylated NCC residues as an absolute indicator of channel 
activity/stimulation (Gagnon et al., 2011). 
Figure 1.10: Proposed mechanisms for mouse SPAK activation. 
[I] A monomer of unactivated SPAK with unmodified T243 (T) and S383 (S) phosphorylation sites and 
P+1 loop T247 hidden between. [II] Inactive SPAK monomers can dimerise. [III] WNK4 binds to 
SPAK and phosphorylates T243 and S383 (shown as *). [IV] A conformational change unmasks the 
P+1 loop T247 residue permitting domain-swapping (shown as swapped coloured “T” circles); it is 
unclear if WNK4 remains in complex with the active SPAK (shown as faded). [V] MO25α (also known 
as CAB39, and shown as CAB in the figure) binds to SPAK and induces a conformational change 
unmasking the P+1 loop T247. [VI] Domain swapping of the P+1 loop and phosphorylation of T243 
activate SPAK; it is unclear if MO25α remains in complex with active SPAK (shown as faded). [Taken 
from (Ponce-Coria et al., 2012)] 
Figure 1.11: Proposed mechanisms of mouse OSR1 activation. 
[A] WNK4 phosphorylates an inactive OSR1 (shown in grey), [B] active OSR1 (shown in yellow) is 
phosphorylated (P in blue circle) at S325 and T185, [C] active conformation phospho-OSR1 monomer 
or [D] dimer, [E] MO25α (CAB39) facilitates and stabilises an active conformation of phospho-OSR1 
monomer or [F] domain-swapped dimer. [Adapted from (Gagnon et al., 2011)]. 
This figure was redacted for copyright reasons. 
The Copyright holder is The American Physiological Society.
The original can be found as Figure 8 in
DOI: 10.1152/ajpcell.00284.2012
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1.3.4  CUL3/KLHL3: The New Players 
Two new gene candidates involved in the pathophysiology of Gordon’s syndrome were 
identified by whole-exome sequencing; namely KLHL3 which encodes kelch-like 3 (KLHL3) 
and CUL3 (CUL3) which encodes cullin-3 involved in the formation of a ubiquitin ligase 
complex (Boyden et al., 2012; Louis-Dit-Picard et al., 2012). A striking finding of this work 
was that mutations between these two new genes accounted for 79% of Gordon syndrome 
patients who did not possess traditional mutations in either WNK1 or WNK4 (WNK1/WNK4 
mutations account for 13%) in the examined patient cohort (Boyden et al., 2012). 
Characterisation of KLHL3 expression within the kidneys demonstrated a restriction of 
expression to DCT and CNT with apical localisation in the DCT, and thus can be assumed to 
colocalise with NCC. While CUL3 was found to be ubiquitously expressed in all renal tubules, 
but with highest expression in the PCT, DCT and CCD (Boyden et al., 2012; Louis-Dit-Picard 
et al., 2012). The ability of KLHL3 to negatively regulate NCC membrane expression is in part 
dependent on the ability to colocalise with NCC; they have been shown to co-
immunoprecipitate and a reduction of KLHL3 at the membrane increases NCC surface 
localisation, presumably through a reduction in NCC ubiquitination (Louis-Dit-Picard et al., 
2012). It was proposed that these represent a promising third candidate for a pathway regulating 
NCC endocytosis/degradation, although significant investigation is warranted to establish if 
KLHL3 and CUL3 administer their actions solely through an endocytotic process or by 
ubiquitination of other NCC regulators. 
1.3.5  PP4/PP3: The counter-regulatory system 
As phosphorylation of NCC by SPAK/OSR1 has a positive regulatory effect on transporter 
activity, it is logical to assume that a counter-regulatory mechanism of dephosphorylation must 
exist, presumably executed by protein phosphatases (PP). For example, PP1 has already been 
reported to reduce NKCC1 activity, by direct dephosphorylation of the channel or indirectly 
by dephosphorylation of SPAK (Gagnon & Delpire, 2010). Data has also shown that PP1 is 
capable of recognising the RFxV motif in conjunction with its regulatory subunits and is 
capable of binding with WNK1 and WNK4, thus potentially negatively regulating channel 
activity at several levels (Villa et al., 2007). PP2A has been found to inhibit NKCC1 activity 
by dephosphorylation, and studies have shown co-immunoprecipitation with SPAK, 
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suggesting perhaps indirect reduction in NKCC1 phosphorylation status by dephosphorylation 
of SPAK, similar to PP1 (Liedtke et al., 2005).  
PP4 which shares 65% of its amino acid sequence with PP2A (Hu et al., 2001), is 
primarily found in the DCT, distal CNT and CD cells (Glover et al., 2010). The human S/T 
protein phosphatase 4 gene (PPP4C) which encodes for PP4 is located on chromosome 16p11-
p12 (Bastians et al., 1997), and although the mouse and human genes sequences differ, the 
resulting amino acid sequence of the protein remains the same for both species (Hu et al., 
1998). PP4 is a developmentally regulated protein phosphatase playing important roles in 
embryonic development; in adult life the protein is abundantly expressed in numerous tissues 
such as the kidneys, heart and skeletal muscle (Hu et al., 2001). Thus constitutive PP4-KO has 
proved to be embryonically lethal in mice and subsequently a conditional knock-out was later 
developed (Shui et al., 2007). The wide and complex activities of PP4 are in part controlled by 
regulatory subunits, namely R1 and R2, which can form complexes and thus in turn help govern 
the specificity of PP4 actions (Cohen et al., 2005). Data from Xenopus oocyte 22Na+ flux 
experiments have illustrated that PP4 can directly reduce NCC activity by dephosphorylation 
of T58 residues. This regulation is dependent on the phosphatase actions of PP4, as 
demonstrated by phosphatase inactive mutants, and the effect is also shown to be completely 
independent of WNK4 regulation of NCC membrane trafficking, which is not impacted by T58 
phosphorylation status (Glover et al., 2010). In vivo evidence for a physiological role of PP4 
may be found in the clinical outcomes of anti-tumour anti-biotic drugs such as fostriecin which 
is a potent and selective inhibitor of PP2A and PP4 (Walsh et al., 1997; Hastie & Cohen, 1998) 
as has been observed previously for other phosphatase inhibitors (Hoorn et al., 2011; Melnikov 
et al., 2011).  
Strong evidence for PP3 (also known as calcineurin) regulation of NCC activity was 
discovered from studying the clinical side effects of immunosuppressive drugs tacrolimus or 
cyclosporine (calcineurin inhibitors), often prescribed to patients who have undergone 
transplant surgery. Administration of either of these drugs has been known to induce 
hypertension, which may be ameliorated with the application of thiazides, furthermore these 
drugs cannot induce elevated blood pressure in NCC-KO mice, thus reinforcing the evidence 
that phosphatase activity is required for negative regulation of NCC activity. It should also be 
noted that PP3 and NCC colocalise, and PP3 inhibitors increase WNK1, WNK4, SPAK and 
NCC levels in addition to increasing phosphorylation of NCC and SPAK (Hoorn et al., 2011; 
Melnikov et al., 2011). Thus it is likely that PP3 is working to negatively regulate NCC activity 
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in vivo directly at the level of NCC and via inhibition of its upstream regulators, though the 
precise mechanisms of this regulation remain unknown. 
 
1.3.6    Parvalbumin: An unexpected regulator of NCC and diuretic response 
A member of the EF-hand Ca2+ binding proteins, parvalbumin (PVALB) is encoded by the 
PVALB gene on chromosome 22q12-q13.1. This Ca2+ sensing and/or buffering protein contains 
a pair of EF-hand motifs capable of binding two Ca2+ ions with high affinity leading to 
conformational change (Belge et al., 2007). In 1986, renal DCT specific expression of PVALB 
was first characterised in rats (Schneeberger & Heizmann, 1986), and later in 2001, also 
profiled in mouse kidneys where expression was specifically confined to the early portion of 
the DCT (DCT1) colocalising with NCC (Loffing et al., 2001), as is also the case in human 
kidneys (Belge et al., 2007). As a result of this specificity, PVALB has been used in studies as 
a marker for distinguishing DCT1 (Grimm et al., 2012), which specifically expresses PVALB 
and NCC only with weak Calbindin D28K, from the late portion of the DCT (DCT2) which 
strongly expresses Calbindin D28K but not PVALB with a progressive decline in NCC 
expression and rise in ENaC  expression along the DCT2 as it approaches the connecting tubule 
(CNT) (Câmpean et al., 2001; Loffing et al., 2001). 
The role of PVALB in the DCT has been somewhat of a mystery for a while and has 
been postulated to play a role in Ca2+ and Mg2+ transport activity (Câmpean et al., 2001). 
Although it was Belge et al that demonstrated that PVALB in fact has an important functional 
role in the maintenance of NCC expression; but is not likely to have a direct role in DCT 
transport of Ca2+ or Mg2+  (Belge et al., 2007; Belge & Devuyst, 2010). Using PVALB-KO 
mice they demonstrated decreases in NCC, WNK1 and WNK4 expression at mRNA and 
protein levels  (Belge et al., 2007; Zacchia & Capasso, 2008). Interestingly this relationship 
with NCC is also apparent in SPAK-KO mice where SPAK has been found to be necessary for 
DCT1 integrity. Mass and lengths of DCT1 are severely diminished with corresponding 
decreases in NCC and PVALB in SPAK-KO mice when compared with WT (Grimm et al., 
2012).  
Using mouse DCT cell lines, the expression of NCC was found to be Ca2+-dependent 
and can be modulated by parvalbumin levels which in turn regulate intracellular Ca2+ 
signalling. This novel finding places parvalbumin as an important player within the intricate 
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network of NCC regulators; although work has not been done to elucidate if the effects of its 
control are solely at the level of NCC membrane abundance or if phosphorylation status is 
affected via PVALB regulation of WNK1 or WNK4. Perhaps most strikingly was their 
discovery that PVALB-KO impairs the diuretic response to hydrochlorothiazide and induces 
marked hypocalciuria when compared with WT; possibly due to several tubular compensatory 
mechanisms  (Belge et al., 2007). At first the discovery of a PVALB-KO phenotype akin to that 
seen in Gitelman syndrome patients was a source of great excitement (Zacchia & Capasso, 
2008),  however initial evaluation of PVALB as a candidate gene for SLC12A3-negative cases 
of Gitelman syndrome revealed no hits within this subset of patients (Riveira-Munoz et al., 
2008). This does not however preclude a role for mutations of the PVALB gene contributing to 
the pathophysiology of other distal tubulopathies or indeed variations in individual patient 
response to thiazide diuretics (Belge & Devuyst, 2010). 
 
1.3.7  RasGRP1/Nedd4-2: Negative regulation of NCC by endocytosis 
Work published by the Hoover group in 2007 (Ko et al., 2007) and 2010 (Ko et al., 2010), was 
the first to demonstrate the role of an endocytotic process in NCC activity regulation. Through 
the use of phorbol ester, TPA, a functional analog of diacylglycerol (DAG) they stimulated the 
Ras guanyl-releasing protein 1 (RasGRP1) which triggered a cascade activating the ERK1/2 
MAPK pathway resulting in a decrease of NCC activity in vitro (Ko et al., 2010). They 
discovered that activation of the ERK1/2 MAPK pathway by TPA simulated RasGRP1 activity 
that was independent of protein kinase C (Ko et al., 2007), and the decrease in NCC activity 
was mediated by a decrease of NCC membrane expression by an active promotion of dynamin-
dependent endocytosis. This process relied on ubiquitination of NCC by ERK1/2, which could 
be disabled by inhibition of ubiquitin-activating enzyme E1 with UBEI-41 (Ko et al., 2010). 
How this pathway may be activated in vivo still awaits further investigation.  
Later in 2011, a second system of NCC endocytosis was discovered involving 
aldosterone, SGK1 and the ubiquitin-protein ligase neuronal precursor cell expressed 
developmentally down-regulated protein (Nedd4-2). This pathway had previously been 
characterised in the regulation of ENaC (Abriel & Staub, 2005; Rotin & Staub, 2012), but 
through in vivo site-specific conditional knock-out of Nedd4-2 in renal tubules, it was also 
discovered to be involved in NCC regulation (Arroyo et al., 2011). In vivo, Nedd4-2 interacts 
with NCC to cause ubiquitination and endocytosis; though once Nedd4-2-KO is induced the 
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DCTs of these mice exhibit a huge increase in NCC expression (Arroyo et al., 2011). In 
Xenopus oocyte and HEK-293 cell work they demonstrated that SGK, a mediator of 
aldosterone action, regulates NCC expression indirectly by inhibiting Nedd4-2 through S328 
and/or S222 phosphorylation, and can interact with NCC directly to compete with and prevent 
Nedd4-2-mediated inhibition of NCC (Arroyo et al., 2011). The importance of SGK1 in this 
process is emphasised with in vivo kidney specific knock-out of SGK1 which results in a 
hypotensive sodium-wasting phenotype with reduced NCC expression (Rotin & Staub, 2012). 
 
1.4   Extrarenal roles of the WNK Pathway 
[This section is principally based on content from the paper in Appendix 2 (Siew & 
O’Shaughnessy, 2013)] 
 
Although the research focus has been predominantly on the renal functions of WNKs, they are 
both highly conserved among various species and widely expressed in a variety of tissues, 
suggesting many more diverse physiological roles (Xu et al., 2000; Veríssimo & Jordan, 2001; 
Wilson et al., 2001; O’Reilly et al., 2003; Vidal-Petiot et al., 2012). It has been proposed that 
the WNK–STE20 interactions and functions are evolutionarily ancient, conserved over 
millions of years and having coincided with the evolution of multicellularity and polarised 
epithelia. This is demonstrated in Caenorhabditis elegans, in which interference of this system 
causes a complete breakdown of osmotic homeostasis and drastically reduces survivability in 
response to hypertonic-induced shrinkage (Choe & Strange, 2007; Lee et al., 2010). In fact, 
the various biological roles of WNKs may be evidenced in the other features of Gordon 
syndrome, which include hyperchloraemic metabolic acidosis, hypercalciuria with 
accompanying low bone mineral density (BMD) and, in some cases, dental abnormalities, short 
stature, muscle weakness and intellectual impairment (Licht et al., 1985; Mayan et al., 2002). 
 
1.4.1   Musculoskeletal system 
Osteoporosis, marked by an abnormally low BMD, has been linked with a downregulation of 
WNK1 and a rare mutation in Exon 17 of WNK4 that does not cause hypertension (Xiao et al., 
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2008; Mendes et al., 2011). In addition, Gordon syndrome patients and mice with the same 
WNK mutations have been documented with hypercalciuria, low BMD, short stature and dental 
abnormalities (Licht et al., 1985; Mayan et al., 2002, 2004; Yang et al., 2010a). Another 
monogenetic disease, namely Gitelman syndrome, which is the phenotypic mirror of Gordon 
syndrome, is caused by loss-of- function mutations in NCC, the downstream target of WNKs. 
Gitelman syndrome patients and mouse models with inactive NCC or disrupted WNK–SPAK 
signalling exhibit a high BMD, hypocalciuria, and in some cases hypophosphataemia and 
hyperphosphaturia (Nicolet-Barousse et al., 2005; Akhtar & Hafeez, 2009; Rafiqi et al., 2010; 
Yang et al., 2010c; Viganò et al., 2012; Pathare et al., 2012). A report also suggests that Ca2+ 
increases the positive actions of WNK4 on NCC activity by enhancing OSR1 phosphorylation 
and that Gordon syndrome mutations disrupt the sensitivity of WNK4 activity to Ca2+, locking 
it chronically in a Ca2+-activated type state (Na et al., 2012). These data provide strong support 
for the hypothesis that WNKs regulate bone, PO43- and Ca2+ homeostasis.  
Data from as far back as the late 1960s show a link between thiazides and increased 
BMD, hypocalciuria and hypophosphataemia, suggesting the role of WNKs in bone 
homeostasis was indirect and via renal Ca2+ homeostasis (Condon & Nassim, 1970; Rejnmark 
et al., 2003; Olmos et al., 2010). This was further supported by research showing that the renal 
transient receptor potential vanilloid (TRPV) ion channels involved in Ca2+ transport are WNK 
regulated. In fact, TRPV5 expression is localised to the apical membrane of the DCT, the 
nephron segment involved in active Ca2+ reabsorption, which is positively regulated by both 
WNK4 and WNK3 (Jiang et al., 2006, 2008; Zhang et al., 2008; Jing et al., 2011). Interestingly 
coexpression of NCC with WNK4 and TRPV5 in vitro blocks the positive regulatory effect of 
WNK4, which is consistent with the changes in NCC activity and altered Ca2+ homeostasis 
observed in Gordon or Gitelman syndromes and may also account for thiazide-induced 
hypocalciuria (Jiang et al., 2006). In contrast, TRPV6, which is expressed along the DCT and 
adjacent CD, is regulated by WNK3 (but not WNK4) in a similar manner to TRPV5 (Zhang et 
al., 2008). However, TRPV6 is considered to be a minor player in Ca2+ reabsorption and 
although upregulated in knock-in mice carrying a WNK4 mutation known to cause Gordon 
syndrome, this does not correct the hypercalciuria phenotype (Yang et al., 2010a). 
The NCC and TRPVs are not restricted to the kidney. Hence, NCC and TRPV6 are 
expressed in the small intestine and may be involved with intestinal Ca2+ absorption under 
WNK–SPAK/OSR1 regulation (Bazzini, 2005; Lieben & Carmeliet, 2012; Pasham et al., 
2012a). Thiazides also inhibit intestinal NCC, suggesting that the gut may be important for the 
51 
 
increased BMD seen in both Gitelman syndrome and thiazide-treated patients (Bazzini, 2005). 
Furthermore, NCC and TRPVs have been implicated in osteocyte, osteoblast and osteoclast 
function, thus representing a second avenue for WNK regulation of Ca2+, PO43- and bone 
homeostasis. Numerous studies have shown osteoblasts, the cells responsible for new bone 
formation, express NCC and can be influenced by thiazide administration in vitro. For example, 
pharmacological inhibition of NCC has been shown to induce membrane depolarisation, 
increase intracellular Ca2+, promote osteoblast differentiation and raise alkaline phosphatase 
activity, which stimulates bone mineralisation (Aubin et al., 1996; Barry et al., 1997; Lalande 
et al., 2001; Dvorak et al., 2007). This antiresorptive effect observed during chronic thiazide 
treatment or Gitelman syndrome is compounded by osteoclast inhibition and hence a reduction 
in their usual catabolic effect on bone and release of Ca2+ and PO43- stores. Osteoblasts produce 
macrophage colony stimulating factor (M-CSF), which promotes recruitment and 
differentiation of precursor osteoclast cells; thiazides have been shown to reduce levels of M-
CSF (Aubin et al., 1996; Lalande et al., 2001). However, thiazides may have direct effects on 
osteoclasts, because a subpopulation express NCC (Hall & Schaueblin, 1994; Dvorak et al., 
2007) and NCC-null mice are reported to have a significantly reduced endosteal osteoclastic 
surface in long bones such as the femur (Nicolet-Barousse et al., 2005). Osteoclasts also 
express TRPV5 on their apical membrane, which is regulated by WNK4 and NCC and provides 
another mechanism to explain the dichotomous BMD in Gitelman and Gordon syndrome 
(Lieben & Carmeliet, 2012). The close paralogue TRPV4 is expressed on the basolateral 
membrane of osteoclasts and is essential for regulating intracellular Ca2+ and differentiation 
but, in contrast with the other TRPVs, WNK4 and WNK1 have been shown to decrease surface 
expression of TRPV4 (Fu, 2006; Lieben & Carmeliet, 2012). Perhaps it is disruption of this 
dynamic regulation of TRPVs and NCC in osteoblasts and/or osteoclasts caused by WNK 
mutations that leads to a low BMD in Gordon syndrome rather than isolated alterations in renal 
Ca2+ homeostasis. A graphical representation of these mechanisms can be seen in (Figure 1.12). 
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Figure 1.12: WNK kinases in Ca2+ homeostasis. 
Transient receptor potential vanilloid (TRPV) ion channels allow the influx of Ca2+ into cells for the 
purposes of absorption, reabsorption and regulating bone homeostasis. The TRPV5/6 channels, present 
in the kidneys and small intestine, enable the transport of Ca2+ from the lumen into the blood. In 
addition, TRPV5 is present on the bone-facing side of osteoclasts for bone resorption. Basolateral 
TRPV4 activity stimulates osteoclast differentiation, as does the release of macrophage colony-
stimulating factor (M-CSF) from osteoblasts, which are themselves stimulated to differentiate by 
TRPV6 activity. These TRPV channels are regulated directly by WNKs and indirectly by the actions 
of WNKs on the Na+-Cl- cotransporter (NCC). As a result, Gordon syndrome patients present with low 
bone mineral density and hypercalciuria, whereas chronic thiazide (HCTZ) treatment indirectly elicits 
the opposite phenotype via effects on the NCC. Green-pointed arrows indicate stimulation; red flat 
arrows indicate inhibition; dashed lines indicate diminished effect, and the size and thickness of the 
NCC and TRPV symbols and arrows represent the relative strength of the activity and/or effect. Cell 
diagrams are orientated so that the basement membrane is uppermost and apical on the bottom. Gordon 
syndrome WNK4 mutations (mWNK4); Differentiation and proliferation (growth); Blood Ca2+ 
concentration ([Ca2+]B). [Taken from (Siew & O’Shaughnessy, 2013)]. 
 
Perhaps the least understood aspects of Gitelman syndrome and chronic thiazide 
administration, namely the hypophosphataemia and/or hyperphosphaturia observed in animal 
models and handful of patient case reports, may also be explained by integrated signalling 
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between kidney, osteoblasts and osteocytes governed by the WNK signalling pathway (Condon 
& Nassim, 1970; Katopodis et al., 1996; Viganò et al., 2012; Pathare et al., 2012). Fibroblast 
growth factor (FGF) 23 is produced by osteoblasts and osteocytes and acts as a potent inhibitor 
of PO43- reabsorption in the renal proximal convoluted tubules (PCT) and of calcitriol (1,25-
(OH)2D), a promoter of intestinal Ca2+ and PO43- absorption and renal Ca2+ reabsorption (Liu 
& Quarles, 2007). Of note, the initial FGF23-mediated signalling that takes place within the 
DCT occurs in tubules adjacent to PCT tubules, where PO43- reabsorption is reduced, 
suggesting a paracrine action (Farrow et al., 2009). This may be necessary if the fine-tuning of 
Ca2+ homeostasis is to take place in the DCT. Production of FGF23 is increased with rising 
plasma Ca2+ levels and shares a strong positive exponential correlation with the Ca2+ x PO43- 
product (Quinn et al., 2012; Rodriguez-Ortiz et al., 2012; Yasin et al., 2013). When the 
presence of NCC and TRPV6 in osteoblasts and osteocytes is taken into account (Dvorak et 
al., 2007; Little et al., 2011), it is possible to imagine that changes in phosphate excretion are 
elicited by osteoblasts and/or osteocytes in an attempt to correct an abnormal Ca2+ x PO43- 
product and prevent calciphylaxis, which becomes exaggerated in Gitelman syndrome and 
thiazide treatment or dysfunctional when WNK–STE20 signalling is disturbed (Quinn et al., 
2012; Pathare et al., 2012; Yasin et al., 2013). 
1.4.2  Cardiovascular system 
Early attempts to investigate WNK function in vivo suffered several setbacks as the phenotype 
of WNK1 homozygote knock-out (KO) mice proved to be embryonically lethal. However this 
difficulty did at least confirm the importance of WNK1 for early cardiovascular development. 
Hence, WNK1 is highly expressed in the early heart, endothelium of blood vessels and in the 
extra-embryonic tissues, including the placenta and yolk sac (Delaloy et al., 2006). It is 
probably no surprise that WNK1 homozygote KO embryos developed obvious cardiovascular 
malformations, including smaller heart chambers, reduced myocardial trabeculation and 
underdevelopment of yolk sac vasculature, failed angiogenesis and aberrant gene expression 
within vascular tissues. The changes led to death before embryonic day 13 (Gamba, 2005). The 
absence of WNK1 from endothelial tissues appears to be the key problem, because the 
phenotype of endothelial-specific KO mice closely matched that of global KO, and global KO 
tissues could be rescued with endothelial-specific transgenic expression of WNK1 (Xie et al., 
2009). The vasculopathy caused by WNK1-KO may extend to other members of the WNK 
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family; in a Japanese cohort, polymorphisms in WNK2 were associated with a higher incidence 
of intracerebral haemorrhage (Yoshida et al., 2010). In fact, Richard Gordon may have been 
premature in assuming that four cases of heart murmur and one of pulmonary stenosis were 
unrelated to Gordon syndrome (Gordon, 1986).  
The WNK1 heterozygote KO mice are viable, although present with a variable 
hypotensive phenotype. Pronounced nitric oxide independent reductions in the contractility of 
the thoracic aorta and mesenteric arteries, as well as a severe decrease in the myogenic response 
to resistance vessels, were also noted (Zambrowicz et al., 2003; Bergaya et al., 2011). The 
partial loss of WNK1 reduced the subsequent phosphorylation of SPAK by approximately 40% 
and, in turn, the phosphorylation of the bumetanide-sensitive Na+-K+-2Cl- cotransporter 1 
(NKCC1) by approximately 30%; both are present in arterial vascular smooth muscle (VSM) 
cells (Zambrowicz et al., 2003; Bergaya et al., 2011). Typically NKCC1 activity will increase 
Cl- influx, causing depolarisation and increased contraction of VSM cells (Orlov et al., 2012); 
however, this effect is diminished when the WNK–SPAK/OSR1 pathway is disrupted because 
NKCC1 activity is phosphorylation dependent. This was demonstrated by homozygote SPAK 
KO mice and heterozygote OSR1 KO mice that showed marked hypotension, significant 
reductions in aortic contractility, decreased levels of phosphorylated (p) NKCC1 and 
phenotypes that closely recapitulate Gitelman and Bartter syndrome, respectively (Yang et al., 
2010c; Lin et al., 2011). 
In addition, WNK4 has been implicated in the modulation of vascular tone by tonic 
inhibition of transient receptor potential canonical (TRPC) 3, which is a major component of 
the Ca2+-dependent vasoconstrictive mechanism. Using ex vivo tissues from rats, WNK4 was 
depleted via short interference (si) RNA silencing, which, in turn, increased apical membrane 
expression of TRPC3 in the VSM cells of mesenteric arteries, enhancing vasoconstriction (Park 
et al., 2011). The TRPC3 activity was also capable of inducing hypertrophic growth of VSM 
cell primary cultures when WNK4 was suppressed (Park et al., 2011), which, in vivo, would 
likely contribute to an increased vessel wall thickness/lumen diameter ratio, causing higher 
vascular resistance and lower vascular compliance. Coexpression of Gordon syndrome-causing 
WNK4 mutations in human cells with TRPC3 suggested that the mutations would have a 
reduced effect on TRPC3 inhibition in vivo (Park et al., 2011). This could raise vascular 
resistance and compound the systemic hypertension caused by salt retention in the DCT and 
subsequent hypervolaemia (Park et al., 2011). A graphical representation of these mechanisms 
can be seen in (Figure 1.13). 
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Figure 1.13: WNKs in vascular smooth muscle cells and the contribution to blood 
pressure control. 
As indicated, WNK4-stimulated Na+-K+-2Cl- cotransporter 1 (NKCC1) activity raises intracellular Cl-, 
depolarising the vascular smooth muscle cell (VSMC), triggering Ca2+ influx via L-type Ca2+ channels, 
which induces vasoconstriction; inhibition of NKCC1 results in vasodilatation. When WNK4 is mutated 
(mWNK4), it can no longer inhibit Ca2+ influx via transient receptor potential canonical (TRPC) 3 
channels and so intracellular Ca2+ increases, triggering intense vasoconstriction and hypertrophic 
growth of VSMC, thus increasing vascular resistance and reducing vascular compliance. Green-pointed 
arrows indicate stimulation; red flat arrows indicate inhibition; dashed lines indicate diminished effect, 
and the size and thickness of the NKCC1, TRPC3 and L-type symbols and arrows represent the relative 
strength of the activity and/or effect. Vasoconstrictor status and the ratio of wall thickness to lumen 
diameter are represented graphically with an example VSMC shown in frame. Sterile 20 kinase 
(STE20); Bumetanide (Bumet); Blood pressure (BP); Vascular resistance (VR); Vascular compliance 
(VC). [Taken from (Siew & O’Shaughnessy, 2013)]. 
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1.4.3   Nervous system 
It has become apparent in recent years that WNKs are more dynamic and complex than was 
first imagined. The WNKs have many yet uncharacterised splice variants with diverse tissue 
specific expression and functions (O’Reilly et al., 2003; Glover et al., 2009; Vidal-Petiot et al., 
2012). The latest focus of attention has been on a previously unknown isoform of WNK1 in 
which a nervous system-specific exon of WNK1, named WNK1/HSN2, when mutated causes 
hereditary sensory and autonomic neuropathy type 2 (HSAN2). Patients with HSAN2 lose 
peripheral sensory nerves and have limited or no perception of touch, heat or pain (Shekarabi 
et al., 2008; Potulska-Chromik et al., 2012). Interestingly, heterozygous carriers of the 
recessive WNK1/HSN2 mutation paradoxically experience heightened sensitivity to thermal 
stimuli (Loggia et al., 2009). Clues to the molecular basis of HSAN2 have come from 
transgenic zebrafish expressing mutant WNK1/HSN2; these fish have significantly increased 
K+-Cl- cotransporter 2 (KCC2) expression, which is known to be important in peripheral nerve 
development and control of intracellular Cl- concentrations, and it is this disruption of normal 
KCC2 expression that may account for pathogenic peripheral sensory nerve development 
(Bercier et al., 2013).  
A WNK3 brain isoform expressed in the nervous system regulates NKCC1 and KCC2 
by altering their phosphorylation state via SPAK/OSR1; pNKCC1 is activated and increases 
intracellular Cl-, whereas pKCC2 is deactivated and reduces the efflux of Cl- from the cell 
(Kahle et al., 2005; Glover et al., 2009). Therefore, WNK3 simultaneously promotes 
complementary actions on NKCC1 and KCC2. This regulation of intracellular Cl- is very 
important for neuronal excitability and is particularly relevant to GABA signalling (Kahle et 
al., 2005). This system may be important in the pathogenesis of autism, in which mutations in 
SPAK (Ramoz et al., 2008) and WNK3 (Qiao et al., 2008) have been identified. Further 
support has come from an intriguing small clinical trial involving five children with infantile 
autistic syndrome who were effectively treated with bumetanide, an inhibitor of NKCC1, 
decreasing their autistic behaviour over a 3 month period (Lemonnier & Ben-Ari, 2010). 
WNK3 may also be involved through its role in RNA processing by regulating the neuronal 
mRNA splicing factor Fox-1. Both WNK3 and Fox-1 are purported to have roles in 
neurodevelopment, so further research into the association of WNKs and autism is warranted 
(Lee et al., 2012a). 
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Numerous studies have linked mutations at virtually each point in the WNK2/WNK3–
SPAK/OSR1–NKCC1/KCC2 axis to the development of schizophrenia in which GABA 
signalling is dysfunctional (Arion & Lewis, 2011; Hyde et al., 2011; Kalkman, 2011; Wang & 
Kriegstein, 2011). Of particular note is the position of WNK3 on the X-chromosome, mutations 
in which may contribute to the higher number of males with schizophrenia and autism than 
females (Veríssimo & Jordan, 2001; Qiao et al., 2008). In normal health, developing neurons 
of the prefrontal cortex and hippocampus have a high NKCC1:KCC2 ratio, thus increasing 
intracellular Cl- under the control of WNK2–SPAK, and the resulting reversal potential ensures 
that GABAA receptor activation causes depolarisation. This excitatory behaviour of GABA is 
required for stimulating the differentiation and proliferation of neurons, as well as the growth 
and formation of dendrites and synapses. As the GABA system matures, the ratio is shifted 
from a high to low NKCC1:KCC2 ratio and becomes increasingly regulated by WNK3–OSR1, 
which reduces intracellular Cl- and shifts its reversal potential so that GABA becomes an 
inhibitory transmitter with GABAA receptor activation causing hyperpolarisation. However, in 
a large cohort of adult schizophrenic patients, the aberrant ‘immature’ GABA physiology 
remains intact with higher NKCC1:KCC2 ratios, lower KCC2 levels and a marked increase in 
WNK3 and OSR1 (Arion & Lewis, 2011; Hyde et al., 2011; Kalkman, 2011; Rinehart et al., 
2011). Perturbation of the signalling axis can also predispose people to or induce schizophrenia. 
For example, seizures that may be made more likely due to the increased neuronal excitability 
promote undesirable acceleration of neuronal development through increased GABA 
excitatory activity (Kalkman, 2011). Strikingly, Danish cohort studies found that those with a 
history of juvenile febrile seizures were at a 44% higher risk of schizophrenia, whereas those 
who also had a history of epilepsy were at a 204% increased risk (Arion & Lewis, 2011). 
However, inappropriate pharmacological manipulation of GABA physiology can also be 
dangerous, because early administration of bumetanide to inhibit NKCC1 activity in neonatal 
seizures can inhibit neuronal development and lead to inhibition of anxiety-related behaviours 
or impairment of the prepulse inhibition of the startle reflex; both are hallmarks of 
schizophrenia (Wang & Kriegstein, 2011). A graphical representation of these mechanisms can 
be seen in (Figure 1.14). 
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Figure 1.14: WNK, GABA and the development of schizophrenia. 
In the developing brain there is a higher ratio of Na+-K+-2Cl- cotransporter 1 (NKCC1) to K+-Cl- 
cotransporter 2 (KCC2), with activity regulated by WNK2. This raises intracellular Cl- due to increased 
influx from NKCC1 and reduced efflux from KCC2. This results in excitatory GABA signalling, which 
stimulates the differentiation and proliferation of neurons. Later in adulthood, WNK3 becomes the 
dominant regulator and the ratio of NKCC1:KCC2 is inversed, intracellular Cl- is decreased and GABA 
signalling becomes inhibitory. In the young brain, schizophrenia can be induced by environmental 
insult, such as febrile seizure, which can exaggerate the excitatory GABA signalling, leading to 
undesirable premature differentiation of neurons. This increased NKCC1 can persist into adulthood, 
accompanied by overexpression of WNK3/sterile 20 kinase (STE20), which leaves inappropriate 
GABA excitatory activity intact. Green-pointed arrows indicate stimulation; red flat arrows indicate 
inhibition; dashed lines indicate diminished effect, and the size and thickness of the WNK, STE20, 
NKCC1, KCC2 symbols and arrows represent the relative strength of the activity and/or effect. 
Intracellular Cl- concentration ([Cl-]ic); GABA excitatory activity (Excit); GABA inhibitory activity 
(Inhib); neuronal differentiation and proliferation (Growth). [Taken from (Siew & O’Shaughnessy, 
2013)]. 
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1.4.4   Immune system and cellular regulation 
As multicellular organisms evolved, so did the requirement to regulate an internal environment, 
maintain a secure external barrier, recover from injury and defend against hostile organisms 
and environmental insult. The WNKs–STE20 represent a signalling axis that integrates these 
things, and an early example can be seen in C. elegans, in which antimicrobial peptide 
neuropeptide-like protein 29 (nlp-29) is released in response to infection, wounds or osmotic 
stress. In C. elegans, WNK1 is activated when osmotic stress is detected, which may often be 
accompanied by infection or injury, and this in turn activates germinal centre kinase (GCK)-3 
(a STE20 kinase), which stimulates nlp-29 to trigger the maintenance of epidermal integrity 
and the innate immune system (Choe & Strange, 2007; Lee et al., 2010).  
In mammals, the role of WNKs in immunity and regulating cellular processes is 
conserved, although poorly understood. For example, WNK2 is a potent tumour suppressor, 
inhibiting up to 78% of glioma cell colony formation in vitro (Hong et al., 2007). Deletions 
and epigenetic silencing of WNK2 strongly correlate with certain central nervous system 
cancers (Hong et al., 2007). For more detailed reviews of WNKs and cancer than is provided 
here, readers are referred to (McCormick & Ellison, 2011) and (Moniz & Jordan, 2010). It has 
been demonstrated that WNK1 and WNK3 can independently, or in synergy with IL-1, increase 
nuclear factor-κB (Pichlmair et al., 2012), a major component of the mammalian innate and 
adaptive immune response. However, WNK1 and WNK3 are also viral targets for disruption 
as part of a viral strategy to impair the host immune response; WNK3 and IL-1, which can 
stimulate IL-8, can also be potently inhibited by the K7 protein of the Vaccinia virus (Pichlmair 
et al., 2012). 
Dendritic cells, which are the antigen-presenting cells that bridge the gap between 
innate and adaptive immunity, express WNK1, WNK3, OSR1, NCC and NKCC1. These cells 
in OSR1 heterozygote KO mice have lower levels of pNKCC1, but higher baseline Na+/H+ 
exchanger activity and increased production of reactive oxygen species. One would assume 
this is beneficial for fighting off pathogens, although, when responding to oxidative stress or a 
foreign antigen, the responses of normal dendritic cells were significantly blunted, illustrating 
the importance of an intact WNK–OSR1–NKCC1 axis for immunity (Pasham et al., 2012b). 
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1.5  Aims 
Given the mounting evidence for the WNK pathway in the regulation of blood pressure and 
electrolyte homeostasis, it has become an intense area of focus for prospective anti-
hypertensive drug targets or to further elucidate the mechanisms which underlie hypertension. 
With this trend in mind, the study had three objectives: 
1) To investigate the aetiology of PHA2E, the most severe form of Gordon syndrome,
with the goal of developing novel anti-hypertensive strategies. Recent evidence
supports a role for the WNK pathway in vascular physiology, and it was hypothesised
an additional vascular phenotype drove the early onset and intensity of hypertension
seen in PHA2E patients.
2) Explore MO25 as an anti-hypertensive drug target. As MO25 is known to be involved
in WNK-independent activation of CCCs, its ablation was hypothesised to lower blood
pressure.
3) Verify SPAK binding disruption as a viable anti-hypertensive strategy for drug
targeting. As loss of SPAK signal by genetic knock-out or inhibition of kinase activity
produces Gitelman syndrome, it was hypothesised that genetic disruption of SPAK
binding to its regulator and substrate would do the same.
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Chapter 2 : Materials & Methods 
 
[This chapter is principally based on and expands upon the content from the abstracts in 
Appendix 1, and papers in Appendix 3 (Schumacher et al., 2015)] and Appendix 4 (Zhang et 
al., 2015). 
 
2.1  Mus musculus Animal Models 
All animal procedures were approved by local ethical committees and performed under a UK 
Home Office-approved licence in accordance with the regulations set by the Universities of 
Cambridge and Dundee. 
 
2.1.1  Generation  
Taconic Biosciences (formerly Taconic Artemis) generated two constitutive knock-in mouse 
models; a deletion of CUL3 exon 9 (Δ403-459) and a leucine to alanine mutation at SPAK 
residue 502 (L502A). In brief, targeting vectors containing the desired mutations were 
constructed, cloned and sequenced before electroporation into competent germline 
C57BL/6NTac embryonic stem cell lines. After homologous recombination, clones with 
targeted alleles containing the positive selection puromycin cassette (which was later removed 
by Flp recombinase) were isolated, validated, injected into mouse blastocysts and transferred 
into pseudo-pregnant females (Figure 2.1; Figure 2.2). The resulting chimeras were bred with 
wild-type mice to ensure germline transmission and produce heterozygous founder males and 
females on a C57Bl/6N background. 
The MO25β null (MO25β-/-) mice on a C57BL/6 x CBA mixed background were 
sourced as frozen embryos from the CARD resource at the University of Kunamoto, Japan. To 
generate this model the MO25β allele was gene trapped at the first exon by using the pU-21W 
promotor trap vector (http://egtc.jp/action/access/vector_detail?vector=pU-21W) on the 
KTPU8 embryonic stem cell line (http://egtc.jp/action/access/cellline_detail?cellline=KTPU8) 
to produce the strain B6;CB-Cab39lGt(pU-21W)191Card (http://cardb.cc.kumamoto-
u.ac.jp/transgenic/strainsDetailAction.do?strainId=1287).  
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Figure 2.1: CUL3 mouse model generation. 
The knock-out strategy of exon 9 of endogenous Cullin3. The endogenous allele is represented and the 
target allele with the puromycin cassette (PuroR) removed by Flp recombinase. The black rectangles 
represent exons, the flippase-recognition target (FRT) sites and primer targets (Oligo) for PCR-based 
genotype confirmation are indicated. [Taken from (Schumacher et al., 2015)]. 
 
 
Figure 2.2: SPAK mouse model generation. 
Diagram depicting the knock-in construct, the endogenous SPAK allele containing exons 15–16 and 
the targeted allele with the puromycin cassette removed by Flp recombinase. The black rectangles 
represent exons, and the grey triangles represent FRT sites. Black lines with arrowheads are used to 
indicate the positions of the probes used for Southern analysis. The knock-in allele containing the 
Leu502Ala mutation in exon 16 is illustrated as a grey rectangle. The knock-in allele can be detected 
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by genotyping using PCR primers (P1 and P2), which are represented by short black lines with 
arrowheads. [Taken from (Zhang et al., 2015)]. 
 
2.1.2  Genotyping 
Genomic DNA (gDNA) from ear and tail biopsies were isolated from samples collected at 3-4 
weeks of age for initial genotyping and again post-mortem for genotype confirmation. 
Genotyping was achieved by standard PCR amplification of gDNA and gel-electrophoresis 
analysis to identify bp lengths of products produced by specific alleles; performed by Gail 
Gilmour and Elaine Forsyth (MRC Protein Phosphorylation and Ubiquitylation Unit, 
University of Dundee). The PCR program consisted of 2 min at 95 °C; 30 s at 95 °C, 1 min at 
60 °C and 1 min at 72 °C: 35 cycles; 10 min at 72 °C. The following primers were used for 
CUL3 mice (Figure 2.1), primer 1: (oligo 1: AAA CTT ACC CAC TTG TTT GCC) and primer 
2: (oligo 2: AGA CAT CTC AGG TTA CTA TGG GC). The CUL3WT allele generate a 683 bp 
product and CUL3Δ403-459 allele generates a shorter 395 bp product. For the SPAK (Figure 2.2), 
Forward Primer (P1: GTC TAG GAC ATG ATG GTA TGG) and Reverse Primer (P2: CCA 
ACA TGG GGT ACC AAC AAA TGC) were used to detect the wild-type and knock-in alleles. 
The SPAKWT generates a 587 bp product whereas the SPAKL502A generates a 679 bp product. 
The larger knock-in allele product is due to the presence of the FRT site and flanking region, 
which remains in an intronic region following Flp-mediated excision of the puromycin 
resistance (PuroR) selection cassette. The genotypes MO25β mice were identified by utilising 
forward primer (ACA CCC CTC CCA ACT TTG TA), reverse primer (GGC CAC TAC GTG 
CTA AGA GG), and a second reverse primer targeting the pU-21W elements (CCT GGC CTC 
CAG ACA AGT AG) to detect the presence of the MO25β+ (larger product) or MO25β- 
(smaller product) alleles. 
Additionally, to confirm correct amino acid substitution for SPAK founder mice the 
resultant PCR products were ligated into the pCR-Topo 2.1 vector and transformed into E. coli, 
and clones were sequenced. DNA sequencing was performed by The Sequencing Service, 
College of Life Sciences, University of Dundee. 
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2.1.3  Animal Care and Husbandry 
Mice were maintained under specific pathogen-free (SPF) conditions in individually ventilated 
cages (IVC) at Temp: 19-23 ºC, Humidity: 40-70%, Air Changes: 12-15 per h, Daylight: 12 h 
daily. All mice were group housed 2-6 per cage, food and water was given ad libitum (unless 
otherwise stated) and cages were changed regularly by animal technicians (Biological Services, 
Wellcome Building Resource Unit, University of Dundee).  
CUL3WT/Δ403-459 heterozygote X CUL3WT/WT wildtype breeding pairs were established 
for generating heterozygote experimental group CUL3WT/Δ403-459 and wild-type control group 
CUL3WT/WT littermates. MO25β+/- X MO25β+/- heterozygote breeding pairs were established 
for generating homozygote experimental group MO25β-/- and wild-type control group 
MO25β+/+ littermates. SPAK+/L502A X SPAK+/L502A heterozygote breeding pairs were 
established for generating homozygote experimental group SPAKL502A/L502A and wild-type 
control group SPAKWT/WT littermates. Excess SPAK+/L502A and MO25β+/- heterozygotes were 
either culled or used for establishing new breeding pairs.  
 
2.2  Physiology and Anatomy 
Data collection and analyses were carried out in a blinded fashion throughout, where possible. 
 
2.2.1  Body Fluid Analysis 
 
2.2.1.1  Creatinine Assay 
Plasma and urine (non-acidified) creatinine levels were assayed by standard Jaffe reaction or 
enzymatic method performed by Keith Burling, Peter Barker and Ashley Clarke (Core 
Biochemical Assay Laboratory, Addenbrooke’s Hospital, Cambridge, UK). 
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2.2.1.2  Fasting Blood Gases and Electrolytes 
To reduce variability introduced by dietary potassium ingestion, animals were fasted for a 4 h 
minimum before being anaesthetised with isoflurane on 100% O2 (induction: 3% v/v, 
maintenance: 1.75% v/v) and placed on a self-regulating rectal probe-coupled heat mat (TC-
1000; CWE) to maintain a body temperature of 37 °C. To minimise air contact of arterial bloods 
during measurements, the right carotid artery was cannulated with a mouse arterial catheter 
(MAC-02; SAI Infusion Technologies) pre-flushed with 10 U heparin-0.9% w/v saline to 
prevent clots. Blood was released via the catheter into the EC8+ cartridge for analysis on the 
iSTAT (Abaxsis).  
 
2.2.1.3  Diet Manipulations and Longitudinal Electrolyte Measurements 
To determine baseline plasma and urine electrolyte homeostasis animals were placed on a 
normal diet containing either 0.25% or 0.3% w/w Na for 2 weeks with urine and plasma time-
matched samples collected between days 7-10 for normal Na (NNa) diet baseline. On day 14 
mice were switched onto a 0.03% w/w Na diet with sampling repeated on days 7-10 for low 
Na (LNa) diet measurements.  
To provide a physiological challenge for renal salt handling some animals were sodium 
loaded on a 3% w/w Na diet for 14 days with urine and plasma samples collected between days 
7-10 for High Na (HNa) diet measurements. On day 14 mice were switched onto a 0.03% w/w 
Na diet (LNa) with urine samples collected at 0, 3, 6, 12, 24 h after Na-diet switch to investigate 
the rapid renal adaptive response to salt restriction. 
Spot urine was collected from awake mice following spontaneous micturition upon 
handling over a sheet of Saran wrap or Parafilm. Samples were then divided and one sample 
received acidification with HNO3 to a final concentration of 1% v/v to prevent precipitation of 
electrolytes, before both were stored at -80 °C. Blood was collected with heparin-coated 
Microvette CB 300 LH (Sarstedt) by saphenous venepuncture in awake restrained animals or 
in the case of MO25β mice, by post-operative exsanguination via cardiac puncture in animals 
under terminal anaesthesia.  Plasma was separated by centrifuged at 2,000 g for 5 min and 
collected for storage at -80 °C. To avoid affecting blood pressure or electrolyte homeostasis in 
longitudinal studies, blood collection intervals were spaced such that no more than 10% of total 
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blood volume was taken on any single occasion or 25% of total blood volume in any 28 day 
period. 
Where sample volumes permitted, MO25β samples were analysed using the Siemens 
Dimension RxL Max Integrated Chemistry System, performed by Keith Burling, Peter Barker 
and Ashley Clarke (Core Biochemical Assay Laboratory, Addenbrooke’s Hospital, Cambridge, 
UK). Otherwise, plasma or urine electrolytes were determined using an inductively coupled 
plasma – optical emission spectrometer (ICP-OES Analyser; Perkin Elmer) at the Cambridge 
Geography Science Laboratories (coordinated by Chris Rolfe, Steve Boreham and Samantha 
Smith). 
Prior to ICP-OES analysis, plasma and urine (acidified) samples were defrosted, 
vortexed and centrifuged for dilution at 1:1000 using ultra-pure polished water containing 1% 
v/v HNO3 in new unopened 15 mL conical centrifuge tubes (Falcon) with the same pipette to 
reduce error. Fresh acid-washed glassware was rinsed three times with ultrapure polished water 
and new unopened pipette tips were used to minimise possible contaminants. Cations were then 
measured by an ICP-OES Analyser equipped with an argon plasma torch and programmable 
autosampler.  Optima blank nitric acid solution and concentration standards in Table 2.1 were 
used to zero the device and generate calibration curves.  
 
Element Calcium Potassium Magnesium Sodium Phosphorous 
Wavelength (nm) 317.933 766.490 285.213 589.592 213.617 
Standard (mg/L) 1 1 1 1 5 
Table 2.1:  ICP-OES element wavelength detection peaks and standards. 
 
Three consecutive measurements were taken per analyte for all 5 elements, followed by a nitric 
acid flush between samples to prevent cross contamination. Samples to be compared were 
analysed in the same session, with urines and plasmas grouped according to dietary 
manipulation. To quantify detector drift, sample groups were bookended with confirmatory 
measurements of the same optima blank and concentration standards used for calibration. A 
sample blank containing 1% v/v of the original HNO3 used to acidify the urine was diluted 
1:1000 in the same solution and tubes as above. This was used to quantify trace contamination 
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from the HNO3 sources, ultra-pure polished water system and leaching from plastic and 
glassware. 
The average and relative standard deviation the three readings are automatically 
calculated and exported into an Excel spreadsheet (Microsoft) for data processing. Samples 
that had abnormally high relative standard deviation, evidence of haemolysis, evaporation or 
insufficient volume were excluded from the analysis. Assuming detector drift is linear, a 
correction factor can be applied using the following formula: (raw values between A and B) x 
(known concentration of standards / average of measures for bookend standards A and B) – 
(average of Optima blanks A and B). The drift corrected sample blank measurements can then 
be subtracted from all drift corrected values to account for trace contaminants. Sample blank 
corrected values are then adjusted for dilution factors (from acidification of urine and sample 
preparation for ICP-OES analysis) converted from mg/L to mMol/L. Urinary electrolytes were 
then normalised against creatinine levels determined in section 2.2.1.1. 
 
2.2.1.4  Aldosterone Assay 
Post-surgery, additional blood samples were collected using heparin-coated Microvette CB 300 
LH (Sarstedt) from animals used in section 2.2.1.2. Samples were centrifuged at 2,000 g for 5 
min to extract plasma before storage at -80 °C.  
Plasma aldosterone was calculated by HTRF (homogeneous time-resolved 
fluorescence) aldosterone assay (cisbio Codolet, France), performed according to 
manufacturer’s protocol using the PheraStar FS (BMG labtech) plate reader by Irish Hardege 
(University of Cambridge). 
 
2.2.2  Cardiovascular Assessment 
When groups of animals were being compared, the order of animals selected for procedures 
was randomised. 
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2.2.2.1  Experimental Setup and Animal Preparation 
In order to record and monitor physiological parameters in real-time, custom LabChart version 
6/7/8 pro (AD Instruments) settings template files were created to display 3 raw data channels 
- Blood pressure, ECG, body temperature and 5 calculate channels - mean arterial pressure, 
systolic blood pressure maximum, diastolic blood pressure maximum, BP first derivative 
maximum and heart rate. For vasopressor experiments a separate settings template file was 
created that had additional windows to monitor and analyse dose responses in real-time. 
At the start of each recording session the 1F Mikro-Tip pressure transducer (SPR-1000; 
Millar) was soaked in 0.9% w/v saline solution to allow for equilibration. A two-point 
calibration was performed by securing the catheter in a sealed water filled chamber connected 
to an aneroid sphygmomanometer with 10 s recordings taken at 0 mmHg and 100 mmHg. 
Between animals the pressure transducer two-point calibration was confirmed and adjusted to 
account for drift if necessary.  
For MO25β blood pressure recordings a polyurethane mouse arterial catheter (MAC-
2B; SAI Infusion Technologies) attached to a physiological pressure transducer (MLT844, AD 
Instruments) was used. The transducer received the pressure signal through a disposable clip-
on BP Dome (MLA844, AD Instruments), which in turn was connected to 3-way stopcocks on 
the front and back ports. The front end 3-way stopcock was connected to the catheter and a 5 
mL syringe filled with 500 U/mL heparin solution used to prime and clear the catheter between 
uses, while the back port 3-way stopcock was connected to an air filled 60 mL syringe and 
mercury sphygmomanometer used for calibration. To avoid air bubbles in the fluid column that 
may dampen the pressure signal, the set-up was assembled under water. A two-point calibration 
was performed by opening the back port 3-way stopcock to connect the air filled syringe and 
sphygmomanometer to the system for 10 s recordings at 0 mmHg and 140 mmHg. Between 
animals the pressure transducer two-point calibration was confirmed and adjusted to account 
for drift if necessary. 
Animals (at least 2 months old) were anaesthetised by gas inhalation of isoflurane 
(chamber induction: 3% v/v with 4 L/min 100% oxygen / nose-cone maintenance: 1.75% v/v 
with 1.5 L/min 100% oxygen).  To minimise stress, animals scheduled for surgery were placed 
in a separate holding room and the surgical space was cleaned between uses to avoid sight, 
sound and smell exposure to urine, blood or carcasses, whilst anaesthetic induction was 
performed in a small red-tinted chamber which was cleaned and voided with 100% oxygen 
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between animals. Once transferred to the nose-cone and depth of anaesthesia was confirmed 
by the absence of self-righting, blinking and pain-withdrawal reflexes. Using surgical tape mice 
were secured with limbs extended in the supine position on a self-regulating rectal probe-
coupled heat mat (TC-1000; CWE) which maintained a body temperature of 37 °C. ECG Lead 
II was recorded using an animal bio amp (FE136; AD Instruments) with needle electrodes 
inserted subcutaneously into fore and hind limbs (MLA1213; AD Instruments). Fur around the 
neck area was shaved with an electric trimmer, and under a dissecting microscope the right 
carotid artery was catheterised (Figure 2.3) with either a 1F Mikro-Tip pressure transducer 
(SPR-1000; Millar) or 1F polyurethane mouse arterial catheter (MAC-2B; SAI Infusion 
Technologies) attached to a physiological pressure transducer (MLT844, AD Instruments), 
which were connected to a bridge amp (FE221 or ML221; AD Instruments) and powerlab 
system (PL3504/P or ML866; AD Instruments). When the animals had acclimated and 
stabilised, recordings of body temperature, ECG and blood pressure pulse waveforms were 
captured at 2000 samples/s using LabChart version 6/7/8 pro (AD Instruments).  
For vasopressor experiments, a length of polyurethane tubing suitable for a 25G needle 
(MAC-02; SAI Infusion Technologies) was measured and cut to ensure its internal volume was 
< 10 µL. After baseline measurements were recorded the right external jugular vein was 
cannulated with a saline filled length of tubing attached to a 10 µL Hamilton syringe. Once 
secure, the cannula was cleared by flushing three times with 10 µL of saline using pre-filled 10 
µL Hamilton syringes and the animals was left to acclimate and stabilise before administering 
vasopressors. 
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Figure 2.3: Surgical catheterisation of major blood vessels. 
[1] Mice were anaesthetised, shaved and secured to the heat mat; [2] A midline incision was made to 
expose subcutaneous (F) fatty tissue and salivary glands; [3] The tissue was then blunt dissected away 
to reveal the trachea (T); [4] A haemostat vice (V) is then used to hold the subcutaneous tissue clear of 
the site; [5] Another haemostat vice holds back skeletal muscles away from the carotid artery to provide 
more working space; [6] A thin layer of muscle and connective tissues (M) obscures access to the artery; 
[7] The carotid artery (A) and vagus nerve (N) are exposed by blunt dissection; [8] Care is taken to 
clean the artery and nerve from surrounding tissues with forceps; [9] The carotid artery is then separated 
from the vagus nerve so as to avoid crush injury during the procedure, which would alter blood pressure 
measurements; [10] Silk suture (S) is manoeuvred under the carotid; [11] The suture is then tied off 
distal to the heart to occlude blood flow and extend the artery; [12] A temporary clamp (C) is then 
placed proximal to the heart to occlude blood flow; [13] Another silk suture is loosely tied proximal to 
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the heart; [14] With a fine ophthalmic scissors (O) a small incision is made into the artery, distal to the 
clamp and loose suture knot; [15] The incision (I) should ideally be at a 30-45 ° angle, and any excess 
blood removed by cotton cue tip; [16] The area is then bathe in saline solution to avoid drying, and a 
Dumont forceps (D) is used to pry open the slit created by the incision; [17] The catheter (Ct) is then 
guided into the opening with the aid of the Dumont forceps, and care must be taken to ensure no air 
bubbles enter; [18] once inside the catheter is guided down the artery as far as the temporary clip; [19] 
The loose suture is then tightened to fasten the artery over the catheter; [20] The temporary clamp is 
released allow pressure measurements. 
 
2.2.2.2  Blood Pressure and Heart Rate 
Data processing and analysis was performed in LabChart 8 pro. After the stabilisation period, 
a representative 10 min selection of the trace was analysed using the blood pressure add-on in 
arterial signal mode with cycle detection set to a minimum height peak of 5 mmHg, no cycle 
averaging and dicrotic notch minimum height at 0.1% of peak height. Identified beats were 
then processed in the classifier view and cross-referenced with the chart view to exclude “bad” 
beats affected by excessive intra-thoracic negative pressure artefact resulting from anaesthetic-
induced changes in respiration. Blood pressure parameters (e.g. systolic, diastolic, dicrotic 
notch pressure) are exported from table view to Excel (Microsoft) and further processing. Mean 
arterial pressure was calculated as (1/3 peak systolic pressure + 2/3 end diastolic pressure) and 
pulse pressure as (peak systolic pressure – end diastolic pressure). Heart rate was measured 
from the R-R wave interval of ECG limb lead II. For measurements taken with the 
physiological pressure transducer (MLT844, AD Instruments) it was only possible to determine 
mean arterial pressure and heart rate based on cycle detection of the pressure trace.  
 
2.2.2.3  Pulse Waveform Analysis 
A combination of in-built tools and custom designed macros (see appendix 5), scripted by Paula 
Croft (AD Instruments, UK), were used to perform pulse waveform analysis on beats analysed 
in Section 2.2.2.1.  
To assess arterial stiffness, a method was developed to calculate pulse wave velocity 
from two pulse arrival time (PATFoot) measurements separated by a known distance using a 
single catheter. In brief, after baseline measurements the sampling rate was increased to 10,000 
samples/s and recorded for 5 min to obtain the distal PATFoot. From the point of the securing 
suture knot, 5 mm was measured and marked with a sharpie pen distal to the knot on the 
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catheter cable. The catheter was then advanced proximal to the heart until the 5 mm ink mark 
was at the base of the securing knot, and measurements were recorded for minutes to obtain 
the proximal PATFoot. A macro was scripted to calculate the PATFoot (Figure 2.4) as the 
difference between the ECG R-wave peak (approximating the aortic valve opening and 
pressure wave leaving the heart) and the peak of the second derivative blood pressure 
waveform (approximating the foot “onset” of the pressure wave arriving at the transducer). 
Pulse wave velocity was calculated for each beat using the following formula: 0.5 mm / (distal 
– proximal PATFoot). However, due to unacceptable experimental error and poor reproducibility 
this technique was not deemed sensitive enough to detect pulse wave velocity differences 
between genotypes and alternative strategies to determine arterial stiffness were explored. 
 
 
Figure 2.4: Strategies to determine augmentation pressure and pulse arrival time. 
1st shoulder systolic peak (anacrotic notch) is identified using the 3rd zero-crossing point of blood 
pressure (BP) 4th derivative (dBP/dt4). Augmentation pressure is calculated as the difference between 
1st and 2nd systolic peak pressures, and is expressed as a percentage of pulse pressure to obtain 
augmentation index; a marker of arterial stiffness. Pulse arrival time (PATFoot) can be calculated from 
peak of ECG R-wave (approximating aortic valve opening) to peak of blood pressure 2nd derivative 
(dBP/dt2) (approximating arrival of pressure wave at the transducer location). 
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The augmentation index was subsequently selected as a well-established indicator of 
arterial stiffness, and was determined using a macro developed to detect the anacrotic notch 
(1st shoulder systolic peak) using the third zero value crossing the fourth derivative of the blood 
pressure waveform (Figure 2.4), as described in (Kelly et al., 1989). The augmentation pressure 
was calculated as (peak systolic pressure – anacrotic notch pressure) and augmentation index 
as (augmentation pressure/pulse pressure). 
To assess a marker of vascular resistance, a macro was designed to measure the slope 
of the log of the diastolic pressure decay (Figure 2.5), 30 ms after the dicrotic notch and 20 ms 
before the end diastolic pressure (to avoid perturbations caused by aortic valve 
opening/closing). The reciprocal of this slope (ignoring the +/- sign and calculated from the 
20% trimmed mean values) was used to determine the time decay constant of the diastolic 
pressure decay (τBourgeois) which correlates with vascular resistance (i.e. higher resistance 
increases “emptying” time of blood from large to small vessels), as described previously 
(Bourgeois et al., 1974). Beats with no identifiable or a misplaced dicrotic notch were excluded 
from the analysis. 
 
Figure 2.5: Strategy to determine slope of diastolic pressure decay. 
The diastolic pressure decay time constant (τBourgeois) is calculated from the reciprocal of the slope of the 
line of the log of the diastolic pressure decay (ignoring the +/- sign) and is used as a surrogate marker 
of vascular resistance. To avoid aortic value closing/opening waveform artefacts, “start” comments are 
placed 30 ms after the dicrotic notch and 20 ms before the end of diastole. 
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2.2.2.4  Vasopressor Dose-Response 
In vivo dose-responses to vasopressor agents were taken after baseline blood pressure traces 
were obtained from mice. The right external jugular vein was cannulated for administration of 
bolus doses in increasing half-log steps of µg/kg bodyweight (bw) until a plateau in response 
was reached (Figure 2.6). Initially phenylephrine was administered and after washout and 
return to baseline, angiotensin II was administered in a similar fashion. Each dose concentration 
was made up as a half-log serial dilution in sterile 0.9% w/v saline and administered at a volume 
of 0.2 mL/kg.bw with an accompanying 20 µL 0.9% w/v saline cannula flush between doses. 
Peak systolic blood pressure responses were measured for each dose and dose-response curves 
generated and analysed (GraphPad Prism 5 and LabChart 8 Pro dose-response add-on) using a 
4-parameter logistical function to determine the estimated dose producing maximum response 
(Emax) and half maximal response (ED50). 
Figure 2.6: Representative in vivo vasopressor dose-response. 
Bolus doses were administered in increasing half-log steps of µg/kg.bw until a plateau was reached. 
Consecutive doses were administered once blood pressure and heart rate had approximately returned to 
baseline. Delivery of drugs and saline flushes were confirmed by transient reflex bradycardia. 
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2.2.3  Morphometry 
 
2.2.3.1  Gross Morphology 
Bodyweight was regularly measured two times per week throughout the study to determine 
differences in mass in age-matched mice. Body length was also recorded using photographs of 
mice post-mortem with a reference scale. Fully body length was determined as well as tail:body 
length ratio using FIJI image analysis software with the set scale and measuring tools.  
 
2.2.3.2  Cardiac Ventricular Mass 
Post-mortem the left ventricle and septum were separated from the heart and wet weight 
measurements were taken. The combined weights of the left ventricle and septum were then 
normalised against bodyweight to compare between genotypes. 
 
2.2.3.3  Vascular Microanatomy 
Three 5 µm sections of thoracic aorta taken at upper (proximal to the heart), mid and lower 
(nearest the diaphragm) segments per mouse. These were de-paraffinised, rehydrated and 
stained with haematoxylin and eosin, dehydrated and mounted by Nichola Figg (Division of 
Cardiovascular Medicine, University of Cambridge). Each section was imaged under 
brightfield illumination and halogen lamp epifluorescent imaging of autofluorescent elastin 
laminae with a GFP filter set. Using FIJI image analysis software, macros were scripted (see 
appendix 5) to draw eight lines at ~22.5 ° to one another that intersect the aortic ring at a total 
of 16 points. At the point of intersection on the outer circumference the distance from the 
external lamina to the inner lumen was measured. The average of the three rings (max of 16 
points per ring, with points excluded if they fell on an arterial branching point or incomplete 
portion of a ring) was used to calculate the average thoracic aorta intima-media wall thickness. 
The above step was repeated to count the average number of elastic laminae in the thoracic 
aorta of each mouse. Data collection and analysis was carried out in a blinded fashion 
throughout by a supervised operator, James Ferryman (University of Cambridge). 
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2.3  Histology  
 
2.3.1  Light Microscopy 
 
2.3.1.1  Sample Preparation 
Excess tissues from harvested mouse organs were carefully removed (e.g. kidney 
decapsulation) prior to immersion fixation in fresh 4% w/v formaldehyde-PBS pH 6.9 for 16 h 
at 37 °C, followed by three washes in PBS and storage at 4 °C. Samples were then paraffin 
embedded and microtome sectioned to 5 µm thickness by Nichola Figg (Division of 
Cardiovascular Medicine, University of Cambridge) and stored in darkness at room 
temperature for later histochemical and immunofluorescent analysis. 
Readily available glass slides of formalin-fixed paraffin embedded human tissue pre-
sectioned to 5 µm thickness were obtained from anonymised male and female donors through 
the Cambridge Human Research Tissue Bank for immunohistochemistry. 
 
2.3.1.2  Antigen Retrieval and Immunostaining 
Sections were deparaffinised in Histoclear (National Diagnostics) and rehydrated in graded 
steps from 100% to 70% methanol. An antigen retrieval step was performed with R-Universal 
buffer in the 2100 antigen retriever for a single heat-pressure cycle (Aptum Biologics). Sections 
were permeabilised with 0.05% v/v Triton-X100-PBS for 20 min and blocked for 1 h at 37 °C 
with sterile-filtered (0.22 µm) 2% v/v donkey serum in 0.05% v/v Triton-X100-PBS. Primary 
antibodies were diluted in sterile-filtered (0.22 µm) 0.05% v/v Triton-X100-PBS with 1% v/v 
donkey serum at the concentrations listed in Table 2.2 and incubated overnight in humidity 
chambers for 16 h at 4 °C. To prevent non-specific staining, phospho-specific antibodies 
included the addition of 10 μg/mL of the non-phospho form of the immunogenic peptide per 2 
µg/mL of antibody used. Negative controls for secondary antibody specificity and 
autofluorescence omitted the primary antibody and were processed in parallel. Slides were then 
washed for 20 min in 0.05% v/v Triton-X100-PBS and incubated in secondary antibody for 1 
h at 37 °C light-shielded humidity chambers. Cross-absorbed donkey IgG conjugated Alexa 
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Fluor 488, 568, 633 and 647 secondary antibodies (Life Technologies/Abcam) were used at 
1:200 diluted in sterile-filtered (0.22 µm) 1% v/v donkey serum in 0.05% v/v Triton-X100-
PBS for immunofluorescent labelling of mouse tissues. Slides were washed as above, and in 
some cases counterstained using Sytox orange nucleic acid stain (S11368 – Life Technologies) 
before being mounted using Prolong gold antifade (P36930 - Life Technologies) and shielded 
from light. Human immunohistochemistry DAB staining was performed by Nichola Figg 
(Division of Cardiovascular Medicine, University of Cambridge) with ImmPRESS Reagent 
peroxidase Universal anti-mouse/rabbit IgG (MP-7500, Vector) kit, after which slides were 
then dehydrated through graded methanol steps and mounted with DPX. 
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Target Immunogen [Residues] Conc. Host Code Source 
CUL3 Peptide [Hu: 681-704] 2 μg/mL Rb - (Sumara et al., 2007)
KLHL3 [Mo] Peptide [Mo: 1-21] 4 μg/mL Sh S740D MRC-PPU 
KLHL3 [Hu] Peptide [Hu: 1-32] 4 μg/mL Rb HPA051291 Atlas Antibodies 
LAMP1 Peptide [Hu: 350-CT]* 1 μg/mL Rb ab24170 Abcam 
NCC Peptide [Rt: 74-95] 2 μg/mL Rb ab95302 Abcam 
pNCC T44 Peptide [Mo: 38-52] 2 μg/mL Sh S242C MRC-PPU 
NKCC2 Protein-GST [Hu: 1-174] 2 μg/mL Sh S838B MRC-PPU 
NKCC2 pS91 Peptide [Hu: 86-97] 2 μg/mL Sh S451C MRC-PPU 
PVALB Protein-HPLC [Rt: FL] 1:2000 Rb PV25 Swant 
SPAK Protein-GST [Mo: 424-556] 4 μg/mL Sh S669D MRC-PPU 
SPAK pT233 Peptide [Hu: 226-238] 4 μg/mL Sh S668D MRC-PPU 
Ubiquitin Protein-KLH [Hu: FL] 1:500 Mo ab7254 Abcam 
MO25β Protein-GST [Hu: FL] 2 μg/mL Sh S082B MRC-PPU 
ROMK PrEST [Hu: 303-387] 1 μg/mL Rb HPA026962 Atlas Antibodies 
OSR1 Peptide [Mo: 333-352] 2 μg/mL Sh S149C MRC-PPU 
FTCD Protein [Rt: FL] 5 μg/mL Mo ab27043 Abcam 
Calnexin Peptide [Hu: 550-CT]* 2 μg/mL Rb ab22595 Abcam 
EEA1 Peptide [Hu: 1350-CT]* 2 μg/mL Rb ab2900 Abcam 
LC3 Peptide [Hu: 1-100]* 5 μg/mL Rb NB100-2220 Novus Biologicals 
WNK1 Protein [1079-1293]* 2 μg/mL Rb ab137687 Abcam 
WNK4 Peptide [Mo: 1-14] 4 μg/mL Sh S726D MRC-PPU 
Table 2.2: Primary antibodies used in immunostaining. 
Antibodies were used for both mouse and human immunostaining unless otherwise stated. 
Abbreviations: Phosphorylated amino acid (p), C-terminal (CT), Full-length (FL), Human 
(Hu), Mouse (Mo), Rabbit (Rb), Rat (Rt), Sheep (Sh), Recombinant Protein Epitope Signature 
Tag (PrEST), * indicates proprietary immunogens where the exact peptide sequence is 
unknown, but lies within the given range. 
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2.3.1.3  Image Acquisition and Processing 
Immunofluorescent images were acquired using a Leica TCS SP2 laser-scanning confocal 
microscope mounted on an upright Leica DM RXA fluorescent microscope body. Argon 488 
nm, HeNe 543 nm and HeNe 633 nm excitation laser lines were used with a triple dichroic 
filter 488/543/633 and a Leica HC PL FLUOTAR 20X/0.5 NA dry or Leica HCX PL APO 
63X/1.40 NA oil objective to acquire images. Acquisition Parameters: 12-bit, 1024x1024 
pixels, digital zoom 2.0X (with 20X objective) or 2.6X (with 63X objective), pinhole 1 airy 
disk, 800 Hz scan speed, 4-line Kalman filtering, sequential (by line) channel imaging, 10 slice 
z-stack of  5 µm.  Laser power intensity, spectral detectors, offset (set to zero) and PMT gain 
settings were kept uniform for all samples to be compared. Images were saved as uncompressed 
TIFF files.  
Immunohistochemically stained specimens were imaged in brightfield with white light 
source set to Köhler illumination on an Olympus BX51 upright epifluorescent microscope 
using a UPLANFL 20X 0.5 NA objective with the Infinity3 (Lumenera) CCD set to 1936x1456 
pixels. Exposure times and light source intensity were kept uniform for all samples to be 
compared. 
Post-acquisition image processing was performed in FIJI image analysis software (64-
bit). Macros were scripted and developed to automate batch processing of image data sets (see 
appendix 5) of multicolour channel confocal z-stacks. Fluorescent z-stacks underwent 
background subtraction (1000 pixel radius rolling ball, no smoothing) and either average or 
maximum intensity z-projection. Brightness and contrast were adjusted by linear histogram 
stretching to enhance visibility. Any images to be compared to one another were processed 
evenly across the whole image in parallel, the exception to this were nuclei images where 
brightness and contrast were performed on each image independently to ensure the best 
visibility. Similarly brightfield images underwent linear histogram stretching to increase 
visibility uniformly across the image. 
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2.3.2  Electron Microscopy 
 
2.3.2.1  Sample Preparation  
A subset of tissues from animal used in section 2.2.1.1 were selected for exploratory electron 
microscopy. Samples were hemisected prior to paraffin embedding and one half was 
impregnated with sucrose in graded steps (10%, 30%, 60% w/v) until the tissue no longer 
floated and was then stored long term at 4 °C until needed. 
Follow-up studies were performed on samples prepared by perfusion fixation. Mice 
were fasted for approximately 4 h before being placed under deep non-recoverable anaesthesia. 
First, an incision was made along the midline to expose the diaphragm and abdominal viscera. 
To access the heart the ribcage was retracted by using surgical scissors to cut along the sides 
of the ribs and diaphragm. Next, a small incision was made into the left ventricle to allow 
placement of a gavage needle which was secured with a haemostat. The right atrium was cut 
for drainage, and the gavage needle connected to the Perfusion One Sacrifice System (Leica 
Biosystems). Blood and extracellular fluids were rapidly removed by flushing 20-50 mL of 
pre-wash solution containing 9.25% w/v sucrose, 0.1% w/v Na Nitrite and 50 IU/mL Heparin; 
this should prevent clotting, tissue shrinkage and preserve the extracellular space. Once the 
solution from the heart ran clear and the liver and kidneys had become pale, 100-150 mL of 
perfusion fixative containing 0.05 M Na Cacodylate, 2% v/v gluataraldehyde, 3% w/v 
formaldehyde and 2 mM CaCl2 at pH 7.4 was run through until the animal was completely 
fixed and stiff (i.e. rigid tail). All solutions were perfused at a constant pressure of 120 mmHg 
at ~37 °C to prevent temperature shock induced translocation of membrane proteins. Tissues 
were then removed and sectioned by slicing cross-sections of 1-2 mm with a fresh razor blade, 
whilst taking care to avoid compression artefact. Sections were further immersion fixed in 
perfusion fixative solution overnight at 4 °C, washed 3 times in 0.05 M Na Cacodylate pH 7.2 
and stored at 4 °C. 
 
2.3.2.2  Block Face Scanning Electron Microscopy  
Immersion-fixed sucrose impregnated samples were subsequently trimmed to 1 mm thick 
slices and further fixed in perfusion fixation solution at 4 °C for 6 h, washed 5 times in cold 
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0.05 M Na Cacodylate pH 7.2 containing 2 mM CaCl2. Right before use, a solution containing 
3% w/v potassium ferricyanide in 0.3 M Na Cacodylate with 4 mM CaCl2 was combined with 
an equal volume of 4% w/v aqueous osmium tetroxide (EMS). Immersion or perfusion fixed 
tissue slices were incubated in this solution for 48 h at 4 °C, rinsed 5 times with deionised water 
at room temperature and then placed in filtered freshly made 1% w/v thiocarbohydrazide 
(Sigma Aldrich) solution for 20 - 30 min at room temperature and protected from light. Wash 
steps were repeated, followed by incubation in 4% aqueous, osmium tetroxide for 60 min at 
room temperature and more washing steps as before. To increase contrast, samples were 
incubated in 1% w/v uranyl acetate (Maleate buffered to pH 5.5) at 4 ° for 4 days and washed 
5 times. Followed by incubation at 60 ◦C for 30 min in freshly made Walton’s lead aspartate 
solution containing 0.02 M lead nitrate and 0.03 M aspartic acid adjusted pH to 5.5; repeat 
rinse steps. Samples were then dehydrated through 2 times each of 50%, 70%, 90%, and 100% 
ethanol.  2 time dried ethanol, 2 times dry acetone and 2 times dry acetonitrile. 50/50 
acetonitrile/Quetol 651(no BDMA) overnight, 3 days in Quetol 651(no BDMA), 3 days Quetol 
651 with BDMA and a final incubation at 60 °C for 48 h minimum. 
Tissue blocks up to 4 x 4 mm attached to 13 mm Cambridge SEM stubs were sectioned 
with a Leica Ultracut UCT to produce 1 µm sections. These were stained with methylene blue, 
cover-slipped and imaged with either a high resolution flat-bed scanner or a macro-scanner. 
The block faces were polished to an ultra-smooth finish with a histo-diamond knife. They were 
coated with 15 nm of carbon and imaged in a FEI Verios 460 operated in Back Scattered 
Electron mode at 4kV with a probe current of 200 – 400 pA.  
Block Face Scanning Electron Microscopy protocols and imaging were performed by 
Jeremy Skepper (Cambridge Advanced Imaging Centre, University of Cambridge). Images of 
the entire 4 x 4 mm block face were obtained at high resolution and stitched together using the 
FEI MAPS software or FIJI stitching plugins for qualitative analysis of cell ultrastructure. 
Distal convoluted tubule (DCT) cells in the renal cortex were identified for the focus of analysis 
by the high degree of basolateral membrane infolding and adjacent high density of columnar 
mitochondria. 
 
82 
 
2.4  Molecular Biology and Biochemistry 
Protocols in sections 2.4 were performed or supervised by either Jinwei Zhang, Frances-Rose 
Schumacher or Paola de los Heros (MRC PPU, University of Dundee), unless otherwise stated. 
 
2.4.1  CUL3 Study 
 
2.4.1.1  Plasmids and protein purification  
The following plasmids and/or protein purifications have been described elsewhere in (Ohta et 
al., 2013):  KLHL3 (DU23218), DAC-TEV-CUL3-RBX1 (DU23291), His-UBE1 (DU32888), 
His-TEV-UBE2D3 (DU15703), and (Kelsall et al., 2013): Nedd8 (DU20689), UBE2M 
(DU15804), APPBP1/UBA3 heterodimer (Nedd8 activating E1) (DU21784).  
DAC-TEV- CUL3Δ403-459-RBX1 (DU23292) was cloned in a comparable way to DAC-
TEV-CUL3WT-RBX1 (DU23291). Specifically, the pFastBac Dual DAC-TEV expression 
system was created by subcloning a BglII-BamHI-flanked PCR product encoding the full 
length DAC-tag followed by a TEV protease site into a pFastBacTM Dual (Life Technologies, 
UK).  Human Cullin3 (Δ403-459; Genbank NM_003590.4) was codon optimised for 
expression in insect cells and custom synthesised (GenScript USA Inc) before being subcloned 
downstream of the DAC-tag in cassette two of this vector.  Human RBX1 (Genbank 
NM_014248.2) was amplified from an EST IMAGE clone 3138751 and subcloned into cassette 
one (untagged).  Human CAND1 (Genbank NM_018448.3) was amplified as a Not1 flanked 
ORF from EST IMAGE clone 5265409 and sub-cloned into pGEX6P-2 (GE Healthcare 
LifeSciences UK) for bacterial expression with an N-terminal GST tag. All PCR reactions were 
carried out using KOD Hot Start DNA Polymerase (Merck Millipore, Germany).  All full-
length products or fragments were cloned into pSc-B (Agilent) and sequenced in full prior to 
further subcloning or manipulation.  DNA sequencing was performed by the Sequencing 
Service at the College of Life Sciences, University of Dundee (www.dnaseq.co.uk)  
Human recombinant CUL3Δ403-459-RBX1 or CUL3WT-RBX1 was expressed in a 
multibac vector with a Dac-TEV-fusion tag on the CUL3 and untagged RBX1 (Lee et al., 
2012b).  Proteins were expressed in the baculovirus system in Sf21 cells cultured in Insect-
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Protein-free Insect Cell Medium (Lonza).  The fusion protein was captured from the lysate by 
incubation with ampicillin-Sepharose.  After washing, the protein was recovered from the solid 
phase by incubation with C-terminally His-tagged TEV-protease (10 μg per 1 mg substrate).  
The protease and any free Dac-tag were removed with Ni-agarose and ampicillin-Sepharose. 
The protein was then concentrated and further purified by size-exclusion chromatography 
(SEC) in 50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol.  
Human recombinant CAND1 was expressed as an N-terminally GST-tagged fusion 
protein in BL21 cells. Expression was induced with 50 μM IPTG at 15 °C for 16 h.  Following 
cell lysis, GST-CAND1 was captured on Glutathione resin, washed and then eluted from the 
resin with 10 mM reduced glutathione in 50 mM HEPES pH 7.5, 150 mM NaCl, 10% glycerol 
w/v, and 1 mM DTT.  The protein was then dialysed to remove glutathione.  
Nedd8 was expressed as an untagged protein in BL21 cells, and following induction 
with 1 mM IPTG at 16 °C cells were lysed and frozen. Upon thawing benzonase and 2 mM 
Mg(C2H3O2)2 were added and cells were disrupted by sonication.  Insoluble material was 
pelleted and this pellet was resuspended in 50 mM Tris pH 7.5, 150 mM NaCl, and washed 
thrice. To extract Nedd8, the pellet was resuspended in 8 M Urea and mixed overnight.  
Following clarification by centrifugation the supernatant was diluted four-fold with MQ water 
and dialyzed thrice to remove Urea and enable Nedd8 refolding.  Contaminants were removed 
by depletion using a Q-Sepharose column. The Nedd8 was concentrated prior to a final 
purification by SEC in 20 mM HEPES pH 7.5, 150 mM NaCl, and 0.03% Brij 35.    
 
2.4.1.2  Antibodies 
The following antibodies were raised in sheep and affinity purified on the appropriate antigen 
by the Division of Signal Transduction Therapy Unit at the University of Dundee: WNK1-total 
antibody (residues 2360-2382 of human WNK1, S62B), WNK4 N-terminal antibody (residues 
1-14 of mouse WNK4, S726D), SPAK-mouse N-terminal antibody (2–76 of mouse SPAK, 
S668D), SPAK-mouse C-terminal antibody (424-556 of mouse SPAK, S669D), SPAK/OSR1 
(T-loop) phospho-Thr233/Thr185 antibody (226–238 of human SPAK or residues 178–190 of 
human OSR1, TRNKVRKpTFVGTP, S204C), SPAK phospho-Thr233 antibody (226–238 of 
human SPAK, TRNKVRKpTFVGTP, S668B and S668D), NKCC1-total antibody (residues 
1-260 of shark NKCC1, S841B), NCC phospho-Thr60 antibody (residues 54–66 of human 
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NCC phosphorylated at Thr60, RTFGYNpTIDVVPT, S995B), NCC phospho-Thr44 antibody 
(residues 38–52 of mouse NCC phosphorylated at Thr44, SQPSHLTpHGSTLYMRRR, 
S242C), KLHL3 N-terminal mouse (1-21 of mouse KLHL3, S740D).   The anti-ERK1/2 
antibody (9102) was purchased from Cell Signaling Technology. The anti-FLAG antibody 
(F1804), anti-β-actin antibody and anti-His antibody were purchased from Sigma-Aldrich. The 
rabbit anti-human CUL3 antibody was a kind gift from Izabela Sumara at the IGBMC, 
Strasbourg (Sumara et al., 2007). The following commercial rabbit anti-human antibodies were 
obtained and used for immunodetection: KLHL3 antibody (HPA051291) from Atlas 
Antibodies, KLHL3 (AB196776) (~14% immunogen peptide homology with KLHL2), NCC-
total [SLC12A3] (AB95302) and LAMP1 (AB24170) from Abcam, PV25 (PVALB) from 
Swant. The goat anti-GFP (AB5450) and the mouse monoclonal anti-ubiquitin (AB7254) were 
purchased from Abcam. The MYPT1 phospho-Thr696 mouse monoclonal antibody 
(MAB0001) was obtained from Abnova. Secondary antibodies coupled to horseradish 
peroxidase used for immunoblotting were obtained from Pierce. Secondary antibodies 
conjugated to fluorochromes for LiCor odessey western blot scanning were obtained from 
Licor (www.licor.com) and Life Technologies.  
2.4.1.3  In vitro assays 
Ubiquitin-E2 discharge assays were performed based on the method described (Plechanovová 
et al., 2011). Firstly, His-UBE2D2 (150 μM) was incubated in the presence of 2 mM ATP, 5 
mM MgCl2, 200 μM ubiquitin and 0.25 μM UBE1 in 50 mM HEPES pH 7.5, 150 mM NaCl, 
10% glycerol, 1 mM DTT at 16 °C for 15 min.  To stop the reaction ATP was depleted by 
incubating the charging mixture with Apyrase (4.5 U/mL; New England Biolabs) at 16 °C for 
10 min.  To this, 1 μM E3 was added and discharge reactions were then allowed to proceed for 
the time indicated in the figure, at 30 °C.  Reactions were stopped by the addition of non-
reducing SDS-Laemmli sample buffer. 16 % Bis-Acrylaminde non-reducing SDS PAGE, 
followed by immunodetection with anti-His antibody allowed visualisation of ubiquitin 
discharge. E3 ubiquitin-ligase activity assays were based on those described previously in 
(Ohta et al., 2013).  When used as a substrate in assays, full-length WNK kinases were purified 
from HEK-293 cells, either 5 μL of immunoprecipated endogenous WNK1 protein derived 
from 0.5 mg of HEK-293 cells, or 5 μL of immunoprecipated over-expressed FLAG-WNK4 
from 0.05 mg of HEK-293 cells was used for each assay reaction.  Ubiquitylation assays 
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typically contained 20 mM HEPES/HCl (pH 7.5), 150 mM NaCl, 2 M DTT, 10% w/v glycerol, 
8 μM CUL3-RBX1 complex (WT or mutant), 7 μM KLHL3, 7 μM UBE1, 60 μM UBE2D3, 
and 3000 μM ubiquitin. The concentrations of some components were altered on occasion (e.g. 
Fig. 3b) to best illustrate a given point.  Reactions were initiated by adding ATP and MgCl2 to 
a final concentration of 1 mM and samples were incubated for the times indicated at 30 °C.  
Reactions were stopped by the addition of SDS sample buffer and samples were analysed after 
SDS-PAGE followed by immunoblotting or Coomassie blue gel staining.  For the N8-ligase 
activity assays: 1 μM E3 was incubated at 30 °C with 68 μM Nedd8, 8 μM UBE2M, and 0.2 
μM NAE in the presence of 0.15 mM ATP, 1.5 mM MgCl2 50 mM HEPES pH 7.5, 150 mM 
NaCl, 20% w/v glycerol for the time indicated. Reactions were stopped by the addition of SDS 
sample buffer and samples were analysed following SDS-PAGE separation and Coomassie 
blue staining.  
 
2.4.1.4  In vitro protein interaction pull downs 
For KLHL3-CUL3: anti-KLHL3 resin was made by covalently coupling anti-KLHL3 antibody 
(S377D) to Protein-G-Sepharose utilising dimethyl pimelimidate. Anti-KLHL3 resin, or 
control resin (prepared in the absence of any antibody) was incubated with saturating amounts 
of purified KLHL3, and washed thrice, resulting in KLHL3-resin. This resin was then 
incubated with CUL3WT or CUL3Δ403-459 at 4 °C for 1 h, before being washed thrice with PBS 
0.02% Tween20.  For CAND1-CUL3: Purified GST-CAND1 or GST was incubated in excess 
with resin at 4 °C resulting in GSH-resin-GST or GSH-GST-CAND1 resin. Each resin was 
then incubated with purified CUL3WT or CUL3Δ403-459 for 1 h at 4 °C before being washed once 
with PBS 0.02% Tween20, then twice with PBS in the absence of detergent. Following 
washing, volumes were reduced to a minimum and proteins were eluted from the resin by the 
addition of SDS sample buffer, prior to analysis by SDS-PAGE and immunoblotting.  
 
2.4.1.5  Cell culture 
HEK (human embryonic kidney)-293 cells were cultured in 14-cm-dishes in DMEM 
(Dulbecco’s modified Eagle’s medium; Life Technologies) supplemented with 10% v/v foetal 
bovine serum, 2 mM L-glutamine, 100 units/mL penicillin and 0.1 mg/mL streptomycin.  
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Protein expression was induced for 24 h with 1 μg/mL tetracycline (Life Technologies). To 
obtain endogenous WNK1 for activity assays the immunoprecipitation protocol was followed 
as described in (Ohta et al., 2013).  To obtain wild type FLAG-WNK4 cell lines were utilised 
from (Ohta et al., 2013; Schumacher et al., 2014).  When FLAG-WNK4 was to be used for in 
vitro ubiquitylation assays, a 14 cm plate of confluent cells was lysed in 0.5 mL ice cold 
Mammalian lysis buffer A (Mammalian lysis buffer A: 50 mM Tris/HCl (pH 7.5), 0.15 M 
NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM Na3VO4, 50 mM NaF, 5 mM Na4P2O7, 0.27 M 
sucrose, 1% w/v Nonidet P40, 1 mM benzamidine, 0.1 mM PMSF, 0.1% 2-mercaptoethanol, 
Roche protease inhibitor mix (1 tablet in 50 mL) for M2 affinity purification). Lysates were 
clarified by centrifugation and to this 10 μL M2-resin per 100 μL lysate was added.  Incubation 
of the resin with the cellular lysate for 1 h at 4 °C was followed by two-washes with Mammalian 
lysis buffer A, and two further washes with 1x PBS to give a pure M2-Flag-WNK4 slurry. For 
interaction studies with FLAG-CUL3WT and FLAG-CUL3Δ403-459, the same method was 
followed as above, with an alternative mammalian lysis buffer B (50 mM HEPES/KOH pH 
7.2, 5 mM Mg(C2H3O2)2, 70 mM KC2H3O2, 0.2 % w/v Triton X-100, 10% w/v glycerol, 0.2 
mM EDTA, 1 mM Na3VO4, 50 mM NaF, 5 mM Na4P2O7 and Roche protease inhibitor mix (1 
tablet in 50 mL). When it was desirable to prevent deneddylation, buffers were supplemented 
with 50 μM 1,10-phenanthrolin.  
 
2.4.1.6  Mass spectrometry analysis 
Prior to SDS PAGE samples were reduced and alkylated in the following way.  Reactions were 
stopped at the time shown and incubated at 95 °C in 1x LDS (Invitrogen) 5 mM DTT for 1 
min.  Alkylation occurred at room temperature for 30 min by addition of 20 mM iodoacetamide 
(20 mM) to the samples.  To quench the reaction DTT was added to a final concentration of 20 
mM and the sample then process on precast 4-12% gradient gel (Invitrogen). Gel pieces were 
excised as shown by the boxed areas in the figure and in gel digestion of the proteins with 5 
μg/mL trypsin and subsequent analysis.  
Mass spectrometric analysis was performed by LC-MS-MS on a Linear ion trap-
orbitrap hybrid mass spectrometer (Orbitrap-VelosPro, Thermo) coupled to a U3000 RSLC 
Hplc (Thermo). Peptides were trapped on a nanoViper Trap column, 2 cm x 100 mm C18 5 
mm 100 Å (Thermo, 164564) then separated on a 15 cm Thermo EasySpray column (ES800) 
equilibrated with a flow of 300 nL/min of 3% Solvent B [Solvent A: 2% Acetonitrile, 0.1% 
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formic acid, 3% DMSO in H2O; Solvent B: 80% acetonitrile, 0.08% formic acid, 3% DMSO 
in H2O]. The elution gradient was as follows, Time(min):Solvent B(%); 0:3, 5:3, 45:35, 47:99, 
52:99, 55:3, 60:3. The instrument was operated with the “lock mass” option to improve the 
mass accuracy of precursor ions and data were acquired in the data-dependent mode, 
automatically switching between MS and MS-MS acquisition.  Full scan spectra (m/z 400-
1600) were acquired in the orbitrap with resolution R = 60,000 at m/z 400 (after accumulation 
to an FTMS Full AGC Target; 1,000,000; FTMS MSn AGC Target; 50,000). The 20 most 
intense ions, above a specified minimum signal threshold (2,000), based upon a low resolution 
(R = 15,000) preview of the survey scan, were fragmented by collision induced dissociation 
and recorded in the linear ion trap, (Full AGC Target; 30,000. MSn AGC Target; 5,000). Data 
files were analysed by Proteome Discoverer 1.4-SP1 (Thermo), using Mascot 2.4.1 
(www.matrixscience.com), and searching an in-house database containing the relevant 
sequences. Scaffold (www.ProteomeSoftware.com) was also used to examine the Mascot 
result files. Allowance was made for the following fixed, Carbamidomethyl (C), and variable 
modifications, Oxidation (M), Dioxidation (M), GlyGly (K), LeuArgGlyGly (K) and Phospho 
(ST). Error tolerances were 10 ppm for MS1 and 0.6 Da for MS2. 
 
2.4.1.7  Mouse kidney & testes lysates 
Mice tissues were rapidly harvested and either; snap frozen in liquid nitrogen and stored at -80 
°C, or incubated in 1 mL RNAlater solution (Sigma-Aldrich) at 4 °C for 16-30 h before being 
removed from this buffer, patted dry with clean tissue and then stored dry at -80 °C. Lysates 
were prepared by homogenising tissue on ice using a Polytron PT1200C homogeniser 
(Kinematica) in 2 mL ice-cold Mammalian lysis buffer and then clarified by centrifugation at 
13,000 rpm for 30 min. The clarified supernatant was then quantified and used immediately.  
Any excess sample was snap-frozen in liquid nitrogen in single-use aliquots for use as required.   
The lysates to be used for immunoprecipitation were prepared in the same way, with 
the following exceptions, all designed to promote deneddylation of the cullin proteins. 
Detergent was not included in the lysis buffer. Following homogenisation samples were 
incubated on ice for 4 h. Following clarification by centrifugation at 13,000 rpm for 30 min, 
samples were aliquoted into fractions and either frozen in liquid nitrogen and stored at -80 °C, 
or used immediately. Clarified supernatant was incubated at room temperature for 1 h to enable 
further deneddylation, samples were then cooled on ice and centrifuged a second time to ensure 
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any precipitate was removed. Anti-CUL3 antibody (S067D) cross-linked (DMP) to Protein G 
agarose was mixed with saturating amount of lysate and incubated rotating overnight at 4 °C. 
The next morning, the agarose beads were washed thrice with mammalian lysis buffer B and 
twice with 1x PBS.  Proteins were eluted from beads by SDS-sample buffer addition and 
boiling at 95 °C for 10 min prior to centrifugation and SDS-PAGE and immunodetection. 
 
2.4.1.8  Immunoblotting 
Lysates, or protein mixes were boiled at 95 °C with 1x SDS Laemmli sample buffer, for 5 min 
before being subject to SDS-PAGE (8 or 10% Tris-Glycine gel, or 4-10% Gradient Gels (Life 
Technologies) or self-prepared 16% bis-acrylamide.  Gels were transferred to nitrocellulose 
membrane using the standard wet transfer method (15% MeOH Towbin transfer buffer).  
Following blocking of the membranes (TBST 5% w/v dried skimmed milk) they were then 
incubated overnight at 4 °C with the primary antibody indicated.  All DSTT produced sheep 
antibodies were used at 2 μg/mL, and phospho-specific antibodies included the addition of 10 
μg/mL of the dephospho-peptide used to raise the antibody. Commercial antibodies were 
diluted 1 in 1000.  Membranes were then washed in TBST five times and incubated with the 
appropriate secondary-HRP antibody at room temperature at 1:5000 dilution.  Membranes were 
subsequently washed five times and the HRP-signal was detected using chemiluminescence 
reagent (Pierce).  Immunoblots were developed using an automatic film processor (SRX-101, 
Konica Minolta Medical).  
 
2.4.1.9  CUL3 structural docking 
Cullin3 was modelled using Phyre2 server (Kelley & Mje, 2009) using human CUL3Δ403-459 as 
the sequence input and Cullin1 chosen for the docking model (Q13616, PDB:1LDK) (Zheng 
et al., 2002). A coil was predicted in place of the missing structural elements. UBE2D~UB was 
docked to RBX1 using PDB: 4AP4.  Images were modified and made in UCSF Chimera 
(http://www.cgl.ucsf.edu/chimera) (Pettersen et al., 2004).  
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2.4.1.10 Immunoprecipitation (mouse tissue and cell extracts)  
Lysates of cellular preparations (buffer B) from FLAG-tagged CUL3 were mixed with M2 
resin in the presence of 50 μM 1,10-phenanthrolin to prevent deneddylation, and were 
incubated rotating at 4 °C for 1 h. Resins were washed twice with Mammalian buffer B and 
twice with 1xPBS the volume was then reduced to ~15 μL and following the addition of SDS-
gel sample buffer to 1x, samples were boiled and the entire sample was loaded to allow analysis 
by SDS-PAGE and immunodetection with the antibodies indicated. 
 
2.4.1.11 Human and mouse aorta sample preparation 
Human aortic tissue were collected from donors through transplant coordinators at 
Addenbrooke’s Hospital, Cambridge.  All samples were handled in accordance with the 
policies and procedures of the Human Tissue Act and with the approval of the Local and 
Regional Ethics Committees. Mouse tissues were rapidly harvested, perivascular fat and 
residual blood were removed and the samples incubated in 1 mL RNAlater solution at 4 °C for 
16-30 h before being removed from this buffer and stored dry at -80 °C. Frozen aortic tissue 
were homogenised using TissueLyser LT  (Qiagen #85600) and protein lysates were extracted 
in NE-PER (Life Technologies #78833) lysis buffers containing protease and phosphatase 
inhibitors (Roche  #11836170001 & #04906845001).  All steps were carried out at 4 °C. Protein 
concentrations were determined with the PierceTM BCA protein assay (Life Technologies 
#23225). These experiments were performed by Iris Hardege and Raya Al Maskari (University 
of Cambridge). 
 
2.4.1.12 Human and mouse aorta immunoblotting 
10 µg of aortic protein lysates were separated by SDS-PAGE. Prior to loading, samples were 
heated at 70 °C for 10 min in 1 x LDS sample buffer and 1X reducing agent (Life Technologies 
#B0007 & # B0009) to a total volume of 20 µL/well. Samples and 5µL of Precision Plus 
molecular weight ladder (Biorad #161-0374) were then loaded onto a Bolt 4-12% Bis-Tris Plus 
Gel (Novex #BG04125BOX) and run at 165 V in 1X MES running buffer (Novex #B0001), 
for 35 min or until the dye front reached the end of the gel. Resolved proteins were then 
transferred to 0.22 μM nitrocellulose membrane (Life Technologies #IB23001) using the iblot2 
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(Life Technologies) at 20 V for 7 min. Antibodies were incubated in 5% milk. Membranes 
were incubated in 5% in milk or BSA in TBS for 1 h at room temperature. Primary antibodies 
were incubated overnight at 4 °C in 5% Milk or BSA in TBS-Tween (0.1% v/v Tween), then 
washed 6X in TBS-Tween. Secondary antibodies were incubated in TBS-Tween for 1h at room 
temperature in the dark, then washed 6X in TBS-Tween. Membranes were imaged and 
integrated intensity values quantified (bands were normalised against β-actin) using the LiCor 
odessey system (www.licor.com). These experiments were performed by Iris Hardege and 
Raya Al Maskari (University of Cambridge). 
 
2.4.2  MO25 Study 
 
2.4.2.1  Antibodies 
The following antibodies were raised in sheep and affinity purified on the appropriate antigen 
by the Division of Signal Transduction Therapy Unit at the University of Dundee: MO25β 
antibody (GST-MO25β human protein, S082B) and MO25α antibody (GST-MO25α human 
protein, S898A). Secondary antibodies coupled to horseradish peroxidase used for 
immunoblotting were obtained from Pierce. 
 
2.4.2.2  Tissue Lysates 
Tissues were rapidly harvested and either; snap frozen in liquid nitrogen and stored at -80 °C, 
or incubated in 1 mL RNAlater solution (Sigma-Aldrich) at 4 °C for 16-30 h before being 
removed from this buffer, patted dry with clean tissue and then stored dry at -80 °C. Lysates 
were prepared by homogenising tissue on ice using a Polytron PT1200C homogeniser 
(Kinematica) in 2 mL ice-cold Mammalian lysis buffer and then clarified by centrifugation at 
13,000 rpm for 30 min. The clarified supernatant was then quantified and used immediately.  
Any excess sample was snap-frozen in liquid nitrogen in single-use aliquots for use as required.   
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2.4.2.3  Immunoprecipitation 
2 mg aliquots of clarified tissue extract were incubated with 15 μg of the indicated total 
antibodies conjugated to 15 μl of protein-G–Sepharose. Incubation was for 2 h at 4 °C with 
gentle agitation, and the immunoprecipitates were washed three times with 1 ml of lysis buffer 
containing 0.15 M NaCl and twice with 1 ml of buffer A. Bound proteins were eluted with 1x 
lithium dodecyl sulfate (LDS) sample buffer. 
 
2.4.2.4  Immunoblotting 
Lysates, or protein mixes in SDS sample buffer were subjected to electrophoresis on 
polyacrylamide gels and transferred to nitrocellulose membranes. The membranes were 
incubated for 30 min with TBS-T containing 5% w/v skim milk. The membranes were then 
immunoblotted in 5% w/v skim milk in TBS-T with the indicated primary antibodies overnight 
at 4 °C. Sheep antibodies were used at a concentration of 1-2 µg/ml. The blots were then 
washed six times with TBS-T and incubated for 1 h at room temperature with secondary HRP-
conjugated antibodies diluted 5000-fold in 5% w/v skim milk in TBS-T. After repeating the 
washing steps, the signal was detected with enhanced chemiluminescence reagent. 
Immunoblots were developed using a film automatic processor (SRX-101; Konica Minolta 
Medical) and films were scanned with a 600-dpi resolution on a scanner (PowerLook 1000; 
UMAX). Figures were generated using Photoshop/Illustrator (Adobe).  
 
2.4.3  SPAK Study 
 
2.4.3.1  Materials 
Lumio Green, Colloidal Blue staining kit and precast SDS polyacrylamide BisTris gels were 
from Invitrogen. GL Biochem synthesised all peptides to a purity of > 95%; peptide sequences 
were determined by MS. Tissue-culture reagents were from Life Technologies. P81 phospho-
cellulose paper was from Whatman and [γ-32P]-ATP was from Perkin Elmer.  
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2.4.3.2  Plasmids and primers 
C-terminal human SPAK, full length, N-, C-terminal mouse SPAKs were amplified employing 
SuperScript III (Invitrogen) from placenta total RNA (Stratagene) using appropriate 
oligonucleotides. The RT-PCR products were ligated into pCR2.1-TOPO vector and 
sequenced. The sequence-verified SPAKs were sub-cloned into bacterial (pGEX-6P-1) and 
mammalian (pCMV5) expression vectors using BamHI and NotI. Required amino acid 
mutations were introduced into the pCR2.1-TOPO clone using site-directed mutagenesis by 
QuikChange method (Stratagene) but substituting the Taq enzyme with KOD Hot Start DNA 
polymerase (Novagen). Oligonucleotides were obtained from Invitrogen Life Sciences. DNA 
sequencing was performed by The Sequencing Service, College of Life Sciences, University 
of Dundee (www.dnaseq.co.uk). All recombinant proteins, plasmids, and antibodies generated 
for the present study are available on request and are described in additional detail on the 
reagents website (https://mrcppureagents.dundee.ac.uk/). 
 
 
Table 2.3: Primer sequences used for quantitative PCR. 
[Taken from (Zhang et al., 2015)]. 
 
2.4.3.3  Expression and purification of proteins 
All pGEX-6P-1 constructs encoding expression of recombinant with N-terminal Glutathione-
S-Transferase (GST) tags were transformed into BL21 E. coli cells and 1-litre cultures were 
grown at 37 °C in Luria Broth containing 100 µg/ml ampicillin until the absorbance at 600 nm 
was 0.8. Isopropyl ß-D-thiogalactopyranoside (30 µM) was then added and the cells were 
cultured for a further 18 h at 26 °C. Cells were isolated by centrifugation, re-suspended in 40 
ml of ice-cold lysis buffer and lysed in one round of freeze/thawing, followed by sonication 
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(Branson Digital Sonifier; ten 15-second pulses with a setting of 45% amplitude) to fragment 
DNA. Lysates were centrifuged at 4 °C for 15 minutes at 26,000 g. The GST-SPAK 
recombinant proteins were affinity-purified on 0.5 ml glutathione-Sepharose and eluted in 
buffer A containing 0.27 M sucrose and 20 mM glutathione.  
 
 
Table 2.4: Summary of purified proteins. 
The division of signal transduction therapy (DSTT), University of Dundee - DU number, purification 
system and affinity tags for purified proteins used in Figure 5.1 and Figure 5.3. [Taken from (Zhang 
et al., 2015)]. 
 
2.4.3.4  Fluorescence polarisation 
Fluorescence polarisation measurements were performed at 25 °C with purified SPAK proteins 
in 50 mM Tris/HCl, pH 7.5, 150 mM NaCl and 2 mM DTT. The concentration of the SPAK 
proteins determined by measuring their absorbance at 280 nm and calculated using the molar 
absorption coefficient determined by the ProtParam Online tool (Gasteiger et al., 2001). All 
peptides (SEEGKPQLVGRFQVTSSK [EP4543] and SEEGKPQLVGAFQVTSSK [EP4544) 
contained an N-terminal linker required for conjugating to the Lumio Green fluorophore 
(CCPGCCGGGG) and were initially resuspended in 50 mM ammonium bicarbonate, pH 8. 
Peptide labelling was achieved by incubating 10 nM of each peptide in a 0.5 ml reaction 
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mixture of 20 μM Lumio Green in 25 mM Tris/HCl, pH 7.5, 200 mM NaCl and 5 mM 2-
mercaptoethanol. Reactions were left to proceed in the dark for 2 h. The peptides were dialysed 
for 4 h into 25 mM Tris/HCl, pH 7.5, 200 mM NaCl and 5 mM 2-mercaptoethanol using a 
Micro DispoDIALYZER with a 100 Da molecular-mass cut-off (Harvard Apparatus), and then 
for another 12 h with changed buffer. For fluorescence polarisation, mixtures were set up 
containing the indicated concentration of protein, 10 nM Lumio-Green-labelled peptide in a 
final volume of 30 μl. All individual bindings were performed in duplicate with at least 12 data 
points per curve. Fluorescence polarisation measures were made using a BMG PheraStar plate 
reader, with an excitation wavelength of 485 nm and an emission wavelength of 538 nm, and 
measurements were corrected to the fluorescent probe alone. Data analysis and graphing were 
then performed in GraphPad Prism6; a one-site specific binding model was assumed 
(Y=Bmax*X/[Kd+X]) and the fitted dissociation constant computed. All experimental 
bindings were repeated at least twice and comparable results to those shown in the present 
study were obtained. 
2.4.3.5  Cell culture and transfections 
HEK293 (human embryonic kidney 293) cells were cultured on 10-cm-diameter dishes in 
DMEM supplemented with 10% v/v foetal bovine serum, 2 mM L-glutamine, 100 U/ml 
penicillin and 0.1 mg/ml streptomycin. For transfection experiments, each dish of adherent 
HEK293 cells was transfected with 20 μl of 1 mg/ml polyethylenimine (Polysciences) and 5-
10 μg of plasmid DNA as described previously (Durocher, 2002). 36 h post-transfection cells 
were lysed in 0.3 ml of ice-cold lysis buffer/dish, lysates were clarified by centrifugation at 4 
°C for 15 minutes at 26,000 g and the supernatants were frozen in aliquots in liquid nitrogen 
and stored at –20 °C. Protein concentrations were determined using the Bradford method.  
2.4.3.6  Buffers  
Lysis buffer was 50 mM Tris/HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 50 mM sodium 
fluoride, 5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1% w/v NP-40 or 1% 
w/v Triton X-100, 0.27 M sucrose, 0.1% v/v 2-mercaptoethanol, and protease inhibitors (1 
tablet per 50 ml). Buffer A was 50 mM Tris/HCl, pH 7.5, 0.1 mM EGTA, and 0.1% v/v 2-
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mercaptoethanol. TBS-Tween buffer (TTBS) was Tris/HCl, pH 7.5, 0.15 M NaCl, and 0.2% 
v/v Tween-20. SDS sample buffer was 1 × NuPAGE LDS sample buffer (Invitrogen), 
containing 1% v/v 2-mercaptoethanol. 
 
2.4.3.7  Antibodies 
The following antibodies were raised in sheep and affinity purified on the appropriate antigen 
by the Division of Signal Transduction Therapy Unit at the University of Dundee: WNK1-total 
antibody (residues 2360-2382 of human WNK1, S62B), WNK4-total antibody (residues 1221-
1243 of human WNK4, S064B), WNK4 N-terminal antibody (residues 1-14 of mouse WNK4, 
S726D), SPAK-mouse antibody (2–76 of mouse SPAK, S668D), OSR1 mouse antibody (389–
408 of mouse OSR1, SAHLPQPAGQMPTQPAQVSL, S149C), SPAK/OSR1 (T-loop) 
phospho-Thr233/Thr185 antibody (226–238 of human SPAK or residues 178–190 of human 
OSR1, TRNKVRKpTFVGTP, S204C), SPAK/OSR1 (S-motif) phospho-Ser373/Ser325 
antibody (367–379 of human SPAK, RRVPGSpSGHLHKT, which is highly similar to residues 
319–331 of human OSR1 in which the sequence is RRVPGSpSGRLHKT, S670B), SPAK 
phospho-Thr233 antibody (226–238 of human SPAK, TRNKVRKpTFVGTP, S668B), 
NKCC1 phospho-Thr203+Thr207+Thr212 (residues 198-217 of human NKCC1, 
HYYYDpTHTNpTYYLRpTFGHNT, S763B), NKCC1 phospho-Thr 212+Thr 217 (residues 
208-223 of human NKCC1, YYLRpTFGHNpTMDAVPR, S063D), NKCC1-total antibody 
(residues 1-260 of shark NKCC1, S841B), NCC phospho-Thr46+Thr50+Thr55 antibody 
(residues 41–60 of human NCC phosphorylated at Thr46+Thr50+Thr55, 
HPSHLpTHSSpTFCMRpTFGYNT, S908B), NCC phospho-Thr46 antibody (residues 40–54 
of human NCC phosphorylated at Thr46, SHPSHLpTHSSTFCMRRR, S241C), NCC phospho-
Thr60 antibody (residues 54–66 of human NCC phosphorylated at Thr60, 
RTFGYNpTIDVVPT, S995B), NCC phospho-Ser91 antibody (residues 85–97 of human NCC 
phosphorylated at Ser91, CTLADLHpSFLKQEGRR, S996B), NCC-total antibody (residues 
906–925 of human NCC, CHTKRFEDMIAPFRLNDGFKD, S965B), NKCC2 phospho-
Thr100 (residues 94-106 of human NKCC2, NTYYLQpTFGHNTM, S431C), NKCC2 
phospho-Ser130 (residues 123-137 of human NKCC2, GPKVNRPpSLLEIHEQ, S888C), 
NKCC2 phospho-Ser91 (residues 86-97 of human NKCC2, RRFHAYDpSHTNTYYRR, 
S451C), NKCC2-total antibody (residues 1–174 of human NKCC2, S838B), GST-total 
antibody (raised against the glutathione S-transferase protein, S902A), ERK1 total antibody ( 
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full-length human ERK1 protein, S221B). The anti-GAPDH antibody (ab8245), anti-NCC-
total [SLC12A3] (AB95302) and the anti-parvalbumin antibody (ab11427) were purchased 
from Abcam. Anti-PVALB (Parvalbumin PV25) from Swant. Anti-NKCC2-total (LS-
C313275) from LifeSpan BioSciences. The anti-ERK1/2 antibody (9102) was purchased from 
Cell Signalling Technology. The anti-FLAG antibody (F1804) was purchased from Sigma-
Aldrich. Secondary antibodies coupled to horseradish peroxidase used for immunoblotting 
were obtained from Pierce. Preimmune IgG used in control immunoprecipitation experiments 
were affinity purified from pre-immune serum using protein G-Sepharose.  
 
2.4.3.8  Immunoprecipitation and assay of SPAK 
One milligram of clarified cell lysate was incubated with 5 µg of the SPAK/OSR1 (total) 
antibody conjugated to 5 µl of protein G-Sepharose and incubated for 2 h at 4 °C with gentle 
agitation. The immunoprecipitates were washed twice with 1 ml of lysis buffer containing 0.5 
M NaCl and twice with 1 ml of buffer A. The SPAK/OSR1 immunoprecipitates were assayed 
with the CATCHtide peptide substrate (RRHYYYDTHTNTYYLRTFGHNTRR) that 
encompasses the SPAK/OSR1 phosphorylation sites on NKCC1 (3). Assays were set up in a 
total volume of 50 µl in buffer A containing 10 mM MgCl2, 0.1 mM [γ32P]ATP and 300 µM 
CATCHtide (37). After incubation for 30 min at 30 °C, the reaction mixture was applied onto 
P81 phosphocellulose paper, the papers were washed in phosphoric acid, and incorporation of 
32P-radioactivity in CATCHtide was quantified by Cerenkov counting. 
 
2.4.3.9  Immunoblotting and total-antibody immunoprecipitation 
Cell lysates (15 µg) in SDS sample buffer were subjected to electrophoresis on polyacrylamide 
gels and transferred to nitrocellulose membranes. The membranes were incubated for 30 min 
with TBS-T containing 5% w/v skim milk. The membranes were then immunoblotted in 5% 
w/v skim milk in TBS-T with the indicated primary antibodies overnight at 4 °C. Sheep 
antibodies were used at a concentration of 1-2 µg/ml. The incubation with phospho-specific 
sheep antibodies was performed with the addition of 10 µg/ml of the dephospho-peptide 
antigen used to raise the antibody. The blots were then washed six times with TBS-T and 
incubated for 1 h at room temperature with secondary HRP-conjugated antibodies diluted 
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5000-fold in 5% w/v skim milk in TBS-T. After repeating the washing steps, the signal was 
detected with enhanced chemiluminescence reagent. Immunoblots were developed using a film 
automatic processor (SRX-101; Konica Minolta Medical) and films were scanned with a 600-
dpi resolution on a scanner (PowerLook 1000; UMAX). Figures were generated using 
Photoshop/Illustrator (Adobe). For total-antibody immunoprecipitation NCC, NKCC1 and 
NKCC2 were immunoprecipitated from indicated kidney extracts. A 2 mg aliquot of the 
indicated clarified kidney extract were incubated with 15 μg of the indicated total NCC, 
NKCC1 and NKCC2 antibodies conjugated to 15 μl of protein-G–Sepharose. Incubation was 
for 2 h at 4 °C with gentle agitation, and the immunoprecipitates were washed three times with 
1 ml of lysis buffer containing 0.15 M NaCl and twice with 1 ml of buffer A. Bound proteins 
were eluted with 1x lithium dodecyl sulfate (LDS) sample buffer. 
 
2.5  Phenotype and Histology Database Mining 
 
2.5.1  Data Sourcing 
To discover potential mouse models targeting MO25β, SPAK and CUL3 with open data, 
searches were initially conducted on the International Mouse Strain Resource (IMSR) 
(http://www.findmice.org/) and Mouse Genome Informatics (MGI) 
(http://www.informatics.jax.org/) websites. Identified strains were then further investigated for 
phenotypic data on these databases and at the International Mouse Phenotyping Consortium 
(IMPC) - Release 5.0 (http://www.mousephenotype.org/) (Koscielny et al., 2014). Searches for 
protein expression and localisation information were done on the Human Protein Atlas - 
Version 17 (www.proteinatlas.org) in various organ tissues and cell lines (Uhlen et al., 2015; 
Thul et al., 2017).  
 
2.5.2  Data Assessment and Extraction 
Data from the IMPC has been gathered in core facilities at participating institutes using 
standardised protocols and procedures from the IMPReSS (International Mouse Phenotyping 
Resource of Standardised Screens) core phenotype pipeline (Figure 2.7). Phenotype 
associations for the genes of interest were viewed in ontological heatmap mode with a p-value 
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threshold set to <0.05. Raw data for selected parameters was then downloaded in XLS format 
for analysis, interpretation and graphical/tabular representation. Expression data and images 
from the Human Protein Atlas were downloaded and processed with FIJI image analysis 
software (64-bit).  
 
 
Figure 2.7: Core IMPC adult and embryonic phenotype pipeline. 
The pipeline schematic details the decision tree used in phenotyping new mouse models. Orange 
sections detail animal age and the periods in which experimental procedures are conducted by either 
embryonic day or postpartum week. For protocols and parameters see the IMPReSS website 
(www.mousephenotype.org/impress).  
 
2.5.2.1  MO25β Study 
The European Conditional Mouse Mutagenesis Program (EUCOMM) as part of the 
International Knockout Mouse Consortium (IKMC) created the mouse strain 
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Cab39ltm1b(EUCOMM)Wtsi on a C57BL/6NTac background at the Wellcome Trust Sanger Institute 
(WTSI) (Figure 2.8), which produces viable homozygous MO25β null mice (referred to 
hereafter as CAB39L-/-). To investigate the phenotype, the mice underwent the IMPC 
mandatory tests (Figure 2.7) at the Medical Research Council Harwell centre with the 
exception of immunophenotyping, and additionally undertook the viability, open field and 
adult LacZ expression tests. 
 
Figure 2.8: Cab39ltm1b(EUCOMM)Wtsi mouse model generation. 
The tm1b knock-out strategy of endogenous MO25β/CAB39L. The endogenous allele is represented 
and the tm1a target allele with the neomycin cassette (neo) and exon 6 flanked by loxP sites, which are 
then removed by Cre recombinase to create a tm1b model. The cassette expresses LacZ in tissues where 
the gene is knocked out. Beta-gaslactosidase staining can be used to follow the tissue expression of the 
gene. The grey rectangles represent exons, the flippase-recognition target (FRT) sites, splice acceptor 
(SA) and polyadenylation (pA) sequences are also indicated. 
 
2.5.2.2  SPAK Study 
The EUCOMM as part of the IKMC created the mouse strain Stk39tm1a(EUCOMM)Wtsi on a 
C57BL/6NTac background at the WTSI (Figure 2.9), which produces viable homozygous 
SPAK knock-out mice (referred to hereafter as STK39-/-). However it should be noted that for 
some genes skipping over the LacZ cassette can restore gene expression to some extent and the 
tm1a strategy can also result in hypomorphs. To investigate the phenotype, the mice underwent 
the following tests at the WTSI: clinical blood chemistry, haematology, body weight, heart 
weight, hot plate, calorimetry, body composition, eye morphology, X-ray and histopathology. 
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Figure 2.9: Stk39tm1a(EUCOMM)Wtsi mouse model generation. 
The tm1a knock-out strategy of endogenous STK39 (which codes for the SPAK protein). The 
endogenous allele is represented and the tm1a target allele with the neomycin cassette (neo) and exon 
3 flanked by loxP sites. The cassette expresses LacZ in tissues where the gene is knocked out. Beta-
galactosidase staining can be used to follow the tissue expression of the gene. The grey rectangles 
represent exons, the flippase-recognition target (FRT) sites, splice acceptor (SA) and polyadenylation 
(pA) sequences are also indicated. 
 
2.6  Statistical Analyses and Power Calculations 
Data presented are mean ± standard error of the mean (SEM), unless otherwise stated. Data 
were tabulated and processed in Microsoft Office Professional Plus 2013 – Excel, with 
statistical analyses performed on either SPSS version 22 or GraphPad Prism 5 
(http://www.graphpad.com/scientific-software/prism/) software. Two-tail student t-tests tests 
were performed either paired or unpaired where appropriate. P < 0.05 was taken as statistically 
significant throughout. 
For myosin phosphatase target subunit 1 (MYPT1) phosphorylation quantification, 
ratiometric expression was calculated for CUL3WT/Δ403-459 vs CUL3WT on each western blot of 
independent biological replicates. The mean of the ratios and bounds of the 95% confidence 
interval were calculated, where ratio = 1 represents no change in phosphorylation and ratio > 
1 represents an increase in the phosphorylation status of CUL3WT/Δ403-459 mice. Statistical 
significance was determined by the ratio t-test <Available at 
http://www.wormbook.org/chapters/www_statisticalanalysis/statisticalanalysis.html>. 
Unless otherwise stated, experiments were performed with an approximately even 
divide of males and females. Power calculations were performed in G*Power to ensure 
experiments, where possible, had a sufficient sample size to provide at least 80% power at a 
5% alpha to measure the desired effect size. 
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Chapter 3 : Gordon Syndrome Reveals CUL3 as a Potent 
Regulator of Blood Pressure 
 
[This chapter is principally based on and expands upon the content from the abstracts in 
Appendix 1 and paper in Appendix 3 (Schumacher et al., 2015)] 
 
3.1  Abstract 
Deletion of exon-9 from Cullin-3 (CUL3, residues 403-459: CUL3Δ403-459) causes 
pseudohypoaldosteronism type IIE (PHA2E), a severe form of Familial Hyperkalaemia and 
Hypertension (FHHt). CUL3 binds the RING protein RBX1 and various substrate-adaptors to 
form Cullin-RING-ubiquitin-ligase complexes. Bound to KLHL3, CUL3-RBX1 ubiquitylates 
WNK kinases, promoting their ubiquitin-mediated proteasomal degradation. Since WNK 
kinases activate Na+/Cl- cotransporters to promote salt retention, CUL3 regulates blood 
pressure. Mutations in both KLHL3 and WNK kinases cause PHA2 by disrupting Cullin-
RING-Ligase formation. We report here that the PHA2E mutant, CUL3Δ403-459, is severely 
compromised in its ability to ubiquitylate WNKs, possibly due to altered structural flexibility. 
Instead, CUL3Δ403-459 auto-ubiquitylates and loses interaction with two important Cullin 
regulators: the COP9-Signalosome and CAND1. A novel knock-in mouse model of 
CUL3WT/Δ403-459 closely recapitulates the human PHA2E phenotype. These mice also show 
changes in the arterial pulse waveform, suggesting a vascular contribution to their hypertension 
not reported in previous FHHt models. These findings may explain the severity of the FHHt 
phenotype caused by CUL3 mutations compared to those reported in KLHL3 or WNK kinases. 
 
3.2  Introduction 
Blood pressure is controlled in part by the WNK kinase pathway, which acts to modulate the 
activity of key cation-chloride cotransporters in the kidney (Kahle et al., 2008; Alessi et al., 
2014). Considerable insight into this pathway has come from exploring the molecular basis for 
mutations described in patients with a rare monogenic form of hypertension called Familial 
Hypertension and Hyperkalaemia (FHHt, also known as Gordon syndrome or 
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pseudohypoaldosteronism type II, PHA2, OMIM #145260). Mutations in the genes encoding 
WNK kinases have been shown to increase protein levels of WNK1 and WNK4 in the kidney, 
leading to increased activation of this pathway (Wilson et al., 2001; Kahle et al., 2008). When 
activated by phosphorylation, the WNK kinases phosphorylate and activate the downstream 
kinases, SPAK (SPS1-related proline/alanine-rich kinase) and OSR1 (oxidative stress–
responsive kinase 1), which in turn phosphorylate and activate cation-chloride cotransporters 
in the kidney, such as NCC (Na+/Cl- cotransporter), which leads to increased sodium ion 
reabsorption (Vitari et al., 2005; Delpire & Gagnon, 2008; Richardson et al., 2008).  It is this 
up-regulation of the WNK signalling pathway that is responsible for the salt retention that 
drives the hypertension in FHHt. These patients also present with disturbed plasma electrolytes 
especially hyperkalaemia and a metabolic acidosis, partly driven by NCC activation (Boyden 
et al., 2012; Tsuji et al., 2013; Osawa et al., 2013; McCormick et al., 2014; Glover et al., 2014). 
As FHHt patients are salt-loaded through NCC activation, the hypertension and electrolyte 
disturbance responds to either salt-restriction or low doses of thiazide diuretics (Gordon & 
Hodsman, 1986; Mayan et al., 2002). 
More recently, the Ubiquitin Proteasome System (UPS) was shown to have a critical 
upstream role in regulating blood pressure by modulating WNK kinase levels (Mori et al., 
2013b; Wu & Peng, 2013; Wakabayashi et al., 2013; Ohta et al., 2013). This was first suggested 
when patients with severe forms of FHHt were described with mutations in Cullin-3 (CUL3; 
PHA2E), and one of its substrate adaptors, KLHL3 (PHA2D) (Boyden et al., 2012; Louis-Dit-
Picard et al., 2012). CUL3 belongs to the Cullin-RING ligase (CRL) family that form the 
largest class of ubiquitin E3 ligases in the cell. Cullins are elongated proteins, which confer an 
extended structure to active CRL complexes (Zheng et al., 2002; Duda et al., 2011). Through 
their C-terminus, Cullins constitutively bind to a small really interesting new gene (RING) 
finger domain protein, either RING-box protein (RBX) 1 or 2, which forms the catalytic core 
of the ligase complex. The binding to various substrate-adaptor proteins at the N-terminal 
domain enables CUL3-RBX1 to appropriately ubiquitylate a plethora of cellular substrates 
(Wee et al., 2005; Harper & M-km, 2012).  In this way, CUL3 acts as an active scaffold to 
direct ubiquitylation, as C-terminally bound RBX1 binds ubiquitin-conjugating E2 enzymes 
that are charged with ubiquitin, while simultaneously binding to the substrate adaptor, in this 
instance KLHL3 (Figure 3.1). The overall structural rigidity of the Cullin, in particular between 
the elongated N-terminus and the globular C-terminus, is important for the ubiquitin E3 ligase 
function of the complex. Alterations in the connecting sequence between the Cullin N- and C-
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terminus are thought to change the relative positioning of the RING domain towards the bound 
substrate, which can prevent substrate modification (Zheng et al., 2002; Liu & Nussinov, 
2011).  
For efficient CRL-dependent ubiquitylation of its targets, a conserved C-terminal lysine 
residue (Lys 721 in CUL3) must be modified by the addition of a single molecule of a ubiquitin-
like protein, namely neural precursor cell expressed developmentally down-regulated protein 
8 (Nedd8) (Pintard et al., 2003).  This modification process, also known as neddylation, is auto-
catalysed by CUL3-RBX1 and aided by Nedd8-E3 ligases (Kurz et al., 2005; Rabut et al., 
2011),  and serves to alter the flexibility of the C-terminal Cullin-RBX1 module to activate E3 
ligase activity (Duda et al., 2008; Scott et al., 2014). While neddylation is required for efficient 
ubiquitylation, studies show that the cycling between a neddylated and deneddylated state is 
crucial in a cellular context (Cope et al., 2002; Pintard et al., 2003).  As such, Cullin 
interactions with the deneddylation complex constitutive photomorphogenesis 9 (COP9)-
signalosome (CSN), a metalloprotease, are also required for activity.  Another regulator of 
CRLs, cullin-associated nedd8-dissociated protein 1 (CAND1), interacts with the N- and C- 
terminus of Cullins only in their deneddylated state to promote the exchange of substrate-
adaptors (Figure 3.1) (Liu et al., 2002; Goldenberg et al., 2004; Pierce et al., 2013; Wu & Peng, 
2013; Zemla et al., 2013).  
 
104 
 
 
Figure 3.1: Illustration of substrate ubiquitylation through Cullin-RING ligase activity. 
For the Cullin-RING ligase (CRL) complexes to become activated they must be [A] neddylated through 
the addition of nedd8 (N8) to a lysine residue on Cullin to promote an active conformation and 
dissociate from CAND1, and [B] recruit a substrate adaptor to the CRL assembly. [C] The RING protein 
of the CRL then binds ubiquitin-conjugating E2 enzymes that are charged with ubiquitin (Ub), to direct 
ubiquitylation of the substrate bound to the adaptor protein. [D] Subsequent COP9-Signalosome (CSN) 
binding promotes removal of the “empty” E2 enzyme and [E] deneddylation of CRL, which allows for 
multiple rounds of neddylation/deneddylation cycling and “new” ubiquitin-charged E2 enzymes 
recruitment for multi-ubiquitylation of the same substrate molecule and/or release of the ubiquitylated 
substrate and recruitment of a new substrate molecule. [F] Deneddylated CRL then binds to CAND1 to 
inactivate it and promote dissociation of the adaptor protein for recycling. [Taken from (Cui et al., 
2016)]. 
 
In the context of PHA2, KLHL3 is the critical adaptor that links the WNK kinases to 
CUL3-RBX1, enabling CUL3 to directly ubiquitylate the bound WNK kinase. Earlier work 
showed the KLHL3 mutations described in FHHt (PHA2D) patients disrupt the formation of 
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the complex and prevent WNK ubiquitylation, leading to WNK stabilisation and increased 
electrolyte flux mediated by the WNK kinase pathway (Mori et al., 2013b; Shibata et al., 2013; 
Wu & Peng, 2013; Wakabayashi et al., 2013; Ohta et al., 2013; Susa et al., 2014; Schumacher 
et al., 2014). Some patients with FHHt have mutations in WNK kinases, which promote WNK 
stabilisation by disrupting WNK-KLHL3 interactions (Akhtar & Hafeez, 2009; Pathare et al., 
2012; Ali et al., 2013; Schumacher et al., 2014) or, in some cases, by the increased expression 
of WNK mRNA (Wilson et al., 2001).   
While FHHt patients with CUL3, KLHL3 or WNK mutations present with the same 
disease, those with mutations in CUL3 display a more severe phenotype, evident both in terms 
of an earlier age-of-onset and the degree of hypertension and electrolyte disturbance reported 
(Boyden et al., 2012; Tsuji et al., 2013; Osawa et al., 2013).  To date, all the reported CUL3 
PHA2E mutations are heterozygous, transmit as autosomal dominant traits and result in the 
deletion of the amino acids encoded for by exon-9 of the CUL3 mRNA (residues 403-459) 
(Boyden et al., 2012; Grimm et al., 2012; Tsuji et al., 2013; Osawa et al., 2013; Glover et al., 
2014). Nevertheless, precisely why and how this truncated form of CUL3 (hereafter referred 
to as CUL3Δ403-459) causes a more severe phenotype is currently unclear.  To investigate this 
question a biochemical in vitro approach to understand the molecular defects caused by the 
mutation and a mouse model of PHA2E to better understand the physiological basis of the 
effects of CUL3Δ403-459 was used.  
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3.3  Results 
 
3.3.1  CUL3Δ403-459 forms an active Cullin-RING ligase complex 
To investigate the molecular defect of CUL3Δ403-459 it was determined if this form of CUL3 
was able to build a CRL complex. First, it was established that CUL3Δ403-459 binds RBX1 
similar to CUL3WT, by showing that both versions of CUL3 form a stable complex with RBX1 
when co-expressed in insect cells (Figure 3.2 A).  A second critical interaction for a functional 
CRL is the ability to bind substrate-adaptor proteins, and in the context of WNK kinase 
modification, CUL3 must interact with KLHL3 (Lamark & Johansen, 2012; Ji & Privé, 2013; 
Canning & Bullock, 2014). The 57-residue deletion in CUL3Δ403-459 lies in a structurally 
distinct domain of CUL3 and would not be expected to perturb binding to substrate adaptors. 
It was confirmed that CUL3Δ403-459 indeed retains the ability to bind KLHL3 by in vitro pull-
down assays with purified proteins (Figure 3.2 B).  It was also shown this interaction is 
maintained in a cellular system, using ectopically expressed FLAG-tagged CUL3 to co-
precipitate endogenous KLHL3 in FLAG immunoprecipitates (Figure 3.6 A). Thus, CUL3Δ403-
459 maintains crucial interactions important for ubiquitin ligase function. Given this, whether 
CUL3Δ403-459-RBX1 also maintains the ability to hydrolyse the thioester bond between the 
catalytic cysteine residue of a recruited E2 enzyme and ubiquitin (E2~UB), a critical step in 
ubiquitylation and a measure for catalytic activity, was tested.  Using ubiquitin-release assays 
from charged E2 enzymes, it was shown that CUL3Δ403-459 hydrolyses E2~UB more efficiently 
than CUL3WT, demonstrating a functionally intact CUL3Δ403-459-RBX1 catalytic core, while 
also suggesting potential hyper-activity (Figure 3.2 C).  Together, these results demonstrate 
that CUL3Δ403-459 maintains interactions and basic functionality critical for CRL activity. 
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Figure 3.2: CUL3Δ403-459 forms a functional Cullin-RING ligase with altered activity. 
[A] Shows the proteins which interact with purified CUL3WT and CUL3Δ403-459 as analysed by SDS–
PAGE and Coomassie blue staining, following expression in SF21 cells. Bands migrating between 62- 
and 98-kDa protein markers are CUL3WT and CUL3Δ403-459, respectively, while the band below 17-kDa 
is RBZ1, which was confirmed by immunoblot (shown in the lower panel). The band in CUL3WT 
denoted with * is co-purified insect cell CAND1. All protein identities were confirmed by mass 
spectrometry. [B] KLHL3 binding to CUL3WT and CUL3Δ403-459 is comparable as shown by pull-down 
assays with anti-KLHL3 resin (KLHLR) and the protein G sepharose control resin (ControlR). [C] 
UBE2D3~ubiquitin-release assays analysed by non-reducing SDS–PAGE and immunodetection shows 
that CUL3Δ403-459 more efficiently hydrolyses the ubiquitin-charged E2 enzyme as shown by lower 
levels of UBE2D3~Ub over time. The lower panel is an immunoblot for CUL3 confirming equivalent 
amounts of CUL3WT and CUL3Δ403-459 were used; the appearance of higher molecular weight bands over 
time represents the modification of CUL3 by covalent attachment of ubiquitin. The first lane is the 
negative control with no CUL3 added, and the right two lanes are positive control lanes incubated for 
10 min with E2~Ub but then treated with reducing agent prior to SDS–PAGE to remove ubiquitin from 
UBE2D3. “~” denotes thioester bond. [Taken from (Schumacher et al., 2015)]. 
 
3.3.2  Structural modelling suggests CUL3Δ403-459 is more flexible than CUL3WT 
To better understand how the deletion in CUL3Δ403-459 may affect the CRL, the structure of 
CUL3 was predicted, using closely related Cullin1 (CUL1) (Figure 3.3).  The region deleted in 
CUL3Δ403-459 likely forms a three-helical bundle juxtaposed to the globular C-terminal domain.  
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Removal of these helices would fuse together two short unstructured regions to create a longer 
loop, which, as well as shortening the elongated structure of the CRL complex, may increase 
the flexibility between the two domains. If correct, this model explains how RBX1 and KLHL3 
binding is maintained (Munir et al., 2007; Calabrese et al., 2011), while also suggesting the 
function of the ligase may be compromised due to the altered relative orientation of the CRL 
components towards each other. Studies investigating the structure of CUL1 demonstrated the 
importance of a rigid Cullin conformation for substrate ubiquitylation, as increasing the 
flexibility of CUL1, in an area that corresponds to the CUL3 deletion, led to strongly decreased 
substrate ubiquitylation (Zheng et al., 2002) (Figure 3.3).  It is therefore possible that due to 
the presence of a predicted unstructured flexible loop, CUL3Δ403-459 may similarly sample non-
productive conformations.   
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Figure 3.3: Cullin homology and structural predictions. 
[A] Clustal-Omega alignment of full length Cullin1 and Cullin3 shows the highly conserved nature of 
the region equating to exon-9 of Cullin3, with ~81% of the residues either the same (dark grey) or 
functionally similar substitutions (light grey). [B] Structural model of CUL3WT and CUL3Δ403-459 made 
based on the structure of full length Cullin1 (PDB: 1LDK), highlighting the residues deleted in the 
PHA2E mutant which (orange) are located close to the N-terminal domain (NTD; in dark blue) and C-
terminal domain (CTD; in cyan) border. [Taken from (Schumacher et al., 2015)]. 
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3.3.3 CUL3Δ403-459 has altered Nedd8-ligase activity and is unable to interact with 
the CRL regulators COP9-Signalosome and CAND1 
Available structural data of CRL proteins bound to Cullin regulators suggest the deleted region 
in CUL3Δ403-459 may also influence neddylation and binding of the COP9-Signalosome (CSN) 
(Lingaraju et al., 2014) and of CAND1  (Figure 3.4) (Goldenberg et al., 2004). This prompted 
further examination to see if these interactions are affected by the PHA2E mutation.   
Figure 3.4: Structural context of the area deleted by the disease-causing mutation in 
CUL3. 
[Top] Schematic representation of the interactions between CRL and CAND1. [Bottom] 
Representation of CAND1 in complex with CUL1-RBX1 (PDB: 1U6G) (Goldenberg et al., 2004). 
Coloured as shown in the schematic representation. Residues 437–493 of CUL1 (equivalent to 403–
459 of CUL3) are coloured orange. [Taken from (Schumacher et al., 2015)]. 
To investigate the ability of CUL3Δ403-459 to be auto-modified with Nedd8, in vitro 
neddylation assays with purified CUL3, Nedd8 activating enzyme (NAE), Nedd8 E1 
(APPBP1-UBA3), Nedd8 E2 (UBE2M) and Nedd8 were used.  As Nedd8 forms a covalent 
isopeptide bond with CUL3, neddylation can be visualised as a slower-migrating band on SDS 
PAGE.  CUL3Δ403-459 was found to retain the ability to auto-neddylate (Figure 3.5 A). However 
unlike CUL3WT, CUL3Δ403-459 appears less efficient at transferring Nedd8 as some unmodified 
CUL3Δ403-459 remained even 45 min after neddylation was initiated. Moreover, while CUL3WT 
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was only mono-neddylated, multiple Nedd8 molecules were attached to CUL3Δ403-459 (Figure 
3.5 A). Both of these differences in neddylation are consistent with increased structural 
flexibility of CUL3Δ403-459. 
 
 
Figure 3.5: CUL3Δ403-459 has altered Nedd8-ligase activity. 
[A] Time course study of in vitro neddylation reactions shows a band shift for CUL3WT (0 vs 5,15,45 
mins) that is representative of a single Nedd8 modification, while multiple bands represent CUL3Δ403-
459 hyperneddylation with attachment of up to three Nedd8 (N8) molecules. Additionally, the continued 
presence of unmodified CUL3Δ403-459 suggests it is less efficient at transferring Nedd8. [B] 
Overexpression experiments in HEK293 cells also show hyperneddylation of CUL3Δ403-459 . Bands are 
labelled as follows: 1. CUL3WT // 2. CUL3WT-N8 // 3. CUL3Δ403-459 // 4. CUL3Δ403-459-N8 // 5. CUL3Δ403-
459-2(N8). [C] Overexpression experiments in HEK293 cells treated with the neddylation inhibitor, 
MLN4924, show that CUL3Δ403-459 has a decreased rate of deneddylation. [Adapted from (Schumacher 
et al., 2015) with changes to labels]. 
 
As previously reported (McCormick et al., 2014), elevated CUL3Δ403-459 neddylation in 
cells was also noticed (Figure 3.5 B). CRLs cycle between neddylated and deneddylated states 
to maintain activity (Pintard et al., 2003).  Therefore, the increased cellular neddylation of 
CUL3Δ403-459 could reflect a decrease in deneddylation by the isopeptidase CSN. The structure 
of the CSN bound to CUL1 supports this idea, as the Cullin C-terminal domain, including the 
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region equivalent to residue 403-459 in CUL3, contacts the CSN subunits directly (Lingaraju 
et al., 2014). To investigate this possibility, neddylation was blocked using an inhibitor of the 
Nedd8-E1 enzyme (MLN4924, Millennium pharmaceuticals) and monitored CUL3 
deneddylation over time. Consistent with decreased rates of deneddylation, CUL3Δ403-459 
remained neddylated for longer than CUL3WT (Figure 3.5 C) and also showed markedly 
reduced binding to CSN subunits (Figure 3.6 A).  As such, the observed elevated Nedd8 
modification of CUL3Δ403-459 in cells is likely due to a combination of Nedd8 ligation to non-
physiological lysine residues and of reduced CSN deneddylation.  
Figure 3.6: CUL3Δ403-459 is unable to interact with CRL regulators. 
[A] HEK293 overexpression pull-down assays revealed reduced CUL3Δ403-459 binding to the COP9-
Signalsome subunit CSN8. Additionally, there was a complete absence of CUL3Δ403-459 binding to 
CAND1, even in the presences of MLN4924 which would be expected to increase the abundance of 
non-neddylated CUL3 for CAND1 to associate with. [B] In vitro pull-down assays using purified 
proteins confirms that CUL3WT but not CUL3Δ403-459 interacts with CAND1. [Taken from (Schumacher 
et al., 2015)]. 
CRLs must be deneddylated for a productive interaction with the substrate-adaptor 
exchange factor CAND1. Furthermore, the structure of CUL1 bound to CAND1 suggests that, 
regardless of neddylation state, CUL3Δ403-459 may be unable to form the required critical 
interactions (Goldenberg et al., 2004; Pierce et al., 2013; Wu & Peng, 2013; Zemla et al., 
2013). Therefore the next step was to investigate whether CUL3Δ403-459 was indeed defective 
in binding to CAND1. Cells expressing either FLAG-CUL3WT or FLAG-CUL3Δ403-459 were 
treated with the neddylation inhibitor MLN4924 to force all of CUL3 into the non-neddylated 
state and then determined interaction with CAND1 by immunoprecipitation. While CUL3WT 
strongly bound to CAND1 in these assays, CUL3Δ403-459 was unable to interact with CAND1 
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(Figure 3.6 A). These findings were confirmed using in vitro assays with purified proteins 
(Figure 3.6 B).  These data advocate that structural perturbations prevent CUL3Δ403-459 from 
binding to CAND1. In combination with the impairment of CSN binding, such defects suggest 
the regulation of CUL3Δ403-459 in cells is likely to be severely disrupted.   
 
3.3.4  CUL3Δ403-459 displays enhanced auto-ubiquitylation 
The data suggests the regulation of CUL3Δ403-459 is disrupted in cells, and it made sense to test 
whether its ubiquitylation activity is similarly affected. The Ellison group suggested that 
CUL3Δ403-459 may stabilise WNK kinases by ectopically degrading the substrate adaptor 
KLHL3; preventing the formation of functional CUL3-KLHL3 complexes (McCormick et al., 
2014). Some CRLs are known to ubiquitylate bound substrate-adaptors (Wee et al., 2005) and 
it is feasible that altering the CUL3 backbone structure could indeed lead to erroneous 
ubiquitylation of KLHL3.  In the in vitro system, it was confirmed that CUL3Δ403-459 directly 
modified KLHL3 with a greater efficiency than CUL3WT (Figure 3.7 A).  Interestingly, 
CUL3Δ403-459 also exhibited markedly increased auto-ubiquitylation (Figure 3.7 B).   
 
 
Figure 3.7: CUL3Δ403-459 displays increased auto-ubiquitylation and ubiquitylation of 
KLHL3. 
In vitro ubiquitylation assays with purified proteins. As ubiquitin is covalently attached to the substrate 
lysine residue, the appearance of higher molecular weight protein bands reflects the modification of the 
protein with ubiquitin. [A] Even at 2× molar concentration of KLHL3 over CUL3, CUL3Δ403-459 was 
capable of much higher levels of KLHL3 ubiquitylation. [B] Time course measurements of basal auto-
ubiquitylation reveal significantly higher levels of CUL3Δ403-459 auto-ubiquitylation. [Taken from 
(Schumacher et al., 2015)]. 
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Auto-ubiquitylation is often utilised as a read-out for ubiquitin ligase activity. In a 
cellular context, self-modification can lead to auto-degradation of the ligase (Silke et al., 2005). 
If CUL3Δ403-459 modifies lysine residues inaccessible to CUL3WT, this could explain the 
increased auto-ubiquitylation.  Alternatively, CUL3Δ403-459 could build longer ubiquitin chains 
on the same lysine residues that are also targeted by CUL3WT. To explore these possibilities, 
in vitro ubiquitylation assays were performed with methylated ubiquitin, a form of ubiquitin 
unable to build ubiquitin-chains (Kirisako et al., 2006). In these assays CUL3Δ403-459 was auto-
modified on multiple lysine residues, while CUL3WT only mono-ubiquitylated one residue 
(Figure 3.8 A). Therefore the observed increase in auto-ubiquitylation is most likely due to 
erroneous modification of multiple lysine residues on CUL3Δ403-459, which is consistent with 
an increase in structural flexibility as suggested by the model proposed here.  Alternatively, the 
mutation may change the active site environment of CUL3, exposing more lysine residues close 
to the E2~UB binding site. To distinguish between these possibilities, the lysine residues 
modified in the in vitro assay system were mapped using mass spectrometry.  In vitro auto-
ubiquitylation reactions of CUL3 were performed with methylated ubiquitin for either five or 
45 min and the ubiquitylated lysine residues were determined by analysing which lysine 
residue(s) carry di-Glycine remnants after trypsin digest (Kim et al., 2011). Using this approach 
it was found that after five min CUL3WT was only auto-ubiquitylated on a single lysine residue 
(K336), while ten lysine residues on CUL3Δ403-459 were modified (Figure 3.8 B-C). After 
running the reaction for 45 min, the modification sites on CUL3WT had increased to five, all of 
which were C-terminal to the original site and contained within the globular C-terminal Cullin 
domain. The ubiquitylation sites on CUL3Δ403-459, however, had increased to 25 sites distributed 
along the entire length of the protein (most N-terminal: K47; most C-terminal: K743) (Figure 
3.8 B-C).  
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Figure 3.8: CUL3Δ403-459 is auto-ubiquitylated at multiple residues. 
[A] In vitro activity assays containing methylated ubiquitin, a form of ubiquitin incapable of forming 
ubiquitin chains, show that CUL3Δ403-459 is ubiquitylated at more lysine residues than CUL3WT as 
evidenced by the higher bands in CUL3Δ403-459. [B] Activity assay performed as in [A] with methyl-
ubiquitin, the boxes shown on the gel are indicative of the gel pieces excised for mass spectrometry 
analysis in [C]. [C] Schematic representation (to linear residue scale) highlighting the domains of CUL3 
and schematic representation of the lysine residues of CUL3WT or CUL3Δ403-459, modified at 5 and 45 
min, as determined by mass spectrometry. [Taken from (Schumacher et al., 2015)]. 
 
These results support the model that the CUL3 exon-9 deletion induces increased 
structural flexibility, leading to the erroneous auto-ubiquitylation of sites normally not 
accessible to CUL3WT (Figure 3.9).   
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Figure 3.9: Schematic representation of the possible structural effects of the mutation. 
[A] Structural docking model of CUL3Δ403-459 based on the structure of full-length CUL1 (PDB: 1LDK) 
using Chimera. The NTD is coloured green, while the CTD is red, and the four panels sample possible 
positioning of the CTD relative to the NTD in CUL3Δ403-459, assuming full flexibility of the linker after 
deletion of three helices encoded by exon-9. [B] The schematics represent a functional CUL3WT 
complex and show two contrasting positions for an active CUL3Δ403-459 that is unable to modify the 
WNK kinases. The structural representations (bottom) correspond to the schematics above. These were 
generated in Chimera, and known structures were utilised as docking references to enable the possible 
orientations to be explored. KLHL3-KELCH domain (red) bound to a WNK peptide (grey) (PDB: 
4CH9). KLHL3-BTB domain (red) bound to CUL3-N-terminal domain (blue), CUL3-C-terminal 
domain (cyan) (based on CUL1 CTD) (PDB: 1LDK). RBX1 (green), UBE2D (purple) and ubiquitin 
(yellow) were docked based on the complex RNF4-E2-UB structure (PBD: 4AP4). [Taken from 
(Schumacher et al., 2015)]. 
 
3.3.5  CUL3Δ403-459 cannot ubiquitylate WNK kinases 
As CUL3Δ403-459 is able to more efficiently auto-ubiquitylate itself and KLHL3, the next 
question asked was whether it similarly shows increased ubiquitylation towards a bound WNK 
substrate in in vitro ubiquitylation assays using purified components. As previously shown, 
CUL3WT efficiently ubiquitylates WNK kinases in vitro (Ohta et al., 2013) (Figure 3.10). 
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CUL3Δ403-459, however, while maintaining the ability to efficiently modify itself and KLHL3, 
was not able to modify either WNK1 or WNK4 (Figure 3.10 A-B).  As described for CUL1 
(Zheng et al., 2002), increasing the flexibility of the Cullin backbone, can lead to a decrease in 
substrate modification, while promoting excessive modification of other CRL components 
(Zheng et al., 2002). Thus, increased structural flexibility of CUL3Δ403-459 may lead to similar 
defects. If so, then it becomes important to understand how this in vitro finding can explain the 
increased WNK stabilisation found in vivo. It is possible that only one of the three defects, the 
lack of substrate ubiquitylation, the increased Cullin auto-ubiquitylation or the increased 
KLHL3 ubiquitylation, is the major driver for the observed phenotypes. Decisively, KLHL3 
levels are not decreased in the kidney of CUL3WT/Δ403-459 mice, while the overall CUL3 levels 
are lower (Figure 3.11 A). This suggests that KLHL3 degradation is unlikely to contribute to 
the observed PHA2E phenotype and instead proposes that CUL3Δ403-459 stabilises WNK levels 
in the following ways: firstly, CUL3Δ403-459 excessively auto-ubiquitylates, leading to its own 
degradation, and secondly, any CUL3Δ403-459 protein that escapes degradation cannot promote 
the ubiquitylation of the WNK kinases. Importantly, all PHA2E patients are heterozygous for 
the mutation, suggesting that with respect to blood pressure regulation CUL3Δ403-459 behaves 
either as a dominant-negative or CUL3WT is haploinsufficient. These data demonstrate that the 
mutation causes a loss-of-function, so a dominant-negative effect seemed less likely. It was 
also found that in vitro, equimolar amounts of CUL3Δ403-459 do not appear to inhibit CUL3WT 
ubiquitylation of WNK4 (Figure 3.10 C), which further supported the concept of 
haploinsufficiency. 
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Figure 3.10: CUL3 Δ403-459 is unable to ubiquitylate WNK1 or WNK4 kinases in an in vitro 
system. 
In vitro ubiquitylation assays using immunoprecipitated proteins show [A] CUL3 Δ403-459 has lost the 
ability to modify either [A] WNK1 or [B] with ubiquitin (Ub), and instead has increased ubiquitylation 
activity directed towards itself and KLHL3. [C] In an equimolar solution of CUL3WT:CUL3Δ403-459 (1:1 
Mix) also containing KLHL3 and WNK4, the presence of CUL3Δ403-459 did not appear to inhibit WNK 
ubiquitylation by CUL3WT. [Taken from (Schumacher et al., 2015)]. 
3.3.6 CUL3WT/Δ403-459 mice have increased WNK kinase pathway signalling with 
typical FHHt phenotypic features of electrolyte imbalance and growth retardation 
To complement the in vitro findings and to determine more accurately what occurs in PHA2E 
patients, a knock-in mouse carrying the same exon-9 deletion of CUL3 as reported in PHA2E 
pedigrees (CUL3Δ403-459) was engineered.  Despite setting up heterozygous mating pairs, no 
homozygous knock-in mice were born suggesting that, like deletion of the entire coding region 
of CUL3, the homozygous deletion of residues 403-459 is lethal (Singer et al., 1999). 
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Nevertheless, all the reported PHA2E pedigrees are heterozygous, so the heterozygous knock-
in mice were phenotyped. Utilising both immunoblotting of whole kidney lysates and 
immunofluorescence confocal microscopy of kidney sections the relative abundance and 
distribution of proteins involved in the WNK signalling pathway was determined.  Whole 
kidney lysate was analysed by immunoblotting confirming the expression of CUL3 and the 
presence of an additional band corresponding to the expected PHA2E form, CUL3Δ403-459, in 
the heterozygous mice (Figure 3.11 A). In the context of the in vitro data, examining the levels 
of KLHL3 and CUL3 in the mouse kidney was especially warranted, and the expression of 
KLHL3 and CUL3 in normal human kidney lysates was confirmed to support inferences about 
the human condition (Figure 3.11 B). Definitively, the overall level of KLHL3 was comparable 
between CUL3WT/WT and CUL3WT/Δ403-459 mice (Figure 3.11 A). In contrast, CUL3Δ403-459 
appears to be less abundant than CUL3WT in the heterozygous mice.  These observations 
suggest that CUL3Δ403-459 does not promote KLHL3 degradation in vivo and moreover, that the 
lower levels of CUL3Δ403-459 may be due to the propensity of CUL3Δ403-459 to self-modify 
presumably causing degradation through the UPS. The lower level of observable CUL3Δ403-459 
may also be due to non-proteolytic hyper-modification of CUL3Δ403-459 with either Nedd8 or 
ubiquitin. Indeed, this may in part be the case, as incubation of kidney extract at room 
temperature to promote de-conjugation of Nedd8 or ubiquitin, increased the abundance of the 
faster migrating CUL3Δ403-459 band, but did not restore it to CUL3WT levels (Figure 3.11 A, 
lower panel). Regardless of precisely why, increased levels of WNK4 and downstream 
signalling of the WNK kinase pathway, reported in other mouse models of FHHt, were also 
observed (Figure 3.11 C-D) and consistent with a PHA2E model. Specifically, there were 
striking increases in phospho-SPAK as well as total and phosphorylated forms of NCC (Figure 
3.11 C). A decrease in the level of total and active ENaC was also noted, without changes in 
its regulator, Nedd4-2 (Figure 3.11 D). This finding is supported by the McCormick group who 
found a blunted natriuretic response to amiloride (Ferdaus et al., 2017), suggesting impaired 
electrogenic Na+ reabsorption through ENaC to provide the drive for potassium secretion, and 
therefore contributing to hyperkalaemia. 
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Figure 3.11: CUL3WT/Δ403-459 mice have over-activation of the renal WNK pathway. 
Western blot of whole kidney lysates from mice culled after a minimum 4-h fast. [A] Immunodetection 
reveals KLHL3 levels do not differ between groups, however levels of CUL3 are significantly decreased 
in CUL3Δ403-459 mice. (Lower panel) Deneddylation of immunoprecipitated CUL3 reveals that 
CUL3Δ403-459 is indeed present within the kidney lysate, and suggests that neddylated CUL3Δ403-459 likely 
overlaps with the non-neddylated CUL3WT band. [B] Western blot analysis confirmed the expression 
of KLHL3 and CUL3 in normal healthy human kidneys. [C] Immunodetection highlights elevated 
signalling through the WNK kinase pathway in CUL3WT/Δ403-459 versus CUL3WT/WT mice. [D] 
CUL3WT/Δ403-459 mice have reduced expression of the inactive uncleaved α-ENaC subunit (95kDa) and 
activated cleaved portion of the α-ENaC subunit (30kDa), but unaltered Nedd4-2 expression. [Adapted 
from (Schumacher et al., 2015)]. 
 
 
Over-activation of the WNK pathway would be expected to perturb electrolyte 
homeostasis.  This was confirmed by measuring urine electrolytes, blood biochemistries and 
aldosterone levels in the mice (Figure 3.12, Figure 3.13, Figure 3.14). The CUL3WT/Δ403-459 
mice showed typical features of FHHt with hyperkalaemia, hyperchloraemia and a 
compensated metabolic acidosis; with the pH maintained by an increased respiratory drive to 
increase CO2 removal, hence reduced total CO2 and pCO2 levels (Figure 3.12). Detailed 
electrolyte analysis of plasma and urine revealed several disturbances in mice fed a normal-
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sodium diet, in particular hypermagnesaemia and hyperphosphataemia, which are the converse 
of the abnormalities reported in Gitelman syndrome/Gitelman-like animal models with several 
of the disturbances partially corrected on a low-sodium diet (Akhtar & Hafeez, 2009; Rafiqi et 
al., 2010; Pathare et al., 2012; Ali et al., 2013) (Figure 3.13, Figure 3.14). The mice also had 
elevated aldosterone levels driven by the hyperkalaemia without pronounced hypervolaemia as 
evidenced by similar haematocrit levels (Figure 3.12, lower panel). Additionally, the 
CUL3WT/Δ403-459 mice have significantly lower body weight and body length relative to the WT 
mice (Figure 3.15). This is consistent with Gordon’s original observation that children with 
PHA2 may present with a low percentile body weight and height for their age (Gordon, 1986) 
and more recent reports that CUL3WT/Δ403-459 patients are growth retarded (Tsuji et al., 2013; 
Osawa et al., 2013).   
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Figure 3.12: CUL3WT/Δ403-459 mice have hyperkalaemia, hyperchloraemia with 
compensated metabolic acidosis. 
Arterial blood biochemistries after a minimum 4-h fast. CUL3WT/Δ403-459 mice present with abnormal 
electrolyte homoeostasis compared to CUL3WT/WT mice, exhibiting hyperkalaemia (***P = 0.0004) and 
hyperchloraemia (***P = 9.5 × 10-5) with a compensated metabolic acidosis (P = 0.7766), marked by 
decreases in bicarbonate (HCO3-) (***P = 3.4 × 10-5), base excess (BE) (***P = 9.1 × 10-5), partial 
pressure of carbon dioxide (pCO2) (***P = 0.0038), total CO2 (***P = 3.7x10-5) with normal anion gap 
(P = 0.1022) and urea levels (P = 0.8914). A 58% increase in aldosterone was detected in CUL3WT/Δ403-
459 (n=22) versus CUL3WT/WT (n=18) mice (*P = 0.0245) with no significant changes in haematocrit (P 
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= 0.8757), a volaemic status marker, or glucose homeostasis (P = 0.8757). Two-tailed unpaired 
Student’s t-test; data are mean ± SEM. [Adapted from (Schumacher et al., 2015) with changes to 
data presentation]. 
 
 
Figure 3.13: Plasma electrolyte homeostasis in response to normal-to-low sodium diet 
switch. 
Plasma (P) electrolytes on either a 0.3% w/w normal-sodium (NNa) or 0.03% w/w low-sodium (LNa) 
diet measured by ICP-OES analysis. The differences between genotypes that are significantly different 
are shown as *, the differences between NNa and LNa for CUL3WT/WT that are significantly different 
are shown as #, and the differences between NNa and LNa for CUL3WT/Δ403-459 that are significantly 
different are shown as † (n-values as follows: CUL3WT/WT: NNa = 16; LNa = 17 // CUL3WT/Δ403-459: NNa 
= 23; LNa = 23). Two-tailed unpaired Student’s t-test for comparisons between genotypes and two-
tailed paired Student’s t-test for comparisons between diets within the same genotype; data are mean ± 
SEM. [Adapted from (Schumacher et al., 2015) with changes to table order]. 
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Figure 3.14: Urine electrolyte homeostasis in response to normal-to-low sodium diet 
switch. 
Urinary (U) electrolytes on either a 0.3% w/w normal-sodium (NNa) or 0.03% w/w low-sodium (LNa) 
diet measured by ICP-OES analysis. The urinary electrolyte values (arbitrary units; AU) are calculated 
as a ratio of the urinary concentration of creatinine ([analyte]U/[creatinine]U). The differences between 
genotypes that are significantly different are shown as *, the differences between NNa and LNa for 
CUL3WT/WT that are significantly different are shown as #, and the differences between NNa and LNa 
for CUL3WT/Δ403-459 that are significantly different are shown as † (n-values as follows: CUL3WT/WT: 
NNa = 18; LNa = 16 // CUL3WT/Δ403-459: NNa = 21; LNa = 19). Two-tailed unpaired Student’s t-test for 
comparisons between genotypes and two-tailed paired Student’s t-test for comparisons between diets 
within the same genotype; data are mean ± SEM. [Adapted from (Schumacher et al., 2015) with 
changes to table order]. 
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Figure 3.15: CUL3WT/Δ403-459 mice have growth retardation. 
[A] Illustrative side-by-side size comparisons of male and female CUL3WT/Δ403-459 and CUL3WT/WT 
littermates. Scale bar = 2cm. [B] CUL3WT/Δ403-459 exhibit features of growth retardation when compared 
with CUL3WT/WT mice. The CUL3WT/Δ403-459 have lower body weight (male: * P=0.0128 // female: *** 
P=3.3x10-5) and length [measured nose-to-anus] (male: *** P=0.0002 // female: *** P=0.0009), 
although with no changes in proportionality as measured by tail-to-body ratio (male: P=0.1654 // female 
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P=0.5817). Data are mean ± SEM (male n-values: CUL3WT/WT = 8, CUL3WT/Δ403-459 = 11 for body length; 
CUL3WT/WT = 8, CUL3WT/Δ403-459 = 6 for body weight // female n-values: CUL3WT/WT = 16, CUL3WT/Δ403-
459 = 21 for body length; CUL3WT/WT = 14, CUL3WT/Δ403-459 = 12 for body weight). Two-tail unpaired 
student t-test; data are mean ± SEM. [Taken from (Schumacher et al., 2015)]. 
3.3.7 WNKs accumulate and form puncta with SPAK and OSR1 in the distal 
tubule of CUL3WT/Δ403-459 mice 
Using immunofluorescence confocal microscopy of kidney sections, the distribution of 
proteins involved in the WNK kinase cascade in both CUL3WT/WT and CUL3WT/Δ403-459 mice 
was studied (Figure 3.16 A). CUL3WT/Δ403-459 mice showed a similar CUL3 distribution 
compared to both the WT mice, and to the WT human kidney (Figure 3.16 A-B). Increases 
were seen in the levels of WNK4 and pSPAK along the length of the distal tubule, which led 
to a rise in total and phospho-NCC levels in the early and late DCT, which was in keeping with 
the levels observed in the kidney immunoblots (Figure 3.11 A). There were no discernible 
changes in ROMK (which was more extensively studied in (Murthy et al., 2016)) or total 
NKCC2 in the thick ascending limb (TAL; Figure 3.16 A), which was verified by the 
McCormick group but also shown to be hyperphosphorylated (Ferdaus et al., 2017). This 
would be expected to increase potassium reabsorption and in combination with overactive 
NCC, decrease delivery of sodium to the ENaC expressing distal segments thereby impeding 
potassium excretion via ROMK. Although, new data is emerging to suggest that nephron 
remodelling underlies the hyperkalaemia in FHHt rather than reduced sodium delivery to 
ROMK-expressing distal tubules (Mccormick & Ellison, 2017). 
In contrast, staining for WNK4, WNK1, SPAK and OSR1 in the CUL3WT/Δ403-459 mice 
revealed these proteins to have a striking punctate appearance in the early and late DCT (Figure 
3.16 A, Figure 3.17), but not in the adjacent thick ascending limb (Figure 3.16 A). Recent 
reports also suggested the presence of these puncta in tubular segments downstream of the DCT 
(Boyd-Shiwarski et al., 2017; Ferdaus et al., 2017), and on further inspection of the data in this 
study a handful of connecting tubules (CNT) were discovered to have puncta which were 
smaller than those seen in the DCT (Figure 3.18 A).  
While WNK1 and OSR1 puncta have been reported in the DCT of SPAK knock-out 
mice, these were smaller in size and far less numerous (Grimm et al., 2012) and resemble the 
WNK1 puncta observed in our CUL3WT/WT mice (Figure 3.18 B).  It was therefore hypothesised 
that the enlarged puncta of CUL3WT/Δ403-459 mice might represent an accumulation of WNK-
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SPAK/OSR1 proteins within a protein-processing compartment, such as the trans-Golgi 
network or activation of secondary protein degradation pathways or storage compartments, due 
to failed proteasomal clearance (D’Urso et al., 1998; Lamark & Johansen, 2012; Wolff et al., 
2014), however these puncta did not colocalise with several common markers of subcellular 
compartments (Figure 3.17). These enlarged puncta appear to represent a previously 
uncharacterised population distinct from that seen in WT mice. In particular, these puncta are 
electron-lucent, membraneless, 1-4 µm structures with preferential basolateral/juxta-nuclear 
localisation in the cytosol, commonly surrounded by dilated Golgi and numerous mitochondria 
(Figure 3.18 C). 
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Figure 3.16: WNK4 accumulates and forms puncta in the distal convoluted tubule of 
CUL3WT/Δ403-459 
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[A] Representative pseudocoloured maximum-intensity z projections of immunofluorescently stained 
kidney sections showing the distribution of the WNK/SPAK pathway components between 
CUL3WT/Δ403-459 and CUL3WT/WT mice at a minimum 4-h fasting baseline (n = 4 per genotype). CUL3 
and KLHL3 are comparable between genotypes, with significantly higher levels of CUL3 in the 
proximal convoluted tubule (PCT) compared to the weaker staining in the distal tubules, while KLHL3 
shows higher expression in the cytosol of the distal tubules with staining of the PCT more prominent in 
the apical membrane. The increase in WNK4 abundance promotes phosphorylation (p) of NCC Thr44 
and SPAK Thr243 and their localisation at the apical membrane of the parvalbumin (PVALB)-positive 
early and late (PVALB-negative) distal convoluted tubule (DCT) of CUL3WT/Δ403-459 mice.  This 
increases total (t) NCC levels but with no changes in total SPAK or NKCC2 and ROMK1 in the thick 
ascending limb (TAL) of the loop of Henle. Unexpectedly, the stabilisation of WNK4 and SPAK 
resulted in the formation of discrete puncta in the DCT of CUL3WT/Δ403-459 mice, but not in the TAL. 
Scale bar, 20 µm. [B] Representative immunohistochemical staining of KLHL3 and CUL3 in human 
kidney sections (n = 6). KLHL3 shows preferential cytosolic staining in the distal tubules similar to the 
mouse despite no evidence of PCT apical staining as seen in [A]. CUL3 exhibits preferential basolateral 
cytosolic staining of the PCT with similarly low levels of diffuse staining in the distal tubules to that of 
the mouse. Scale bar, 100 µm. [Taken from (Schumacher et al., 2015)]. 
Figure 3.17: WNK4 puncta colocalise with other components of the WNK pathway and 
do not localises to any known subcellular compartments. 
Representative pseudocoloured average-intensity z projections of immunofluorescently stained 
CUL3WT/Δ403-459 mouse kidney sections (n = 4). Immunolocalisation of total (t) WNK4, WNK1, SPAK 
and OSR1showed they colocalise and form discrete punctate structures in the distal convoluted tubule 
at a 4-h fasting baseline. Surprisingly, these puncta do not colocalise with either autophagosome (LC3), 
Golgi apparatus (FTCD), ubiquitylated aggregate (Ubiquitin), endosome (EEA1), lysosome (LAMP1) 
or endoplasmic reticulum (Calnexin) markers. Scale bar, 20 µm. [Adapted from (Schumacher et al., 
2015)]. 
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Figure 3.18: The enlarged WNK pathway puncta seen in CUL3WT/Δ403-459 mice represent 
a previously uncharacterised population of subcellular structures. 
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[A] Representative pseudocoloured average-intensity z projections of phospho-SPAK (pSPAK) and 
total NCC (tNCC) immunofluorescently stained CUL3WT/Δ403-459 mouse kidney sections (n = 4). While 
the puncta were not observed in the thick ascending limb of the loop of Henle, a very small population 
of these puncta were observed adjacent to the NCC-positive distal convoluted tubules (DCT) in the 
NCC-negative early connecting tubules (CNT). Scale bar, 20 µm. [B] Representative epifluorescent 
kidney sections (n = 4 per genotype) immunostained for WNK1 at a 4-h fasting baseline. A population 
of tiny WNK1 puncta can be seen in CUL3WT/WT mice, whereas puncta in CUL3WT/Δ403-459 mice appear 
to have two populations, one resembling that seen in CUL3WT/WT and a second population of enlarged 
puncta with a predominantly basolateral or juxta-nuclear preference. Scale bar, 20 µm. [C] Block-face 
scanning electron microscopy of osmium, uranium and lead stained DCT of a CUL3WT/Δ403-459 mouse, 
revealed the enlarged puncta (P) to be electron-lucent, membraneless structures that generally abut the 
nucleus (N) and are surrounded by mitochondria (M) and dilated Golgi (G). Scale bar, 5 µm. [Inset] 
Scale bar, 1 µm. 
3.3.8 CUL3WT/Δ403-459 mice have hypertension and a novel vascular phenotype 
Over-activation of the WNK pathway as observed in our CUL3WT/Δ403-459 mice (Figure 3.11 A, 
Figure 3.16 A) should lead to salt retention and elevated blood pressure. Therefore the blood 
pressure (BP) of the CUL3WT/Δ403-459 mice was measured using a pressure-transducer catheter 
in the common carotid artery under general anaesthesia.  Both male and female CUL3WT/Δ403-
459 mice exhibited significantly higher BP relative to CUL3WT/WT littermates (Figure 3.19 A).  
Strikingly, a previously unreported haemodynamic change in the blood pressure trace 
of the CUL3WT/Δ403-459 mice was also observed. The systolic aortic pressure wave of the 
heterozygous mice is augmented while the diastolic pressure decay time constant (τ) is 
significantly slowed, a surrogate marker of increased vascular resistance (Munir et al., 2007) 
(Figure 3.19 B).  These changes suggest early wave reflection of the pressure wave and 
compliance changes consistent with a stiffened vascular tree. This stiffening could reflect a 
primary change in the contractile state of vascular smooth muscle, so to explore this the in vivo 
vasoconstrictor responses to intravenous administration of phenylephrine and angiotensin II 
was studied (Bergaya et al., 2011) (Figure 3.19 C). The resulting dose-response curves showed 
that the maximal constrictor response to both vasopressor agents was substantially higher in 
the CUL3WT/Δ403-459 mice.   
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Figure 3.19: Increased arterial stiffness contributes towards the hypertension of 
CUL3WT/Δ403-459 mice. 
[A] CUL3WT/Δ403-459 mice have elevated systolic (SBP) (***P = 1 × 1012) and diastolic (DBP) blood 
pressure (***P = 8.5 × 108), although they also present with 7% lower heart rates (*P = 0.0485) when 
compared to CUL3WT/WT mice. Two-tailed unpaired Student’s t-test; data are mean ± SEM. [B] Pulse 
waveform analysis of blood pressure traces obtained in [A] reveals that CUL3WT/Δ403-459 mice have an 
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increased pulse pressure (PP) [SBP – DBP] (***P = 2.1 × 1010), augmentation pressure (AP) [SBP – 
anacrotic notch (AN) pressure] (***P = 3.5 × 106), dicrotic notch (DN) pressure (***P = 4.7 × 1013) 
and mean arterial pressure (MAP) [1/3 × SBP + 2/3 × DBP] (***P = 1.3 × 109). This hypertensive 
phenotype is in part due to changes in vascular contractility in CUL3WT/Δ403-459 mice as evidenced by 
their higher augmentation index (AIx) [AP/PP] (**P = 0.0096), a marker of arterial stiffness, and is 
further supported by an increase in their diastolic pressure decay time constant (τbourgeois) [1/slope of 
diastolic pressure decay; measured 30 ms after DN and 20 ms before end DBP] (**P = 0.0083), a 
surrogate marker of increased vascular resistance. Two-tailed unpaired Student’s t-test; data are mean 
± SEM. [C] In vivo dose–responses to phenylephrine and angiotensin II, after baseline measurements 
were obtained from mice in [A]. The fitted Emax for phenylephrine was increased in CUL3WT/Δ403-459 
versus CUL3WT/WT (183.9 ± 2.5 versus 164.9 ± 1.4 mmHg) (***P = 1 × 10-6) indicating an increased 
vasoconstrictor response to adrenergic stimulation elevating systolic blood pressure substantially above 
the CUL3WT/WT maximum. Similarly, the fitted Emax for angiotensin II stimulation was higher in 
CUL3WT/Δ403-459 versus CUL3WT/WT (155.5 ± 1.8 versus 138.3 ± 2.2 mmHg) (***P = 1.7 × 10-6). 
However, there was no change between CUL3WT/Δ403-459 versus CUL3WT/WT sensitivity (as measured by 
ED50) to phenylephrine (36.6 ± 5.1 versus 31.4 ± 2.8 µg/kg.bw) (P = 0.3778) or angiotensin II (0.77 ± 
0.16 versus 0.93 ± 0.13 µg/kg.bw) (P = 0.4401). Two-tailed unpaired Student’s t-test; data are mean ± 
SEM. [Taken from (Schumacher et al., 2015)]. 
 
3.3.9  CUL3 and KLHL3 is expressed in the mouse and human aorta, and 
CUL3WT/Δ403-459 mice have aortic wall thickening 
We also looked for evidence of biochemical changes in the vasculature and confirmed the 
expression of CUL3 and KLHL3 in mouse and human aorta by immunoblot analysis (Figure 
3.20). Similar to the kidneys (Figure 3.11 A), no differences were seen in KLHL3 expression 
between CUL3WT/Δ403-459 and CUL3WT/WT mice, while the levels of CUL3 WT protein were 
lower in CUL3WT/Δ403-459 aorta.  
Image analysis of mouse and human aortae confirmed that both have strong CUL3 and 
KLHL3 staining of the vascular endothelium and smooth muscle cells of the intimal and medial 
layers of the vessel wall (Figure 3.21 A). To address the altered contractility in the vessel wall 
in vivo, the level of phospho-myosin phosphatase target subunit 1 (pMYPT1) in aortic vessel 
lysates was also measured and showed a significant 1.7-fold increase, indicative of stimulation 
of the myosin-actin contractile machinery (Figure 3.21 B) (Feng et al., 1999; Somlyo & 
Somlyo, 2003).  
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Figure 3.20: CUL3 and KLHL3 are present in mouse and human aorta. 
[A] Western blot of tunica media-intima thoracic aorta lysates from mice culled after a minimum 4-h 
fast confirmed the expression of KLHL3 and CUL3. Similar to the kidney, the aorta of CUL3 WT/Δ403-459 
showed slightly lower levels of CUL3 compared to CUL3WT/WT without any change in KLHL3 levels. 
[B] Western blot analysis confirmed the expression of KLHL3 and CUL3 in normal healthy human 
aorta. No obvious sex or age differences were observed. Human kidneys were used as positive controls. 
[C] Western blot of HEK-293 cell lysates over-expressing KLHL2-GFP or KLHL3-FLAG. The anti-
KLHL3 antibody shows an intense band at the predicted molecular weight of FLAG modified KLHL3, 
confirming its ability to detect KLHL3. [D] Dual channel multiplex western blot of HEK-293 cell 
lysates over-expressing KLHL2-GFP showing a band at the predicted molecular weight for GFP 
modified KLHL2 with an anti-GFP antibody (red). The anti-KLHL3 antibody (green) detects a non-
specific higher weight band that does not overlap with KLHL2-GFP, therefore confirming specificity 
for KLHL3 with no cross-reactivity for KLHL2. [Adapted from (Schumacher et al., 2015) with 
changes to labels]. 
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Figure 3.21: Biochemical evidence for increased aortic contractility. 
[A, left] Representative maximum-intensity z projections of immunofluorescently stained thoracic aorta 
sections showing the distribution of CUL3 and KLHL3 between CUL3 WT/Δ403-459 and CUL3WT/WT mice 
at a minimum 4-h fasting baseline (n = 4 per genotype). CUL3 and KLHL3 localisation is comparable 
between genotypes. The highest levels were detected in the vascular smooth muscle cells and 
endothelium, with a minimal expression in the perivascular adipose tissue of the adventitia. Scale bar, 
50 µm. [A, right] Representative immunohistochemical staining of KLHL3 and CUL3 in human 
thoracic aorta sections (n = 6). Similar to the mouse staining, vascular smooth muscle cells in the tunica 
media of the human aortic wall are positive for KLHL3 and CUL3. Scale bar, 50 µm. [B, left] A 
representative western blot of thoracic aorta MYPT1 phospho-Thr696 isoforms and β-actin expression 
from CUL3WT/Δ403-459 and CUL3WT/WT mice run on the same gel. [B, right] CUL3WT/Δ403-459 thoracic 
aorta have increased phosphorylation of MYPT1 isoforms. Ratiometric expression of quantified 
MYPT1 phospho-T696 isoforms (normalised against β-actin) were calculated for CUL3WT/Δ403-459 vs 
CUL3WT/WT on each western blot. The mean of the ratios and bounds of the 95% confidence interval are 
>1, confirming significantly increased phosphorylation (where ratio = 1 represents no change in 
phosphorylation). Results are from three separate blots containing independent biological replicates of 
aortic lysates from both genotypes (total n-values across three blots: CUL3WT/WT = 19 / CUL3WT/Δ403-459 
= 21). Statistical significance was determined by the ratio t-test (see methods for more information); * 
P = 0.02. [Adapted from (Schumacher et al., 2015) with changes to labels]. 
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Figure 3.22: CUL3WT/Δ403-459 mice undergo aortic vascular remodelling. 
Morphometric analysis of thoracic aortae reveals vascular remodelling in CUL3WT/Δ403-459 mice. There 
is an increase of ~21% in the vessel wall intima-media thickness (demarcated by arrows) of 
CUL3WT/Δ403-459 compared to CUL3WT/WT mice (***P = 0.0003). However, there is no change in the 
number of elastin laminae (P = 0.1458) and therefore no increase in the number of medial muscle layers 
between genotypes. Two-tailed unpaired Student’s t-test; data are mean ± SEM. [Taken from 
(Schumacher et al., 2015)] 
Finally, to explore further the vascular phenotype a morphometric analysis of the aortas 
of CUL3 mice was performed that confirmed significant thickening of the vessel wall in the 
heterozygote mice (Figure 3.22). This probably reflects hyperplasia/hypertrophy of the 
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vascular smooth muscle cells in the medial layer, as the numbers of elastic laminae were not 
significantly different (Figure 3.22). 
3.4 Discussion 
This study describes the first successful PHA2E mouse model involving CUL3 and highlights 
the molecular differences and defects of the mutant CUL3 protein.  The deletion of 57 amino 
acids in CUL3Δ403-459 does not affect the ability of the bound RING domain to hydrolyse 
E2~UB, and as such CUL3Δ403-459 is still an active E3 ligase, although, the Sigmund group also 
showed impaired CUL3Δ403-459 binding to RBX1 suggesting a mechanism for decreased 
ubiquitylation efficiency of bound substrates. Additionally, the structural predictions and 
experimental findings provide a second mechanism, suggesting that the CUL3Δ403-459 CRL 
scaffold lacks a level of rigidity required for substrate ubiquitylation. These results are 
consistent with a previous report that demonstrated ubiquitylation of the Cullin1 substrate (p27) 
was abrogated when a linker was inserted between the NTD and CTD of the closely related 
CUL1 protein (Zheng et al., 2002). Thus the CUL3Δ403-459 mutation is a novel physiological 
example of the importance of this CRL rigidity and to our knowledge the first example of a 
human mutation that impedes the scaffolding function of a Cullin, and these data are consistent 
with the working hypothesis that the CUL3Δ403-459 mutation has increased structural flexibility. 
The deletion of three helices fuses together two unstructured regions, which likely allows 
greater movement between the N-terminal and C-terminal domains of the Cullin. This prevents 
the complex from successfully directing ubiquitin towards a bound substrate, and instead, leads 
to increased auto-ubiquitylation of CUL3. Importantly, it appears as if in vivo this auto-
ubiquitylation triggers degradation of the mutant form of the Cullin, as only relatively low 
amounts of CUL3Δ403-459 are detectable in tissue from the mouse model. 
Initially, it was suspected that the auto-degradation of CUL3 is likely to be the major 
driver for the associated phenotype in patients, and while some CUL3Δ403-459 remains in cells, 
the data shows that this remaining protein is unable to ubiquitylate WNK substrates. Taken 
together, the data in this study suggested that the disease-associated deletion of exon-9 from 
CUL3 is a loss-of-function mutation with respect to substrate-ubiquitylation. Importantly, all 
PHA2E patients are heterozygotes, so they retain a functioning copy of CUL3WT.  Thus the 
CUL3Δ403-459 mutation either behaves as a dominant-negative to inhibit CUL3WT or is 
haploinsufficient in the context of blood pressure regulation with the single functional copy of 
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CUL3 unable to sustain the physiological need for WNK ubiquitylation. These data supported 
a haploinsufficiency model (Figure 3.23), as a large proportion of the mutant protein is 
removed from the cell by auto-degradation and in vitro the data did not show CUL3Δ403-459 to 
inhibit CUL3WT. However, two recent studies have provided strong evidence that a reduction 
in CUL3 levels alone is not sufficient to develop FHHt. The Uchida group generated 
constitutive CUL3G(−1)A/+ knock-in mice containing the same pathogenic mutation of the C-
terminus of intron 8 found in human PHA2E pedigrees (Araki et al., 2015). Although instead 
of disrupting activity at splice site to produce an exon-9 skipped mRNA transcript as seen in 
PHA2E patients (Glover et al., 2014), the mutation unexpectedly acted like a knock-out allele. 
These mice had approximately half the CUL3 mRNA and protein levels of wildtype mice and 
had no changes in WNK pathway protein abundance or activity, blood pressure or electrolyte 
homeostasis (Araki et al., 2015). The McCormick group sought to directly test our 
haploinsufficiency model and produced an inducible renal epithelial–specific mouse 
heterozygous for CUL3WT (CUL3Het), which had approximately half the CUL3 protein 
abundance of wildtype controls and similar phenotype to wildtype mice (Ferdaus et al., 2017). 
Notably, they directly compared the levels of CUL3 protein between CUL3Het and CUL3Het/Δ9 
mice, and while CUL3Het levels were more variable overall they found a remarkable similarity 
in the average CUL3 protein abundance between the mice (Ferdaus et al., 2017). Taken 
together these studies imply that a model of substrate-ubiquitylation loss-of-function due to 
CUL3 haploinsufficiency cannot alone fully explain the aetiology of CUL3Δ403-459 mutants. 
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Figure 3.23: The haploinsufficiency model of dysregulated cullin ring ligase activity by 
the PHA2E-causing CUL3 Δ403-459 mutant. 
The haploinsufficiency model proposes that the underlying mechanism is a simple reduction in the total 
levels of functional CUL3 protein available to ubiquitylate WNKs, due to auto-ubiquitylation and 
degradation of CUL3Δ403-459. [Taken from (Ferdaus & McCormick, 2018)]. 
In vitro the BTB-BACK substrate adaptor, KLHL3, is ubiquitylated by CUL3WT and 
with even greater efficiency by CUL3Δ403-459, which has been reported to enhance KLHL3 
degradation in cells (McCormick et al., 2014) leading to the proposal by several groups of a 
KLHL3 degradation model (Figure 3.24) to explain PHA2E aetiology (McCormick et al., 
2014; Ferdaus et al., 2017; Yoshida et al., 2017; Ferdaus & McCormick, 2018). In contrast 
with the in vitro data, the in vivo levels of KLHL3 appear unaffected in our model; a finding 
replicated by the McCormick group’s inducible renal epithelial–specific CUL3Het/Δ9 mice with 
an identical mutation (Ferdaus et al., 2017). This was disputed by the Uchida group, who’s 
CUL3WT/Δ403-259 mouse had a 75% reduction in KLHL3 abundance compared to wildtypes 
(Yoshida et al., 2017) which was detected by immunoblot using a KLHL3 antibody validated 
in KLHL3 knock-out mice (Sasaki et al., 2017). However, the McCormick group could not 
successfully immunoblot kidney lysates with the same antibody, and instead showed no 
significant difference in KLHL3 levels by immunofluorescence with this antibody (Ferdaus et 
al., 2017). Similar to the McCormick group the mouse kidney lysates were immunoblotted 
This figure was redacted for copyright reasons. 
The Copyright holder is The American 
Physiological Society.
The original can be found as Figure 1 in
DOI: 10.1152/ajprenal.00593.2017
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using anti-KLHL3 antibodies that may also detect KLHL2 (mouse KLHL2 and KLHL3 have 
87.4% similarity), which is known to interact with and ubiquitylate WNKs in the kidney 
(Takahashi et al., 2013; Kasagi et al., 2017), and so it can’t be rule out that the results may 
reflect a compensatory rise in renal KLHL2 levels in the face of decreased KLHL3. The 
discrepancies between the in vitro and in vivo data of these studies might simply be attributed 
to the inappropriate use of overexpression studies in Xenopus oocytes and HEK293 cells (N.B. 
– The HEK293 line is suspected to be neuronal in origin – www.hek293.com), which would
result in supraphysiological levels of CUL3 in a context that poorly reflects the in vivo DCT 
(McCormick et al., 2014). In HEK293T cells (a line derived from HEK293), there is evidence 
for enhanced KLHL3 degradation by p62/SQSTM1-mediated selective autophagy when 
proteasomal degradation of WNK 4 is inhibited (Mori et al., 2015), a phenomenon which may 
not occur in the DCT. Furthermore, CUL3 auto-ubiquitylation possibly precedes ubiquitylation 
of KLHL3 in vivo, leading to rapid proteasomal degradation of CUL3Δ403-459 leaving KLHL3 
untouched. It is also known that neddylation/deneddylation cycling is required for CUL3 
activity in vivo, whereby: 1) CUL3 neddylation promotes recruitment of a ubiquitin charged 
E2 enzyme for ubiquitin transfer, 2) the CSN then deneddylates CUL3 to release the “empty” 
E2 enzyme, and 3) subsequent rounds of neddylation/deneddylation cycling allows recruitment 
of “new” E2 enzymes conjugated to ubiquitin to repeat the process (Figure 3.1) (Pintard et al., 
2003). This allows multi-ubiquitylation of the same target molecule and formation of chains of 
ubiquitin moieties, with four to eight moieties necessary for recognition and subsequent 
proteasomal degradation of ubiquitylated substrates (Piotrowski et al., 1997). Therefore, the 
poly-neddylation of CUL3Δ403-459 and loss of CSN-dependent deneddylation would be expected 
to halt neddylation/deneddylation cycling leaving “empty” E2 enzymes stuck within the CRL 
complex. If this is considered in combination with the increased structural flexibility of 
CUL3Δ403-459, the ubiquitylation of KLHL3 may be constituted of smaller sub-threshold 
ubiquitin moieties at multiple sites not normally accessible to CULWT, that do not lead to 
proteasomal degradation in vivo. Importantly, heterozygous KLHL3 knock-out (KLHL3+/-) 
mice do not manifest the phenotypic hallmarks of FHHt (Sasaki et al., 2017), and taking the 
above into consideration, these data argue against KLHL3 degradation as the primary driver 
for FHHt development in CUL3Δ403-459 mutants. Ultimately, further investigation will be 
necessary to provide unequivocal confirmation that KLHL3 levels are unchanged in vivo to 
rule out augmented KLHL3 degradation as a contributing factor in mutant CUL3Δ403-259 
PHA2E aetiology. Indeed, it would be interesting to cross CUL3Het and KLHL3+/- mice to see 
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if a hybrid CUL3 haploinsufficiency-KLHL3 degradation model provides a viable explanation 
for PHA2E. 
Figure 3.24: The KLHL3 degradation model of dysregulated cullin ring ligase activity by 
the PHA2E-causing CUL3Δ403-459 mutant. 
The KLHL3 degradation model proposes that increased ubiquitylation and degradation of KLHL3 by 
CUL3Δ403-459 is the primary driver of the disease. [Taken from (Ferdaus & McCormick, 2018)]. 
A third model was proposed by the Sigmund group, in which CUL3Δ403-459 acts in gain-
of-function dominant-negative fashion by sequestering substrate adaptors and disrupting 
CUL3WT complexes through the formation of  CUL3WT-CUL3Δ403-459 heterodimers (Figure 
3.25) (Ibeawuchi et al., 2015). Like the Sigmund and Ellison groups, an increased binding 
between CUL3Δ403-459 and KLHL3 was noted (McCormick et al., 2014; Ibeawuchi et al., 2015), 
and a reduced affinity for CAND1 which would be predicted to prevent the release of KLHL3 
from the non-functional CUL3Δ403-459 complexes (Figure 3.6 A). This would reduce the amount 
of unbound KLHL3 available to CUL3WT without necessarily leading to a change in the overall 
abundance of the protein. An issue that may be compounded by a simultaneous increase in the 
amount of CAND1 available to CUL3WT, which would lead to exaggerated removal of KLHL3 
from CUL3WT and prolonged sequestration of CUL3WT by CAND1 thereby inhibiting 
subsequent re-binding of KLHL3 to CUL3WT (Lo & Hannink, 2006; Kim et al., 2010). 
Additionally, certain substrates require the formation of dimerised active CRL complexes to 
ubiquitylate their substrates (McMahon et al., 2006; Kigoshi et al., 2011). This may also be 
true for WNKs, with a stoichiometry for the association of CUL3 and KLHL3 measured as 1:1, 
but crystal structure data revealing a 2:2 complex is formed made up of two CUL3 monomers 
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independently bound to two equivalent and non-overlapping surfaces of a KLHL3 homodimer 
(Ji & Privé, 2013). In vitro, KLHL3 has been shown to dimerise in HEK293T cells, with the 
dominant negative effect of the KLHL3 R528 mutant demonstrated to be dependent on dimer 
formation, suggesting it acts by forming an excess of non-productive heterodimers to hinder 
its wildtype counterpart (Sasaki et al., 2017). Furthermore, Nedd8 has been shown to mediate 
the formation of an active CUL3 dimer comprised of one neddylated and one unneddylated 
CUL3. The arrangement in this dimer positions the substrate of one CUL3 so that it is closer 
to the ubiquitin-conjugating E2 enzymes of its partner CUL3 than that of its own, which may 
be necessary for effective ubiquitylation of specific sets of protein substrates, but is unlikely to 
be useful for WNK ubiquitylation, as the distance between the CUL3 binding sites for substrate 
adaptors is increased and may limit the binding of KLHL3 homodimers to a single CUL3 arm 
in this CUL3 dimer arrangement (Wimuttisuk & Singer, 2007). Interestingly, coexpression of 
CUL3Δ403-459 with CUL3WT in HEK293T cells showed that while CUL3Δ403-459-CUL3Δ403-459 
homodimers were highly unstable and almost undetectable at baseline, heterodimers of 
CUL3WT-CUL3Δ403-459 could be formed although were less stable than CUL3WT-CUL3WT 
homodimers. Of particular note, was the finding that cotransfection of HEK293TCUL3KO cells 
with either 1µg CUL3Δ403-459 and 1µg CUL3WT plasmids or 0.5µg empty vector, 0.5µg 
CUL3Δ403-459 and 1µg CUL3WT plasmids yielded the same reduction in the levels of “active” 
neddylated CUL3WT (Ibeawuchi et al., 2015). These data suggest CUL3Δ403-459 impairs 
CUL3WT activity, and while intact WNK4 ubiquitylation was observed in equimolar mixtures 
of CUL3Δ403-459 and CUL3WT in vitro (Figure 3.10 C), the experiment in our study was not 
performed in live cells with an intact UPS nor was WNK4 degradation quantified, so this 
possibility cannot be ruled out. It is conceivable that the same scenario described above for 
KLHL3 may apply here, whereby the observed WNK4 ubiquitylation is a combination of 
normal CUL3WT-CUL3WT homodimer activity and smaller sub-threshold ubiquitin moieties 
placed by CUL3WT-CUL3Δ403-459 heterodimers. The reduction in neddylated CUL3WT may be 
attributed to the absence of CUL3Δ403-459 competition for CSN and CAND1, which would 
increase their availability for CUL3WT binding to enhance and maintain deneddylation (Kim et 
al., 2010). In conjunction with this, the increased structural flexibility and loss of CSN affinity 
for CUL3Δ403-459 results in chronic hyperneddylation at potentially non-physiological residues, 
which may cause CUL3Δ403-459 to preferential sequester unneddylated CUL3WT to form 
inherently unstable CUL3WT-CUL3Δ403-459 heterodimers that trap CUL3WT in an unneddylated 
state rendering it unable to ubiquitylate WNKs (Wimuttisuk & Singer, 2007). However, the 
major caveat of this dominant negative sequestration model is the relatively low levels of 
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CUL3Δ403-459 detectable in vivo and the uncertainty surrounding the in vivo dependence of 
WNK ubiquitylation and degradation on dimerised active CRL complexes. Nonetheless, strong 
evidence for this model has emerged from the McCormick group which produced a mouse with 
two CUL3WT alleles and inducible renal epithelial–specific expression of a third CUL3Δ403-459 
allele (CUL3WT/WT/Δ9) reported to have increased WNK4 abundance, pNCC and pNKCC2 
levels despite similar quantities of CUL3WT when compared to kidneys of CUL3WT/WT mice 
(Ferdaus et al., 2017). Similarly, the Sigmund group produced a mouse with two CUL3WT 
alleles and inducible smooth muscle–specific expression of a third CUL3Δ403-459 allele (CUL3S-
Δ9), which presented with increases in another CUL3 substrate, RhoA, and surprisingly 
decreases in both the neddylated and total levels of CUL3WT when compared with the aortae 
of non-transgenic mice (Agbor et al., 2016). 
Figure 3.25: The sequestration model of dysregulated cullin ring ligase activity by the 
PHA2E-causing CUL3Δ403-459 mutant. 
The dominant negative model suggestions that CUL3Δ403-459 sequesters KLHL3 and/or impairs dimer 
functions necessary for WNK ubiquitylation and degradation. [Adapted from (Ferdaus & McCormick, 
2018) with modification to the schematic]. 
The CUL3WT/Δ403-459 mice have high blood pressure and up-regulated signalling in the 
context of the WNK-kinase pathway, which parallels the WNK4 D565E (Chowdhury et al., 
2013), WNK4 D561A/+ (Yang et al., 2007b) and KLHL3 R528H (Susa et al., 2014) PHA2 
mouse models previously described.  Mechanistically, the data in our study suggest CUL3Δ403-
459 promotes its own degradation, as it has a heightened propensity to self-ubiquitylate and is 
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less abundant in mouse kidney extract.  Hence it would be predicted that PHA2E CUL3WT/Δ403-
459 patients would similarly have lower overall CUL3 levels.  As CUL3 ubiquitylates a number 
of other proteins, it seems remarkable then that PHA2E patients do not have a plethora of other 
phenotypic manifestations. However this may not be surprising if considered in the context of 
either the dominant negative sequestration model or a hybrid CUL3 haploinsufficiency-
KLHL3 degradation model. The Sigmund and Ellison groups showed that compared to 
CUL3WT, CUL3Δ403-459 has an  approximately 2-fold increased binding to various substrate 
adaptors, namely, Bacurd1, RhoBTB1, BTBD1 and KCTD6, whereas KLHL3 binding is as 
least 3.5-fold higher (McCormick et al., 2014; Ibeawuchi et al., 2015). But the most surprising 
finding was that the in vitro expression of CUL3Δ403-459 either did not affect or actually 
increased abundance of these substrate adaptors in cells (McCormick et al., 2014; Ibeawuchi 
et al., 2015), which was not always true for KLHL3 (McCormick et al., 2014). These studies 
imply CUL3Δ403-459 directed degradation or sequestration of substrate adaptors may be 
preferentially targeted towards KLHL3, and in a similar vein, the requirement for functional 
CUL3 dimers to facilitate substrate ubiquitylation may be a phenomenon relatively specific to 
WNKs, however these possibilities need to be tested directly in vivo. Additionally, BP 
homeostasis requires reactive and precise control of vascular tone and of ion fluxes in the distal 
nephron, especially the DCT, as changes in intake and output of salt are constantly balanced. 
The phosphorylation of the NCC/NKCC ion transporters by WNK kinases appears to be 
regulated by two complementary systems: the regulation of total WNK protein levels by CUL3-
KLHL3, and the level of WNK activation by phosphorylation. Currently our understanding of 
the sensing-mechanisms that leads to WNK-phosphorylation or the degradation of the WNK 
kinases by CUL3-KLHL3 is limited. Only recently have DCT cells been discovered to sense 
changes in extracellular potassium via membrane voltage, effectively coupling serum 
potassium levels with DCT intracellular chloride concentration to direct WNK activity, 
achieved through increased chloride ion binding to WNKs which inhibits WNK 
autophosphorylation necessary for activation (Terker et al., 2015b, 2015a). Another recent 
breakthrough was the discovery that WNK interactions with KLHL3 are impaired by 
phosphorylation of KLHL3 at serine 433 (Wang & Peng, 2017), which can be induced in vivo 
and in vitro by angiotensin II, vasopressin, insulin and potassium depletion to prevent WNK 
degradation (Shibata et al., 2014; Yoshizaki et al., 2015; Ishizawa et al., 2016). Hence, while 
most other CUL3 substrates may be unaffected in the CUL3WT/Δ403-459 mice, the rapid and 
signal-dependent switching of WNK ubiquitylation may require a larger complement of 
functional CUL3-KLHL3 CRL complexes within blood vessel and kidney cells for the system 
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to respond adequately. The lack of a gross phenotype in either heterozygous CUL3 or KLHL3 
knock-out mice support this concept of redundancy with respect to most CUL3 substrates 
(Araki et al., 2015; Ferdaus et al., 2017; Sasaki et al., 2017), with the threshold for CUL3 
insufficiency-induced cell lethality previously demonstrated to lie somewhere between 45% 
and 50% CUL3 expression in mouse embryonic fibroblasts (McEvoy et al., 2007). 
Another intriguing finding from our study was the discovery of WNK-SPAK/OSR1 
containing puncta in the DCT/CNT of CUL3WT/Δ403-459 mice. Subcellular structures containing 
WNK-SPAK/OSR1 have been reported in vitro in a various cell lines and in vivo rodent 
models, often referred to as either puncta, foci or ‘WNK bodies’ (Boyd-Shiwarski et al., 2017), 
with the latter description perhaps the most apt. While there are now numerous reports of WNK 
bodies in animals undergoing dietary potassium manipulations or Gitelman-like genetic knock-
out mice (Grimm et al., 2012; Mori et al., 2015; Terker et al., 2015b), this is to our knowledge 
the first report of a FHHt model exhibiting these structures. A running theme for the appearance 
of WNK bodies seems to be perturbations of serum potassium concentration, with both high 
and low levels triggering their DCT/CNT restricted formation. However, the two stimuli create 
morphologically different populations of WNK bodies; low potassium produces bodies with a 
basolateral preference averaging 2µm in diameter, while high potassium results in a 
significantly lower number of sub-apical bodies averaging 1µm in diameter (Boyd-Shiwarski 
et al., 2017). Interestingly, the bodies associated with low serum potassium in wildtype animals 
(Terker et al., 2015b; Boyd-Shiwarski et al., 2017) bear a closer resemblance to that of our and 
the McCormick group’s CUL3WT/Δ403-459 mice despite the presence of pronounced 
hyperkalaemia (Ferdaus et al., 2017), which may suggest that this population of bodies plays 
a role in promoting WNK-SPAK/OSR1 pathway activity. This is supported by the presence of 
phospho-SPAK T243 and autophosphorylated WNK1 S382 in WNK bodies of our 
CUL3WT/Δ403-459 mice and animals fed a low potassium high sodium diet (Terker et al., 2015b), 
respectively, while the opposite is true for high potassium-induced WNK bodies that were 
noted to have an absence of phospho-WNK1 T60 (Boyd-Shiwarski et al., 2017). The 
Subramanya lab also bolstered the argument for WNK bodies having an important functional 
role by demonstrating that they are kidney-specific WNK1 (KS-WNK1) dependent, and that 
formation requires an evolutionary conserved cysteine-rich hydrophobic motif in the unique 
exon-4a of the KS-WNK1 isoform, which may have emerged to facilitate the transition of life 
from water to land (Boyd-Shiwarski et al., 2017). This would mean that KS-WNK1 abundance 
would be expected to rise in CUL3WT/Δ403-459 mice due failed ubiquitylation, which may be 
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sufficient to drive activity-promoting WNK body formation even in the face of hyperkalaemia. 
In fact the extreme hyperkalaemia and overactivation of the WNK pathway in PHA2E presents 
a paradox, as the currently accepted model for potassium-dependent WNK activation predicts 
that hyperkalaemia would increase intracellular chloride to a concentration capable of totally 
inhibiting the activating-autophosphorylation of WNKs, irrespective of their increased 
abundance. WNK bodies may offer a solution to this FHHt paradox, by serving to recruit 
components of the WNK pathway into densely packed compartments which effectively 
occludes the chloride ion binding sites of WNKs through a process known as ‘macromolecular 
crowding’ (Parker, 1993; Kuznetsova et al., 2014), permitting them to autophosphorylate 
regardless of the intracellular chloride levels in the rest of the cytosol. As the WNK pathway 
is known to also be activated by decreases in cell volume, it was proposed by the Goldsmith 
team who discovered the chloride binding site, that this response might be mediated by 
crowding effects which could compete with chloride to promote an autophosphorylation-
competent conformation (Piala et al., 2014). To support this, Goldsmith has demonstrated in 
vitro that macromolecular surrogates such as polyethylene glycol can activate WNK1/3 in a 
manner which is opposed by chloride (Goldsmith et al., 2017), and Subramanya has shown in 
FRAP and supernatant-pellet assays that KS-WNK1 movement is confined to a biochemically 
distinct fraction of the cell when compared to full-length ‘long’ WNK1 (L-WNK1), leading 
them to propose that WNK bodies are demixed hydrophobic microdomains of the cytosol 
designed to partition signalling processes (Boyd-Shiwarski et al., 2017). Originally, it was 
suspected WNK bodies in CUL3WT/Δ403-459 DCT cells may represent deployment of secondary 
protein degradation pathways to manage excess WNK proteins, such as the autophagy-
lysosomal system, aggresome or juxta-nuclear quality control compartment (JUNQ) in an 
attempt to compensate for loss of proteasomal degradation (Lamark & Johansen, 2012; Wolff 
et al., 2014). However, as these WNK bodies have not been found to colocalise with any known 
subcellular organelle, quality control compartment or pathogenic aggregations, this concept 
was abandoned (Boyd-Shiwarski et al., 2017). Instead, a surprising discovery was made linking 
WNK bodies to the seemingly unrelated 60s ribosomal subunit L22 (RPL22), with high 
potassium colocalising with ~35% of RPL22 that then dramatically increases to >80% in low 
potassium (Boyd-Shiwarski et al., 2017). In animals suspected to have hypokalaemia induced 
by chronic administration of aldosterone, RPL22 formed puncta which were morphologically 
similar to WNK bodies. Interestingly, these bodies were also found to have an almost the 80% 
colocalisation with the 20s proteasome (Cheema et al., 2014), which can degrade damaged and 
misfolded proteins via an ubiquitin-independent pathway (Ben-Nissan & Sharon, 2014). 
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Therefore, it is attractive to postulate that WNK bodies simultaneously recruit these additional 
proteins to ensure the integrity of WNK signalling by degrading and replacing worn out WNK-
SPAK/OSR1 complexes during low potassium stimulation. Although it remains to be seen if 
WNK-SPAK/OSR1 signalling is contingent on WNK body formation or if the 20s proteasome 
colocalises with WNK bodies in vivo. 
Mutations in CUL3, KLHL3, WNK1 and WNK4 are known to cause FHHt with 
constitutive activation of the NCC cotransporter (Boyden et al., 2012; Tsuji et al., 2013; Osawa 
et al., 2013; Glover et al., 2014; Alessi et al., 2014). What has been less clear is why the 
mutation of CUL3 has resulted in a more severe form of FHHt (PHA2E).  The unexpected 
discovery of a vascular phenotype in the CUL3WT/Δ403-459 mice, led to speculation that their 
hypertension may not be driven by salt-retention in the DCT alone. It is possible that part of 
their hypertension originates from an increased contractile state in their vasculature tree. If a 
similar phenomenon occurs in PHA2E, this may explain the early-onset and severity of the 
blood pressure that occurs in these patients.  The CUL3WT/Δ403-459 mice have an altered aortic 
pulse-wave form and slowed diastolic relaxation that is consistent with stiffening of their 
arterial tree. These changes have been reported before in humans with hypertension (Kaess et 
al., 2012), but not previously in a hypertensive mouse model. It is also worth noting that 
augmentation of the aortic pressure wave is often not detected by brachial cuff BP 
measurements, so it could have gone unnoticed in the routine clinical assessment of PHA2E 
patients. The increase in pMYPT1 in the aortas from the CUL3WT/Δ403-459 mice and the increase 
in their in vivo pressor responses to phenylephrine and angiotensin-II further suggest that the 
altered contractile state could be a primary phenomenon rather than simply a secondary 
response to hypertension. If this is the case, the contraction could occur by at least two distinct 
pathways. Firstly the WNK1/WNK3/SPAK/OSR1 pathway is thought to be important for 
regulating vascular tone by controlling the phosphorylation state of the NKCC1 cotransporter 
and hence the membrane potential of vascular smooth muscle (VSM) cells (Zeniya et al., 
2013). So if either WNK1 or WNK3 accumulates in the vessel wall of the CUL3WT/Δ403-459 
mice, the contractile tone would be expected to rise through depolarisation of VSM and 
increased calcium entry. Alternatively, the mutant Cullin-3 protein may directly affect the 
phosphorylation state of myosin light chain by regulating RhoA/RhoA kinase (ROCK) levels 
(Ibeawuchi et al., 2015). RhoA protein levels in the VSM are thought to be regulated by CUL3 
in complex with the substrate adaptor RhoBTB1 (Pelham et al., 2012). Indeed the Sigmund 
group’s CUL3S-Δ9 mouse model with smooth muscle-specific ectopic expression of CUL3Δ403-
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459 on a CUL3WT/WT background provides the strongest evidence that the hypercontractile state 
is a primary phenomenon. Isolated blood vessel work with basilar arteries showed that CUL3S-
Δ9 have a higher contractile response to phenylephrine, angiotensin II and endothelin-1, and 
impaired vasodilation in response to acetylcholine, angiotensin 1-7, cromakalim and sodium 
nitroprusside, but surprisingly nifedipine-induced vasodilatation was normal (Agbor et al., 
2016). Similarly, acetylcholine-induced relaxation of the aorta was impaired due to higher 
levels of RhoA and pMYPT1 caused by increased ROCK activity, which could by inhibited by 
Y27632 to restore normal acetylcholine-dependent vasodilatation in basilar arteries/aortae. 
These vascular defects lead to sleep-period systolic hypertension and increased pulse wave 
velocity, the gold standard measurement for increased arterial stiffness (Agbor et al., 2016), all 
of which confirms our own finding in CUL3WT/Δ403-459 mice. Though it appears as if vascular 
story does not end here, and additional endothelia mechanisms may contribute to the altered 
vascular tone in CUL3Δ403-459 mutants. The Sigmund group developed an additional model 
similar to CUL3S-Δ9, but this time with endothelial-specific inducible promotor to produce E-
CUL3Δ9 mice. The basilar and carotid arteries of these mice exhibited impaired endothelium-
dependent relaxation in response acetylcholine without a change in VSM function, and similar 
to CUL3S-Δ9 mice, the E-CUL3Δ9 manifested nocturnal hypertension and elevated pulse wave 
velocity (Wu et al., 2017b, 2017a). The underlying mechanism for this appeared to be impaired 
turnover of Cullin-3 substrate protein phosphatase 2A (PP2A), a marked decrease in 
phosphorylated endothelial nitric oxide synthase (eNOS), and reduced nitric oxide (NO) 
bioavailability, which could be rescued by PP2A inhibitors Calyculin A and Okacaic acid (Wu 
et al., 2017b, 2017a). 
If these same pathways are operational in human PHA2E, then they suggest that 
treatment with a thiazide diuretic or dietary sodium restriction while effective in reversing the 
electrolyte disturbances, may be less effective in reversing any central aortic pressure changes 
in PHA2E. Given the overactivation of the RhoA/ROCK pathway and impairment of eNOS 
function, a direct arterial vasodilator or a specific ROCK inhibitor (Liao et al., 2007) might be 
the most appropriate drug of choice. The contribution of WNK/SPAK/OSR1 to this vascular 
phenotype has yet to be determined, and a loop diuretic such as bumetanide may be more 
effective than a thiazide, as it would target both NKCC1 and NKCC2. Central aortic pressure 
elevation is now widely accepted to be an important and independent cardiovascular risk factor 
(Liao & Farmer, 2014), so if it is elevated in patients with PHA2E it will be important to show 
that it is normalised by appropriate pharmacotherapy. 
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Chapter 4 : MO25 as a Master Regulator of SPAK/OSR1 in vivo 
 
[This chapter is principally based on and expands upon the content from the abstracts in 
Appendix 1] 
 
4.1  Abstract  
Recently mouse protein-25 (MO25) isoforms were discovered to be master regulators of 
SPAK/OSR1; which form a cascade with WNKs to regulate the Cation–Cl Cotransporters 
involved in cell volume, blood pressure and electrolyte homeostasis. MO25α (also known as 
calcium-binding protein 39; CAB39) colocalises with renal NCC, increases SPAK/OSR1 
activity up to 100-fold independent of WNKs, facilitates SPAK/OSR1 monomer interactions 
and stabilises their active conformations, which in turn would promote an increase in NCC 
activity and Na+ reabsorption. The paralog MO25β (also known as calcium-binding protein 39-
like; CAB39L) shares 79% sequence identity with MO25α, has high renal expression and 
interacts similarly with substrates such as the tumour suppressor liver kinase B1 (LKB1) which 
phosphorylates adenosine monophosphate-activated protein kinase (AMPK). However, the 
embryonic lethality of MO25α knock-out mice has limited in vivo data gathering, and MO25β 
knock-out mice were selected as an alternative model to test the hypothesis that MO25 
deficiency would produce a hypotensive salt-wasting phenotype. It was found that MO25β 
knock-out mice do not recapitulate the expected Gitelman syndrome phenotype (salt-wasting 
hypotension), with few electrolyte abnormalities and were normotensive even in the face of 
prolonged salt restriction. With the exception of slight differences in haematology and body 
composition the mice otherwise appeared to be healthy. It was therefore concluded that 
mammalian MO25β does not play a significant role in blood pressure or electrolyte 
homoeostasis in vivo. 
 
4.2  Introduction   
MO25α (also known as Calcium-binding protein 39; CAB39) is part of a protein scaffold with 
STRAD (STE20-Related ADaptor protein) isoforms that binds and activates members of the 
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STE20 (Sterile 20) family of serine/threonine kinases (Filippi et al., 2011).  The C-terminus of 
STRAD binds through a conserved WEF motif to MO25 and this conformation increases the 
catalytic activity of the bound STK (Serine-Threonine Kinase) (Figure 1.9). The STE20 family 
includes both SPAK and OSR1 kinases that act through well-defined WNK/SPAK/OSR1 
signalling pathways to regulate members of the SLC12A (solute carrier family 12) family of 
electroneutral CCCs (cation-chloride cotransporters) in the kidney and elsewhere (Richardson 
et al., 2008, 2011; Richardson & Alessi, 2008; Rafiqi et al., 2010). The role of SLC12A 
transporters is to regulate intracellular chloride concentration that is critical for controlling cell 
volume and ultimately blood pressure (Rafiqi et al., 2010; Yang et al., 2010c; Filippi et al., 
2011). SPAK/OSR1 protein kinases drive chloride influx by phosphorylation and activation of 
sodium-driven CCC members. These include the NCC (Na–Cl Cotransporter) in the distal 
convoluted tubule (DCT) of the kidney (Yang et al., 2010c; Zeniya et al., 2013), the NKCC2 
(Na–K–2Cl Cotransporter 2) in the thick ascending limb (TAL) of the kidney (Giménez & 
Forbush, 2003; Ponce-Coria et al., 2008) and the ubiquitously expressed NKCC1 (Vitari et al., 
2006; Zeniya et al., 2013). 
 
 The MO25 protein is highly conserved in evolutionary terms across humans, mice, 
zebrafish, flies and yeast (Miyamoto et al., 1993; Nozaki et al., 1996; Zhang et al., 2013), but 
in mammals it exists as closely related isoforms, MO25α and MO25β (also known as Calcium-
binding protein 39-like; CAB39L), that share 79% of their amino acid sequence (Boudeau et 
al., 2003). They are both widely expressed in tissues, although MO25β has a more restricted 
pattern of expression than MO25α. SPAK is one of a subgroup of members of the STE20 family 
that are unusual in having four conserved WEW motifs that can bind to MO25 (Figure 1.6). 
Using in vitro phosphorylation assays the MO25 isoforms stimulate the activity of SPAK 100-
fold and silencing the gene in HEK293 cells reduces NKCC1 phosphorylation (Filippi et al., 
2011). As the putative interaction model predicts (Filippi et al., 2011), MO25 has its action 
without affecting the key phosphorylation site in the T–loop of SPAK.  
Study of growth and development in Drosophila melanogaster, led to the initial 
discovery that dMo25 and Fray (orthologs of mammalian MO25α/β and SPAK/OSR1, 
respectively) work together in the same pathway (Yamamoto et al., 2008), and later purified 
proteins were used to show that dMo25 can stimulate Fray phosphorylation of the fly NKCC 
in vitro (Rodan et al., 2017). In these flies, neither overexpression of a chloride-insensitive 
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WNKL421F (predicted to be constitutively active), nor knockdown/overexpression of dMo25 in 
the fly renal tubule in vivo altered transepithelial potassium flux under isotonic conditions. 
However, simultaneous overexpression of dMo25 and WNKL421F increased potassium flux 
under isotonic conditions, while dMo25 knockdown prevented any increase in potassium flux 
in response to a hypotonic stimulus (Rodan et al., 2017). Taken together, these data and the 
highly conserved nature of MO25, would predict that mammalian MO25 isoforms have an 
active role in electrolyte homeostasis and therefore blood pressure control.  
The aim of this study was to explore the roles of mammalian MO25 isoforms in vivo. 
Initial attempts were made to knock-out MO25α to explore its functions directly (Alessi et al. 
unpublished data), however, in our hands knock-out of MO25α proved to be lethal in utero. In 
contrast MO25β knock-out embryos are viable to adulthood, allowing the investigation of the 
role of this isoform in the adult kidney. 
 
4.3  Results  
 
4.3.1  Expression and Localisation of MO25β 
Database mining revealed the existence of a phenotyped Cab39ltm1b(EUCOMM)Wtsi heterozygous 
(CAB39L+/-) mouse model with a β-galactosidase (LacZ) reporter in the MO25β null allele. X-
gal staining indicated that MO25β gene expression was strongest in cartilaginous tissues, 
bladder mucosa, renal papilla, adrenal medulla and parathyroid glands. Gene expression was 
also detected in the heart, lungs, thyroid, brain ventricles and spinal cord central canal (Figure 
4.1). Of particular interest, moderate to high levels of gene expression were detected in small 
blood vessels (Figure 4.1 B) and the renal cortex and inner medulla (Figure 4.1 A). 
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Figure 4.1: MO25β gene expression and distribution in mouse tissues. 
X-gal staining was performed in various whole-mount organs and tissues of male and female 
Cab39ltm1b(EUCOMM)Wtsi heterozygous (CAB39L+/-) mice, which have a β-galactosidase (LacZ) reporter 
in the MO25β null allele. Blue staining indicates gene expression. [A] Kidney, axial section; [B] 
Ribcage and sternum; [C] Heart and aortic arch; [D] Adrenal gland, transverse section; [E] Bladder; 
[F] Trachea, thyroid and parathyroid glands; [G] Brain, sagittal section; [H] Lung. Abbreviations: 
Cortex (Cor), Outer Medulla (OM), Inner Medulla (IM), Papilla (Pap), Cartilage (Cart), Bone (Bo), 
Blood Vessels (BV), Aorta (Ao), Atria (At), Ventricle (V), Medulla (M), Tunica Mucosa (TMuc), 
Tunica Muscularis (TMus), Thyroid (T), Parathyroid (PT), Cerebellum (Cer), Central Canal (CC). 
Images by IMPC [http://www.mousephenotype.org/data/genes/MGI:1914081], copyright by © 2016 
IMPC. 
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Our MO25β knock-out heterozygous (MO25β+/-) and homozygous (MO25β-/-) embryos 
proved to be viable and produced fertile adult mice. MO25α/β proteins expression was detected 
in the heart, lungs and kidneys by immunoblot of wildtype mice, with confirmation of 
successful MO25β knock-out by immunoprecipitation and immunoblotting of tissue lysates. 
Interestingly, there was no marked compensatory upregulation of MO25α protein expression 
(Figure 4.2). 
 
 
Figure 4.2: Protein expression of MO25 isoforms in mice. 
Immunoblot (IB) of MO25α and MO25β from either immunoprecipitates (IP) or lysates from tissue 
homogenates of MO25β+/+, MO25β+/-, and MO25β-/- mice. The complete knock-out of MO25β was 
confirmed, with no compensatory overexpression of MO25α detected. 
 
To explore the distribution of MO25β in the kidney, clues were first sought from the 
Human Protein Atlas. In the human renal cortex, MO25β immunohistochemistry shows diffuse 
staining within the cytosol of the distal tubules which is totally absent from proximal tubules 
and glomeruli (Figure 4.3). This suggests a potential role in renal distal tubular salt transport. 
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Figure 4.3: Localisation of MO25β in the human kidney. 
Representative immunohistochemically-stained wildtype kidney section (n = 3) showing the 
distribution of MO25β in the renal cortex, as identified by the presence of glomeruli (G). MO25β is 
absent from human proximal tubules (PT) and is generally confined to the cytosol of the distal tubules 
(DT). Sections were stained with a mouse monoclonal antibody (H00081617-M01; Abnova) raised 
against full length recombinant MO25β protein. Scale bar = 50μm. This image of CAB003686 (Patient 
ID1943) is from the Human Protein Atlas [https://v17.proteinatlas.org/ENSG00000102547-
CAB39L/tissue/kidney], used under CC BY-SA 4.0. Brightness and contrast were adjusted from 
original by linear histogram stretching to enhance visibility. 
 
Immunofluorescent staining of the mouse renal cortex showed a similar pattern of 
distribution to that seen in human kidneys. MO25β exhibited minimal or no staining in the 
proximal tubules and glomeruli, and was generally confined to the cytosol of distal tubules 
(Figure 4.4). MO25β has a diffuse staining with the basolateral preference unlike MO25α 
which is concentrated at the apical membrane of distal tubules (Grimm et al., 2012). Further 
exploration of the Human Protein Atlas revealed that at the subcellular level MO25β associated 
with cytosolic vesicles in both mouse and human cell lines (Figure 4.5). 
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Figure 4.4: Localisation of MO25β in the mouse kidney. 
Representative pseudocoloured maximum-intensity z projections of immunofluorescent-stained 
wildtype kidney sections (n = 4) showing the distribution of MO25β in the renal cortex, as identified 
by the presence of glomeruli (G). [A] Based on the absence of a brush border and the high density of 
nuclei, MO25β generally mimics human localisation and is confined to the cytosol of the distal tubules 
(DT) with a basolateral preference, and is very low or non-existent in proximal tubules (PT); [B] 
Primary antibody negative control (i.e. secondary antibody only). Scale bar = 50μm.  
 
 
Figure 4.5: Subcellular localisation of MO25β. 
Representative pseudocoloured immunofluorescent-stained cells (n = 2) showing the sub-cellular 
distribution of MO25β in human and mouse cell lines. [A] In the CACO-2 (human colon 
adenocarcinoma) cell line, MO25β is localised to vesicles in the cytosol. [B] In the NIH 3T3 (mouse 
embryonal fibroblast) cell line, MO25β is similarly localised to cytosolic vesicles, although at lower 
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abundance than CACO-2 cells. Cells were stained with a rabbit polyclonal antibody (HPA045954; Atlas 
Antibodies) raised against a recombinant protein epitope signature tag (PrEST) MO25β antigen 
sequence. Scale bar = 50μm. HPA045954 stained CACO-2 and NIH 3T3 images are from the  Human 
Protein Atlas [https://v17.proteinatlas.org/ENSG00000102547-CAB39L/cell], used under CC BY-SA 
4.0. Re-pseudocolouring, brightness and contrast were adjusted from original by linear histogram 
stretching to enhance visibility. 
 
4.3.2  Morphometry 
Neither of the MO25β-/- or CAB39L-/- mice models presented with developmental issues or 
exhibited gross morphological abnormalities in the adult. However, CAB39L-/- male mice did 
have a higher percentage of body fat despite no differences in body weight or bone mineral 
density. Additionally, an enlarged heart was found in one male CAB39L-/- mouse, although no 
significant difference was found in heart weights between the sexes of each genotype (Table 
4.1). 
 
Parameter  CAB39L+/+ CAB39L-/- P-value
♂ Bodyweight (g) 29.93 ± 0.06 (n=1388) 30.50 ± 0.60 (n=12) 0.3803
♀ Bodyweight (g) 24.37 ± 0.05 (n=1628) 25.53 ± 0.29 (n=12) 0.1384
♂ BMD (g/cm2) 0.0549 ± 0.0001 (n=1452) 0.0559 ± 0.0008  (n=7) 0.4630
♀ BMD (g/cm2) 0.0545 ± 0.0001 (n=1438) 0.0534 ± 0.0005 (n=8) 0.2498
♂ Body Fat (%) 18.48 ± 0.12 (n=1452) 22.17 ± 1.05 (n=7) *0.0294
♀ Body Fat (%) 18.23 ± 0.09 (n=1438) 17.83 ± 0.94 (n=8) 0.7525
♂ Heart (mg) 137.4 ± 0.5 (n=1407) 144.1 ± 4.1 (n=8) 0.3609
♀ Heart (mg) 113.2 ± 0.4 (n=1382) 116 ± 2.1 (n=8) 0.5665
♂ Enlarged Heart -  1 of 4       - 
Table 4.1: Morphometry and body composition. 
DEXA scans for bone mineral density (BMD) and body composition were performed at age 14 weeks. 
Terminal bodyweight and organ wet weights were taken at age 16 weeks. Cab39ltm1b(EUCOMM)Wtsi 
homozygous knock-out (CAB39L-/-) mice showed no significant differences from the wildtype 
CAB39L+/+ with the exception of male percentage body fat and a single male with an enlarged heart. 
*(P<0.05). Data from IMPC [http://www.mousephenotype.org/data/genes/MGI:1914081] and 
copyright © 2016 IMPC. 
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4.3.3  Haematology 
IMPC database records indicate that CAB39L-/- mice have several significant differences in a 
complete blood count analysis. Females have a higher white blood cell count, although overall 
CAB39L-/- mice have a lower mean corpuscular volume, accompanied by increased red blood 
cell count, haematocrit and haemoglobin, despite no change in mean corpuscular haemoglobin 
concentration (Table 4.2).  
 
Parameter  CAB39L+/+ CAB39L-/- P-value
♂ Platelets (103/µL) 1472.7 ± 13.5 (n=128) 1465.4 ± 38.3 (n=8) 0.8946
♀ Platelets (103/µL) 1189.4 ± 10.0 (n=145) 1128.0 ± 37.9 (n=7) 0.1880
♂ WBC  (103/µL) 9.049 ± 0.217 (n=128) 8.0413 ± 0.660 (n=8) 0.2566
♀ WBC  (103/µL) 6.346 ± 0.128 (n=145) 8.090 ± 0.587 (n=7) **0.0040
RBC  (106/µL) 10.184 ± 0.025 (n=273) 10.784 ± 0.110 (n=15) ***1.4x10-7
Haematocrit (%) 49.06 ± 0.12 (n=273) 50.51 ± 0.40 (n=15) **0.0060
Haemoglobin 15.00 ± 0.03 (n=272) 15.56 ± 0.08 (n=15) ***4.0x10-6
MCV (fL) 48.19 ± 0.07 (n=273) 46.86 ± 0.24 (n=15) ***1.7x10-5
MCHC (d/dL) 30.61 ± 0.07 (n=272) 30.83 ± 0.22 (n=15) 0.4765
Table 4.2: Complete blood count. 
Cab39ltm1b(EUCOMM)Wtsi homozygous knock-out (CAB39L-/-) mice have decreased mean corpuscular 
volume (MCV) and increased haematocrit, haemoglobin and red blood cell (RBC) counts with no 
changes in mean corpuscular haemoglobin concentration (MCHC) or platelet counts, however only 
females have a higher white blood cell (WBC) count.   *(P<0.05), **(P<0.01), ***(P<0.001). Copyright 
data (© 2016 IMPC) is from IMPC [http://www.mousephenotype.org/data/genes/MGI:1914081]. 
 
4.3.4  Electrolyte Homeostasis 
To determine a potential role for MO25β in salt homeostasis in vivo, plasma and urine 
electrolytes were analysed on various sodium diets. At baseline, CAB39L-/- mice had a lower 
plasma creatinine level (Table 4.3) which might be reflective of their higher body fat 
percentage (Table 4.2). CAB39L-/- also have roughly 1 mmol/L higher plasma sodium (Table 
4.3) despite no significant differences observed in sodium handling for MO25β-/- on a normal 
Na diet, however these mice do have excess magnesium excretion (Table 4.4).  
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Parameter  CAB39L+/+ CAB39L-/- P-value
[Creat]P (µmol/L) 9.51 ± 0.03 (n=2785) 8.69 ± 0.57 (n=16) *0.0454
[Na+]P (mmol/L) 147.11 ± 0.04 (n=2804) 148.25 ± 0.50 (n=16) *0.0217
[K+]P (mmol/L) 4.47 ± 0.01 (n=2802) 4.36 ± 0.11 (n=16) 0.3266
[Cl-]P (mmol/L) 110.65 ± 0.04 (n=2803) 110.75 ± 0.34 (n=16) 0.8349
[Ca2+]P (mmol/L) 2.31 ± 0.00 (n=2804) 2.30 ± 0.01 (n=16) 0.7006
[PO43-]P (mmol/L) 1.76 ± 0.01 (n=2804) 1.80 ± 0.06 (n=16) 0.6116
Table 4.3: Baseline Plasma Electrolytes. 
Cab39ltm1b(EUCOMM)Wtsi homozygous knock-outs (CAB39L-/-) have lower creatinine (Creat) and higher 
sodium plasma levels compared to CAB39L+/+ mice. *(P<0.05). Please note data for baseline plasma 
Mg2+ was not available. Data from IMPC [http://www.mousephenotype.org/data/genes/MGI:1914081] 
and copyright by © 2016 IMPC. 
 
Parameter  MO25β+/+ MO25β-/- P-value
[Creat]U (mmol/L) 5.00 ± 0.39 (n=10) 4.17 ± 0.24 (n=10) 0.0877
[Na+]U / [Creat]U ratio 8.06 ± 1.18 (n=10) 10.31 ± 0.68 (n=10) 0.1159
[K+]U / [Creat]U ratio 13.22 ± 1.23 (n=10) 15.96 ± 1.43 (n=10) 0.1649
[Cl-]U / [Creat]U ratio 17.85 ± 1.12 (n=10) 21.01 ± 1.68 (n=10) 0.1345
[Ca2+]U / [Creat]U ratio 0.95 ± 0.15 (n=7) 1.59 ± 0.26 (n=8) 0.0625
[Mg2+]U / [Creat]U ratio  22.41 ± 1.46 (n=7) 28.46 ± 2.15 (n=8) *0.0416
[PO43-]U / [Creat]U ratio 4.15 ± 0.97 (n=7) 1.94 ± 0.63 (n=8) 0.0735
Table 4.4: Baseline urine electrolytes. 
On a normal Na diet (0.25% w/w) MO25β-/- have a higher excretion of magnesium compared to 
MO25β+/+ mice. Normalised electrolyte values were expressed as ratios (electrolyte concentration 
divided by creatinine concentration). *(P<0.05). 
 
To exaggerate differences or reveal a compensated phenotype, the sodium intake of 
MO25β-/- mice was modified via dietary manipulation in order to assess homeostatic responses 
to physiological extremes. This was achieved by sodium loading mice on a high Na diet (3% 
w/w) for several days before switching to a low Na (0.03% w/w) diet to provide a sodium 
restriction; a strategy which proved to be successful in elucidating the SPAK kinase inactive 
mouse phenotype (Rafiqi et al., 2010). However, despite the presence of small difference in 
plasma and urine electrolytes at baseline, no significant differences were observed in sodium 
restricted plasma electrolytes (Table 4.5) or urine electrolytes for the time-course sodium diet 
switch (Figure 4.6).  
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Parameter  MO25β+/+ MO25β-/- P-value
[Creat]P (µmol/L) 45.33 ± 1.76 (n=6) 40.91 ± 2.16 (n=11) 0.1898
[Na+]P (mmol/L) 124.50 ± 0.85 (n=6) 124.45 ± 1.49 (n=11) 0.9833
[K+]P (mmol/L) 5.17 ± 0.60 (n=6) 4.86 ± 0.19 (n=11) 0.6479
[Cl-]P (mmol/L) 91.00 ± 1.13 (n=6) 92.18 ± 1.10 (n=11) 0.5017
[Ca2+]P (mmol/L) 2.50 ± 0.03 (n=6) 2.47 ± 0.03 (n=11) 0.5521
[Mg2+]P (mmol/L) 0.97 ± 0.10 (n=6) 0.96 ± 0.04 (n=11) 0.8964
[PO43-]P (mmol/L) 1.89 ± 0.09 (n=6) 2.00 ± 0.09 (n=11) 0.4551
Table 4.5: Plasma electrolytes on a low Na+ diet. 
No significant difference were found in plasma electrolytes between MO25β-/- and MO25β+/+ mice after 
sodium restriction. *(P<0.05). 
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Figure 4.6: Urine electrolyte homeostasis during a time-course sodium diet switch. 
Normalised urinary electrolyte excretion expressed as ratios (electrolyte concentration divided by 
creatinine concentration) at various time points after sodium loaded animals were switched from a high 
(3% w/w) to a low (0.03% w/w) Na diet. Please note data for 3h Cl- was not available. No significant 
differences were observed between MO25β-/- and MO25β+/+ mice at any time point. [Creatinine] n = 7-
14; [Na+] n = 5-13; [K+] n = 5-13; [Cl-] n = 3-10; [Mg2+] n = 5-13; [PO43-] n = 5-13; *(P<0.05).  
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4.3.5  Cardiovascular Function 
To assess the impact of MO25β knock-out on blood pressure maintenance, direct invasive 
blood pressure measurements were recorded in MO25β-/- and MO25β+/+ mice on various Na 
diets. Low Na diet was expected to exaggerate any potential phenotypic difference as per 
previous studies with mouse models of Gitelman syndrome (Rafiqi et al., 2010). However, no 
significant differences in blood pressure or heart rate were observed between MO25β-/- and 
MO25β+/+ mice on either normal or low Na diets (Figure 4.7). 
 
 
Figure 4.7: Cardiovascular function in response to Na diet manipulations. 
Invasive carotid blood pressure measurements did not reveal any differences in systemic blood pressure 
or heart rate between MO25β-/- and MO25β+/+ mice on either salt diet. Normal Na (NNa), n= 3-4 per 
genotype; Low Na (LNa), n = 10-11 per genotype; *(P<0.05). 
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4.4  Discussion 
Our study was designed to investigate the role of MO25 in blood pressure and electrolyte 
homeostasis. For in vivo studies, attempts were originally made to obtain a MO25α knock-out 
mouse model, although this genotype did not produce viable offspring and a MO25β knock-
out model was developed instead. In hindsight this should not have come as a surprise given 
that the MO25 gene was first cloned from mouse cleavage-stage embryos and discovered to be 
one of the first genes to be transcribed in the 2-cell stage mouse embryo, implying it serves an 
essential general function in embryological development (Miyamoto et al., 1993). 
Additionally, dMo25 is expressed in Drosophila embryogenesis and was mapped to left arm of 
the third chromosome at the 73AB interval, which was known to harbour several 
uncharacterised genes that when mutated were recessively lethal in the embryonic or early 
larval stages (Nozaki et al., 1996). Definitive evidence for this was provided when dMo25 and 
Fray were discovered in a screen of maternal effect lethal mutations to identify genes regulating 
neuroblast asymmetric division, with knock-out of dMO25 shown to result in mislocalisation 
of cell-fate determinants and improper embryo development (Yamamoto et al., 2008). 
Similarities in our approach to study MO25α/β can be drawn with the SPAK/OSR1 story, 
where a constitutive homozygote OSR1 knock-out proved embryonically lethal, and the 
alternative strategy of disrupting the closely related SPAK protein was opted for to infer OSR1 
functions (Rafiqi et al., 2010; Yang et al., 2010c; Lin et al., 2011), while alternative conditional 
OSR1 knock-outs were under development.  
Relatively little information exists in the literature on the roles of MO25β/CAB39L and 
this work represents the first study to directly explore the gene’s functions in vivo. Other than 
the odd study linking MO25β to coffee drinking (Amin et al., 2012) or male infertility (Garrido 
et al., 2009), the only two areas of MO25β which have garnered attention are in cancer biology 
and energy metabolism. 
So far MO25β has been purported to have anti-tumoural activity primarily through its 
actions on LKB1 and STK24, with frameshift mutations in MO25β implicated as drivers of 
gastric and colorectal cancers (Choi et al., 2016), and higher MO25β transcript and protein 
expression identified in the early stage of oral cancer but not correlated with tumour 
progression (Lo et al., 2012). Interestingly, MO25β has been implicated in the anti-cancer 
mechanism of actions of metformin, a first-line medication for the treatment of overweight 
type 2 diabetes patients, with particularly promising results as an adjunctive therapy in breast 
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(Pulito et al., 2017) and endometrial cancers (Meireles et al., 2017). Metformin-induces 
downregulation of microRNA 21-5p to increase MO25β expression which leads to AMPK 
activation and inhibition of mammalian target of rapamycin (mTOR), which significantly 
reduces clonogenicity, migration and invasion of cancer cells (Pulito et al., 2017). Additionally, 
a splice variant of CAB39L has been linked with acute monocytic leukaemia (Zhang et al., 
2009), which appears to promote cancer by inhibition of apoptosis (Zhang, 2012; Zhang et al., 
2017), with high levels of this novel acute monocytic leukaemia (M5)-associated antigen 34 
(MLAA-34) independently associated with a poorer relapse-free and overall survivability 
(Zhao et al., 2011).  Our study did not test for this, however, findings in the literature suggest 
that MO25β-/- and CAB39L-/- mouse models would be more susceptible to these forms of 
cancer, while counterintuitively specifically resistant to acute monocytic leukaemia. The only 
phenotypic findings on this front relate to changes in whole blood counts where white blood 
cell counts were elevated only in female CAB39L-/- mice (Table 4.2). 
Morphologically CAB39L-/- male mice also exhibit increased body fat percentage, 
although there appears to be no overall difference in body weights (Table 4.1). This may in 
part be explained by the role of AMPK in the modulation of energy balance, where MO25β 
has been associated with bodyweight and food intake in chickens (Zhang et al., 2011; Lei & 
Lixian, 2012; Yuan et al., 2015), and bodyweight and obesity in humans (Rahmioglu et al., 
2015). Additionally, out of the four CAB39L-/- male mice examined post-mortem, one was 
found to have an enlarged heart (Table 4.1). Elevated levels of microRNAs which target 
MO25α have been implicated in the development of cardiac hypertrophy through suppression 
of LKB1/AMPK pathway, which suggests that loss of MO25β-dependent LKB1/AMPK 
signalling may have a similar effect (Chen et al., 2012; Kuwabara et al., 2015). These same 
microRNAs are strongly induced in during erythropoiesis and their ablation in mice leads to 
mild anaemia (Fang et al., 2017). The subsequent loss of MO25β-dependent 
LKB1/AMPK/mTOR pathway activation promotes red cell precursor survival and offers an 
explanation for the increases in red blood cell counts, haematocrit, haemoglobin, and perhaps 
decreased mean corpuscular volume observed in CAB39L-/- mice (Table 4.2), athough further 
investigation would be required to confirm this phenotype and the underlying mechanisms.  
Electrolyte homeostasis appears almost identical between the genotypes with only 
slight, although statistically significant differences between the baseline plasma creatinine and 
sodium of CAB39L-/- and wild types (Table 4.3), which either retained a non-statistically 
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significant trend or normalised in MO25β-/- mice on a low salt diet (Table 4.5). A near total 
absence of any meaningful alterations in renal excretory functions provides no clear 
explanation for the changes seen in plasma (Table 4.4). Similarly the increased renal excretion 
of magnesium in MO25β-/- mice at baseline (Table 4.5) is hard to account for without any signs 
of hypomagnesaemia (Table 4.3) and with normalisation of renal excretion on high and low 
salt diets (Figure 4.6). Interpretation of this result is further hampered by the generally poor 
understanding of renal magnesium homeostasis, with TRPM6 being the only identified apical 
transcellular magnesium-selective channel in the DCT and currently not known to be regulated 
by the WNK pathway (Blaine et al., 2015).  
These data suggest that MO25β has a limited role in electrolyte homeostasis, whereas 
recent work has provided evidence for a role of MO25α in electrolyte homeostasis. In Xenopus 
laevis oocyte studies it was revealed that the sodium-driven CCCs can also be activated by a 
SPAK-independent pathway involving MO25α and WNK4 (Ponce-Coria et al., 2014). The 
importance of this novel pathway was highlighted by the enhanced MO25α/WNK/NKCC1 
signalling observed in spontaneously hypertensive rats which was found to increase their 
susceptibility to ischaemic brain damage (Bhuiyan et al., 2016). However, the in vivo role of 
MO25α in the mammalian kidney is largely unexplored. MO25α is expressed in the DCT and 
TAL where it co-localises with NCC and NKCC2, but unlike OSR1 its expression and 
localisation does not change in a SPAK knock-out mouse (Grimm et al., 2012). This is striking 
as NCC phosphorylation in SPAK knock-out and loss-of-function knock-in mouse models is 
only reduced and not completely absent (Rafiqi et al., 2010; Yang et al., 2010c). A possible 
explanation for this is a putative MO25α/WNK/NCC pathway which partially compensates for 
the loss of WNK/SPAK/NCC signalling and disrupted MO25α stabilisation and activation of 
OSR1 monomers and dimers due to displacement of OSR1 from the apical membrane to 
cytosolic puncta in the DCT (Gagnon et al., 2011; Grimm et al., 2012; Ponce-Coria et al., 2012, 
2014; Li et al., 2014). This may also help to explain the divergent nature of NKCC2 
hyperphosphorylation in SPAK knock-out models (Yang et al., 2010c; Grimm et al., 2012) and 
NKCC2 hypophosphorylation in loss-of-function SPAK knock-in models (Rafiqi et al., 2010). 
In the DCT of wildtype animals SPAK is predominantly full length, whereas most SPAK 
isoforms in the TAL are truncated splice variants, KS-SPAK and SPAK2 (Mccormick et al., 
2011), which lack intact kinase domains and can inhibit NKCC2 phosphorylation by competing 
for binding sites (Park et al., 2013). Therefore, in SPAK knock-out models with no isoforms 
to compete for NKCC2 binding sites, the uninhibited activity of the MO25α/WNK/NKCC2, 
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MO25α/OSR1/NKCC2 and WNK/OSR1/NKCC2 signalling pathways would lead to 
hyperphosphorylation in the TAL. While in the TAL of loss-of-function SPAK knock-in 
models, the hypophosphorylation of NKCC2 may be explained by inactive mutant full length 
SPAK acting as a third inhibitory isoform, working alongside the intact KS-SPAK and SPAK2 
isoforms to further compete for binding sites, thus preventing any compensation for the loss of 
SPAK activity by other MO25α, WNK or OSR1 dependent pathways (Gagnon et al., 2011; 
Grimm et al., 2012; Ponce-Coria et al., 2012, 2014; Li et al., 2014). 
Similarly the data in this study suggests that MO25β has a limited role in blood pressure 
maintenance (Figure 4.7). However, in the case of MO25α, preliminary reports show that mice 
with renal tubule-specific overexpression MO25α result in seemingly phenotypically normal 
animals with elevated phosphorylation of SPAK, NKCC2 and NCC. Although when these mice 
are subjected to salt loading they develop marked hypertension with slight hyperkalaemia, 
reminiscent of familial hyperkalaemia hypertension syndrome (FHHt) (Yang et al., 2013). 
Additionally, when these mice are crossed with WNK4 knock-out mice with a Gitelman-like 
phenotype, they can partially rescue the hypotension, hypokalaemia, hypomagnesaemia, 
hypocalciuria and reduced abundance of phosphorylated SPAK/OSR1 and NCC (Yang et al., 
2014), most likely through enhanced WNK-independent MO25α activation of SPAK/OSR1 
(Gagnon et al., 2011; Filippi et al., 2011; Ponce-Coria et al., 2012; Li et al., 2014). This makes 
MO25α a potential anti-hypertensive target, and a recent small-molecule compound library 
screening identified HK01 as a promising candidate for indirect SPAK/OSR1 kinase inhibition. 
In live cell assays, HK01 reduced NKCC1 phosphorylation in a dose-dependent manner by 
binding to the hydrophobic site of MO25 and competing with the WEW motifs of SPAK/OSR1 
(Kadri et al., 2017).  
 In conclusion, the in vivo data gathered from the MO25β knock-out mice suggest that 
either MO25β has no role in blood pressure or electrolyte homeostasis or has a limited 
redundant role where MO25α is the physiologically dominant isoform and normal levels are 
sufficient to compensate for MO25β loss. Though this model may be useful in exploring the 
role of the MO25β in cancer biology. 
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Chapter 5 : Gitelman Syndrome Validates SPAK as a Novel Anti-
Hypertensive Target 
 
[This chapter is principally based on and expands upon the content from the abstracts in 
Appendix 1 and paper in Appendix 4 (Zhang et al., 2015)] 
 
5.1  Abstract 
The STE20/SPS1-related proline/alanine-rich kinase (SPAK) controls blood pressure by 
phosphorylating and stimulating the Na-Cl (NCC) and Na-K-2Cl (NKCC2) cotransporters, 
which regulate salt reabsorption in the kidney. SPAK possesses a conserved carboxy-terminal 
(CCT) domain, which recognises RFxV/I motifs present in its upstream activator (isoforms of 
the With-No-lysine (K) kinases [WNKs]) as well as its substrates (NCC and NKCC2). To 
define the physiological importance of the CCT domain, knock-in mice were generated in 
which the critical CCT domain Leu502 residue required for high affinity recognition of the 
RFxI/V motif was mutated to Alanine. The SPAK CCT domain defective knock-in animals are 
viable, and the Leu502Ala mutation abolished co-immunoprecipitation of SPAK with WNK1, 
NCC and NKCC2. The CCT domain defective animals displayed markedly reduced SPAK 
activity and phosphorylation of NCC and NKCC2 cotransporters at the residues 
phosphorylated by SPAK. This was also accompanied by a reduction in the expression of NCC 
and NKCC2 protein without changes in mRNA levels. The SPAK CCT domain knock-in mice 
showed typical features of Gitelman Syndrome with mild hypokalaemia, hypomagnesaemia, 
hypocalciuria and displayed salt-wasting on switching to a low Na-diet. These observations 
establish that the CCT domain plays a crucial role in controlling SPAK activity and blood 
pressure. Our results indicate that CCT domain inhibitors would be effective at reducing blood 
pressure by lowering phosphorylation as well as expression of NCC and NKCC2. 
 
5.2  Introduction 
SPAK (SPS1-related proline/alanine rich kinase) and OSR1 (oxidative stress-responsive kinase 
1) are closely related protein kinases, which play key roles in regulating cellular ion 
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homeostasis and blood pressure (BP) (Delpire & Gagnon, 2008; Richardson & Alessi, 2008). 
SPAK and OSR1 are activated following the phosphorylation of their T-loop residue (SPAK 
Thr233 and OSR1 Thr185) by one of the four isoforms of the WNK [With No lysine (K) 
kinase] protein kinase (Moriguchi et al., 2005; Vitari et al., 2005). The activity of SPAK and 
OSR1 is further enhanced following interaction with the scaffolding protein termed MO25 
(Filippi et al., 2011). The best-characterised SPAK/OSR1 substrates comprise the SLC12A 
(solute carrier family 12) family of electroneutral CCCs (cation–chloride cotransporters) 
(Piechotta et al., 2002; Anselmo et al., 2006; Gagnon et al., 2006; Richardson et al., 2008, 
2011; de Los Heros et al., 2014). These transporters regulate intracellular chloride 
concentration critical in controlling blood pressure and cell volume homoeostasis (Gagnon & 
Delpire, 2013). SPAK/OSR1 protein kinases drive chloride influx by phosphorylation and 
activating sodium-driven CCC members. These include the NCC (Na+–Cl- Cotransporter) in 
the distal convoluted tubule of the kidney (Richardson et al., 2008), the NKCC2 (Na+–K+–2Cl- 
Cotransporter 2) in the thick ascending limb of the kidney (Richardson et al., 2011) and the 
ubiquitously expressed NKCC1 (Piechotta et al., 2002; Anselmo et al., 2006; Gagnon et al., 
2006). SPAK/OSR1 also phosphorylate and inhibit potassium-driven CCCs that drive chloride 
efflux (de Los Heros et al., 2014), which comprise four different K+–Cl- cotransporters 
(KCC1–KCC4) (Kahle et al., 2010; Gagnon & Delpire, 2013). This reciprocal regulation of 
Na+- and K+-driven CCCs by SPAK and OSR1 ensures that cellular Cl− influx and efflux is 
tightly co-ordinated (Kahle et al., 2010; Gagnon & Delpire, 2013).  
The importance of the WNK signalling pathway is exemplified by its evolutionary 
conservation from worms to humans and that several Mendelian hypertension disorders in 
humans are caused by mutations in WNK pathway components (Kahle et al., 2008; Alessi et 
al., 2014). These include various mutations that lead to increased expression of the WNK1 and 
WNK4 genes causing PHAII (PseudoHypoAldosteronism type II, OMIM #145260) (Wilson 
et al., 2001; Boyden et al., 2012; Louis-Dit-Picard et al., 2012; Shibata et al., 2013; 
Wakabayashi et al., 2013; Ohta et al., 2013; Schumacher et al., 2014). Conversely, loss-of-
function mutations in NCC and NKCC2 cause familial forms of hypotension and hypokalaemia 
termed Gitelman (OMIM #263800) and Bartter type 1 syndrome (OMIM #601678) 
respectively (Simon et al., 1996). A mutation that ablates the key activating WNK-regulated 
SPAK/OSR1 phosphorylation site on NCC (T60M (Richardson et al., 2008)) also causes 
Gitelman syndrome (Lin et al., 2005; Shao et al., 2008). Moreover, SPAK-knock-out mice 
(Yang et al., 2010c; Mccormick et al., 2011; Grimm et al., 2012), or knock-in mice expressing 
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a form of SPAK that cannot be activated by WNK kinase isoforms (Rafiqi et al., 2010), exhibit 
low blood pressure and are resistant to hypertension when crossed to animals bearing a PHAII-
causing knock-in mutation that enhances WNK4 expression (Chiga et al., 2011). Genome-wide 
association studies have also identified intronic SNPs within the SPAK gene (STK39) that 
correlate with increased blood pressure in humans (Wang et al., 2009) and have been shown to 
increase SPAK-CCC activity in cells expressing these SNPs (Mandai et al., 2015). Two 
common types of drugs used in the treatment of high blood pressure also target SPAK sodium-
driven CCC substrates, namely thiazide diuretics (such as bendroflumethiazide) that inhibit 
NCC and the loop diuretics (such as furosemide) that inhibits NKCC2 (Gordon & Hodsman, 
1986; Gordon et al., 1995). 
These data suggest that chemical agents that inhibit SPAK would have the potential to 
treat hypertension, but without the off-target effects of agents like thiazide diuretics (Glover & 
O’Shaughnessy, 2011; Alessi et al., 2014). One approach would be to elaborate small molecule 
compounds that directly inhibit SPAK/OSR1 protein kinase activity (Cohen & Alessi, 2013). 
However, to our knowledge no highly selective and potent kinase inhibitors of SPAK and 
OSR1 have been reported. There is also concern whether sufficiently selective SPAK/OSR1 
kinase inhibitors could be synthesised for the management of a chronic largely asymptomatic 
condition, without them inhibiting other protein kinases or ATP binding enzymes and causing 
intolerable off-target effects. An alternative strategy to suppress SPAK/OSR1 function would 
be to target the docking domain within the non-catalytic C-terminal region of SPAK/OSR1 
called the CCT (Conserved C-Terminal) domain. In vitro and overexpression studies indicate 
that the CCT domain binds to conserved RFxV/I motifs present on WNK isoforms and that 
these interactions facilitate phosphorylation and activation of SPAK/OSR1 (Vitari et al., 2006; 
Gagnon et al., 2007). Furthermore, the sodium-driven CCC members also possess conserved 
RFxI/V motifs at their N-terminus which experimental data indicate are critical for enabling 
SPAK/OSR1 to interact with, phosphorylate and stimulate activity of these transporters 
(Gagnon et al., 2007; Richardson et al., 2008, 2011; Mori et al., 2013a).  
This study sought to define the role that the CCT domain plays in vivo by generating 
and characterising SPAK knock-in mice in which function of the CCT domain has been ablated 
by a mutation of the critical Leu502 residue required for high affinity binding of the RFxI/V 
motif.  
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5.3  Results 
 
5.3.1  Characterisation of a mutation that inhibits the CCT domain of SPAK 
Previous crystallographic analysis of the human OSR1 CCT domain complexed to an RFxI 
motif containing peptide derived from WNK4 (Villa et al., 2007), revealed that the highly 
conserved Leu473 CCT residue lying at the base of a deep hydrophobic pocket, formed critical 
hydrophobic contacts with the Phe residue of the RFxI motif (Figure 5.1 A). Consistent with 
this, mutation of Leu473 to Ala reduced binding of OSR1 to RFxI WNK4 peptide over 100-
fold (Villa et al., 2007). Mutation of the equivalent residue (Leu502) in mouse SPAK also 
prevented full-length mouse SPAK co-immunoprecipitating with endogenously expressed 
WNK1 and NKCC1 in HEK293 cells (Figure 5.1 B). Moreover, in vitro fluorescence 
polarisation studies confirmed that mutation of this Leu residue in the SPAK CCT domain 
reduced binding to an RFxV-motif possessing peptide derived from WNK4 by ~100-fold 
(Figure 5.1 C). 
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Figure 5.1: Evidence that SPAK associates with WNK1 and interaction is disrupted by 
SPAK CCT mutation. 
[A] Molecular interaction of the RFxV peptide with the conserved carboxy-terminal domain of OSR1 
based on (PDB: 2V3S) CCT domain of OSR1 (residues 434–527) coloured in grey (β-strands and α-
helices) bound to the GRFQVT WNK4-derived peptide coloured in blue. [B] Pull-down assays of 
transfected HEK293 cells show that SPAK L502A has significantly reduced interactions with WNK1 
and NKCC1 compared to WT. Similar results were obtained in three separate experiments. [C] Analysis 
of SPAK–WNK interaction confirmed impaired binding of the SPAK CCT mutant to the WNK docking 
motif, as evidenced by reduced fluorescence polarisation. [Taken from (Zhang et al., 2015)]. 
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5.3.2  Characterisation of CCT domain deficient SPAKL502A/L502A mice 
We exploited these observations to explore the impact that mutation of the CCT domain 
Leu502 residue had, by generating knock-in mice on an inbred C57BL/6J background, in which 
the Leu502 CCT domain residue was changed to Ala (Figure 5.2 A). Homozygous 
SPAKL502A/L502A mice were born at the expected Mendelian frequency (Table 5.1), were of 
normal size and appearance, and did not display any overt phenotype, at least up to 1 year of 
age (the oldest animals analysed in this study).  
 
 
Table 5.1: Breeding of ratios SPAK knock-in mice. 
Mating pairs for SPAK were set up as outlined above and the progeny were genotyped as described in 
the methods. The percentage of each genotype observed is indicated in parenthesis followed by its 
expected Mendelian frequency. [Taken from (Zhang et al., 2015)]. 
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Figure 5.2: Targeting strategy used to generate SPAK knock-in mutations. 
[A, left] Southern blot analysis of genomic DNA purified from the targeted ES cells and subjected to 
enzymatic digestion permitted the identification the wild-type and knock-in alleles for genotyping. [A, 
middle] PCR amplification of genomic DNA can be used to determine genotype with the knock-in 
allele producing a larger product than WT allele due to the presence of a FRT site and flanking region, 
which remains in an intronic region following Flp-mediated excision of the puromycin resistance 
(PuroR) selection cassette. [A, right] DNA sequencing of PCR products encompassing the knock-in 
mutation region show successful point mutation of the target site. [B] Total levels of SPAK, OSR1 
NKCC1 in various tissues was unaltered in knock-in versus wildtype mice, although phosphorylation 
of SPAK and NKCC1 was markedly reduced. Similar results were obtained in three separate 
experiments. [C] Pull-down assays of SPAK from kidney, testis and brain lysates from wild-type and 
knock-in mice confirm impaired SPAK-WNK and SPAK-CCC binding in vivo. [D] 
Immunoprecipitates subjected to activity measurements using the CATCHtide peptide substrate show 
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that SPAK L502A is dramatically reduced without any impact on OSR1 activity (Moriguchi et al., 
2005). [Taken from (Zhang et al., 2015)]. 
 
Immunoblot analysis of tissues (kidney, brain, heart and testis) derived from littermate 
wild type and SPAKL502A/L502A homozygous animals of 2 months of age employing a novel 
mouse SPAK antibody that was generated which does not recognise mouse OSR1 (Figure 5.3), 
revealed that the L502A mutation did not influence expression of SPAK in these tissues. In all 
tissues analysed deriving from SPAKL502A/L502A mice, a significant reduction of the 
phosphorylation of SPAK at a key WNK phosphorylation site (Ser373) (Moriguchi et al., 2005) 
was observed in comparison to wild type mice (Figure 5.2 B). This is consistent with the L502A 
mutation suppressing the ability of WNK isoforms to phosphorylate SPAK. Furthermore, the 
SPAKL502A/L502A knock-in animals displayed markedly reduced phosphorylation of NKCC1, in 
agreement with the CCT domain being required for SPAK to bind to and phosphorylate 
NKCC1 (Figure 5.2 B).  
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Figure 5.3: Generation and characterisation of specific SPAK antibodies. 
Immunoblots of HEK293 cell lysates [A] and kidney lysates [B] with the newly generated SPAK and 
OSR1 mouse antibodies. The N-terminal SPAK antibody was generated by ligating cDNA 
corresponding to amino acids 2–76 of mouse SPAK downstream of the GST open reading frame in the 
pGEX-6P-1 vector. The resulting fusion protein was injected into sheep to produce polyclonal 
antibodies. HEK293 cells were transfected with the constructs encoding the full-length mouse FLAG-
tagged SPAKWT and SPAKL502A. [Taken from (Zhang et al., 2015)]. 
 
To obtain further evidence that the L502A mutation impacted on the ability of SPAK 
to bind WNK1 and NKCC1, SPAK was immunoprecipitated from kidney, brain and testis, 
derived from littermate wild type and SPAKL502A/L502A homozygous animals of 2 months of 
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age and tested how CCT domain mutation effected association with WNK1 and NKCC1. This 
revealed that in the SPAKL502A/L502A knock-in animals co-immunoprecipitation of WNK1 and 
NKCC1 with SPAK was markedly reduced in all tissues analysed (Figure 5.2 C). In the kidney 
it was also observed that mutation of the CCT domain inhibited co-immunoprecipitation of 
NCC and NKCC2 with SPAK (Figure 5.2 C). Further immunoblot analysis of SPAK 
immunoprecipitates confirmed that the L502A mutation inhibited phosphorylation of SPAK at 
the two key residues that WNK isoforms phosphorylate (Thr243 and Ser373) (Figure 5.2 C) 
(Vitari et al., 2005). SPAK as well as OSR1 immunoprecipitates from tissues (kidney, brain 
and testis) were also subjected to a protein kinase assay activity assay employing the previously 
described CATCHtide peptide that encompasses the NKCC1 phosphorylation sites (Vitari et 
al., 2006). This revealed that SPAK immunoprecipitated from all tissues derived from 
SPAKL502A/L502A knock-in mice displayed significantly reduced activity compared to wild type 
animals (Figure 5.2 D). As expected, activity of OSR1 was not affected in SPAKL502A/L502A 
knock-in mice (Figure 5.2 D). 
 
5.3.3  SPAKL502A/L502A mice display reduced phosphorylation of NCC and 
NKCC2 in kidney 
We next compared the relative levels of phosphorylation of NCC in total kidney extracts 
derived from male and female 2-month-old wild type and SPAKL502A/L502A knock-in littermate 
animals (Figure 5.4 A-D). Phosphorylation of NCC was monitored by employing different 
previously characterised phosphospecific antibodies recognising major SPAK NCC 
phosphorylation sites (Thr46, Thr50, Thr55, Thr60 and Ser91) (Richardson et al., 2011). This 
revealed that in both male and female mice the phosphorylation of NCC at all residues analysed 
was drastically reduced in kidney derived from SPAKL502A/L502A knock-in mice compared to 
wild type (Figure 5.4 B). Similar to what was previously observed in SPAK kinase inactive 
(SPAKT243A/T243A) knock-in mice (Rafiqi et al., 2010) as well as SPAK knock-out mice (Yang 
et al., 2010c; Mccormick et al., 2011; Grimm et al., 2012), ~2-fold reduction in total levels of 
NCC protein in kidney extracts of SPAKL502A/L502A knock-in mice was also observed when 
compared to wild type (Figure 5.4 B). In contrast, kidney mRNA levels of NCC were similar 
in wild type and of SPAKL502A/L502A knock-in mice (Figure 5.5). 
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Figure 5.4: Reduced phosphorylation of SPAK, NCC, NKCC1, NKCC2 and expression 
of NCC and NKCC2 in both male and female SPAKL502A/L502A. 
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Immunoblot analysis of immunoprecipitates and lysates from kidneys of wild-type and knock-in male 
and female mice. This study has been repeated over three times each with kidney extracts derived from 
different animals on each occasion with consistent results. The right-hand side panels show 
quantification of the results of the blots (n = 6, mean ± SEM). [A] Expression of WNK1, WNK4, SPAK, 
OSR1 and Parvalbumin is unaltered, however phosphorylation of SPAK is significantly reduced in 
knock-in mice. [B] Analysis of NCC protein levels and phosphorylation reveal that wildtype females 
have higher levels of total NCC and increased phosphorylation compared to males. SPAK CCT 
mutation dramatically reduced NCC protein and phosphorylation at multiple residues, abolishing the 
sex differences. [C] Similar to NCC, immunoprecipitated total NKCC2 protein levels were higher in 
female vs male wildtypes, although there were no significant differences in NKCC2 phosphorylation 
between sexes. SPAK CCT mutation markedly reduced NKCC2 protein levels, phosphorylation and 
abolished the sex differences. [D] While NKCC1 protein levels were not different between sexes, 
immunoprecipitated NKCC1 had greater levels of phosphorylation in female versus male wildtype 
mice. SPAK CCT mutation did not alter NKCC1 levels but decreased phosphorylation and abolished 
sex differences. *P < 0.05; **P < 0.01; ***P < 0.001. [Taken from (Zhang et al., 2015)]. 
 
We next monitored NKCC2 expression and similarly to NCC observed that levels were 
reduced ~2-fold in the kidney of SPAKL502A/L502A knock-in male and female mice compared to 
wild type animals (Figure 5.4 C). NKCC2 was immunoprecipitated  and analysed its 
phosphorylation at 3 residues that SPAK phosphorylates (Ser91, Thr100 and Ser130) 
(Richardson et al., 2011), and found that phosphorylation of each of these residues was 
substantially reduced in both male and female kidney derived from SPAKL502A/L502A knock-in 
animals (Figure 5.4 C). Kidney mRNA levels of NKCC2 were similar in wild type and of 
SPAKL502A/L502A knock-in mice (Figure 5.5). 
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Figure 5.5: Quantitative real-time PCR analysis of sodium ion cotransporter expression 
in the kidney. 
Quantitative real-time PCR analysis of mRNA levels quantified from five separate mice, each PCR 
performed in triplicate, results normalised to 18S rRNA expression with levels presented relative to 
wild type expression. No significant differences were found.[Taken from (Zhang et al., 2015)]. 
 
We also analysed NKCC1 and found that the levels of this cotransporter were 
unaffected in kidney extracts derived from wild type and SPAKL502A/L502A knock-in male and 
female mice (Figure 5.4 D). NKCC1 was immunoprecipitated and analysed its phosphorylation 
at 4 sites that SPAK phosphorylates (Thr203, Thr207, Thr212 and Thr217 (Vitari et al., 2005; 
Filippi et al., 2011)) and found that phosphorylation of these sites was markedly diminished in 
both male and female kidney extracts derived from SPAKL502A/L502A knock-in animals 
compared to wild type. Kidney mRNA levels of NKCC1 were similar in wild type and of 
SPAKL502A/L502A knock-in mice (Figure 5.5). 
 
5.3.4  SPAKL502A/L502A mice show a marked reduction in immunostaining for 
phosphorylated NCC and NKCC2 without remodelling of kidney tubules 
Confocal imaging of kidney sections from the SPAKL502A/L502A mice confirmed the modest 
reduction in total NCC and NKCC2 in the tubules of the distal convoluted (DCT) and thick 
ascending limb (TAL) tubules compared to wild type mice, with no obvious changes in the 
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morphology and numbers of tubules or the intracellular protein distribution between genotypes 
(Figure 5.6). In striking contrast, staining for the phosphorylated forms of NCC and NKCC2 
in the same tubules was almost completely lost in the SPAKL502A/L502A mice in keeping with 
the immunoblots from whole kidney lysates (Figure 5.4). Additionally no changes were 
observed in the intracellular localisation of WNK4 in the DCT or TAL (Figure 5.7). 
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Figure 5.6: Immunolocalisation of NCC and NKCC2 in the renal tubules of 
SPAKL502A/L502A mice. 
181 
 
Representative pseudocoloured average intensity z projections of immunofluorescent-stained kidney 
sections (n = 4 per genotype) showing the distribution of total and phospho proteins in the TAL marked 
by total NKCC2 (tNKCC2), early distal convoluted tubule (DCT1) marked by parvalbumin (PVALB) 
and whole distal convoluted tubule (DCT1/2) marked by total NCC (tNCC). Phospho-NCC T46 
(pNCC) and phospho-NKCC2 S91 (pNKCC2) are virtually undetectable in the SPAKL502A/L502A mice. 
Scale bar = 100 μm. [Taken from (Zhang et al., 2015)]. 
 
 
Figure 5.7: Immunolocalisation of WNK4 in the renal tubules of SPAKL502A/L502A mice. 
Immunolocalisation of WNK4 appears unaltered between groups in the DCT marked by tNCC and TAL 
marked by NKCC2 (n=4 per genotype. Scale bar = 50μm). [Taken from (Zhang et al., 2015)]. 
 
5.3.5  SPAKL502A/L502A mice display reduced blood pressure and augmentation 
index. 
To study the cardiovascular phenotype of these mice, the arterial blood pressure (BP) was 
measured in the SPAKL502A/L502A knock-in animals by carotid artery cannulation under general 
anaesthesia, which showed that their systolic, diastolic and mean arterial BPs were ~20mmHg 
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lower than wild type littermates (Figure 5.8 A). In vivo dose-response to phenylephrine, 
suggested that vascular tone may be altered, however due to scatter in the data this did not 
reach statistical significance (Figure 5.8 B). Although, the lower BP of the 
SPAKL502A/L502A knock-in animals was also reflected in a significantly lower left 
ventricular mass in these animals (Figure 5.8 C).  
 
 
Figure 5.8: Blood pressure, vasopressor response and cardiac ventricular mass of 
SPAKL502A/L502A mice. 
[A] SPAKL502A/L502A have significantly lower systemic systolic blood pressure (SBP), diastolic blood 
pressure (DBP), and heart rate (HR) compared to wildtypes. [B] For in vivo phenylephrine dose–
responses, no significant differences between SPAKL502A/L502A versus SPAK+/+ mice were detected for 
the estimated dose producing half-maximal response (ED50) (45.6 ± 3.7 vs 45.6 ± 6.3 µg/kg.bw) (P = 
0.9964) and fitted maximum response (Emax) (114.4 ± 3.7 vs 121.3 ± 2.7 mmHg) (P = 0.1552). Two-
tailed unpaired Student’s t-test; data are mean ± SEM, n = 9 per genotype [C] The wet weights of the 
left ventricle and septum combined (LV+S) expressed as a % of bodyweight (BW) are significantly 
lower for SPAKL502A/L502A mice. Bars are mean ± SEM, n=14-16. * P<0.05; ** P<0.01. [Adapted from 
(Zhang et al., 2015)]. 
 
183 
 
 
Figure 5.9: Arterial pressure waveform analysis of SPAKL502A/L502A mice. 
Pulse waveform analysis reveals no change in pulse pressure (PP) [SBP–DBP] but does show decreased 
augmentation pressure (AP) [SBP–anacrotic notch (AN) pressure], dicrotic notch (DN) pressure and 
MAP [1/3 SBP + 2/3 DBP] in the SPAKL502A/L502A versus SPAK+/+. This hypotensive phenotype is in 
part owing to changes in vascular contractility in SPAKL502A/L502A mice as evidenced by their lower 
augmentation index (AIx) [AP/PP], a marker of arterial stiffness, and is further supported by a decrease 
in their diastolic pressure decay time constant (τbourgeois) [1/slope of diastolic pressure decay; measured 
30 ms after DN and 20 ms before end DBP], a surrogate marker of decreased vascular resistance. Bars 
are mean ± SEM, n= 8–9. Significant differences from the SPAK wild type are shown by: *P < 0.02, 
**P < 0.001. [Taken from (Zhang et al., 2015)]. 
 
Further analysis of the BP traces from the mice also showed that the shape of the arterial 
pressure wave was significantly different (Figure 5.9). The SPAKL502A/L502A knock-in animals 
have a lower diastolic pressure time decay constant (τbourgeois), an index of vascular resistance 
(Bourgeois et al., 1974), suggesting decreased vascular tone compared to wild type littermates 
(Figure 5.9). Specifically, the SPAKL502A/L502A knock-in animals had lower augmentation of 
the peak systolic pressure (AIx) with no change in pulse pressure consistent with a reduction 
in arterial stiffness (Figure 5.9) (Safar, 2001).  
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5.3.6  SPAKL502A/L502A mice show a Gitelman Syndrome pattern of plasma and 
urinary electrolytes and salt-wasting 
Analysis of the plasma electrolytes showed that the SPAKL502A/L502A mice had a typical 
Gitelman pattern of plasma electrolytes with hypokalaemia and mild hypomagnesaemia 
compared to the wild-type animals (Figure 5.10 A). This is consistent with reduced WNK 
pathway signalling caused by inactivation of the SPAK CCT domain. The urinary electrolytes 
also showed a Gitelman-like pattern of electrolytes with marked hypocalciuria compared to the 
wild-type mice (Figure 5.10 B). The salt wasting expected of a Gitelman-like phenotype was 
also confirmed by salt restricting the SPAKL502A/L502A knock-in animals after salt loading by 
switching to a 100-fold lower Na-diet (Figure 5.10 C). 
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Figure 5.10: Plasma and urine electrolyte levels of SPAKL502A/L502A mice. 
[A] Plasma electrolytes analysis shows SPAKL502A/L502A mice have hypokalaemia and 
hypomagnesaemia (n= 12–16 per genotype per electrolyte) and [B] creatinine normalised urinary 
electrolyte analysis reveals SPAKL502A/L502A mice have hypocalciuria (n = 16–18 per genotype per 
electrolyte). [C, left] Urinary Na+ excretion expressed as Na+ (mmol)/creatinine (mmol) at various time 
points after switching from a 3% w/w to a 0.03% w/w salt diet. [C, right] area under the curve (AUC) 
analysis demonstrates that SPAKL502A/L502A mice are sodium wasting in the face of adaptation to 
physiological extremes (n = 16 per genotype). Bars are mean ± SEM. Significant differences from the 
SPAK wild type are shown by: *P < 0.02, **P < 0.01, ***P < 0.005. [Adapted from (Zhang et al., 
2015)]. 
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5.3.7  STK39-/- Gitelman syndrome mouse model has altered body composition 
Stk39tm1a(EUCOMM)Wtsi SPAK homozygous knock-out (STK39-/-) mice on a normal diet present 
with increased bone mineral density (BMD) which is consistent with reports of increased BMD 
in Gitelman patients and mouse models (Table 5.2) (Nicolet-Barousse et al., 2005; Pathare et 
al., 2012; Hsu et al., 2015), which is primarily due to hypocalciuria that was also observed in 
the SPAKL502A/L502A mice (Figure 5.10 B). Interestingly, STK39-/- mice also have decreased fat 
mass with no changes in lean mass, which leads to a lower bodyweight in age-matched female 
STK39-/- but not male mice on a normal diet (Table 5.2). The difference in male bodyweight 
did not likely reach significance due to the larger magnitude of difference in BMD in males 
versus females, which may offset the decreased fat mass. 
 
Parameter  STK39+/+ STK39-/- P-value
♂ Bodyweight (g) 38.50 ± 0.13 (n=644) 36.50 ± 1.66 (n=7) 0.1144
♀ Bodyweight (g) 32.52 ± 0.13 (n=613) 28.71 ± 1.24 (n=7) **0.0026
♂ BMD (g/cm2) 0.0493 ± 0.0001 (n=634) 0.0528 ± 0.0007  (n=7) ***0.0004
♀ BMD (g/cm2) 0.0495 ± 0.0000 (n=604) 0.0506 ± 0.0011 (n=7) *0.0116
♂ Fat mass (g) 17.17 ± 0.10 (n=635) 14.25 ± 1.44 (n=7) **0.0031
♀ Fat mass (g) 14.13 ± 0.12 (n=603) 11.52 ± 1.03 (n=7) *0.0161
♂ Lean mass (mg) 21.80 ± 0.07 (n=635) 22.52 ± 0.68 (n=7) 0.3096
♀ Lean mass (mg) 18.71 ± 0.05 (n=603) 17.80 ± 0.34 (n=7) 0.0524
Table 5.2: Body composition analysis. 
DEXA scans for bone mineral density (BMD) and body composition were performed at age 14 weeks. 
Stk39tm1a(EUCOMM)Wtsi homozygous knock-out (STK39-/-) mice have increased bone mineral density 
(BMD) and lower fat mass compared to wildtypes (STK39+/+) with no change in lean mass, although 
only females have a significant difference in bodyweight. *(P<0.05), **(P<0.01), **(P<0.001). Data 
from IMPC [http://www.mousephenotype.org/data/genes/MGI:1858416] and copyright © 2016 IMPC. 
 
5.4  Discussion 
Our results define the importance that the CCT docking domain plays in regulating the ability 
of WNK isoforms to control the activation as well as function of SPAK in regulating 
NCC/NKCC2 ion cotransporters and hence blood pressure. Most importantly these findings 
establish that a single point mutation ablating the ability of the CCT domain to interact with 
RFxI motifs on its WNK activators or ion cotransporters substrates, is sufficient to markedly 
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reduce phosphorylation and levels of NCC/NKCC2 resulting in a ~20mmHg reduction in blood 
pressure. Strikingly, impact of the CCT domain mutation is similar to that observed previously 
by ablating SPAK kinase activity in SPAKT243A/T243A knock-in mice (Rafiqi et al., 2010) or by 
complete knock-out of SPAK protein in mice (Yang et al., 2010c; Mccormick et al., 2011; 
Grimm et al., 2012), and recent work suggests that inhibition of SPAK activity can even 
attenuate angiotensin II-induced hypertension (Cervantes-Perez et al., 2018). The 
SPAKL502A/L502A animals still possess OSR1, which is activated normally by WNK isoforms 
(Figure 5.2 D), emphasising that inhibiting SPAK without effecting OSR1 is sufficient to 
markedly lower blood pressure. This is consistent with previous analysis indicating that SPAK 
in mammals evolved as a result of a gene duplication of OSR1, to undertake more specialised 
roles such as control of NCC/NKCC2 in the kidney and regulation of blood pressure (Delpire 
& Gagnon, 2008).  
Intriguingly, in the SPAKL502A/L502A knock-in animals in addition to a reduced 
phosphorylation of NCC/NKCC2, had levels of NCC and NKCC2 protein that were 
significantly reduced (Figure 5.4), under conditions which mRNA levels were unaffected 
(Figure 5.5). Similar results were also observed when analysing catalytically inactive SPAK 
knock-in mice (Rafiqi et al., 2010). In converse, in mouse models in which the WNK signalling 
pathway is activated by introducing knock-in mutations that inhibit the ubiquitylation of and 
proteasomal degradation of WNK4 (i.e. WNK4 [D561A] knock-in mice (Yang et al., 2007a; 
Chiga et al., 2011) or KLHL3[R528H] knock-in mice (Susa et al., 2014)), NCC and NKCC2 
protein levels are markedly elevated. Taken together these results provide strong genetic 
evidence that phosphorylation of NCC/NKCC2 by SPAK in addition to regulating 
cotransporter activity; also promote the stability of these critical cotransporters. Further work 
is required to unravel the mechanism, by which NCC and NKCC2 expression is controlled by 
SPAK phosphorylation. 
The plasma and urinary electrolyte pattern of the SPAKL502A/L502A knock-in mice 
resembles Gitelman Syndrome. In fact, it recapitulates closely the phenotype of the previously 
reported SPAKT243A/T243A kinase-dead knock-in mouse (Rafiqi et al., 2010). The extensive loss 
of NKCC2 and phospho-NKCC2 from the TAL tubules could be expected to produce a more 
extensive or even Bartter-like Syndrome (Kemter et al., 2010). Levels of NKCC2 were also 
reduced in the kinase-dead SPAK knock-in mouse, but the reduction was modest in comparison 
to almost complete loss of phosphorylated NKCC2 from the SPAKL502A/L502A mouse kidney 
(Figure 5.4; Figure 5.6). Nevertheless, the presence of both hypocalciuria and 
188 
 
hypomagnesaemia in the SPAKL502A/L502A mice is in keeping with a predominant loss of NCC 
function, since the loss of NKCC2 function in the mouse is associated with the opposite 
phenotype of hypermagnesaemia and hypercalciuria (Kemter et al., 2010). In fact, plasma 
magnesium levels and urinary calcium excretion are clinical measures used routinely to 
distinguish between Gitelman and the related Bartter syndrome (Knoers et al., 2003). The 
finding that the total level and phosphorylation of NKCC2 is reduced in the kidneys of the 
SPAKL502A/L502A mouse is also notable because previous SPAK knock-out models reported 
hypophosphorylated NCC in the DCT, but markedly hyperphosphorylated NKCC2 in the TAL 
with increases in total NKCC2 levels (Yang et al., 2010c) or without a change in total NKCC2 
levels (Mccormick et al., 2011; Grimm et al., 2012). The authors suggested this was due to 
removal of inhibitory isoforms of SPAK (SPAK2 and KS-SPAK), which are a product of 
alternative splice variants and enzymatic cleavage (Koumangoye & Delpire, 2017), and 
assumed to compete with full-length SPAK/OSR1 in the TAL to prevent overactivation of 
NKCC2 (Park et al., 2013). Alternatively, as yet unidentified kinases may act to phosphorylate 
SPAK/OSR1-dependent sites as a compensatory mechanism (Ferdaus et al., 2016). Another 
intriguing finding in these models was that the hypophosphorylation of NCC was accompanied 
by physical reduction in numbers of DCT1 tubular segments. In particular, the Welling group 
found that mice expressing a constitutively active form of SPAKT243E/S383D (CA-SPAK) 
restricted to the DCT1 on a background of global SPAK knock-out was sufficient to reproduce 
the salient PHAII electrolyte abnormalities. When these mice were treated with thiazides the 
subsequent restoration of sodium was not immediately followed by potassium excretion and 
instead took 2-3 days. On closer inspection they found CA-SPAK mice to have remodelling of 
the aldosterone-sensitive distal nephron, specifically and increase in DCT1 and decrease in 
connecting tubule (CNT) masses (Grimm et al., 2017). Conversely, other studies with mouse 
models of NCC genetic ablation (Loffing et al., 2004), knock-out of the DCT1 specific calcium 
binding protein, parvalbumin (Belge et al., 2007), and SPAK knock-outs have shown atrophy 
of the DCT1 with CNT hypertrophy and CCD remodelling, partially attributed to increased α-
ketoglutarate paracrine signalling (Grimm et al., 2015, 2017; Mccormick & Ellison, 2017; 
Lazo-Fernandez et al., 2018). SPAK has been reported to be directly involved with stabilisation 
of OSR1 at the apical membrane in the DCT and SPAK knock-out results in a significant 
reduction of parvalbumin expression (Grimm et al., 2012). However, unlike the knock-out 
models used in these studies the SPAK scaffolding functions in all tubular segments remained 
intact in the point-mutant knock-in SPAKL502A/L502A and SPAKT243A/T243A mice. This may 
explain why no changes were observed in the levels or staining of parvalbumin (Figure 5.4 A; 
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Figure 5.6) or gross changes in DCT morphology.  It is therefore, possible to postulate that 
these remodelling phenomena may largely be due to loss of key components of regulatory 
pathways which maintain normal tubular structure, rather than simply due to changes in NCC 
activity. 
The altered shape of the arterial pressure waveform in the SPAKL502A/L502A mice (Figure 
5.9) is consistent with increased vascular compliance and reduced wave reflection in the 
periphery as compared to the wild type animals. Although this may be explained in part by a 
diminished cardiac output arising from possible reductions in cardiac contractility due to loss 
of NKCC1 activity in the heart (Prasad et al., 2008) (Figure 5.2 B) and the lower heart rates of 
the SPAKL502A/L502A mice (Figure 5.8 A), since augmentation is negatively correlated with heart 
rate in humans (Crilly, 2014). It has also been previously shown that intracranial administration 
of bumetanide can be used to inhibit the over activity of NKCC1 in the hypothalamic 
paraventricular nucleus of spontaneously hypertensive rats. The inhibition of NKCC1 in these 
hypertensive animals acts to reduce sympathetic vasomotor tone and lower their heart rates (Ye 
et al., 2012). A similar phenomenon may be occurring in the SPAKL502A/L502A mice due to 
reductions in brain phospho-NKCC1 (Figure 5.2), thus providing a potential neurological 
explanation for their lower heart rate and reduced vascular tone. 
However, SPAK directly affects vascular smooth muscle contraction through WNK1 
(Bergaya et al., 2011) and WNK3 (Zeniya et al., 2013) signalling and NKCC1 (Yang et al., 
2010c), the activity of which is necessary for maintaining vascular smooth muscle tone (Meyer 
et al., 2002), so it is likely that reduced augmentation also reflects hypophosphorylation of 
NKCC1 in blood vessels in a parallel fashion to ther findings in the kidney and other tissues 
(Figure 5.2; Figure 5.4). This is further supported by the shorter τbourgeois found in 
SPAKL502A/L502A mice, which implies reduced vascular resistance consistent with a reduction 
in vascular contractility. This suggests that targeting the CCT domain of SPAK may have an 
additional effect on blood pressure through a direct reduction in vascular tone. It also suggests 
a reduced arterial stiffness without a change in pulse pressure (Figure 5.9), and both are 
importantly independent risk factors for cardiovascular mortality (Safar, 2001).  
There is increasing interest in targeting the WNK-SPAK/OSR1 signalling pathway as 
a new therapeutic strategy to treat hypertension (Glover & O’Shaughnessy, 2011; Alessi et al., 
2014). The finding that ablation of the CCT domain function is sufficient to reduce blood 
pressure to the same extent as a kinase ablating knock-in mutation (Rafiqi et al., 2010), 
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suggests that the CCT domain of SPAK plays a similarly important role as the kinase domain 
in controlling blood pressure. Thus inhibitors that prevent the CCT domain recognising RFxV 
motifs should be as effective as compounds that target the protein kinase domain of SPAK in 
lowering blood pressure. Structural analysis reveals that CCT domain recognises RFxV/I 
motifs by adopting a unique fold not observed on other proteins (Villa et al., 2007). This may 
indicate that CCT domain inhibitors might be inherently more specific than ATP competitive 
kinase inhibitors that would have the potential to target other protein kinases and/or ATP 
binding enzymes. For the treatment of a chronic largely asymptomatic condition such as 
hypertension, it is particularly important that therapies are as specific as possible in order to 
reduce poorly tolerated off-target side effects. Although, owing to the high degree of homology 
between the CCT domain of SPAK and OSR1 it may be impossible to develop drugs that 
selectively inhibit SPAK. However, even a drug that partially inhibited both SPAK and OSR1 
isoforms might reduce phosphorylation and expression of NCC and NKCC1/2 enough to lower 
blood pressure without significant adverse effects. 
On the other hand, not all off-target effects are undesirable. Chronic thiazide users and 
Gitelman syndrome patients are noted to have increased bone mineral density (BMD) which 
results in a reduced rate of fractures, primarily attributed to hypocalciuria (Aung & Htay, 2011; 
Santos et al., 2016); an electrolyte abnormality that was also observed in SPAKL502A/L502A mice. 
This strongly suggests that like STK39-/- (Table 5.2) and SPAKT243A/T243A mice (Pathare et al., 
2012), disruptors of SPAK binding would also increase BMD, making them particularly 
attractive for treating hypertension in elderly or osteoporotic patients. However, Gitelman 
syndrome is also known to be associated with poorer glucose homeostasis and insulin 
responsiveness (Ren et al., 2013; Yuan et al., 2017), while chronic thiazide users have a well-
documented higher risk of new-onset diabetes mellitus (Agarwal, 2008). Yet, surprisingly no 
reports of mice deficient in SPAK activity have ever reported glucose or insulin homeostatic 
abnormalities. Recently, some exciting new work from the Gamba group on SPAKT243A/T243A 
mice has shed some light on this discrepancy between SPAK Gitelman syndrome-like animal 
models and thiazide users/Gitelman syndrome patients. They demonstrated that inhibition of 
SPAK activity actually led to greatly improved whole body glucose tolerance and insulin 
sensitivity compared to wildtypes on both control and high-fat diets, specifically showing that 
these animals were capable of increasing insulin-dependent AKT phosphorylation in the liver 
and skeletal muscles (Torre-Villalvazo et al., 2017). Another astounding finding of their study 
was that SPAKT243A/T243A mice fed a high-fat diet had lower circulating levels of cholesterol, 
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triglycerides and leptin, in addition to being resistant to obesity due to higher energy 
expenditure by brown adipose tissue and mitochondrial activity in skeletal muscle which 
prevented white adipocyte hypertrophy (Torre-Villalvazo et al., 2017). Interestingly, a higher 
degree of epigenetic silencing of STK39 through DNA methylation has been associated with 
increasing body mass index in humans (Wilson et al., 2017), which was also supported by the 
discovery of reduced fat mass without a change in lean mass in STK39-/- mice at baseline (Table 
5.2). If these findings can be replicated in SPAKT243A/T243A mice, it could have profound 
implications for the treatment of metabolic syndrome and obesity-related disorders. 
In conclusion, these results establish that the SPAK CCT domain plays a major role in 
regulating blood pressure. These data suggest that the SPAK CCT domain regulates blood 
pressure via SPAK activation by WNK isoforms that in turn enhance both activity and 
expression of the renal sodium cotransporters NCC and NKCC2 with potential concomitant 
effects on NKCC1 in the nervous and cardiovascular systems. The hypotensive phenotype of 
the SPAKL502A/L502A mice, validate the CCT domain as a promising new target for future anti-
hypertensive agents, while SPAKT243A/T243A and SPAK KO mice suggest CCT binding 
disruptors may also have the added benefit of increasing BMD, insulin sensitivity and obesity 
resistance, potentially representing a long-awaited panacea for metabolic syndrome. 
Importantly, the lack of an overt phenotype in these mice also indicates that CCT domain 
inhibitors may be well tolerated. Thus far a CCT domain inhibitor termed STOCK 1S-50699 
has been reported that has an IC50 of ~ 3 µM, that is capable of inhibiting WNK-SPAK 
phosphorylation of NKCC1 and NCC in mammalian cell lines (Mori et al., 2013a; de Los 
Heros et al., 2014). STOCK 1S-50699 is highly hydrophobic, displays poor solubility and 
cannot be used in animal models, but the data obtained so far provides evidence that the 
development of CCT domain inhibitors is feasible. 
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Chapter 6 : Conclusions 
 
6.1  Monogenic diseases in drug target identification and validation 
The cloning and characterisation of NCC and WNKs occurred in 1990’s (Gamba et al., 1993, 
1994; Mastroianni et al., 1996) and 2000’s (Xu et al., 2000; Veríssimo & Jordan, 2001; 
Nakamichi et al., 2002), respectively, but it was the study of the monogenic diseases, FHHt 
and Gitelman syndrome, a few years later that provided the first genetic confirmation that these 
genes are major players in blood pressure control (Simon et al., 1996; Lemmink et al., 1998; 
Wilson et al., 2001; Achard et al., 2003). Effectively serving as nature’s knock-out 
experiments, their intense study and modelling over the past two decades have revealed the 
existence of an evolutionarily ancient pathway compromised of opposing phosphorylation and 
ubiquitylation cascades to control ion fluxes and regulate cell volume, and later the electrolyte 
and blood pressure homeostasis of more complex lifeforms (Choe & Strange, 2007). 
 With this in mind, the study set out to investigate the most severe form of FHHt 
(PHA2E) to probe the physiological extremes of WNK pathway perturbation, in the hopes of 
developing new anti-hypertensive strategies. This led to discovery that there may be non-renal 
contributions to the FHHt phenotype, further highlighting the importance of WNKs for blood 
pressure regulation and finally confirming increased WNK abundance to be the common 
endpoint for FHHt-causing mutations. While thiazides and dietary salt restriction appears to 
alleviate the symptoms of FHHt, our findings imply that current treatment strategies 
inadequately address the abnormal vascular activity that underlies the arterial stiffness in these 
patients, which if left untreated could increase a plethora of cardiovascular and cognitive risk 
factors despite blood pressure and electrolyte normalisation (Liao & Farmer, 2014; Acampa et 
al., 2017; Tanaka et al., 2017). 
 Spurred on by this, the next step was to begin looking for ways to inhibit the WNK 
pathway-dependent activation of CCCs as means to lower blood pressure. As MO25 can 
activate SPAK/OSR1 independent of WNKs (Gagnon et al., 2011; Filippi et al., 2011; Ponce-
Coria et al., 2012; Li et al., 2014) and MO25 can complex with WNKs to activate CCCs in a 
SPAK/OSR1-independent manner  (Ponce-Coria et al., 2014; Bhuiyan et al., 2016), the first 
approach was to try knock-out of MO25 isoforms to investigate their potential as druggable 
targets. However, to our disappointment complete knock-out of MO25α proved embryonically 
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lethal and MO25β knock-outs did not present with a blood pressure phenotype. In hindsight, 
the embryonic lethality of MO25α homozygous knock-outs might have been anticipated, as the 
evolutionarily conserved gene was originally discovered in the cleavage stages of mouse 
embryos (Miyamoto et al., 1993; Nozaki et al., 1996). For this reason our work with 
constitutive MO25 knock-outs does not completely preclude MO25α as viable drug target in 
adults, and a more elegant study design would seek to create an animal model with inducible 
knock-out or knockdown of MO25α to better assess its potential. 
In light of this stumbling block, it was logical to target areas of the WNK pathway that 
might result in fewer off-target effects. So far, study of SPAK-KO and SPAKT243A/T243A 
Gitelman-like mouse models suggests that SPAK would make for an attractive drug target with 
a reduced profile of adverse side-effects (Rafiqi et al., 2010; Yang et al., 2010c; Mccormick et 
al., 2011; Grimm et al., 2012). However, drug-induced knockdown of SPAK proteins, direct 
antagonism of its kinase domain, or SPAK-activating phosphorylation and ATP site blockade 
seemed impractical approaches and with unacceptable potential for non-specific activity 
directed towards other kinases. Consequently, disruption of SPAK binding to its regulators and 
substrates was investigated as an alternative approach, and given the highly conserved nature 
of this binding mechanism it was predicted to have a higher probability of being specific to the 
WNK pathway. To our delight, this approach proved successful and suggests this it is the most 
viable strategy for targeting WNK-SPAK-CCC signalling. Therefore, SPAK binding 
disruptors would serve as a new class of anti-hypertensives that simultaneously act on the 
kidneys, heart, blood vessels and sympathetic nervous system to lower blood pressure, 
effectively duplicating the combined actions of diuretics, vasodilators, ionotropes and 
chronotropes in a monotherapy without their adverse effects. Another exciting aspect of these 
novel anti-hypertensives would be their implications for the treatment of co-morbidities such 
as obesity, diabetes type 2 and osteoporosis, representing a potential silver bullet for metabolic 
syndrome. 
 
6.2  Drug discovery and development of WNK pathway based therapeutics 
Almost a decade ago, the first compounds with activity towards the WNK pathways were 
identified. Using an novel screening assay the Alessi group had submitted for patent, revealed 
Hypericin, an extract of Saint John’s wort, to have an IC50 of 1.5 µM at 20 µM ATP for 
inhibition of OSR1 phosphorylation by WNK1 (Alessi & Vitari, 2006). Using a similar assay, 
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the Sode group screened a commercially available library of 86 kinase inhibitors and identified 
the following compounds to have IC50 values ranging from 1.9-32 µM at 25 µM ATP for 
inhibition of OSR1 phosphorylation by WNK1: Staurosporine (PKA, PKG, CaMK, tyrosine 
kinases, and phosphorylase kinase inhibitor), Tyrophostin 47 (EGF receptor kinase inhibitor), 
PP1 (Hck, Lck and Src inhibitor), PP2 (Hck, Lck and Src inhibitor) (Yagi et al., 2009). 
However, all of these appeared to rely on ATP-competitive kinase inhibition and were by their 
very nature of discovery non-specific for the WNK pathways and not pursued further. It is only 
within the last 5 years that new agents have been discovered or developed with relatively 
specific activity for the WNK pathway, which are detailed in the following sections.  
 
6.2.1  WNK kinase inhibition 
A classic strategy for targeting WNKs would be to directly inhibit their kinase activity, 
typically through an ATP-competitive mechanism. A group led by Yamada et al at Novartis 
introduced the first orally bioavailable pan-WNK kinase inhibitor, WNK463, that exploits the 
unusual structure of the WNK kinase domain to bind the hinge portion of the ATP pocket 
(Yamada et al., 2016a). WNK463 is a low nanomolar binder of both WNK1 and WNK4, 
regardless of activation state with incredible selectivity for the WNK kinase family. At 10 µM, 
2,500-fold higher than the binding KD for human WNK1/4, WNK463 showed >50% inhibition 
against 2 out of 442 human kinases tested. When tested in spontaneously hypertensive rats, 
WNK463 decreased blood pressure in a dose-dependent manner with simultaneous increases 
in heart rate, urinary volume, sodium and potassium excretion. Similarly, FHHt mice 
overexpressing WNK1 also had a significant drop in blood pressure after oral administration 
of WNK463, accompanied by dose-dependent reduction in renal levels of phospho-
SPAK/OSR1. Unfortunately as WNK463 acts on a conserved site within the WNK family it 
functions as a pan-WNK inhibitor, and given the essential roles of WNKs throughout the body, 
development of it as a therapeutic was discontinued due to an unacceptable preclinical safety 
profile (Yamada et al., 2016a). 
 Novartis also sought an ATP-noncompetitive means of WNK kinase inhibition. To 
identify compounds that bind outside of the ATP pocket, they performed screening at high ATP 
concentrations. This led to the discovery of Compound 2, an allosteric inhibitor with an 
exquisite specificity for members of the WNK family, and operating with an ATP and substrate 
noncompetitive mode of inhibition. When tested in HeLa and HT29 cells, Compound 2 was 
195 
 
capable of inhibiting the bumetanide-sensitive NKCC1-mediated rubidium uptake (Yamada et 
al., 2016b). Although potent, the pharmacokinetic profile of compound 2 was inadequate for 
in vivo efficacy testing of this mode of WNK inhibition. To overcome this, several 
modifications were made to the compound 2 to create compound 11 which had a 150-fold 
improvement in potency and significantly higher lipophilic efficiency (Yamada et al., 2017). 
Interestingly, even after modification the new compound still retained the ATP noncompetitive 
mode of inhibition with few significant off-targets, though curiously it now had a nearly 1,000-
fold selectivity for WNK1 vs WNK4. In rat pharmacokinetic studies compound 11 showed 
moderate clearance but low oral bioavailability and absolute exposure, so another modification 
was made to create compound 12 which had lower clearance, improved absolute exposure and 
double the oral bioavailability. Similar to WNK463, compound 12 reduced blood pressure in 
WNK1 FHHt mice and dose-dependent increases in urinary volume, sodium and potassium 
excretion in spontaneously hypertensive rats (Yamada et al., 2017). A particularly exciting 
advantage of allosteric vs ATP-site WNK inhibition, is the ability to achieve selectivity among 
the WNK family members, this suggests that it might be possible to develop allosteric 
inhibitors with a high affinity for WNK4 which would be a more useful target for blood 
pressure control. 
 
6.2.2  SPAK kinase inhibition 
The Uchida group has been quite active on the drug discovery front and has developed several 
screening systems to find novel SPAK inhibitors. Using an ELISA-based system that looks at 
SPAK-dependent phosphorylation of NKCC2 in vitro, STOCK 1S-14279 was found to bind to 
SPAK and potently inhibit phosphorylation of NKCC2 in an ATP-noncompetitive way (IC50 
of 0.26 µM). A drug repositioning strategy was then utilised to reveal existing drugs that may 
also inhibit SPAK activity, and this led to the identification of closantel, an oral antiparasitic 
agent commonly used in livestock. In mpkDCT and MOVA cells both drugs reduced NCC and 
NKCC1 phosphorylation, respectively, in a dose-dependent manner. This was replicated in 
mouse aorta and kidneys, without a change in NKCC2 status following acute in vivo 
administration. Unfortunately, repeated doses of STOCK 1S-14279 proved lethal and it could 
not be taken forward for further in vivo testing, although closantel was confirmed to produce 
decreases in blood pressure and heart rate (Kikuchi et al., 2015). 
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 Until recently the exact mechanism of inhibition for both STOCK 1S-14279 and 
closantel have been unclear. New work by the Mehellou group has identified the highly 
conserved secondary pocket in the C-terminal domain of SPAK/OSR1 as a site of allosteric 
inhibition of SPAK kinase activity. Modelling shows that the majority of documented SPAK 
inhibitor agents (STOCK 1S-14279, STOCK 1S-50699, STOCK 2S-26016, closantel and 
rafoxanide) dock with this secondary pocket, and surprisingly show minimal if any interaction 
with the primary pocket which is involved in binding to the conserved RFxI/V motif present in 
WNKs, NKCC1/2 and NCC.  Interestingly, STOCK 1S-50699, closantel and rafoxanide were 
capable of inhibiting constitutively active OSR1T185E  in vitro but this effect was abolished if 
the OSR1T185E was truncated and lacking a C-terminal. Additionally, closantel and rafoxanide 
do not show see changes in either HEK293 phospho-SPAK S373 levels or WNK RFQV motif 
– endogenous SPAK pulldowns assays but have a decrease in phospho-NKCC1 across a range 
of doses, suggesting that allosteric binding to the secondary pocket does not affect interactions 
between WNK-SPAK/OSR1 but rather hinders the capability of SPAK to phosphorylate CCCs 
(AlAmri et al., 2017).  
  
6.2.3  SPAK binding disruption 
An alternative strategy to indirectly inhibit SPAK function is to disrupt its binding to regulators 
and substrates. Using a newly developed in vitro WNK4 RFQV motif and SPAK CCT binding 
inhibition assay, the Uchida group identified the first agents discovered to have this potential, 
namely STOCK 1S-50699 and STOCK 2S-26016, which showed clinically relevant IC50 
values in the micromolar range. In mpkDCT and MOVA cells, these agents were also cable of 
decreasing phosphorylation of CCCs in a dose dependent fashion (Mori et al., 2013a). An 
intriguing possibility is that these drugs may actually have dual mechanisms of action, in which 
they bind and inhibit SPAK/OSR1 activation of CCCs via allosteric interaction with the 
secondary pocket of the CCT, while at higher concentrations inhibiting the interactions with 
WNKs through the CCT as evidenced by the decreases in phospho-SPAK levels (Mori et al., 
2013a; Austin et al., 2015; AlAmri et al., 2017). 
 However, STOCK 1S-50699 and STOCK 2S-26016 do not represent true primary 
pocket CCT binding inhibitors and due to their hydrophobic nature and poor solubility, they 
are not suitable for in vivo testing. To get around this issue the Uchida group, redeployed its 
screening assay and discovered viable compound that was subsequently altered to produce 
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compound 10 and compound 20, which have high potency, low cytotoxicity and increased 
solubility. These compounds are suspected to be true CCT binding disruptors and their acute 
testing in vivo produced marked dose-dependent decreases in the phosphorylation of SPAK 
and NCC, with slight but noticeable changes in NKCC1/2 phosphorylation (Ishigami-yuasa et 
al., 2017). 
 
6.2.4  MO25 binding disruption 
A unique strategy adopted by the Mehellou group was to side-step perturbations of WNK-
SPAK/OSR1 and instead target the MO25-dependent amplification of SPAK/OSR1 activity. 
To screen for potential candidates they developed a fluorescent polarisation assay using MO25 
and the WEW motif of SPAK/OSR1. Out of a library of ~4,000 compounds they identified one 
small-molecule inhibitor, HK01, which is capable of inhibiting the activity of OSR1T185E dose-
dependent manner. Based on the evidence from the competition experiment for MO25 binding 
to the SPAK WEW motif peptide by HK01 and subsequent pulldown assay, the authors believe 
the drug binds directly binds to MO25 to deny access to the SPAK/OSR1 WEW motif to 
prevent interaction. In HEK293 cells, HK01 inhibits the phospho-NKCC1 response to 
hypotonic solution, in a dose-dependent manner without changes in phospho-SPAK. Although 
the authors express their desire to direct efforts towards structural optimisation of HK01 to 
achieve better binding affinity before moving to animal tests. 
 
6.3  WNKs as signal transducers – a new paradigm 
In recent years the field of WNK biology has seen an explosion of interest. Many labs, funding 
bodies and pharma now recognise that importance of the WNK pathway in blood pressure 
maintenance and its potential for discovering new drug targets. Importantly, a new body of 
work has emerged which has caused a paradigm shift in the understanding of the physiological 
relevance of WNKs, suggesting that they are in fact the long awaited chloride/pressure sensing 
kinases.  
The Goldsmith group identified a chloride binding site within WNK1, that through 
prevention of autophosphorylation results in inhibition of WNK activity in the presence of high 
chloride concentrations (Piala et al., 2014). Two key leucine residues (L369/L371) of WNK1, 
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which are conserved in WNK3 (L295/L297) and WNK4 (L322/L324), were demonstrated to 
be essential for mediating the inhibitory effects of chloride on WNK autophosphorylation. 
However, the Ellison group showed that the WNKs are not equally sensitive to chloride. In 
vitro WNK4 is inhibited at the physiological ranges of DCT cell intracellular chloride 
concentration, with most potent effects between 0-40 mmol/L. While WNK1 was inhibited 
between 60-150 mmol/L and WNK3 between 100-150mmol/L (Terker et al., 2015a). Mutation 
of these leucines to phenylalanines (i.e. LLFF) blocked chloride binding, but unexpectedly 
expression in mammalian cells led to differing effects between the WNKs. Phospho-NCC 
(pNCC) levels in HEK293 cells did not differ between WNK3LLFF and WNK3WT, supporting 
the notion WNK3 is the least chloride sensitive of the WNKs. On the other hand, WNK1LLFF 
increased pNCC by 140% compared WNK1LLFF, confirming the findings of the Goldsmith 
group (Terker et al., 2015a), whereas WNK4LLFF increased pNCC by a dramatic 339% 
compared to WNK4WT, which has led to the interesting proposition by the Goldsmith group 
that while WNK4 is key chloride sensor, WNK1 and WNK3 may instead be primarily 
osmotic/hydrostatic pressure sensors, as they can be activated by macromolecular crowding 
mechanisms and that this regulation is opposed by chloride (Goldsmith et al., 2017). 
Previous reports have reported that WNK4WT decreases pNCC when expressed in 
HEK293 and Xenopus oocytes, suggesting that the intracellular chloride concentrations of 
these cells is greater than the physiological levels found in DCT cells in vivo (Terker et al., 
2015a). This may provide an explanation for a long standing controversy between in vitro data 
which purports a negative regulation of NCC by WNK4 (Golbang et al., 2006; Zhou et al., 
2010), and in vivo data which suggests that WNK4 is the major WNK positively regulating 
NCC in the kidney (Takahashi et al., 2014). WNKs are capable of dimerising with one another 
via a HQ motif in their conserved C-terminal (Thastrup et al., 2012), in particular stimulation 
of NCC activity by WNK1 was shown to be antagonised by WNK4 and dependent on their 
interactions via their HQ motif (Chávez-Canales et al., 2014). Although, seeing as WNK4LLFF 
stimulates and WNK4WT inhibits SPAK-NCC activity in these cells, it suggests that chloride 
acts as a switch between these two actions, and is dependent on WNK4 kinase activity as 
evidenced by the fact that inactivation of the WNKLLFF kinase domain returned SPAK-NCC 
activity to WNKWT levels (Terker et al., 2015a). Therefore, at the concentrations of chloride in 
the DCT in vivo WNK4 would be expected to provide tonic activation of NCC through its 
kinase activity directed at activating SPAK, but should this level rise it would cause WNK4 
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kinase inactivation whilst simultaneously antagonising WNK1 stimulation of NCC by the 
formation of heterodimers.  
Another major breakthrough by the Ellison group is that DCT cells can sense and 
respond to changes in serum potassium via alterations in cell voltage, effectively coupling 
intracellular chloride to extracellular potassium concentration through Kir4.1 (encoded by 
KCNJ10), Kir5.1 (encoded by KCNJ16) and CLC-K2 (also known as CLC-Kb, and encoded 
by CLCNKB) voltage-gated channels to modulate WNK activity (Terker et al., 2015b), thereby 
transducing serum potassium levels into changes in electrolyte and blood pressure homeostasis. 
Not unlike the zona glomerulosa cells of the adrenal glands which release aldosterone, the DCT 
cells appear capable of responding to changes in serum potassium levels, and thereby dietary 
potassium intake (Figure 6.1Error! Reference source not found.). A particularly noteworthy 
finding was that a diet deficient in potassium activates NCC, even when coupled with high 
sodium diet (i.e. a western diet), resulting in salt loading and elevated blood pressure (Terker 
et al., 2015b).  
 
 
Figure 6.1: Effects of serum potassium concentration on cells of the adrenal and kidney. 
Similar changes in membrane voltage due to alterations in extracellular K+ result in opposite effects on 
cellular activity/inhibition of the kidneys and adrenal glands. [Taken from (Terker et al., 2015b)]. 
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Interestingly, this suggested an explanation for the blood pressure lowering effects of a 
diet rich in potassium (i.e. DASH diet), and indeed animals fed a high potassium diet had 
reduced pNCC. Additionally, extracellular potassium concentration was confirmed to be 
inversely related to the levels of pNCC in ex vivo models. Using kidney slices bathe in solutions 
of varying potassium concentration allowed the assessment of the effects on NCC 
phosphorylation without hormonal or neural confounding factors, while isolated microperfused 
tubules were used to verify that the extracellular potassium concentration is detected on the 
basolateral side of DCT cells (Penton et al., 2016). However, the first holes began to emerge 
in the Ellison group’s model on closer inspection of the effects of high extracellular potassium 
on NCC dephosphorylation by the Loffing group. The hypothesis states that decreases in 
extracellular potassium will cause a change in DCT membrane potential to drive chloride out 
of the cell, thereby lowering intracellular chloride concentration to increase WNK-dependent 
SPAK and NCC phosphorylation. While this was verified to be the case in ex vivo kidney slices 
under standard conditions of 110 mmol/L of extracellular chloride, the effect was abolished 
when extracellular chloride was lowered to 5 mmol/L by replacing NaCl with Na gluconate in 
the buffer solution, suggesting that SPAK-NCC was already at higher level of activation in the 
5 mmol/L chloride buffer and that decreasing potassium in this buffer did little to meaningfully 
lower intracellular chloride to activate them further. In contrast, increasing extracellular 
potassium in both 110 and 5 mmol/L chloride buffers actually promoted NCC 
dephosphorylation to a similar degree, surprisingly without any significant change in SPAK 
phosphorylation from control potassium levels. To confirm this finding the Loffing group also 
used a chloride channel blocker DID, and found that it too did not prevent NCC 
dephosphorylation in response to rising extracellular potassium levels, contradictory to the 
Ellison hypothesis. Given the rapid SPAK-independent nature of dephosphorylation in 
response to high extracellular potassium, they investigated if this effect might be mediated by 
protein phosphatases. However, pharmacological inhibition of PP1, PP2A and PP3 had no 
effect on dephosphorylation of NCC in response to high extracellular potassium (Penton et al., 
2016). This suggests that NCC phosphorylation is under the control of a chloride-dependent 
involving the WNK-SPAK pathway, whereas NCC dephosphorylation is likely governed by a 
chloride-independent pathway which may include other signalling cascades or phosphatases, 
such as PP4 (Glover et al., 2010). 
Furthermore, work involving WNK4 knock-out (WNK4-KO) mice has confirmed that 
WNK4 is the primary chloride sensor and its ablation abolishes the phosphorylation of NCC 
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in response to low potassium intake (Yang et al., 2018). Notwithstanding this, the Ellison group 
hypothesis presents another conundrum, in that high NCC activity would be expected to 
increase intracellular chloride, effectively creating a negative feedback loop in the WNK-
SPAK-NCC pathway if the apical NaCl entry is not sufficiently coupled to basolateral exit. 
While conditions of low extracellular potassium may be sufficient to keep intracellular chloride 
low in the face of high NCC activity, it is not the case for increased luminal NaCl delivery to 
the DCT which is also known to increase NCC activity. To test the effects of increase luminal 
NaCl delivery, the Huang group chose to avoid using loop diuretics which may induce 
compensatory upregulation of NCC resulting from loop diuretic-induced diuresis and volume 
loss. Instead they administered subcutaneous injections of 0.5mL normal saline twice daily 
until the mice reached a new steady-state sodium balance with no volume expansion and the 
entire injected quantity of sodium excreted in the urine, therefore confirming increased luminal 
delivery of sodium. As expected, NaCl loaded wildtype animals had dramatically increased 
thiazide-induced sodium excretion and NCC phosphorylation, but surprisingly so did the 
WNK4-KO mice despite no differences in serum potassium or renin mRNA (Yang et al., 
2018). Taken together the Loffing and Huang studies suggest that the Ellison hypothesis cannot 
be generalised to all physiological circumstances, and there are many as of yet unidentified 
pathways regulating NCC activity that warrant further investigation. A current working model 
of the integrated signalling pathways is summarised in Figure 6.2.  
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Figure 6.2: Diagram of integrated CUL3-KLHL3-MO25α-WNK-SPAK/OSR1 signalling. 
In response to a low potassium diet, decreases in plasma K+ levels are detected by changes in DCT 
membrane voltage (mV) which lowers intracellular Cl- levels promoting WNK auto-phosphorylation 
and activation. Angiotensin II (AngII), vasopressin (AVP) and K+ depletion stimulate phosphorylation 
of KLHL3 via PKC and PKA signalling. This simultaneously destabilises KLHL3 levels and blocks the 
ability of CUL3-KLHL3 to bind and ubiquitylate WNKs, leading to their accumulation. Aldosterone 
(Aldo) also promotes transcription of KS-WNK1 which is essential for puncta formation and is believed 
to promote WNK-SPAK/OSR1 phosphorylation through macromolecular crowding mechanisms. 
Together these actions stimulate phosphorylation of SPAK/OSR1 to increase NCC/NKCC transporter 
activity via phosphorylation, with additional modulation provided by KS-SPAK and PP3/PP4 negative 
regulation or MO25α-dependent amplification of WNK and SPAK/OSR signalling. Phosphorylation of 
NCC along with aldosterone/SGK1- dependent inhibition of Nedd4-2 activity, increases NCC apical 
abundance to promote salt retention, which in addition to NKCC1-dependent increases in vascular tone 
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contributes to a rise in blood pressure. Green pointed arrows indicate a positive effect; blue pointed 
arrows indicate positive effects that are dependent on a secondary component; Red flat-head arrows 
indicate an inhibitory effect; grey flat-head arrows indicate inhibitory effect that has been removed. 
 
6.4  Future work 
Although FHHt is a rare disease, the discovery of a vascular phenotype in our animal model of 
PHA2E has worrying implications for current treatment strategies. A useful follow-up study 
would be to compare various pharmacological treatments of PHA2E to assess the best strategy 
for tackling the drivers of arterial stiffness in this disease. This would look at the following 
therapies as standalones or in combination: 
 Hydrochlorothiazide; an NCC-inhibiting diuretic and classic therapy of choice for 
treating FHHt. 
 Fasudil; a potent Rho-kinase inhibitor and vasodilator used in the treatment of stroke 
victims. 
 Furosemide, an NKCC2-inhibiting loop diuretic often deployed in the treatment of 
hyperkalaemia, but with potential vascular effects via NKCC1 inhibition. 
 
 Following this evaluation of therapies, it would necessary to perform non-invasive 
arterial pulse wave velocity (aPWV) measurements in thiazide-treated PHA2E patients and 
unaffected family members to determine if PHA2E patients have persistent arterial stiffness 
even when blood pressure is normalised. However, given the rarity of these patients, it might 
be more useful to determine Z-score of aPWV against age-matched blood pressure-matched 
healthy populations. If the same CUL3WT/Δ403-459 vascular phenotype exists in human patients, 
it would be advisable to adjust the treatment guidelines based on the outcomes of the 
CUL3WT/Δ403-459 pharmacotherapies comparison. 
 Given that MO25α overexpression has been demonstrated to predispose mice to salt-
sensitive hypertension (Yang et al., 2013), it is worth revisiting genetic animal models to 
validate MO25α as a viable anti-hypertensive target. In particular, the growing evidence for 
MO25α-WNK3-SPAK-NKCC1 signalling affecting the susceptibility and outcomes of 
ischaemic brain injury and post-haemorrhagic hydrocephalus (Bhuiyan et al., 2016; Zhang et 
al., 2016; Karimy et al., 2017), implies that MO25α inhibitors may have relevance in the 
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treatment of stroke injury. An improved study design employing inducible homozygous and 
heterozygous MO25α knock-outs would be useful not only in assessing blood pressure 
changes, but also recovery outcomes from surgical animal models of ischaemic and 
haemorrhagic stroke. However, should knockdown/knock-out strategies still result in a more 
extreme phenotype due to pleiotropic effects, animal models homozygous and heterozygous 
for inducible dual alanine mutations in the WEW motif of SPAK (W382A/W374A) and OSR1 
(W336A/W338A) required for MO25α-SPAK/OSR1 interactions, could provide an alternative 
for validating MO25α binding inhibition, which would be expected to have a less severe off-
target profile (Kadri et al., 2017). 
 Similarly, it may be worth revisiting the SPAKL502A/L502A animal models to establish if 
the same bone mineral density, metabolic and endocrine features observed in SPAKT243A/T243A 
mice can be recapitulated. Building on the previous work, as SPAK CCT inhibiting agents 
would be expected to also affect OSR1 due to their highly conserved nature, it would be 
important to generate, characterise and cross mice with the equivalent mutation in the CCT 
OSR1 (i.e. L473A), to ensure that the additional inhibition of OSR1 does not significantly 
expand the adverse side effect profile. Arguably the best study design to address CCT inhibition 
would be to generate inducible animal models, heterozygous and homozygous for SPAKL502A 
and OSR1L473A to investigate any dose depended effects and bypass the issue of embryonic 
lethality associated with OSR1 homozygous knock-out (Lin et al., 2011).  
 Many unanswered questions still remain in WNK biology. In particular, the 
transduction of dietary/serum potassium into electrolyte and blood pressure changes has yet to 
be fully validated in an intact living animal. Also to date, there has been no adequate 
explanation for the paradox that FHHt presents to the model of serum potassium-intracellular 
chloride coupling regulating WNK activity in the DCT, which would predict that 
hyperkalaemia and hyperchloraemia would inhibit WNK activity irrespective of protein 
abundance. Conversely, it might be expected that the hypokalaemia seen in SPAK activity-
deficient models of Gitelman syndrome would trigger overactivation of WNK-OSR1 
signalling, yet there is limited evidence to support this either. Resolving these issues will be 
essential to underpin our understanding of WNK based signal transduction and provide a sound 
basis for therapeutics targeting the WNK pathway.  
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Research Article
Characterisation of the Cullin-3 mutation that
causes a severe form of familial hypertension and
hyperkalaemia
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Abstract
Deletion of exon 9 from Cullin-3 (CUL3, residues 403–459:
CUL3D403–459) causes pseudohypoaldosteronism type IIE (PHA2E), a
severe form of familial hyperkalaemia and hypertension (FHHt).
CUL3 binds the RING protein RBX1 and various substrate adaptors
to form Cullin-RING-ubiquitin-ligase complexes. Bound to KLHL3,
CUL3-RBX1 ubiquitylates WNK kinases, promoting their ubiquitin-
mediated proteasomal degradation. Since WNK kinases activate
Na/Cl co-transporters to promote salt retention, CUL3 regulates blood
pressure. Mutations in both KLHL3 and WNK kinases cause PHA2 by
disrupting Cullin-RING-ligase formation. We report here that the
PHA2E mutant, CUL3D403–459, is severely compromised in its ability to
ubiquitylate WNKs, possibly due to altered structural flexibility.
Instead, CUL3D403–459 auto-ubiquitylates and loses interaction with
two important Cullin regulators: the COP9-signalosome and CAND1. A
novel knock-in mouse model of CUL3WT/D403–459 closely recapitulates
the human PHA2E phenotype. These mice also show changes in the
arterial pulse waveform, suggesting a vascular contribution to their
hypertension not reported in previous FHHt models. These findings
may explain the severity of the FHHt phenotype caused by CUL3
mutations compared to those reported in KLHL3 or WNK kinases.
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Introduction
Blood pressure is controlled in part by the WNK kinase pathway,
which acts to modulate the activity of key cation–chloride
co-transporters in the kidney (Kahle et al, 2008; Alessi et al, 2014).
Considerable insight into this pathway has come from exploring the
molecular basis for mutations described in patients with a rare
monogenic form of hypertension called familial hypertension and
hyperkalaemia [FHHt, also known as pseudohypoaldosteronism
(PHA2); OMIM: 145260]. Mutations in the genes encoding WNK
kinases have been shown to increase protein levels of WNK1 and
WNK4 in the kidney, leading to increased activation of this pathway
(Wilson et al, 2001; Kahle et al, 2008). When activated by phospho-
rylation, the WNK kinases phosphorylate and activate the down-
stream kinases, SPAK (SPS1-related proline/ alanine-rich kinase)
and OSR1 (oxidative stress–responsive kinase 1), which in turn
phosphorylate and activate cation–chloride co-transporters in the
kidney, such as NCC (Na+/Cl co-transporter), which leads to
increased sodium ion reabsorption (Vitari et al, 2005; Delpire &
Gagnon, 2008; Richardson et al, 2008, 2011). It is this up-regulation
of the WNK signalling pathway that is responsible for the salt reten-
tion that drives the hypertension in FHHt. These patients also
present with disturbed plasma electrolytes especially hyperkalaemia
and a metabolic acidosis, partly driven by NCC activation (Boyden
et al, 2012; Osawa et al, 2013; Tsuji et al, 2013; Glover et al, 2014;
McCormick et al, 2014). As FHHt patients are salt-loaded through
NCC activation, the hypertension and electrolyte disturbance
respond to either salt restriction or low doses of thiazide diuretics
(Gordon & Hodsman, 1986; Mayan et al, 2002).
More recently, the ubiquitin–proteasome system (UPS) was
shown to have a critical upstream role in regulating blood pressure
by modulating WNK kinase levels (Mori et al, 2013; Ohta et al,
1 MRC Protein Phosphorylation and Ubiquitylation Unit, College of Life Sciences, University of Dundee, Dundee, UK
2 Division of Experimental Medicine and Immunotherapeutics, University of Cambridge, Cambridge, UK
3 Division of Cardiovascular Medicine, Department of Medicine, University of Cambridge, Cambridge, UK
4 Institute of Biochemistry, ETH Zürich, Zürich, Switzerland
*Corresponding author. Tel: +44 1382 384241; E-mail: francesrose.schumacher@gmail.com
**Corresponding author. Tel: +44 1223 762578; E-mail: kmo22@medschl.cam.ac.uk
***Corresponding author. Tel: +44 1382 388371; E-mail: t.kurz@dundee.ac.uk
†These authors contributed equally to this work
‡Current address: Proteomics and Biological Resource Management, Department of Protein Chemistry, Genentech, 1 DNA Way, South San Francisco, CA, USA
ª 2015 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine Vol 7 | No 10 | 2015 1285
3XEOLVKHGRQOLQH$XJXVW
2013; Wakabayashi et al, 2013; Wu & Peng, 2013). This was first
suggested when patients with severe forms of FHHt were described
with mutations in Cullin-3 (CUL3; PHA2E), and one of its substrate
adaptors, KLHL3 (PHA2D) (Boyden et al, 2012; Louis-Dit-Picard
et al, 2012; OMIM:145260). CUL3 belongs to the Cullin-RING ligase
(CRL) family that form the largest class of ubiquitin E3 ligases in the
cell. Cullins are elongated proteins, which confer an extended struc-
ture to active CRL complexes (Zheng et al, 2002; Duda et al, 2011).
Through their C-terminus, Cullins constitutively bind to a small
RING finger protein, either RBX1 or RBX2, which forms the catalytic
core of the ligase complex. The binding to various substrate-adaptor
proteins at the N-terminal domain enables CUL3-RBX1 to appropri-
ately ubiquitylate a plethora of cellular substrates (Wee et al, 2005;
Harper & Tan, 2012). In this way, CUL3 acts as an active scaffold to
direct ubiquitylation, as C-terminally bound RBX1 binds ubiquitin-
conjugating E2 enzymes that are charged with ubiquitin, while
simultaneously binding to the substrate adaptor, in this instance
KLHL3. The overall structural rigidity of the Cullin, in particular
between the elongated N-terminus and the globular C-terminus, is
important for the ubiquitin E3 ligase function of the complex. Alter-
ations in the connecting sequence between the Cullin N- and
C-terminus are thought to change the relative positioning of the
RING domain towards the bound substrate, which can prevent
substrate modification (Zheng et al, 2002; Liu & Nussinov, 2011).
Efficient CRL ubiquitylation also requires the modification of a
conserved C-terminal lysine residue (Lys 721 in CUL3) by a single
molecule of the ubiquitin-like protein Nedd8 (Pintard et al, 2003).
This modification, auto-catalysed by CUL3-RBX1, is aided by
Nedd8-E3 ligases (Kurz et al, 2005; Rabut et al, 2011) and alters the
flexibility of the C-terminal Cullin-RBX1 module to activate E3 ligase
activity (Duda et al, 2008; Scott et al, 2014). While neddylation is
required for efficient ubiquitylation, studies show that the cycling
between a neddylated and deneddylated state is crucial in a cellular
context (Cope et al, 2002; Pintard et al, 2003). As such, Cullin inter-
actions with the deneddylation complex COP9-signalosome (CSN), a
metalloprotease, are also required for activity. Another regulator of
CRLs, CAND1, interacts with the N- and C-terminus of Cullins only
in their deneddylated state to promote the exchange of substrate
adaptors (Liu et al, 2002; Goldenberg et al, 2004; Pierce et al, 2013;
Wu et al, 2013; Zemla et al, 2013).
In the context of PHA2, KLHL3 is the critical adaptor that links
the WNK kinases to CUL3-RBX1, enabling CUL3 to directly ubiquity-
late the bound WNK kinase. In earlier work, we and others showed
the KLHL3 mutations described in FHHt (PHA2D) patients disrupt
the formation of the complex and prevent WNK ubiquitylation, lead-
ing to WNK stabilisation and increased flux through the WNK
kinase pathway (Mori et al, 2013; Ohta et al, 2013; Shibata et al,
2013; Wakabayashi et al, 2013; Wu & Peng, 2013; Schumacher
et al, 2014; Susa et al, 2014). Some patients with FHHt have muta-
tions in WNK kinases, which promote WNK stabilisation by
disrupting WNK-KLHL3 interactions (Wakabayashi et al, 2013;
Schumacher et al, 2014) or, in some cases, by the increased expres-
sion of WNK mRNA (Wilson et al, 2001).
While FHHt patients with CUL3, KLHL3 or WNK mutations
present with the same disease, those with mutations in CUL3 display
a more severe phenotype, evident in terms of both an earlier age-of-
onset and the degree of hypertension and electrolyte disturbance
reported (Boyden et al, 2012; Osawa et al, 2013; Tsuji et al, 2013).
To date, all the reported CUL3 PHA2E mutations are heterozygous,
transmit as autosomal dominant traits and result in the deletion of
the amino acids encoded for by exon 9 of the CUL3 mRNA (residues
403–459) (Boyden et al, 2012; Grimm et al, 2012; Osawa et al, 2013;
Tsuji et al, 2013; Glover et al, 2014). Nevertheless, precisely why
and how this truncated form of CUL3 (hereafter referred to as
CUL3D403–459) causes a more severe phenotype is currently unclear.
We have investigated this question using a biochemical in vitro
approach to understand the molecular defects caused by the
mutation and a mouse model of PHA2E to better understand the
physiological basis of the effects of CUL3D403–459. This has uncov-
ered a number of critical molecular and physiological factors that
enhance our understanding of Cullin-RING ligase mechanisms, the
physiology of CUL3, and importantly its pathophysiology in FHHt
patients.
Results
CUL3D403–459 forms an active Cullin-RING ligase complex
To investigate the molecular defect of CUL3D403–459, we determined
whether this form of CUL3 was able to build a CRL complex. First,
we established that CUL3D403–459 binds RBX1 similar to CUL3WT, by
showing that both versions of CUL3 form a stable complex with
RBX1 when co-expressed in insect cells (Fig 1A). A second critical
interaction for a functional CRL is the ability to bind substrate-adap-
tor proteins, and in the context of WNK kinase modification, CUL3
must interact with KLHL3 (Lamark & Johansen, 2012; Ji & Prive´,
2013; Canning & Bullock, 2014). The 57-residue deletion in
CUL3D403–459 lies in a structurally distinct domain of CUL3 and
would not be expected to perturb binding to substrate adaptors. We
confirmed that CUL3D403–459 indeed retains the ability to bind KLHL3
by in vitro pull-down assays with purified proteins (Fig 1B). We also
showed this interaction is maintained in a cellular system, using
ectopically expressed FLAG-tagged CUL3 to co-precipitate endoge-
nous KLHL3 in FLAG immunoprecipitates (Fig 1H, lower panel). Thus,
CUL3D403–459 maintains crucial interactions important for ubiquitin-
ligase function. Given this, we tested whether CUL3D403–459-RBX1 also
maintains the ability to hydrolyse the thioester bond between the
catalytic cysteine residue of a recruited E2 enzyme and ubiquitin
(E2~UB), a critical step in ubiquitylation and a measure for catalytic
activity. Using ubiquitin-release assays from charged E2 enzymes,
we show that CUL3D403–459 hydrolyses E2~UB more efficiently than
CUL3WT, demonstrating a functionally intact CUL3D403–459-RBX1
catalytic core, while also suggesting potential hyper-activity
(Fig 1C). Together, these results demonstrate that CUL3D403–459
maintains interactions and basic functionality critical for CRL activity.
Structural modelling suggests CUL3D403–459 is more flexible
than CUL3WT
To better understand how the deletion in CUL3D403–459 may affect
the CRL, we predicted the structure of CUL3, using closely related
Cullin-1 (CUL1; Fig 1D; Appendix Fig S1). The region deleted in
CUL3D403–459 likely forms a three-helical bundle juxtaposed to the
globular C-terminal domain. Removal of these helices would fuse
together two short unstructured regions to create a longer loop,
EMBO Molecular Medicine Vol 7 | No 10 | 2015 ª 2015 The Authors
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which, as well as shortening the elongated structure of the CRL
complex, may increase the flexibility between the two domains. If
correct, this model explains how RBX1 and KLHL3 binding is main-
tained (Munir et al, 2007; Calabrese et al, 2011), while also suggest-
ing the function of the ligase may be compromised due to the
altered relative orientation of the CRL components towards each
other. Studies investigating the structure of CUL1 demonstrated the
importance of a rigid Cullin conformation for substrate ubiquityla-
tion, as increasing the flexibility of CUL1, in an area that
corresponds to the CUL3 deletion, led to strongly decreased
substrate ubiquitylation (Zheng et al, 2002; Appendix Fig S1). It
is therefore possible that due to the presence of a predicted
unstructured flexible loop, CUL3D403–459 may similarly sample non-
productive conformations.
CUL3D403–459 has altered Nedd8-ligase activity and is unable to
interact with the CRL regulators COP9-signalosome and CAND1
Available structural data of CRL proteins bound to Cullin regulators
suggest the deleted region in CUL3D403–459 may also influence neddy-
lation and binding of the CSN (Lingaraju et al, 2014) and of CAND1
(Goldenberg et al, 2004; Fig EV1). This prompted us to examine
whether these interactions are affected by the PHA2E mutation.
To investigate the ability of CUL3D403–459 to be auto-modified
with Nedd8, we used in vitro neddylation assays with purified
CUL3, Nedd8 E1 (APPBP1-UBA3), Nedd8 E2 (UBE2M) and Nedd8.
As Nedd8 forms a covalent isopeptide bond with CUL3, neddylation
can be visualised as a slower-migrating band on SDS–PAGE. We
found CUL3D403–459 retains the ability to auto-neddylate (Fig 1E,
Appendix Fig S2A). However, CUL3D403–459 appears less efficient at
transferring Nedd8, as unlike for CUL3WT, some unmodified
CUL3D403–459 remained even 45 min after neddylation was initiated.
Moreover, while CUL3WT was only mono-neddylated, multiple
Nedd8 molecules were attached to CUL3D403–459 (Fig 1E). Both of
these differences in neddylation are consistent with increased struc-
tural flexibility of CUL3D403–459.
As reported (McCormick et al, 2014), we also noticed that
CUL3D403–459 neddylation is elevated in cells (Fig 1F). CRLs cycle
between neddylated and de-neddylated states to maintain activity
(Pintard et al, 2003). Therefore, the increased cellular neddyla-
tion of CUL3D403–459 could reflect a decrease in de-neddylation
by the isopeptidase CSN. The structure of the CSN bound to
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CUL1 supports this idea, as the Cullin C-terminal domain,
including the region equivalent to residue 403–459 in CUL3,
contacts the CSN subunits directly (Lingaraju et al, 2014). To
investigate this possibility, we blocked neddylation using an inhi-
bitor of the Nedd8-E1 enzyme (MLN4924; Millennium Pharma-
ceuticals) and monitored CUL3 de-neddylation over time.
Consistent with decreased rates of deneddylation, CUL3D403–459
remained neddylated for longer than CUL3WT (Fig 1G) and also
showed markedly reduced binding to CSN subunits (Fig 1H,
Appendix Fig S2B). As such, the observed elevated Nedd8
modification of CUL3D403–459 in cells is likely due to a combination
of Nedd8 ligation to non-physiological lysine residues and of
reduced CSN de-neddylation.
CRLs must be de-neddylated for a productive interaction with the
substrate-adaptor exchange factor CAND1. Furthermore, the struc-
ture of CUL1 bound to CAND1 suggests that, regardless of neddyla-
tion state, CUL3D403–459 may be unable to form the required critical
interactions (Goldenberg et al, 2004; Pierce et al, 2013; Wu et al,
2013; Zemla et al, 2013). We therefore investigated whether
CUL3D403–459 was indeed defective in binding to CAND1. We treated
cells expressing either FLAG-CUL3WT or FLAG- CUL3D403–459 with
the neddylation inhibitor MLN4924 to force all of CUL3 into the
non-neddylated state and then determined interaction with CAND1
by immunoprecipitation. While CUL3WT strongly bound to CAND1
in these assays, CUL3D403–459 was unable to interact with CAND1
(Fig 2H, Appendix Fig S2B). We confirmed these findings using
in vitro assays with purified proteins (Fig 1I). These data advocate
that structural perturbations prevent CUL3D403–459 from binding to
CAND1. In combination with the impairment of CSN binding, such
defects suggest that the regulation of CUL3D403–459 in cells is likely
severely disrupted.
CUL3D403–459 displays enhanced auto-ubiquitylation
Our data indicate that the regulation of CUL3D403–459 is defective in
cells, and we wanted to test whether its ubiquitylation activity is
similarly affected. McCormick et al suggested that CUL3D403–459 may
stabilise WNK kinases by ectopically degrading the substrate adap-
tor KLHL3, preventing the formation of functional CUL3-KLHL3
complexes (McCormick et al, 2014). Some CRLs are known to ubiq-
uitylate bound substrate adaptors (Wee et al, 2005), and it is feasi-
ble that altering the CUL3 backbone structure could indeed lead to
erroneous ubiquitylation of KLHL3. In our in vitro system, we con-
firmed that CUL3D403–459 directly modified KLHL3 with a greater effi-
ciency than CUL3WT (Fig 2A, Appendix Fig S2C). Interestingly, we
observed that CUL3D403–459 also exhibited markedly increased auto-
ubiquitylation (Fig 2B, Appendix Fig S2D).
Auto-ubiquitylation is often utilised as a read-out for ubiquitin-
ligase activity. In a cellular context, self-modification can lead to
auto-degradation of the ligase (Silke et al, 2005). If CUL3D403–459
Figure 1. CUL3D403–459 forms a functional Cullin-RING ligase with altered activity and is unable to interact with CRL regulators.
A Purified CUL3WT and CUL3D403–459 analysed by SDS–PAGE and Coomassie blue staining, following expression in SF21 cells, and DAC-tag-affinity purification and tag
cleavage (see Materials and Methods). Bands migrating between 62- and 98-kDa protein markers are CUL3WT and CUL3D403–459, respectively, while the band below 17
kDa is Rbx1. The immunoblot for RBX1 is shown on the right. The band in CUL3WT denoted with * is co-purified insect cell CAND1, which was later removed by SEC.
All protein identities were confirmed by mass spectrometry.
B KLHL3 binding to CUL3WT and CUL3D403–459 is comparable as shown by pull-down assays with a KLHL3 resin generated from cross-linking anti-KLHL3 antibody to
Protein G sepharose, and then binding saturating amounts of KLHL3 to the anti-KLHL3 resin (denoted KLHL3R), the control resin (ControlR) is Protein G sepharose (see
Materials and Methods for further detail). CUL3WT or CUL3D403–459 was incubated with either KLHL3R or ControlR at 4°C for 1 h and then washed thrice with 1× PBS,
resin volumes were minimised, and SDS–Laemmli buffer was used to elute protein from resin prior to analysis by SDS–PAGE and staining with colloidal blue.
C UBE2D3~ubiquitin-release assays analysed by non-reducing SDS–PAGE and immunodetection. His-tagged UBE2D3 was charged with ubiquitin by incubation with
ATP and UAE, and charging was stopped by ATP depletion with apyrase. No CUL3 (negative control, lane 1), CUL3WT or CUL3D403–459 was then added to the charged
E2 and the activity of the RING domain, RBX1, monitored by the hydrolysis of ubiquitin from UBE2D3, visualised by immunodetection with anti-His antibody (upper
panel, “~” denotes thioester bond). The lower panel is an immunoblot for CUL3, showing equivalent amount of both CUL3WT and CUL3D403–459 was added to the
reaction mix; over time, the appearance of higher molecular weight bands represents the modification of CUL3 by covalent attachment of ubiquitin. The right two
lanes are control lanes incubated for 10 min with E2~Ubi but then treated with reducing agent prior to SDS–PAGE.
D Structural model of CUL3WT based on the structure of CUL1 (PDB:1LDK), highlighting the residues deleted in the PHA2E mutant which are located close to the
N-terminal domain (NTD) and C-terminal domain (CTD) border, using Phyre2 and Chimera (see Materials and Methods). The NTD is coloured purple, the CTD cyan,
and residues 403–459 orange.
E Time course of in vitro neddylation reactions. Purified NAE, UBE2M and Nedd8 were mixed with either CUL3WT or CUL3D403–459 and incubated at 30°C for the time
indicated. Due to the covalent attachment of Nedd8 (8.6 kDa), modified proteins have decreased mobility. The band shift observed for CUL3WT (lane 1 versus lane 2) is
representative of a single Nedd8 modification, while the multiple bands in the CUL3D403–459 reaction reflect the attachment of up to three Nedd8 molecules (lane 5
versus lane 8).
F HEK-293 cells over-expressing either FLAG-CUL3WT or FLAG-CUL3D403–459 were immunoprecipitated with M2 Flag-binding sepharose, in the presence of a deneddylase
inhibitor (OPT). Extract, cells were lysed in the presence of OPT and clarified by centrifugation. IP:M2, clarified supernatant samples were incubated for 1 h at 4°C
with M2 (anti-Flag) sepharose, then washed with PBS and eluted with SDS–Laemmli buffer, prior to SDS–PAGE and immunodetection with anti-FLAG antibody. Bands
are labelled as follows: 1. CUL3WT, 2. CUL3WT-N8, 3. CUL3D403–459, 4. CUL3D403–459-N8, 5. CUL3D403–459-2(N8).
G Neddylation in HEK-293 cells over-expressing FLAG-CUL3WT or FLAG-CUL3D403–459 was blocked by treatment with a Nedd8-E1-enzyme inhibitor, 3 lM MLN4924
(Millennium Pharmaceuticals), in cells over-expressing FLAG-CUL3WT and FLAG-CUL3D403–459 respectively. Cell extracts were sampled over time in the presence of OPT
to prevent de-neddylation and subjected to SDS–PAGE and immunodetection of the FLAG tag.
H FLAG-CUL3WT or FLAG-CUL3D403–459 was immunoprecipitated with M2-sepharose as described in (F). +MLN4924 indicates cell culture media supplementation with
3 lM MLN4924 for 5 h prior to cell lysis to achieve complete deneddylation of CUL3. Following SDS–PAGE, immunoblotting with COP9 Signalosome (CSN) or CAND1
antibodies determined the interaction between these Cullin regulators and FLAG-CUL3WT and FLAG-CUL3D403–459, respectively.
I GST-CAND1 pull-down assays with CUL3 proteins. Purified GST or GST-CAND1 immobilised on glutathione–sepharose was mixed with either purified CUL3WT or
CUL3D403–459 and incubated at 4°C for 1 h. The sepharose was then washed thrice and eluted from the resin by incubation with SDS–Laemmli buffer prior to SDS–
PAGE and Coomassie staining. CUL3WT but not CUL3D403–459 interacts with CAND1.
Source data are available online for this figure.
◀
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modifies lysine residues inaccessible to CUL3WT, this could explain
the increased auto-ubiquitylation. Alternatively, CUL3D403–459 could
build longer ubiquitin chains on the same lysine residues that are
also targeted by CUL3WT. To explore these possibilities, we
performed in vitro ubiquitylation assays with methylated ubiquitin,
a form of ubiquitin unable to build ubiquitin chains (Kirisako et al,
2006). In these assays, CUL3D403–459 was auto-modified on multiple
lysine residues, while CUL3WT only mono-ubiquitylated one residue
(Fig 2C). Therefore, the observed increase in auto-ubiquitylation is
most likely due to erroneous modification of multiple lysine resi-
dues on CUL3D403–459, which is consistent with an increase in struc-
tural flexibility as suggested by our model. Alternatively, the
mutation may change the active site environment of CUL3, exposing
more lysine residues close to the E2~UB binding site. To distinguish
between these possibilities, we mapped the lysine residues modified
in our in vitro assay system using mass spectrometry. We performed
in vitro auto-ubiquitylation reactions of CUL3 with methylated
ubiquitin for either 5 or 45 min and determined the ubiquitylated
lysine residues by analysing which lysine residue(s) carry di-glycine
remnants after trypsin digest (Fig 2D and E; Kim et al, 2011). Using
this approach, we found that after 5 min, CUL3WT was only
auto-ubiquitylated on a single lysine residue (K336), while ten
lysine residues on CUL3D403–459 were modified (Fig 2D and E). After
running the reaction for 45 min, the modification sites on CUL3WT
had increased to five, all of which were C-terminal to the original
site and contained within the globular C-terminal Cullin domain.
The ubiquitylation sites on CUL3D403–459, however, had increased to
25 sites distributed along the entire length of the protein (most
N-terminal: K47; most C-terminal: K743). These results support our
model that the CUL3 deletion induces increased structural flexibility,
leading to the erroneous auto-ubiquitylation of sites normally not
accessible to CUL3WT (Figs 2E and F and EV2).
CUL3D403–459 cannot ubiquitylate WNK kinases
As CUL3D403–459 is able to more efficiently auto-ubiquitylate itself
and KLHL3, we next asked whether it similarly shows increased
ubiquitylation towards a bound WNK substrate in in vitro ubiquityla-
tion assays using purified components. As we previously showed,
CUL3WT efficiently ubiquitylates WNK kinases in vitro (Fig 3; Ohta
et al, 2013). CUL3D403–459, however, while maintaining the ability to
efficiently modify itself and KLHL3, was not able to modify either
WNK1 or WNK4 (Fig 3A and B). As described for CUL1 (Zheng et al,
2002), increasing the flexibility of the Cullin backbone can lead to a
decrease in substrate modification, while promoting excessive modi-
fication of other CRL components (Zheng et al, 2002). Thus,
increased structural flexibility of CUL3D403–459 may lead to similar
defects. If so, then it becomes important to understand how this
in vitro finding can explain the increased WNK stabilisation found
in vivo. It is possible that only one of the three defects, the lack of
substrate ubiquitylation, the increased Cullin auto-ubiquitylation or
the increased KLHL3 ubiquitylation, is the major driver for the
observed phenotypes. Decisively, KLHL3 levels are not decreased in
the kidney of CUL3WT/D403–459 mice, while the overall CUL3 levels
are lower. This suggests that KLHL3 degradation does not contribute
to the observed PHA2E phenotype, and instead, we propose that
CUL3D403–459 stabilises WNK levels in two ways: firstly, CUL3D403–459
excessively auto-ubiquitylates, leading to its own degradation; and
secondly, any CUL3D403–459 protein that escapes degradation cannot
promote the ubiquitylation of the WNK kinases. Importantly, all
PHA2E patients are heterozygous for the mutation, suggesting that
with respect to blood pressure regulation either CUL3D403–459
behaves as a dominant-negative or CUL3WT is haploinsufficient. Our
data demonstrate that the mutation causes a loss-of-function, so a
dominant-negative effect seems less likely. We also find that in vitro,
equimolar amounts of CUL3D403–459 do not inhibit CUL3WT (Fig 3C),
further supporting the concept of haploinsufficiency.
CUL3WT/D403–459 mice have increased flux through the WNK
kinase pathway and typical FHHt phenotypic features of
electrolyte imbalance
To complement our in vitro findings and to determine more accu-
rately what occurs in PHA2E patients, we engineered a knock-in
(KI) mouse carrying the same exon 9 deletion of CUL3 as reported
in PHA2E pedigrees (CUL3D403–459; Appendix Fig S3). Despite setting
up heterozygous mating pairs, no homozygous KI mice were born
suggesting that, like deletion of the entire coding region of CUL3,
the homozygous deletion of residues 403–459 is lethal (Singer et al,
1999). Nevertheless, all the reported PHA2E pedigrees are heterozy-
gous, so we phenotyped the heterozygous KI mice. Utilising both
immunoblotting of whole kidney lysates and immunofluorescence
Figure 2. CUL3D403–459 displays increased auto-ubiquitylation and ubiquitylation of KLHL3.
A–D In vitro ubiquitylation assays with purified proteins. As ubiquitin is covalently attached to the substrate lysine residue, the appearance of higher molecular weight
protein bands reflects the modification of the protein with ubiquitin. All assays contain purified UBE1, UBE2D3, ubiquitin, 0.1 mM ATP, 1 mM MgCl2 and were
buffered in 50 mM HEPES, 150 mM NaCl and incubated at 30°C for the time indicated. Reactions were stopped by the addition of SDS–Laemmli buffer to a
concentration of 1×. SDS–PAGE, staining with Coomassie blue, or detection with the indicated antibody following immunoblotting enabled the visualisation of
ubiquitylation. (A) to determine the relative modification of KLHL3 by CUL3WT and CUL3D403–459, KLHL3 was included into the reaction at 2× molar concentration
over CUL3WT and CUL3D403–459. (B, C) Reactions serve to determine basal auto-ubiquitylation of CUL3WT or CUL3D403–459 and do not contain KLHL3 or other
potential substrate proteins. Lysine residues on CUL3WT or CUL3D403–459 act as the substrate. (B) High molecular weight bands reflect ubiquitin chain linkages on
CUL3 or the multiple mono-ubiquitylation of a number of CUL3 lysine residues. (C) Activity assays contain methylated ubiquitin, a form of ubiquitin incapable of
forming ubiquitin chains; as such, higher band shifts reflect the attachment of mono-ubiquitin to one more lysine residue on CUL3WT or CUL3D403–459, respectively.
(D) Activity assay performed as in (C) with methyl-ubiquitin, the boxes shown on the gel are indicative of the gel pieces excised for mass spectrometry analysis in (F).
E Schematic representation (to linear residue scale) highlighting the domains of CUL3 and schematic representation of the lysine residues of CUL3WT or CUL3D403–459,
modified at 5 and 45 min, respectively, in the in vitro ubiquitylation assay shown in (D) and as determined by mass spectrometry.
F Structural docking model of CUL3D403–459 based on the structure of full-length CUL1 (1LDK) using Chimera (see Materials and Methods). The NTD is coloured green,
while the CTD is red, and the four panels sample possible positioning of the CTD relative to the NTD in CUL3D403–459, assuming full flexibility of the linker after
deletion of three helices encoded by exon 9.
Source data are available online for this figure.
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confocal microscopy of kidney sections, we determined the relative
abundance and distribution of proteins involved in the WNK signal-
ling pathway. Whole kidney lysate was analysed by immunoblotting
confirming the expression of CUL3 and the presence of an additional
band corresponding to the expected PHA2E form, CUL3D403–459, in
the heterozygous mice (Fig 4A). Increased levels of WNK4 and the
downstream components of the WNK kinase pathway, reported in
other mouse models of FHHt, were also observed (Fig 4A). Specifi-
cally, there were striking increases in both total and phosphorylated
forms of SPAK and NCC (Fig 4A). We also confirmed the expression
of KLHL3 and CUL3 in normal human kidney lysates (Fig 4B). In
the context of our in vitro data, we were especially interested in
examining the levels of KLHL3 and CUL3 in the mouse kidney
(Fig 4A). Definitively, the overall level of KLHL3 was comparable
between CUL3WT/WT and CUL3WT/D403–459 mice. In contrast,
CUL3D403–459 appears to be less abundant than CUL3WT in the
heterozygous mice. These observations suggest that CUL3D403–459
does not promote KLHL3 degradation in vivo and, moreover, that
the lower levels of CUL3D403–459 may be due to the propensity of
CUL3D403–459 to self-modify presumably causing degradation
through the UPS. The lower level of observable CUL3D403–459 may
also be due to non-proteolytic hyper-modification of CUL3D403–459
with either Nedd8 or ubiquitin. Indeed, this may in part be the case,
as incubation of kidney extract at room temperature to promote
de-conjugation of Nedd8 or ubiquitin increased the abundance of
the faster migrating CUL3D403–459 band, but did not restore it to
CUL3WT levels (Fig 4A, lower panel). Regardless of precisely why,
the stabilisation of WNK4 and increased signalling through the
WNK cascade is consistent with a PHA2E model.
Over-activation of the WNK pathway would be expected to
perturb electrolyte homoeostasis. We confirmed this by measuring
urine electrolytes, blood biochemistries and aldosterone levels in
the mice (Figs 4C and D and EV3). The CUL3WT/D403–459 mice
showed the typical electrolyte disturbance of FHHt with hyper-
kalaemia, hyperchloraemia and a compensated metabolic acidosis,
with the pH maintained by an increased respiratory drive to increase
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Figure 3. CUL3D403–459 is unable to ubiquitylateWNK1 orWNK4 kinases in an in vitro system, and this deficiency cannot be rescued by the presence of CUL3WT.
A–C In vitro ubiquitylation assays were performed as described in Figure 2, but with the addition of immunoprecipitated WNK1 in (A), or immunoprecipitated over-
expressed FLAG-WNK4 in (B, C) (see Materials and Methods). The WNK kinases are modified by CUL3WT-KLHL3, with the higher molecular weight smear observed in
anti-WNK1 and anti-FLAG panels representative of multiple ubiquitin molecules being covalently attached to the WNK protein. CUL3D403–459 is unable to modify
WNKs. Samples from the same assay reactions were divided to allow immunodetection of the different protein components modified within the same assay
reaction. (C) CUL3WT, CUL3D403–459 and an equimolar solution CUL3WT:CUL3D403–459 (1:1 Mix) were incubated with KLHL3 and immunoprecipitated FLAG-WNK4 in
ubiquitylation reactions to determine the influence of CUL3D403–459 on the ubiquitylation activity of CUL3WT. Notably, the presence of CUL3D403–459 does not inhibit
WNK ubiquitylation by CUL3WT.
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CO2 removal and hence reduced total CO2 and pCO2 levels. The
mice also had elevated aldosterone levels (Fig 4C) driven by the
hyperkalaemia without pronounced hypervolaemia as evidenced by
similar haematocrit levels (Fig EV3). Hypermagnesaemia and hyper-
phosphataemia were noted on detailed electrolyte analysis of
plasma and urine, which are the converse of the abnormalities
reported in Gitelman syndrome (Fig EV3; Akhtar & Hafeez, 2009;
Rafiqi et al, 2010; Pathare et al, 2012; Ali et al, 2013; Zhang et al,
2015). Additionally, we also found that the CUL3WT/D403–459 mice
have significantly lower body weight and body length relative to the
WT mice (Appendix Fig S4). This is consistent with Gordon’s origi-
nal observation that children with PHA2 may present with a low
percentile body weight and height for their age (Gordon, 1986) and
more recent reports that CUL3WT/D403–459 patients are growth
retarded (Osawa et al, 2013; Tsuji et al, 2013).
WNK4 and SPAK accumulate and form puncta in the distal
convoluted tubule of CUL3WT/D403–459 mice
Using immunofluorescence confocal microscopy of kidney
sections, we studied the distribution of proteins involved in the
WNK kinase cascade in both CUL3WT/WT and CUL3WT/D403–459
mice (Fig 5A). CUL3WT/D403–459 mice showed a similar CUL3 distri-
bution compared to both the WT mice, and to the WT human
kidney (Fig 5A and B). This was in keeping with the abundance
observed in the kidney immunoblots (Fig 4A). In contrast, staining
for WNK4 and SPAK in the CUL3WT/D403–459 mice revealed these
proteins to have a striking punctate appearance in the DCT, but
not in adjacent segments of the nephron including the thick
ascending limb (TAL; Figs 5A and EV4). While WNK1 and OSR1
puncta have been reported in the DCT of SPAK knockout mice,
these were smaller in size and far less numerous (Grimm et al,
2012). As these puncta do not co-localise with the lysosomal
marker LAMP1 or form ubiquitin-containing aggregates (Figs 5A
and EV4), they may represent an accumulation of WNK and SPAK
proteins within a protein-processing compartment, such as the
trans-Golgi network or activation of secondary protein degradation
pathways or storage compartments, due to failed proteasomal
clearance (D’Urso et al, 1998; Lamark & Johansen, 2012; Wolff
et al, 2014).
CUL3WT/D403–459 mice have hypertension and a novel
vascular phenotype
Over-activation of the WNK pathway as observed in our
CUL3WT/D403–459 mice (Figs 4 and 5) should lead to salt retention
and elevated blood pressure. We therefore measured the blood pres-
sure (BP) of the CUL3WT/D403–459 mice using a carotid pressure
transducer catheter under general anaesthesia. Both male and
female CUL3WT/D403–459 mice exhibited significantly higher BP rela-
tive to CUL3WT/WT littermates (Fig 6A).
Strikingly, we also observed a previously unreported haemody-
namic change in the blood pressure trace of the CUL3WT/D403–459
mice. The systolic aortic pressure wave of the heterozygous mice is
augmented, while the diastolic relaxation (s) is significantly slowed
(Munir et al, 2007; Fig 6B). These changes suggest early wave
reflection of the pressure wave and compliance changes consistent
with a stiffened vascular tree. This stiffening could reflect a primary
change in the contractile state of vascular smooth muscle, so to
explore this we studied the in vivo vasoconstrictor responses to
intravenous administration of phenylephrine and angiotensin II
(Fig 6C; Bergaya et al, 2011). The resulting dose–response curves
showed that the maximal constrictor response to both vasopressor
agents was substantially higher in the CUL3WT/D403–459 mice.
CUL3 and KLHL3 are expressed in the mouse and human aorta,
and CUL3WT/D403–459 mice have aortic wall thickening
We also looked for evidence of biochemical changes in the vascula-
ture and confirmed the expression of CUL3 and KLHL3 in mouse
and human aorta by immunoblot analysis (Fig 7A and B, Appendix
Fig S5). Similar to the kidneys (Fig 4A), no differences were seen in
KLHL3 expression between CUL3WT/D403–459 and CUL3WT mice,
while the levels of CUL3 WT protein were lower in CUL3WT/D403–459
aorta. To address the altered contractility in the vessel wall in vivo,
we also measured the level of pMYPT1 in aortic vessel lysates and
showed a significant 1.7-fold increase (Feng et al, 1999; Somlyo &
Somlyo, 2003; Appendix Fig S6). Image analysis of mouse and
human aortae confirmed that both have strong CUL3 staining of the
vascular endothelium and smooth muscle cells of the intimal and
medial layers of the vessel wall (Fig 7C and D). Finally, to explore
◀ Figure 4. CUL3WT/D403–459 mice recapitulate PHAII electrolyte imbalances due to over-activation of the renal WNK4-SPAK pathway.A Western blot of whole kidney lysates from mice culled after a minimum 4-h fast. Following exsanguination after surgery, mouse tissues were rapidly harvested and
stored, samples were then homogenised, clarified and quantified prior to SDS–PAGE. Immunodetection with the antibodies shown highlights elevated signalling
through the WNK kinase pathway in CUL3WT/D403–459 versus CUL3WT mice. The lowest panel is an anti-CUL3 immunoprecipitation of the kidney lysate samples,
whereby the CUL3 antibody was cross-linked to Protein G sepharose and used to affinity purify CUL3WT and CUL3D403–459 from kidney lysates. The samples were
incubated together overnight to allow deneddylation of CUL3 proteins to occur and maximise CUL3 binding to the anti-CUL3 resin. Samples were thoroughly washed
and eluted from the resin prior to SDS–PAGE and immunodetection for CUL3. The IP highlights that CUL3D403–459 is indeed present within the kidney lysate.
B Fresh frozen kidney tissues from transplant patient and donor cadavers were homogenised, clarified and quantified prior to SDS–PAGE. Western blot analysis
confirmed the expression of KLHL3 and CUL3 in normal healthy human kidneys.
C Plasma aldosterone after a minimum 4-h fast was calculated by HTRF (homogeneous time-resolved fluorescence) aldosterone assay. The average aldosterone level
per mouse was calculated from duplicate samples run in parallel on the assay. Blood was rapidly harvested in heparin-coated plasma extraction tubes following
exsanguination after surgery, and samples were snap-frozen for storage. A 58% increase in aldosterone was detected in CUL3WT/D403–459 versus CUL3WT mice
(*P = 0.0245). Two-tailed unpaired Student’s t-test; data are mean  SEM.
D Arterial blood biochemistries after a minimum 4-h fast. Under anaesthesia, the right carotid artery was cannulated to minimise atmospheric exposure of samples
collected for iSTAT blood gas and electrolyte measurements. CUL3WT/D403–459 mice present with abnormal electrolyte homoeostasis compared to CUL3WT mice,
exhibiting hyperkalaemia (***P = 0.0004) and hyperchloraemia (***P = 9.5 × 105) with a compensated metabolic acidosis (P = 0.7766), marked by a decrease in
bicarbonate (HCO3 ) (***P = 3.4 × 10
5), base excess (BE) (***P = 9.1 × 105) and partial pressure of carbon dioxide (pCO2) (***P = 0.0038). Two-tailed unpaired
Student’s t-test; data are mean  SEM.
Source data are available online for this figure.
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further the vascular phenotype, we performed a morphometric anal-
ysis of the aortae of CUL3 mice that confirmed significant thickening
of the vessel wall in the heterozygote mice (Fig 7E). This probably
reflects hyperplasia/hypertrophy of the vascular smooth muscle
cells in the medial layer, as the numbers of elastic laminae were not
significantly different (Fig 7E).
Discussion
This study describes the first successful PHA2E mouse model
involving CUL3 and highlights the molecular differences and defects
of the mutant CUL3 protein. The deletion of 57 amino acids in
CUL3D403–459 does not affect the ability of the bound RING domain
to hydrolyse E2~UB, and as such CUL3D403–459 is still an active E3
ligase. Instead, our structural predictions and experimental findings
suggest that the CUL3D403–459 CRL scaffold lacks a level of rigidity
required for substrate ubiquitylation. Our results are consistent with
a previous report that demonstrated ubiquitylation of the Cullin-1
substrate (p27) was abrogated when a linker was inserted between
the NTD and CTD of the closely related CUL1 protein (Zheng et al,
2002). Thus, the CUL3D403–459 mutation is a novel physiological
example of the importance of this CRL rigidity and to our knowledge
the first example of a human mutation that impedes the scaffolding
function of a Cullin. Our data are consistent with the working
hypothesis that the CUL3D403–459 mutation has increased structural
flexibility. The deletion of three helices fuses together two unstruc-
tured regions, which likely allows greater movement between the
N-terminal and C-terminal domains of the Cullin. This prevents the
complex from successfully directing ubiquitin towards a bound
substrate, and instead, leads to increased auto-ubiquitylation of
CUL3 and KLHL3. Importantly, it appears as if in vivo this auto-
ubiquitylation triggers degradation of the mutant form of the Cullin,
as only relatively low amounts of CUL3D403–459 are detectable in
tissue from the mouse model, while the levels of KLHL3 are unaf-
fected. In vivo, CUL3 auto-ubiquitylation possibly precedes ubiquity-
lation of KLHL3, leading to rapid proteasomal degradation of
CUL3D403–459 leaving KLHL3 untouched. The auto-degradation of
CUL3 is likely to be the major driver for the associated phenotype in
patients. While, some CUL3D403–459 remains in cells, we show that
this remaining protein is unable to ubiquitylate WNK substrates.
Taken together, our data suggest that the disease-associated deletion
of exon 9 from CUL3 is a loss-of-function mutation with respect to
substrate ubiquitylation. Importantly, all PHA2E patients are
heterozygotes, so they retain a functioning copy of CUL3WT. Thus,
the CUL3D403–459 mutation either behaves as a dominant-negative to
inhibit CUL3WT or is haploinsufficient in the context of blood pres-
sure regulation with the single functional copy of CUL3 unable to
sustain the physiological need for WNK ubiquitylation. Our data
support a haploinsufficiency model, as a large proportion of the
mutant protein is removed from the cell by auto-degradation and
in vitro CUL3D403–459 does not inhibit CUL3WT. However, it is possi-
ble that in vivo the remaining CUL3D403–459 may still sequester
KLHL3 from CUL3WT in a dominant-negative fashion, as in cells we
observed increased binding between CUL3D403–459 and KLHL3
(Fig 1H) and the reduced affinity for CAND1 may prevent the
release of KLHL3 from non-functional CUL3D403–459 complexes.
These two possibilities could be addressed in a heterozygous mouse
model carrying a full-length CUL3 deletion; under the haploinsuffi-
ciency model, it should show WNK stabilisation.
The CUL3WT/D403–459 mice have high blood pressure and up-regu-
lated signalling in the context of the WNK kinase pathway, which
parallels the WNK4 (D568E; Yang et al, 2007; Chowdhury et al,
2013) and KLHL3 (R528H; Mori et al, 2013) PHA2 mouse models
previously described. Mechanistically, our data suggest CUL3D403–459
promotes its own degradation, as it has a heightened propensity to
self-ubiquitylate and is less abundant in mouse kidney extract.
Hence, we would predict that PHA2E CUL3WT/D403–459 patients
would similarly have lower overall CUL3 levels. As CUL3 ubiquity-
lates a number of other proteins, it seems remarkable then that
PHA2E patients do not have other phenotypic manifestations.
However, this may not be surprising if considered in the context of
a haploinsufficiency model. BP homoeostasis requires reactive and
precise control of ion fluxes in the distal nephron, especially the
DCT, as changes in intake and output of salt are constantly
balanced. The phosphorylation of the NCC/NKCC ion transporters
by WNK kinases appears to be regulated by two complementary
systems: the regulation of total WNK protein levels by CUL3-KLHL3,
and the level of WNK activation by phosphorylation. Currently, the
sensing mechanisms that lead to WNK phosphorylation or the
degradation of the WNK kinases by CUL3-KLHL3 are largely
unknown. However, sufficient amounts of CUL3 must be available
for signalling-dependent ubiquitylation of the WNK kinases. It is
possible that having only half the amount of functional CUL3 within
kidney cells is not enough for the system to respond rapidly. The
presence in our knock-in mice of WNK4 puncta in vivo also suggests
that DCT cells may deploy secondary protein degradation pathways
to manage excess WNK proteins, such as the autophagy–lysosomal
system. However, the nuclear proximity of the large puncta and the
absence of lysosomal staining or formation of ubiquitylated aggre-
gates suggest that these excess WNK proteins are shunted to
protein quality control compartments such as the aggresome or
◀ Figure 5. WNK4 and SPAK specifically accumulate and form puncta in the distal convoluted tubule of CUL3WT/D403–459 mice.A Representative pseudocoloured maximum-intensity z projections of immunofluorescently stained kidney sections showing the distribution of the WNK/SPAK pathway
components between CUL3WT/D403–459 and CUL3WT mice at a minimum 4-h fasting baseline (n = 4 per genotype). CUL3 and KLHL3 are comparable between
genotypes, with significantly higher levels of CUL3 in the proximal convoluted tubule (PCT) compared to the weak staining in distal convoluted tubule (DCT) and thick
ascending limb of the loop of Henle (TAL), while KLHL3 shows higher expression in the DCT/TAL cytosol with staining of the PCT confined to the apical membrane.
Total (t) and phospho (p) NCC Thr44 and SPAK Thr243 show increased apical membrane expression in the parvalbumin (PVALB)-positive early and late (PVALB-
negative) DCT of CUL3WT/D403–459 mice. Unexpectedly, the increased levels of WNK4 and SPAK resulted in the formation of discrete puncta specifically in the DCT of
CUL3WT/D403–459 mice. It is possible that the autophagy–lysosomal system may attempt to compensate and degrade these excess proteins although the WNK4 puncta
do not colocalise with the lysosomal marker LAMP1. Scale bar, 20 lm.
B Representative immunohistochemical staining of KLHL3 and CUL3 in human kidney sections (n = 6). KLHL3 shows preferential DCT/TAL cytosolic staining similar to
the mouse despite no evidence of PCT apical staining as seen in (A). CUL3 exhibits preferential basolateral cytosolic staining of the PCT with similarly low levels of
diffuse staining in the DCT/TAL to that of the mouse. Scale bar, 100 lm.
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juxta-nuclear quality control compartment (JUNQ) in an attempt to
compensate for loss of proteasomal degradation (Lamark &
Johansen, 2012; Wolff et al, 2014). Hence, while other CUL3
substrates may be unaffected in the CUL3WT/D403–459 mice, the rapid
and signal-dependent switching of WNK ubiquitylation may be
executed abnormally in these mice and PHA2E patients.
Mutations in CUL3, KLHL3, WNK1 and WNK4 are known to
cause FHHt with constitutive activation of the NCC co-transporter
(Boyden et al, 2012; Osawa et al, 2013; Tsuji et al, 2013; Alessi
et al, 2014; Glover et al, 2014). What has been less clear is why
the mutation of CUL3 has resulted in a more severe form of FHHt
(PHA2E). Our unexpected discovery of a vascular phenotype in
the CUL3WT/D403–459 mice leads us to speculate that their hyperten-
sion may not be driven by salt retention in the DCT alone. It is
possible that part of their hypertension originates from an
increased contractile state in their vasculature tree. If a similar
phenomenon occurs in PHA2E, this may explain the early onset
and severity of the blood pressure that occurs in these patients.
The CUL3WT/D403–459 mice have an altered aortic pulse waveform
and slowed diastolic relaxation that is consistent with stiffening of
their arterial tree. These changes have been reported before in
humans with hypertension (Kaess et al, 2012), but not previously
in a hypertensive mouse model. It is also worth noting that
augmentation of the aortic pressure wave is often not detected by
brachial cuff BP measurements, so it could have gone unnoticed in
the routine clinical assessment of PHA2E patients. The increase in
pMYPT1 in the aortae from the CUL3WT/D403–459 mice and the
increase in their in vivo pressor responses to phenylephrine and
angiotensin II further suggest that the altered contractile state
could be a primary phenomenon rather than simply a secondary
response to hypertension. If this is the case, the contraction could
occur by at least two distinct pathways. Firstly, the WNK1/WNK3/
SPAK/OSR1 pathway is thought to be important for regulating
vascular tone by controlling the phosphorylation state of the
NKCC1 co-transporter and hence the membrane potential of vascu-
lar smooth muscle (VSM) cells (Yang et al, 2010; Bergaya et al,
2011; Zeniya et al, 2013). So if either WNK1 or WNK3 accumu-
lates in the vessel wall of the CUL3WT/D403–459 mice, the contractile
tone would be expected to rise through depolarisation of VSM and
increased calcium entry. Alternatively, the mutant Cullin-3 protein
may directly affect the phosphorylation state of myosin light chain
by regulating RhoA/RhoA kinase (ROCK) levels (Ibeawuchi et al,
2015). RhoA protein levels in the VSM are thought to be regulated
by CUL3 in complex with the substrate adaptor RhoBTB1 (Pelham
et al, 2012). If these pathways are operational in PHA2E, then they
suggest that treatment with a thiazide diuretic or dietary sodium
restriction, while effective in reversing the electrolyte disturbances,
may be less effective in reversing any central aortic pressure
changes in PHA2E. If WNK/SPAK/OSR1 is the predominant path-
way causing disease, a loop diuretic such as bumetanide may be
more effective than a thiazide, while for the RhoA/ROCK pathway
a direct arterial vasodilator or a specific ROCK inhibitor (Liao et al,
2007) may be the more appropriate drug of choice. Central aortic
pressure elevation is now widely accepted to be an important and
independent cardiovascular risk factor (Liao & Farmer, 2014), so if
it is elevated in patients with PHA2E, it will be important to show
that it is normalised by appropriate pharmacotherapy.
Materials and Methods
All plasmids, antibodies and recombinant proteins that we have
generated for this study are available on request from the MRC-PPU
reagents website (http://mrcppureagents.dundee.ac.uk/).
Plasmids and protein purification
The following plasmids and/or protein purifications have been
described elsewhere in Ohta et al (2013): KLHL3 (DU23218), DAC-
TEV-CUL3-RBX1 (DU23291), His-UBE1 (DU32888) and His-TEV-
UBE2D3 (DU15703); and in Kelsall et al (2013): Nedd8 (DU20689),
UBE2M (DU15804) and APPBP1/UBA3 heterodimer (Nedd8 activating
E1) (DU21784).
DAC-TEV-CUL3D403–459-RBX1 (DU23292) was cloned in a
comparable way to DAC-TEV-CUL3WT-RBX1 (DU23291). Specifi-
cally, the pFastBac Dual DAC-TEV expression system was created
by subcloning a BglII-BamHI-flanked PCR product encoding the
full-length DAC-tag followed by a TEV protease site into a
◀ Figure 6. Increased arterial stiffness contributes towards the hypertension of CUL3WT/D403–459 mice.A Continuous blood pressure measurements were taken in mice under general anaesthesia with thermostatically controlled body temperature, right carotid artery
pressure transducer catheterisation and ECG Lead II heart rate monitoring. CUL3WT/D403–459 mice have elevated systolic (SBP) (***P = 1 × 1012) and diastolic (DBP)
blood pressure (***P = 8.5 × 108), although they also present with 7% lower heart rates (*P = 0.0485) when compared to CUL3WT mice. Two-tailed unpaired
Student’s t-test; data are mean  SEM.
B Pulse waveform analysis of blood pressure traces obtained in (A) reveals that CUL3WT/D403–459 mice have an increased pulse pressure (PP) [SBP – DBP]
(***P = 2.1 × 1010), augmentation pressure (AP) [SBP – anacrotic notch (AN) pressure] (***P = 3.5 × 106), dicrotic notch (DN) pressure (***P = 4.7 × 1013) and
mean arterial pressure (MAP) [1/3 × SBP + 2/3 × DBP] (***P = 1.3 × 109). This hypertensive phenotype is in part due to changes in vascular contractility in
CUL3WT/D403–459 mice as evidenced by their higher augmentation index (AIx) [AP/PP] (**P = 0.0096), a marker of arterial stiffness, and is further supported by an
increase in their diastolic pressure decay time constant (sbourgeois) [1/slope of diastolic pressure decay; measured 30 ms after DN and 20 ms before end DBP]
(**P = 0.0083), a surrogate marker of increased vascular resistance. Two-tailed unpaired Student’s t-test; data are mean  SEM
C In vivo dose–responses to phenylephrine and angiotensin II. After baseline measurements were obtained from mice in (A), the right external jugular vein was
cannulated for administration of bolus doses of vasopressors in increasing half-log steps. Dose–response curves were generated and data analysed using a logistical
function to determine the estimated dose producing half-maximal response (ED50) and maximum response (Emax). The fitted Emax for phenylephrine was increased in
CUL3WT/D403–459 versus CUL3WT (183.9  2.5 versus 164.9  1.4 mmHg) (***P = 1 × 106) indicating an increased vasoconstrictor response to adrenergic stimulation
elevating systolic blood pressure substantially above the CUL3WT maximum. Similarly, the fitted Emax for angiotensin II stimulation was higher in CUL3
WT/D403–459
versus CUL3WT (155.5  1.8 versus 138.3  2.2 mmHg) (***P = 1.7 × 106). However, there was no change between CUL3WT/D403–459 versus CUL3WT sensitivity (as
measured by ED50) to phenylephrine (36.6  5.1 versus 31.4  2.8 lg/kg bw) (P = 0.3778) or angiotensin II (0.77  0.16 versus 0.93  0.13 lg/kg bw) (P = 0.4401).
Two-tailed unpaired Student’s t-test; data are mean  SEM.
Source data are available online for this figure.
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pFastBacTM Dual (Life Technologies, UK). Human Cullin-3 (D403–459;
GenBank NM_003590.4) was codon-optimised for expression in
insect cells and custom synthesised (GenScript USA Inc.) before
being subcloned downstream of the DAC-tag in cassette two of this
vector. Human RBX1 (GenBank NM_014248.2) was amplified from
an EST IMAGE clone 3138751 and subcloned into cassette one (un-
tagged). Human CAND1 (GenBank NM_018448.3) was amplified as
a Not1 flanked ORF from EST IMAGE clone 5265409 and
subcloned into pGEX6P-2 (GE Healthcare LifeSciences UK) for
bacterial expression with an N-terminal GST tag. All PCRs were
carried out using KOD Hot Start DNA Polymerase (Merck Millipore,
Germany). All full-length products or fragments were cloned into
pSc-B (Agilent) and sequenced in full prior to further subcloning or
manipulation. DNA sequencing was performed by the Sequencing
Service at the College of Life Sciences, University of Dundee
(www.dnaseq.co.uk).
Human recombinant CUL3D403–459-RBX1 or CUL3WT-RBX1 was
expressed in a multibac vector with a Dac-TEV-fusion tag on the
CUL3 and untagged RBX1 (Lee et al, 2012). Proteins were
expressed in the baculovirus system in Sf21 cells cultured in
Insect-Protein-free Insect Cell Medium (Lonza). The fusion protein
was captured from the lysate by incubation with ampicillin-
sepharose. After washing, the protein was recovered from the solid
phase by incubation with C-terminally His-tagged TEV protease
(10 lg per 1 mg substrate). The protease and any free Dac-tag
were removed with Ni-agarose and ampicillin–sepharose. The
protein was then concentrated and further purified by size-
exclusion chromatography (SEC) in 50 mM HEPES pH 7.5,
150 mM NaCl and 10% glycerol.
Human recombinant CAND1 was expressed as an N-terminally
GST-tagged fusion protein in BL21 cells. Expression was induced
with 50 lM IPTG at 15°C for 16 h. Following cell lysis, GST-CAND1
was captured on glutathione resin, washed and then eluted from the
resin with 10 mM reduced glutathione in 50 mM HEPES pH 7.5,
150 mM NaCl, 10% glycerol (w/v) and 1 mM DTT. The protein was
then dialysed to remove glutathione.
Nedd8 was expressed as an untagged protein in BL21 cells, and
following induction with 1 mM IPTG at 16°C, cells were lysed and
frozen. Upon thawing, benzonase and 2 mM Mg(C2H3O2)2 were
added and cells were disrupted by sonication. Insoluble material
was pelleted, and this pellet was resuspended in 50 mM Tris pH 7.5
and 150 mM NaCl and washed thrice. To extract Nedd8, the pellet
was resuspended in 8 M urea and mixed overnight. Following
clarification by centrifugation the supernatant was diluted fourfold
with MQ water and dialysed thrice to remove urea and enable
Nedd8 refolding. Contaminants were removed by depletion using a
Q-sepharose column. The Nedd8 was concentrated prior to a final
purification by SEC in 20 mM HEPES pH 7.5, 150 mM NaCl and
0.03% Brij 35.
Antibodies
The following antibodies were raised in sheep and affinity-puri-
fied on the appropriate antigen by the Division of Signal Trans-
duction Therapy Unit at the University of Dundee: WNK1-total
antibody (residues 2,360–2,382 of human WNK1, S62B), WNK4
N-terminal antibody (residues 1–14 of mouse WNK4, S726D),
SPAK-mouse N-terminal antibody (2–76 of mouse SPAK, S668D),
SPAK-mouse C-terminal antibody (424–556 of mouse SPAK,
S669D), SPAK/OSR1 (T-loop) phospho-Thr233/Thr185 antibody
(226–238 of human SPAK or residues 178–190 of human OSR1,
TRNKVRKpTFVGTP, S204C), SPAK phospho-Thr233 antibody
(226–238 of human SPAK, TRNKVRKpTFVGTP, S668B and
S668D), NKCC1-total antibody (residues 1–260 of shark NKCC1,
S841B), NCC phospho-Thr60 antibody (residues 54–66 of human
NCC phosphorylated at Thr60, RTFGYNpTIDVVPT, S995B), NCC
phospho-Thr44 antibody (residues 38–52 of mouse NCC phospho-
rylated at Thr44, SQPSHLTpHGSTLYMRRR, S242C) and KLHL3
N-terminal mouse (1–21 of mouse KLHL3, S740D). The anti-ERK1/2
antibody (9102) was purchased from Cell Signaling Technology.
The anti-FLAG antibody (F1804), anti-b-actin antibody and anti-
His antibody were purchased from Sigma-Aldrich. The rabbit anti-
human CUL3 antibody was a kind gift from Izabela Sumara at
the IGBMC, Strasbourg (Sumara et al, 2007). The following
commercial rabbit anti-human antibodies were obtained and used
for immunodetection: KLHL3 antibody (HPA051291) from Atlas
Antibodies; KLHL3 (AB196776) (~14% immunogen peptide
homology with KLHL2), NCC-total [SLC12A3] (AB95302) and
LAMP1 (AB24170) from Abcam; and PV25 (PVALB) from Swant.
The goat anti-GFP (AB5450) and the mouse monoclonal anti-
ubiquitin (AB7254) were purchased from Abcam. The MYPT1
phospho-Thr696 mouse monoclonal antibody (MAB0001) was
obtained from Abnova. Secondary antibodies coupled to horse-
radish peroxidase used for immunoblotting were obtained from
◀ Figure 7. CUL3 and KLHL3 are present in mouse and human aorta, and CUL3WT/D403–459 mice undergo aortic vascular remodelling.A Western blot of tunica media-intima thoracic aorta lysates from mice culled after a minimum 4-h fast. Following exsanguination after surgery, mouse tissues were
rapidly harvested and the tunica adventitia removed before storage, and later, the samples were homogenised, clarified and quantified prior to SDS–PAGE. Western
blot analysis confirmed the expression of KLHL3 and CUL3. Similar to the kidney, the aorta of CUL3WT/D403–459 showed slightly lower levels of CUL3 compared to
CUL3WT without any change in KLHL3 levels.
B Fresh frozen thoracic aorta tissues from donor cadavers were homogenised, clarified and quantified prior to SDS–PAGE. Western blot analysis confirmed the
expression of KLHL3 and CUL3 in normal healthy human aorta.
C Representative maximum-intensity z projections of immunofluorescently stained thoracic aorta sections showing the distribution of CUL3 and KLHL3 between
CUL3WT/D403–459 and CUL3WT mice at a minimum 4-h fasting baseline (n = 4 per genotype). CUL3 and KLHL3 localisation is comparable between genotypes. The
highest levels were detected in the vascular smooth muscle cells and endothelium, with a minimal expression in the perivascular adipose tissue of the adventitia.
Scale bar, 50 lm.
D Representative immunohistochemical staining of KLHL3 and CUL3 in human thoracic aorta sections (n = 6). Similar to the mouse staining seen in (C), vascular
smooth muscle cells in the tunica media of the aortic wall are positive for KLHL3 and CUL3. Scale bar, 50 lm.
E Morphometric analysis of thoracic aortae reveals vascular remodelling in CUL3WT/D403–459 mice. There is an increase of ~21% in the vessel wall intima-media
thickness (demarcated by arrows) of CUL3WT/D403–459 compared to CUL3WT mice (***P = 0.0003). However, there is no change in the number of elastin laminae
(P = 0.1458) and therefore no increase in the number of medial muscle layers between genotypes. Two-tailed unpaired Student’s t-test; data are mean  SEM.
Source data are available online for this figure.
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Pierce. Secondary antibodies conjugated to fluorochromes for
LiCor Odyssey Western blot scanning were obtained from Licor
(www.licor.com) and Life Technologies. Fluorochrome-conjugated
secondary antibodies for immunofluorescent confocal microscopy
were obtained from Life Technologies and Abcam.
In vitro assays
Ubiquitin E2 discharge assays were performed based on the
method described (Plechanovova´ et al, 2011). Firstly, His-UBE2D2
(150 lM) was incubated in the presence of 2 mM ATP, 5 mM
MgCl2, 200 lM ubiquitin and 0.25 lM UBE1 in 50 mM HEPES pH
7.5, 150 mM NaCl, 10% glycerol and 1 mM DTT at 16°C for
15 min. To stop the reaction, we depleted ATP by incubating the
charging mixture with apyrase (4.5 U/ml; New England Biolabs)
at 16°C for 10 min. To this, 1 lM E3 was added and discharge
reactions were then allowed to proceed for the time indicated in
the figure, at 30°C. Reactions were stopped by the addition of
non-reducing SDS–Laemmli sample buffer. 16% bis-acrylamide
non-reducing SDS–PAGE, followed by immunodetection with anti-
His antibody, allowed visualisation of ubiquitin discharge. E3
ubiquitin-ligase activity assays were based on those described
previously in Ohta et al (2013). When used as a substrate in
assays, full-length WNK kinases were purified from HEK-293 cells,
and either 5 ll of immunoprecipitated endogenous WNK1 protein
derived from 0.5 mg of HEK-293 cells or 5 ll of immunoprecipi-
tated over-expressed FLAG-WNK4 from 0.05 mg of HEK-293 cells
was used for each assay reaction. Ubiquitylation assays typically
contained 20 mM HEPES/HCl (pH 7.5), 150 mM NaCl, 2 M DTT,
10% (w/v) glycerol, 8 lM CUL3-RBX1 complex (WT or mutant),
7 lM KLHL3, 7 lM UBE1, 60 lM UBE2D3 and 3,000 lM ubiqui-
tin. The concentrations of some components were altered on occa-
sion (e.g. Fig 3B) to best illustrate a given point. Reactions were
initiated by adding ATP and MgCl2 to a final concentration of
1 mM, and samples were incubated for the times indicated at
30°C. Reactions were stopped by the addition of SDS sample
buffer, and samples were analysed after SDS–PAGE followed by
immunoblotting or Coomassie blue gel staining. For the N8-ligase
activity assays, 1 lM E3 was incubated at 30°C with 68 lM
Nedd8, 8 lM UBE2M and 0.2 lM NAE in the presence of
0.15 mM ATP, 1.5 mM MgCl2 50 mM HEPES pH 7.5, 150 mM
NaCl and 20% (w/v) glycerol for the time indicated. Reactions
were stopped by the addition of SDS sample buffer, and samples
were analysed following SDS–PAGE separation and Coomassie
blue staining.
In vitro protein interaction pull downs
For KLHL3-CUL3, anti-KLHL3 resin was made by covalently coupling
anti-KLHL3 antibody (S377D) to Protein G sepharose utilising
dimethyl pimelimidate. Anti-KLHL3 resin, or control resin (prepared
in the absence of any antibody), was incubated with saturating
amounts of purified KLHL3 and washed thrice, resulting in KLHL3
resin. This resin was then incubated with CUL3WT or CUL3D403–459 at
4°C for 1 h, before being washed thrice with PBS 0.02% Tween-20.
For CAND1-CUL3, purified GST-CAND1 or GST was incubated in
excess with resin at 4°C resulting in GSH-resin-GST or GSH-GST-
CAND1 resin. Each resin was then incubated with purified CUL3WT
or CUL3D403–459 for 1 h at 4°C before being washed once with PBS
0.02% Tween-20 and then twice with PBS in the absence of deter-
gent. Following washing, volumes were reduced to a minimum and
proteins were eluted from the resin by the addition of SDS sample
buffer, prior to analysis by SDS–PAGE and immunoblotting.
Cell culture
HEK (human embryonic kidney)-293 cells were cultured in 14-cm
dishes in DMEM (Dulbecco’s modified Eagle’s medium; Life Tech-
nologies) supplemented with 10% (v/v) foetal bovine serum, 2 mM
L-glutamine, 100 units/ml penicillin and 0.1 mg/ml streptomycin.
Protein expression was induced for 24 h with 1 lg/ml tetracycline
(Life Technologies). To obtain endogenous WNK1 for activity
assays, we followed the immunoprecipitation protocol described in
Ohta et al (2013). To obtain wild-type FLAG-WNK4, we utilised the
cell lines from Schumacher et al (2014) and Ohta et al (2013).
When FLAG-WNK4 was to be used for in vitro ubiquitylation
assays, a 14-cm plate of confluent cells was lysed in 0.5 ml ice-cold
mammalian lysis buffer A (mammalian lysis buffer A: 50 mM
Tris/HCl (pH 7.5), 0.15 M NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM
Na3VO4, 50 mM NaF, 5 mM Na4P2O7, 0.27 M sucrose, 1% (w/v)
Nonidet P-40, 1 mM benzamidine, 0.1 mM PMSF, 0.1% 2-mercap-
toethanol, and Roche protease inhibitor mix (1 tablet in 50 ml) for
M2 affinity purification). Lysates were clarified by centrifugation,
and to this, 10 ll M2 resin per 100 ll lysate was added. Incubation
of the resin with the cellular lysate for 1 h at 4°C was followed by
two washes with mammalian lysis buffer A, and two further washes
with 1× PBS to give a pure M2-Flag-WNK4 slurry. For interaction
studies with FLAG-CUL3WT and FLAG-CUL3D403–459, the same
method was followed as above, with an alternative mammalian lysis
buffer B (50 mM HEPES/KOH pH 7.2, 5 mM Mg(C2H3O2)2, 70 mM
KC2H3O2, 0.2% (w/v) Triton X-100, 10% (w/v) glycerol, 0.2 mM
EDTA, 1 mM Na3VO4, 50 mM NaF, 5 mM Na4P2O7 and Roche
protease inhibitor mix (1 tablet in 50 ml)). When it was desirable to
prevent deneddylation, buffers were supplemented with 50 lM
1,10-phenanthrolin.
Mass spectrometry analysis
Prior to SDS–PAGE, samples were reduced and alkylated in the
following way. Reactions were stopped at the time shown and incu-
bated at 95°C in 1× LDS (Invitrogen) 5 mM DTT for 1 min. Alkyla-
tion occurred at room temperature for 30 min by the addition of
20 mM iodoacetamide (20 mM) to the samples. To quench the reac-
tion, DTT was added to a final concentration of 20 mM, and the
sample was then processed on precast 4–12% gradient gel (Invitro-
gen). Gel pieces were excised as shown by the boxed areas in the fig-
ure and in gel digestion of the proteins with 5 lg/ml trypsin and
subsequent analysis. Mass spectrometric analysis was performed by
LC-MS-MS on a linear ion trap–orbitrap hybrid mass spectrometer
(Orbitrap-VelosPro; Thermo) coupled to a U3000 RSLC HPLC
(Thermo). Peptides were trapped on a NanoViper trap column,
2 cm × 100 mm C18 5 mm 100 A˚ (Thermo, 164564) and then sepa-
rated on a 15-cm Thermo EasySpray column (ES800) equilibrated
with a flow of 300 nl/min of 3% solvent B [solvent A: 2% acetoni-
trile, 0.1% formic acid and 3% DMSO in H2O; solvent B: 80%
acetonitrile, 0.08% formic acid and 3% DMSO in H2O]. The elution
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gradient was as follows: time (min): solvent B (%): 0:3, 5:3, 45:35,
47:99, 52:99, 55:3 and 60:3. The instrument was operated with the
“lock mass” option to improve the mass accuracy of precursor ions,
and data were acquired in the data-dependent mode, automatically
switching between MS and MS-MS acquisition. Full-scan spectra
(m/z 400–1,600) were acquired in the orbitrap with resolution
R = 60,000 at m/z 400 (after accumulation to an FTMS Full AGC
Target, 1,000,000; FTMS MSn AGC Target, 50,000). The 20 most
intense ions, above a specified minimum signal threshold (2,000),
based upon a low-resolution (R = 15,000) preview of the survey
scan, were fragmented by collision-induced dissociation and
recorded in the linear ion trap (Full AGC Target, 30,000; MSn AGC
Target, 5,000). Data files were analysed by Proteome Discoverer 1.4-
SP1 (Thermo), using Mascot 2.4.1 (www.matrixscience.com), and
searching an in-house database containing the relevant sequences.
Scaffold (www.ProteomeSoftware.com) was also used to examine
the Mascot result files. Allowance was made for the following fixed,
Carbamidomethyl (C), and variable modifications, Oxidation (M),
Dioxidation (M), GlyGly (K), LeuArgGlyGly (K) and Phospho (ST).
Error tolerances were 10 ppm for MS1 and 0.6 Da for MS2.
Generation and genotyping of WT and CUL3D403–459 mice
Standard housing conditions were used to maintain the mice.
Taconic Artemis generated the CUL3D403–459 mice on a C57BL/6N
background, which were backcrossed onto C57BL/6J to maintain
the colony. All experiments were performed using littermates that
were backcrossed at least once onto C57BL/6J. Genomic DNA from
ear biopsies was isolated and used to genotype all mice in the study.
Genotyping by PCR utilising primer 1: AAACTTACCCACTTGTT
TGCC, and primer 2: AGACATCTCAGGTTACTATGGGC detected
the presence of the CUL3WT (683 bp) or CUL3D403–459 (395 bp)
allele. Studies were conducted on groups of approximately equal
ratios of male-to-female mice with the exception of in vivo cardio-
vascular phenotyping in which a 1:2 ratio of male-to-female mice
was used. All animal studies and breeding were approved by the
University of Dundee ethical committee and performed under a UK
Home Office-approved licence.
Mouse kidney and testes lysates
Mouse tissues were rapidly harvested and either snap-frozen in
liquid nitrogen and stored at 80°C or incubated in 1 ml RNAlater
solution (Sigma-Aldrich) at 4°C for 16–30 h before being removed
from this buffer, patted dry with clean tissue and then stored dry at
80°C. Lysates were prepared by homogenising tissue on ice using
a Polytron PT1200C homogenizer (Kinematica) in 2 ml ice-cold
mammalian lysis buffer and then clarified by centrifugation at
18,000 g for 30 min. The clarified supernatant was then quantified
and used immediately. Any excess sample was snap-frozen in
liquid nitrogen in single-use aliquots for use as required.
The lysates to be used for immunoprecipitation were prepared in
the same way, with the following exceptions, all designed to
promote deneddylation of the cullin proteins. Detergent was not
included in the lysis buffer. Following homogenisation, samples
were incubated on ice for 4 h. Following clarification by centrifuga-
tion at 18,000 g for 30 min, samples were aliquoted into fractions
and either frozen in liquid nitrogen and stored at 80°C or used
immediately. Clarified supernatant was incubated at room tempera-
ture for 1 h to enable further deneddylation, and samples were then
cooled on ice and centrifuged a second time to ensure any precipi-
tate was removed. Anti-CUL3 antibody (S067D) cross-linked (DMP)
to Protein G agarose was mixed with saturating amount of lysate
and incubated rotating overnight at 4°C. The next morning, the
agarose beads were washed thrice with mammalian lysis buffer B
and twice with 1× PBS. Proteins were eluted from beads by SDS
sample buffer addition and boiling at 95°C for 10 min prior to
centrifugation and SDS–PAGE and immunodetection.
Immunoblotting
Lysates or protein mixes were boiled at 95°C with 1× SDS–Laemmli
sample buffer, for 5 min before being subject to SDS–PAGE (8 or
10% Tris–glycine gel, or 4–10% gradient gels (Life Technologies) or
self-prepared 16% bis-acrylamide). Gels were transferred to nitrocel-
lulose membrane using the standard wet transfer method (15%
MeOH Towbin transfer buffer). Following blocking of the
membranes (TBST 5% (w/v) dried skimmed milk), they were then
incubated overnight at 4°C with the primary antibody indicated. All
DSTT-produced sheep antibodies were used at 2 lg/ml, and phos-
pho-specific antibodies included the addition of 10 lg/ml of the
dephospho-peptide used to raise the antibody. Commercial antibod-
ies were diluted 1 in 1,000. Membranes were then washed in TBST
five times and incubated with the appropriate secondary HRP anti-
body at room temperature at 1:5,000 dilution. Membranes were
subsequently washed five times, and the HRP signal was detected
using chemiluminescence reagent (Pierce). Immunoblots were
developed using an automatic film processor (SRX-101; Konica
Minolta Medical).
CUL3 structural docking
Cullin-3 was modelled using Phyre2 server (Kelley & Sternberg,
2009) using human CUL3D403–459 as the sequence input and Cullin-1
chosen for the docking model (Q13616, PDB:1LDK; Zheng et al,
2002). A coil was predicted in place of the missing structural
elements. UBE2D~UB was docked to RBX1 using PDB: 4AP4. Images
were modified and made in UCSF Chimera (Pettersen et al, 2004;
http://www.cgl.ucsf.edu/chimera).
Immunoprecipitation (mouse tissue and cell extracts)
Lysates of cellular preparations (buffer B) from FLAG-tagged
CUL3 were mixed with M2 resin in the presence of 50 lM 1,10-
phenanthrolin to prevent deneddylation and were incubated rotating
at 4°C for 1 h. Resins were washed twice with mammalian buffer B
and twice with 1× PBS, the volume was then reduced to ~15 ll, and
following the addition of SDS gel sample buffer to 1×, samples were
boiled and the entire sample was loaded to allow analysis by SDS–
PAGE and immunodetection with the antibodies indicated.
Human and mouse aorta sample preparation
Human aortic tissues were collected from donors through trans-
plant coordinators at Addenbrooke’s Hospital, Cambridge. All
samples were handled in accordance with the policies and
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procedures of the Human Tissue Act and with the approval of the
Local and Regional Ethics Committees. Mouse tissues were rapidly
harvested, perivascular fat and residual blood were removed, and
the samples were incubated in 1 ml RNAlater solution at 4°C for
16–30 h before being removed from this buffer and stored dry at
80°C. Frozen aortic tissues were homogenised using TissueLyser
LT (Qiagen #85600), and protein lysates were extracted in NE-PER
(Life Technologies #78833) lysis buffers containing protease and
phosphatase inhibitors (Roche #11836170001 and #04906845001).
All steps were carried out at 4°C. Protein concentrations were
determined with the PierceTM BCA protein assay (Life Technologies
#23225).
Human and mouse aorta immunoblotting
A total of 10 lg of aortic protein lysates was separated by SDS–
PAGE. Prior to loading, samples were heated at 70°C for 10 min in
1× LDS sample buffer and 1× reducing agent (Life Technologies
#B0007 and # B0009) to a total volume of 20 ll/well. Samples and
5 ll of Precision Plus molecular weight ladder (Biorad #161-0374)
were then loaded onto a Bolt 4–12% Bis–Tris Plus Gel (Novex
#BG04125BOX) and run at 165 V in 1× MES running buffer
(Novex #B0001), for 35 min or until the dye front reached the
end of the gel. Resolved proteins were then transferred to 0.22 lM
nitrocellulose membrane (Life Technologies #IB23001) using the
iblot2 (Life Technologies) at 20 V for 7 min. Antibodies were incu-
bated in 5% milk. Membranes were incubated in 5% in milk or
BSA in TBS for 1 h at room temperature. Primary antibodies were
incubated overnight at 4°C in 5% milk or BSA in TBS–Tween
(0.1% v/v Tween) and then washed 6× in TBS–Tween. Secondary
antibodies were incubated in TBS–Tween for 1 h at room tempera-
ture in the dark and then washed 6× in TBS–Tween. Membranes
were imaged and integrated intensity values quantified (bands
were normalised against b-actin) using the LiCor Odyssey system
(www.licor.com).
Sample preparation and immunostaining for imaging
Formal-fixed, paraffin-embedded human tissue sections were
obtained from the Cambridge Human Research Tissue Bank.
Harvested mouse tissues were immersion-fixed in fresh 4% w/v
formaldehyde–PBS pH 6.9 for 16 h at 37°C and washed 3× in PBS
and stored at 4°C until paraffin embedding. Five-micrometre
sections were deparaffinised in Histoclear (National Diagnostics)
and rehydrated in graded methanol steps. An antigen retrieval step
was performed with R-Universal buffer in the 2100 antigen retriever
for a single heat–pressure cycle (Aptum Biologics). Sections were
permeabilised with 0.05% v/v Triton X-100–PBS for 20 min and
blocked for 1 h at 37°C with 2% v/v donkey serum in 0.05% v/v
Triton X-100–PBS. Primary antibodies were incubated overnight for
16 h at 4°C at the following concentrations diluted in 1% v/v donkey
serum in 0.05% v/v Triton X-100–PBS: 2 lg/ml for pNCC T44, tNCC,
CUL3 (Sumara et al, 2007); 4 lg/ml for KLHL3 N-terminal,
WNK4 N-terminal, SPAK C-terminal and pSPAK T233 (to detect
mouse pSPAK T243); and 1 lg/ml for LAMP1, 1:500 for ubiquitin
and 1:2,000 for PVALB. Phospho-specific antibodies included the
addition of 10 lg/ml of the non-phospho form of the peptide used to
raise the antibody per 2 lg/ml of antibody used. Slides were then
washed for 20 min in 0.05% v/v Triton X-100–PBS and incubated in
secondary antibody for 1 h at 37°C. Pre-absorbed donkey IgG-conju-
gated Alexa Fluor 488, 568, 633 and 647 secondary antibodies (Life
Technologies/Abcam) were used at 1:200 dilution in 1% v/v
donkey serum in 0.05% v/v Triton X-100–PBS for immunofluores-
cent labelling. Slides were washed as described above, mounted
using Prolong Gold Antifade (P36930; Life Technologies) and
shielded from light. Human IHC DAB staining was performed with
ImmPRESS Reagent peroxidase universal anti-mouse/rabbit IgG
(MP-7500, Vector) kit, after which slides were then dehydrated
through graded methanol steps and mounted with DPX.
Image acquisition and processing
Immunofluorescence images were acquired on the Leica TCS SP2
laser scanning confocal microscope with 488-, 543- and 633-nm
laser lines mounted on an upright Leica DM RXA fluorescence
microscope using a HCX PL APO 63×/1.40NA oil immersion objec-
tive. Acquisition parameters were as follows: 12-bit, 1,024 × 1,024
pixels, 2.6× digital zoom, 800 Hz scan speed, 4-line Kalman filter-
ing, sequential (by line) channel imaging, and 10-slice z-stack of
5 lm. Immunohistochemically stained specimens were imaged in
brightfield on an Olympus BX51 upright epifluorescent microscope
using a UPLANFL 20×/0.5NA dry objective with the Infinity3
(Lumenera) CCD set to 1,936 × 1,456 pixels.
In FIJI image analysis software (http://fiji.sc/Fiji), fluorescent z-
stacks underwent background subtraction (1,000-pixel-radius rolling
ball, no smoothing) and maximum-intensity z-projection. Brightness
and contrast were adjusted by linear histogram stretching to
enhance visibility. Any images to be compared to one another were
processed in parallel. Similarly, brightfield images underwent linear
histogram stretching to increase visibility uniformly across the
image.
Morphometric analysis
Body weight was regularly measured two times per week through-
out the study to determine differences in mass in age-matched mice.
Body length was measured using photographs of mice post-mortem
with a reference scale. Full body length was determined as well
as tail:body length ratio. Three 5-lm sections of thoracic aorta
were taken at upper (heart), mid and lower (near diaphragm)
segments per mouse. These were deparaffinised, rehydrated and
stained with haematoxylin and eosin, and then dehydrated and
mounted. Each section was imaged under brightfield illumination
and epifluorescent imaging of autofluorescent elastin laminae with
a GFP filter set. Using FIJI image analysis software, macros were
scripted to draw eight lines at ~22.5° to one another that intersect
the aortic ring at a total of 16 points. At the point of intersection
on the outer circumference, the distance from the external lamina
to the inner lumen was measured. The average of the three rings
(max of 16 points per ring, with points excluded if they fell on
an arterial branching point or incomplete portion of a ring) was
used to calculate the average thoracic aorta intima-media wall
thickness. The above step was repeated to count the average
number of elastic laminae in the thoracic aorta of each mouse.
Data collection and analysis were carried out in a blinded
fashion throughout.
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In vivo cardiovascular physiology
Animals were anaesthetised with isoflurane on 100% O2 (induction:
3%, maintenance: 1.75%) and placed on a self-regulating rectal
probe-coupled heat mat (TC-1000; CWE) to maintain a body temper-
ature of 37°C. Heart rate was measured by the R-R wave interval
from ECG Lead II using an animal bio amp (FE136; AD Instruments)
with needle electrodes inserted into fore and hind limbs (MLA1213;
AD Instruments). The right carotid artery was catheterised with a 1F
Mikro-Tip pressure transducer (SPR-1000; Millar) connected to a
bridge amp (FE221; AD Instruments) and powerlab system
(PL3504/P; AD Instruments). When the animals had stabilised,
measurements were taken at 2,000 samples/s using LabChart ver-
sion 7/8 Pro (AD Instruments) to record ECG and blood pressure
pulse waveforms. In vivo dose–responses to vasopressor agents
were taken after baseline blood pressure traces were obtained from
mice. The right external jugular vein was cannulated for administra-
tion of bolus doses in increasing half-log steps of lg/kg body weight
(bw); initially, phenylephrine was administered, and after washout
and return to baseline, angiotensin II was administered in a similar
fashion. Each dose concentration was made up as a half-log serial
dilution in sterile 0.9% w/v saline and administered at a volume of
0.2 ml/kg.bw with an accompanying 20 ll 0.9% w/v saline cannula
flush between doses.
Data processing and analysis were performed in LabChart 8
Pro. Using the blood pressure add-on, systolic, diastolic and
dicrotic notch blood pressures were automatically detected per
beat (beats with respiratory-induced artefact were gated out of the
analysis using the beats classifier). Mean arterial pressure was
calculated as (1/3 peak systolic pressure + 2/3 end diastolic pres-
sure) and pulse pressure as (peak systolic pressure – end diastolic
pressure). A macro was scripted to detect the anacrotic notch, by
using the third zero value crossing the fourth derivative of the
blood pressure, as described in Kelly et al (1989). The augmenta-
tion pressure was calculated as (peak systolic pressure – anacrotic
notch pressure) and augmentation index as (augmentation pres-
sure/pulse pressure). A macro was scripted to measure the slope
of the diastolic pressure decay, 30 ms after the dicrotic notch and
20 ms before the end diastolic pressure (to avoid perturbations
caused by aortic valve opening/closing). The reciprocal of this
slope (ignoring the sign and calculated from the 20% trimmed
mean values) was used to determine the time decay constant of
the diastolic pressure decay which correlates with vascular resis-
tance, as described previously (Bourgeois et al, 1974). Dose–
response curves were generated and data analysed (GraphPad
Prism 5 and LabChart 8 Pro) using a 4-parameter logistical func-
tion to determine the estimated dose producing half-maximal
response (ED50) and maximum response (Emax). Data collection
and analysis were carried out in a blinded fashion throughout.
Sample sizes for the mouse work were decided based on previous
experience in a related mouse model (Rafiqi et al, 2010). When
groups of animals were being compared, procedures were
performed on animals selected at random from the groups.
Blood and urine analytes
To reduce variability introduced by dietary potassium ingestion,
animals were fasted for a minimum of 4 h before being anaes-
thetised with isoflurane on 100% O2 (induction: 3%, maintenance:
1.75%) and placed on a self-regulating rectal probe-coupled heat
mat (TC-1000; CWE) to maintain a body temperature of 37°C. To
minimise air contact of arterial bloods during measurements, the
right carotid artery was cannulated with a mouse arterial catheter
(MAC-02; SAI Infusion Technologies) pre-flushed with 10 U
heparin-0.9% w/v saline to prevent clots. Blood was released
via the catheter into the EC8+ cartridge for analysis on the iSTAT
(Abaxsis). Post-surgery additional blood was collected by using
Microvette CB 300 LH (Sarstedt) and centrifuged at 2,000 g for
5 min to extract plasma before storage at 80°C. Plasma aldos-
terone was calculated by HTRF (homogeneous time-resolved fluo-
rescence) aldosterone assay (Cisbio, Codolet, France), according to
the manufacturer’s protocol using the PheraStar FS (BMG Labtech)
plate reader.
To determine plasma and urine electrolyte homoeostasis,
animals were placed on a 0.3% w/w Na diet for 2 weeks with
urine and plasma time-matched samples collected between days 7
and 10 for normal Na (NNa) diet baseline. On day 14, mice were
switched onto a 0.03% w/w Na diet with sampling repeated on
days 7–10 for low-Na (LNa) diet measurements. Spot urine was
collected from awake mice following spontaneous micturition on
handling over a sheet of Saran wrap or Parafilm. Samples were
then divided, and one sample received acidification with HNO3 to
a final concentration of 1% v/v to prevent precipitation of elec-
trolytes, before both were stored at 80°C. Blood was collected by
saphenous venepuncture in awake restrained animals, and plasma
was separated and stored in a similar fashion to that described
above. Plasma and urine (non-acidified) creatinine levels were
assayed in the Core Biochemical Assay Laboratory, Addenbrooke’s
Hospital, Cambridge, UK. Plasma and urine (acidified) samples
were diluted 1:1,000 using ultrapure polished water containing 1%
v/v HNO3. Cations were then measured by inductively coupled
plasma-optical emission spectrometry (Perkin Elmer ICP-OES Anal-
yser) with known concentration standards and preset elemental
spectra. Data collection and analysis were carried out in a blinded
fashion throughout.
Statistical analysis
Data presented are mean  standard error of the mean (SEM),
unless otherwise stated. Statistical analyses were performed on
either SPSS version 22 or GraphPad Prism (http://www.graph
pad.com/scientific-software/prism/) software. Two-tailed Student’s
t-tests were performed either paired or unpaired where appropriate.
P < 0.05 was taken as statistically significant throughout.
For MYPT1 phosphorylation quantification (Appendix Fig S6),
ratiometric expression was calculated for CUL3WT/D403–459 versus
CUL3WT on each Western blot of independent biological replicates.
The mean of the ratios and bounds of the 95% confidence interval
were calculated, where ratio = 1 represents no change in phosphory-
lation and ratio > 1 represents an increase in the phosphoryla-
tion status of CUL3WT/D403–459 mice. Statistical significance was
determined by the ratio t-test (http://www.wormbook.org/chapters/
www_statisticalanalysis/statisticalanalysis.html).
Expanded View for this article is available online:
http://embomolmed.embopress.org
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Expanded View Figures
Cullin NTD
Rbx1
CAND1
CTD
Figure EV1. Structural context of the area deleted by the disease-causing mutation in CUL3.
Top: Schematic representation of the interactions between CRL and CAND1. Bottom: Representation of CAND1 in complex with CUL1-RBX1, PDB 1u6g (Goldenberg et al,
2004). Coloured as shown in the schematic representation. Residues 437–493 of CUL1 (equivalent to 403–456 CUL3) are coloured orange.
CUL3WT
CUL3 NTD
KLHL3
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CTD
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Ub
CUL3 NTD
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WNK4
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CTD
E2
Ub
CUL3 NTD
Productive complex Possible unproductive complexes
Figure EV2. Schematic representation of the
possible structural effects of the mutation.
The top schematics represent a functional CUL3WT
complex and show two contrasting positionings for
an active CUL3 D403–456 that is unable to modify the
WNK kinases. The lower structural representations
correspond to the schematics above. These were
generated in Chimera, and known structures were
utilised as docking references to enable the possible
orientations to be explored. KLHL3-KLECH domain
(red) bound to a WNK peptide (grey) PDB: 4CH9.
KLHL3-BTB domain (red) bound to CUL3-N-terminal
domain (blue), CUL3-C-terminal domain (cyan) (based
on CUL1 CTD) PDB: 1LDK. RBX1 (green), UBE2D
(purple) and ubiquitin (yellow) were docked based on
the complex RNF4-E2-UB structure PBD: 4AP4.
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Figure EV3. Plasma and urine electrolyte response to normal and low sodium diets.
A–C The upper (A) and middle panels (B) show plasma (P) and urinary (U) electrolytes, respectively, for CUL3WT mice (■) versus CUL3WT/D403–459 (□) on either a normal-
salt (NNa) (0.3%) or low-salt (LNa) (0.03%) diet measured by ICP-OES analysis. The urinary values (AU) are individually ratioed to the urinary concentration of
creatinine ([analyte]U/[creatine]U). The lower panel (C) shows blood biochemistries not reported in Figure 5D taken after a minimum 4-h fast by iSTAT analysis. The
differences between genotypes that are significantly different are shown as *, the differences between NNa and LNa for CUL3WT that are significantly different are
shown as #, and the differences between NNa and LNa for CUL3WT/D403–459 that are significantly different are shown as † (n-values as follows: CUL3WT: plasma
NNa = 16; plasma LNa = 17; urine NNa = 18; urine LNa = 16; blood biochemistry = 13; CUL3WT/D403–459: plasma NNa = 23; plasma LNa = 23; urine NNa = 21;
urine LNa = 19; blood biochemistry = 13). Two-tailed unpaired Student’s t-test for comparisons between genotypes and two-tailed paired Student’s t-test for
comparisons between diets within the same genotype; data are mean  SEM. A full table of P-values for this figure is shown in Appendix Table S1.
Source data are available online for this figure.
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Figure EV4. WNK4 and SPAK puncta do not colocalise with LAMP1 or form ubiquitin-containing aggregates.
Representative pseudocoloured confocal single focal plane images of immunofluorescently stained kidney sections (n = 4 per genotype). WNK4 and SPAK form discrete
puncta in the distal convoluted tubule of CUL3WT/D403–459 mice. These puncta do not colocalise with lysosomes (LAMP1) or form ubiquitylated aggregates. The puncta have a
predominantly basolateral preference with several large juxta-nuclear puncta per cell.
A Immunolocalisation of total SPAK protein (tSPAK) puncta and LAMP1 in the distal convoluted tubule of CUL3WT/D403–459 versus CUL3WT mice at a 4-h fasting baseline.
Scale bar, 20 lm.
B Immunolocalisation of total WNK4 puncta, ubiquitin and LAMP1 in the distal convoluted tubule of CUL3WT/D403–459 versus CUL3WT mice at a 4-h fasting baseline.
Scale bar, 10 lm.
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Abstract
The STE20/SPS1-related proline/alanine-rich kinase (SPAK) controls blood pressure (BP) by phosphorylating and stimulating the
Na-Cl (NCC) andNa-K-2Cl (NKCC2) co-transporters, which regulate salt reabsorption in the kidney. SPAK possesses a conserved
carboxy-terminal (CCT) domain, which recognises RFXV/I motifs present in its upstream activator [isoforms of the With-No-
lysine (K) kinases (WNKs)] aswell as its substrates (NCC andNKCC2). To deﬁne the physiological importance of theCCTdomain,
we generated knock-inmice inwhich the critical CCT domain Leu502 residue required for high afﬁnity recognition of the RFXI/V
motif was mutated to Alanine. The SPAK CCT domain defective knock-in animals are viable, and the Leu502Ala mutation
abolished co-immunoprecipitation of SPAK with WNK1, NCC and NKCC2. The CCT domain defective animals displayed
markedly reduced SPAK activity and phosphorylation of NCC and NKCC2 co-transporters at the residues phosphorylated
by SPAK. This was also accompanied by a reduction in the expression of NCC and NKCC2 protein without changes in mRNA
levels. The SPAK CCT domain knock-in mice showed typical features of Gitelman Syndrome with mild hypokalaemia,
hypomagnesaemia, hypocalciuria and displayed salt wasting on switching to a low-Na diet. These observations establish that
theCCTdomainplays a crucial role in controlling SPAKactivityandBP. Our results indicate that CCTdomain inhibitorswould be
effective at reducing BP by lowering phosphorylation as well as expression of NCC and NKCC2.
Introduction
SPAK (SPS1-related proline/alanine-rich kinase) andOSR1 (oxida-
tive stress-responsive kinase 1) are closely related protein
kinases, which play key roles in regulating cellular ion homeosta-
sis and blood pressure (BP) (1,2). SPAK and OSR1 are activated fol-
lowing the phosphorylation of their T-loop residue (SPAK Thr233
and OSR1 Thr185) by one of the four isoforms of the WNK [with
no lysine (K) kinase] protein kinase (3,4). The activity of SPAK
and OSR1 is further enhanced following interaction with the
scaffolding protein termed MO25 (5). The best-characterised
SPAK/OSR1 substrates comprise the SLC12A (solute carrier family
12) family of electroneutral CCCs (cation–Cl co-transporters)
(6–11). These transporters regulate intracellular chloride concen-
tration critical in controlling BP and cell volume homoeostasis
(12,13). SPAK/OSR1 protein kinases drive chloride inﬂux by phos-
phorylation and activating sodium-driven CCC members. These
include the NCC (Na–Cl co-transporter) in the distal convoluted
tubule of the kidney (10), the NKCC2 (Na–K–2Cl co-transporter
2) in the thick ascending limb (TAL) of the kidney (9) and the ubi-
quitously expressed NKCC1 (6–8). SPAK/OSR1 also phosphorylate
and inhibit potassium-driven CCCs that drive chloride efﬂux (11),
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which comprise four different K–Cl− co-transporters (KCC1–
KCC4) (13,14). This reciprocal regulation of Na+- and K+-driven
CCCs by SPAKandOSR1 ensures that cellular Cl− inﬂux and efﬂux
is tightly co-ordinated (13,14).
The importance of theWNKsignalling pathway is exempliﬁed
by its evolutionary conservation fromworms to humans and that
several Mendelian hypertension disorders in humans are caused
by mutations in WNK pathway components (15,16). These in-
clude various mutations that lead to increased expression of
theWNK1 andWNK4 genes causing PHAII [PseudoHypoAldoster-
onism type II, OMIM (17–23)]. Conversely, loss-of-function muta-
tions in NCC andNKCC2 cause familial forms of hypotension and
hypokalaemia termed Gitelman (OMIM #263800) and Bartter type
1 syndrome (OMIM #601678), respectively (24). A mutation that
ablates the key activating WNK-regulated SPAK/OSR1 phosphor-
ylation site on NCC [T60M (10)] also causes Gitelman’s syndrome
(25,26). Moreover, SPAK-knockout mice (27–29) or knock-in mice
expressing a form of SPAK that cannot be activated by WNK ki-
nase isoforms (30) exhibit low BP and are resistant to hyperten-
sion when crossed with animals bearing a PHAII-causing
knock-in mutation that enhances WNK4 expression (31). Gen-
ome-wide association studies have also identiﬁed intronic SNPs
within the SPAK gene (STK39) that correlate with increased BP in
humans (32). Two commonly used drugs in medicine to lower
high BP also target SPAK sodium-driven CCC substrates, namely
thiazide diuretics (such as bendroﬂumethiazide) that inhibit NCC
and the loop diuretics (such as furosemide) that inhibits NKCC2
(33,34).
These data suggest that chemical agents that inhibit SPAK
would have the potential to treat hypertension, but without
the off-target effects of agents like thiazide diuretics (16,35).
One approachwould be to elaborate smallmolecule compounds
that directly inhibit SPAK/OSR1 protein kinase activity (36).
However, to our knowledge, no highly selective and potent ki-
nase inhibitors of SPAK and OSR1 have been reported. There is
also concern whether sufﬁciently selective SPAK/OSR1 kinase
inhibitors could be synthesized for themanagement of a chron-
ic largely asymptomatic condition, without them inhibiting
other protein kinases or ATP-binding enzymes and causing in-
tolerable off-target effects. An alternative strategy to suppress
SPAK/OSR1 function would be to target the docking domain
within the non-catalytic C-terminal region of SPAK/OSR1 called
the CCT (conserved C-Terminal) domain. In vitro and overex-
pression studies indicate that the CCT domain binds to con-
served RFXV/I motifs present on WNK isoforms and that these
interactions facilitate phosphorylation and activation of SPAK/
OSR1 (37,38). Furthermore, the sodium-driven CCC members
also possess conserved RFXI/V motifs at their N-terminus
which experimental data indicate are critical for enabling
SPAK/OSR1 to interact with, phosphorylate and stimulate activ-
ity of these transporters (9,10,38,39).
In this study,we sought to deﬁne the role that theCCTdomain
plays in vivo by generating and characterising SPAK knock-in
mice in which function of the CCT domain has been ablated by
a mutation of the critical Leu502 residue required for high-afﬁn-
ity binding of the RFXI/V motif. Our data demonstrate that the
CCT domain of SPAK does indeed play an essential role in regu-
lating the activation and function of SPAK. Our ﬁndings establish
that SPAK CCT domain knock-in mice display markedly reduced
phosphorylation and expression of NCC andNKCC2 in the kidney
resulting in lower BP. Our data provide genetic validation that
targeting the CCT domain would be therapeutically effective in
reducing BP, by lowering phosphorylation as well as expression
of NCC and NKCC2 in the kidney.
Results
Characterisation of a mutation that inhibits the CCT
domain of SPAK
Previous crystallographic analysis of the human OSR1 CCT do-
main complexed to an RFXI motif-containing peptide derived
from WNK4 (40) revealed that the highly conserved Leu473 CCT
residue lying at the base of a deep hydrophobic pocket formed
critical hydrophobic contacts with the Phe residue of the RFXI
motif (Fig. 1A). Consistent with this, mutation of Leu473 to Ala re-
duced binding of OSR1 to RFXI WNK4 peptide over 100-fold (40).
Mutation of the equivalent residue (Leu502) in mouse SPAK
also prevented full-length mouse SPAK co-immunoprecipitating
with endogenously expressed WNK1 and NKCC1 in HEK293 cells
(Fig. 1B). Moreover, in vitro ﬂuorescence polarisation studies con-
ﬁrmed thatmutation of this Leu residue in the SPAK CCT domain
reduced binding to an RFXV-motif-possessing peptide derived
from WNK4 by ∼100-fold (Fig. 1C).
Characterization of CCT domain-deﬁcient
SPAKL502A/L502A mice
We exploited these observations to explore the impact that mu-
tation of the CCT domain Leu502 residue had, by generating
knock-in mice on an inbred C57BL/6J background, in which the
Leu502 CCT domain residuewas changed to Ala (Fig. 2A). Homo-
zygous SPAKL502A/L502A mice were born at the expected Mendel-
ian frequency (Supplementary Material, Table S1), were of
normal size and appearance and did not display any overt
phenotype, at least up to 1 year of age (the oldest animals we
have analysed).
Immunoblot analysis of tissues (kidney, brain, heart and testis)
derived from littermate wild-type and SPAKL502A/L502A homozy-
gous animals of 2 months of age employing a novel mouse SPAK
antibody that we generated that does not recognise mouse OSR1
(Supplementary Material, Fig. S1) revealed that the L502A muta-
tion did not inﬂuence expression of SPAK in these tissues. We ob-
served that all tissues analysed derived from SPAKL502A/L502A mice
displayed a signiﬁcant reduction of the phosphorylation of SPAK
at a key WNK phosphorylation site [Ser373 (3)], compared with
wild-type mice (Fig. 2B). This is consistent with the L502A muta-
tion suppressing the ability of WNK isoforms to phosphorylate
SPAK. Furthermore, the SPAKL502A/L502A knock-in animals dis-
played markedly reduced phosphorylation of NKCC1, in agree-
ment with the CCT domain being required for SPAK to bind to
and phosphorylate NKCC1 (Fig. 2B).
To obtain further evidence that the L502Amutation impacted
on the ability of SPAK to bind WNK1 and NKCC1, we immuno-
precipitated SPAK from kidney, brain and testis, derived from
littermate wild-type and SPAKL502A/L502A homozygous animals
of 2 months of age and tested how CCT domain mutation
effected in association with WNK1 and NKCC1. This revealed
that in the SPAKL502A/L502A knock-in animals, co-immunopreci-
pitation of WNK1 and NKCC1 with SPAK was markedly reduced
in all tissues analysed (Fig. 2C). In the kidney, we also observed
that mutation of the CCT domain inhibited co-immunoprecipi-
tation of NCC and NKCC2 with SPAK (Fig. 2C). Further immuno-
blot analysis of SPAK immunoprecipitates conﬁrmed that the
L502A mutation inhibited phosphorylation of SPAK at the two
key residues that WNK isoforms phosphorylate [Thr243 and
Ser373 (3)] (Fig. 2C). SPAK as well as OSR1 immunoprecipitates
from tissues (kidney, brain and testis) were also subjected to a
protein kinase assay activity assay employing the previously
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described CATCHtide peptide that encompasses the NKCC1
phosphorylation sites (37). This revealed that SPAK immunopre-
cipitated from all tissues derived from SPAKL502A/L502A knock-in
mice displayed signiﬁcantly reduced activity compared with
wild-type animals (Fig. 2D). As expected, the activity of OSR1
was not affected in SPAKL502A/L502A knock-in mice (Fig. 2D).
SPAKL502A/L502A mice display reduced phosphorylation of
NCC and NKCC2 in kidney
We next compared the relative levels of phosphorylation of NCC
in total kidney extracts derived from male and female 2-month-
old wild-type and SPAKL502A/L502A knock-in littermate animals
(Fig. 3A–D). We monitored phosphorylation of NCC employing
different previously characterised phosphospeciﬁc antibodies
recognising major SPAK NCC phosphorylation sites (Thr46,
Thr50, Thr55, Thr60 and Ser91) (10). This revealed that in both
male and femalemice, the phosphorylation of NCC at all residues
analysed was drastically reduced in kidney derived from
SPAKL502A/L502A knock-in mice compared with wild type
(Fig. 3B). Similar to what was previously observed in SPAK kinase
inactive (SPAKT243A/T243A) knock-in mice (30) as well as SPAK
knockout mice (27–29), we also observed ∼2-fold reduction in
total levels of NCC protein in kidney extracts of SPAKL502A/L502A
knock-in mice compared with wild type (Fig. 3B). In contrast,
kidney mRNA levels of NCC were similar in wild-type and of
SPAKL502A/L502A knock-in mice (Supplementary Material, Fig. S2).
We next monitored NKCC2 expression and similarly to NCC
observed that levels were reduced ∼2-fold in the kidney of
SPAKL502A/L502A knock-in male and female mice compared with
wild-type animals (Fig. 3C). We immunoprecipitated NKCC2
and analysed its phosphorylation at three residues that
SPAK phosphorylates [Ser91, Thr100 and Ser130 (9)] and
found that phosphorylation of each of these residues was sub-
stantially reduced in both male and female kidney derived from
SPAKL502A/L502A knock-in animals (Fig. 3C). KidneymRNA levels of
NKCC2 were similar in wild type and of SPAKL502A/L502A knock-in
mice (Supplementary Material, Fig S2).
We also analysed NKCC1 and found that the levels of this co-
transporterwere unaffected in kidneyextracts derived fromwild-
type and SPAKL502A/L502A knock-inmale and femalemice (Fig. 3D).
We immunoprecipitated NKCC1 and analysed its phosphoryl-
ation at four sites that SPAK phosphorylates [Thr203, Thr207,
Thr212 and Thr217 (3,5)] and found that phosphorylation of
these sites was markedly diminished in both male and female
kidney extracts derived from SPAKL502A/L502A knock-in animals
compared with wild type. Kidney mRNA levels of NKCC1 were
similar in wild-type and of SPAKL502A/L502A knock-in mice
(Supplementary Material, Fig. S2).
SPAKL502A/L502A mice show a marked reduction in
immunostaining for phosphorylated NCC and NKCC2
without remodelling of kidney tubules
Confocal imaging of kidney sections from the SPAKL502A/L502A
mice conﬁrmed the modest reduction in total NCC and NKCC2
in the tubules of the distal convoluted (DCT) and TAL tubules
compared with wild-type mice, with no obvious changes in
the morphology and numbers of tubules or the intracellular pro-
tein distribution between genotypes (Fig. 4). In striking contrast,
staining for the phosphorylated forms of NCC and NKCC2 in the
same tubules was almost completely lost in the SPAKL502A/L502A
mice in keeping with the immunoblots from whole kidney
lysates (Fig. 3). Additionally no changes were observed in the
intracellular localisation ofWNK4 in theDCTor TAL (Supplemen-
tary Material, Fig. S3).
Figure 1. Evidence that SPAK associates with WNK1 and interaction is disrupted
by SPAK CCT mutation. (A) Molecular interaction of the RFXV peptide with the
conserved carboxy-terminal domain of OSR1 based on PDB 2V3S: CCT domain
of OSR1 (residues 434–527) coloured in grey (β-strands and α-helices) bound to
the GRFQVT WNK4-derived peptide coloured in blue. (B) HEK293 cells were
transfected with constructs encoding a Flag empty vector or the indicated wild-
type or mutant construct of N-terminal FLAG epitope-tagged full-length mouse
SPAK. Thirty-six hours post-transfection, cells were lysed. Total cell extracts
were subjected to immunoprecipitation (IP) with the indicated SPAK antibody,
and immunoprecipitates were subjected to immunoblot (IB) analysis employing
WNK1, SPAK and NKCC1 antibodies. Similar results were obtained in three
separate experiments. (C) Analysis of SPAK–WNK interaction by ﬂuorescence
polarization. Puriﬁed human SPAK 452–547(end) and human SPAK 452–547 with
L491A (equivalent to L502 in mouse) were diluted appropriately and mixed at a
1:1 volume ratio with 20 n Lumino-Green-labelled WNK peptide to the
concentration stated in the figure, with the peptide concentration consistent at
10 n, and ﬂuorescent polarization measurements were made. Binding curves,
assuming one-site-speciﬁc binding, were then generated with Prism6 using
milli-polarization (mP) units.
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Figure 2. Targeting strategy used to generate SPAK knock-in mutations. (A-1) Diagram depicting the knock-in construct, the endogenous SPAK allele containing exons
15–16 and the targeted allele with the puromycin cassette removed by Flp recombinase. The black/grey rectangles represent exons, and the grey triangles represent
FRT sites. Black lines with arrowheads are used to indicate the positions of the probes used for Southern analysis. The knock-in allele containing the Leu502Ala
mutation in exon 16 is illustrated as a grey rectangle. The knock-in allele can be detected by genotyping using PCR primers P1 and P2, which are represented by short
black lines with arrowheads. (A-2) Genomic DNA puriﬁed from the targeted ES cells from the indicated genotypes was digested with either the SexAI or Kpnl and Aﬂll
and subjected to Southern analysis with the corresponding DNA probes. In the case of the 5′ probe, the wild-type allele generates a 13.5-kb fragment whereas the
knock-in allele produces a 11.2-kb fragment. Similarly, the 3′ probe detects a fragment of 11.9 kb from the wild-type allele and 10.2 kb from the targeted knock-in
allele. (A-3) Genomic DNA was PCR ampliﬁed with primers P1 and P2. The wild-type allele generates a 344-bp product whereas the knock-in allele generates a 419-bp
product. The larger knock-in allele product is due to the presence of the 75-bp FRT site and ﬂanking region, which remains in an intronic region following Flp-
mediated excision of the puromycin resistance (PuroR) selection cassette, whereas the Thymidine kinase as a negative selection. (A-4) Genomic DNA puriﬁed from
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SPAKL502A/L502A mice display reduced BP and
augmentation index
To study the cardiovascular phenotype of these mice, we mea-
sured the arterial BP in the SPAKL502A/L502A knock-in animals by
carotid artery cannulation under general anaesthesia, which
showed that their systolic, diastolic and mean arterial BPs were
∼20 mmHg lower than wild-type littermates (Fig. 5A). The lower
BP of the SPAKL502A/L502A knock-in animals was also reﬂected in
a signiﬁcantly lower left ventricular mass in these animals (Sup-
plementary Material, Fig. S4).
Further analysis of the BP traces from the mice also showed
that the shape of the arterial pressurewavewas signiﬁcantly dif-
ferent (Fig. 5B). The SPAKL502A/L502A knock-in animals have a
lower diastolic pressure time decay constant (τbourgeois), an
index of vascular resistance (41), suggesting decreased vascular
tone compared with wild-type littermates (Fig. 5B). Speciﬁcally,
the SPAKL502A/L502A knock-in animals had lower augmentation
of the peak systolic pressure (AIx) with no change in pulse pres-
sure consistent with a reduction in arterial stiffness (42) (Fig. 5B).
SPAKL502A/L502A mice show a Gitelman syndrome pattern
of plasma and urinary electrolytes and are salt wasting
Analysis of the plasma electrolytes showed that the SPAKL502A/L502A
mice had a typical Gitelman pattern of plasma electrolytes with
hypokalaemia and mild hypomagnesaemia compared with the
wild-type animals (Fig. 6A). This is consistent with reduced
WNK pathway signalling caused by the inactivation of the SPAK
CCT domain. The urinary electrolytes also showed a Gitelman-
like pattern of electrolytes with marked hypocalciuria compared
with the wild-type mice (Fig. 6B). The salt wasting expected of a
Gitelman-like phenotype was also conﬁrmed by salt restricting
the SPAKL502A/L502A knock-in animals by switching to a 100-fold
lower Na diet (Fig. 6C).
Discussion
Our results deﬁne the importance that the CCT-docking domain
plays in regulating the ability of WNK isoforms to control the ac-
tivation as well as function of SPAK in regulating NCC/NKCC2 ion
co-transporters and hence BP. Most importantly, our ﬁndings es-
tablish that a single-point mutation ablating the ability of the
CCT domain to interact with RFXI motifs on its WNK activators
or ion co-transporters substrates is sufﬁcient to markedly reduce
phosphorylation and levels of NCC/NKCC2 resulting in a
∼20 mmHg reduction in BP. Strikingly, the impact of the CCT do-
main mutation is similar to that observed previously by ablating
SPAK kinase activity in knock-in mice (30) or by complete knock-
out of SPAK protein in mice (27–29). The SPAKL502A/L502A animals
still possess OSR1, which is activated normally byWNK isoforms
(Fig. 2D), emphasising that inhibiting SPAK without effecting
OSR1 is sufﬁcient to markedly lower BP. This is consistent with
previous analysis indicating that SPAK in mammals evolved as
a result of a gene duplication of OSR1, to undertake more
specialized roles such as control of NCC/NKCC2 in the kidney
and regulation of BP (1).
Intriguingly, in the SPAKL502A/L502A knock-in animals in add-
ition to a reduced phosphorylation of NCC/NKCC2, we observed
that the levels of NCC and NKCC2 protein were signiﬁcantly re-
duced (Fig. 3), under conditions which mRNA levels were un-
affected (Supplementary Material, Fig. S2). Similar results were
also observed when analysing catalytically inactive SPAK
knock-in mice (30). In converse, in mouse models in which the
WNK signalling pathway is activated by introducing knock-in
mutations that inhibit the ubiquitylation of and proteasomal
degradation of WNK4 (i.e. WNK4 [D561A] knock-in mice (31,43)
or KLHL3[R528H] knock-in mice (42)), NCC and NKCC2 protein le-
vels aremarkedly elevated. Taken together results provide strong
genetic evidence that phosphorylation of NCC/NKCC2 by SPAK in
addition to regulating co-transporter activity also promotes the
stability of these critical co-transporters. Furtherwork is required
to unravel themechanism, by which NCC and NKCC2 expression
is controlled by SPAK phosphorylation.
The plasma and urinary electrolyte pattern of the
SPAKL502A/L502A knock-in mice resembles Gitelman Syndrome.
In fact, it recapitulates closely the phenotype of our previous re-
portwith a kinase-dead SPAK knock-inmouse (30). The extensive
loss of NKCC2 and phospho-NKCC2 from the TAL tubules could
be expected to produce amore extensive or even Bartter-like Syn-
drome (44). The levels of NKCC2 were also reduced in the kinase-
dead SPAK knock-in mouse, but the reduction was modest in
comparison with almost complete loss of phosphorylated
NKCC2 from the SPAKL502A/L502A mouse kidney (Figs 3 and 4).
Nevertheless, the presence of both hypocalciuria and hypomag-
nesaemia in the SPAKL502A/L502A mice is in keeping with a pre-
dominant loss of NCC function, because the loss of NKCC2
function in themouse is associated with the opposite phenotype
of hypermagnesaemia and hypercalciuria (45). In fact, plasma
magnesium levels and urinary calcium excretion are clinical
measures used routinely to distinguish between Gitelman and
the related Bartter syndrome (46). Our ﬁnding that the total
level and phosphorylation of NKCC2 is reduced in the kidneys
of the SPAKL502A/L502A mouse is also notable because previous
SPAK knockout models reported hypophosphorylated NCC in
the DCT, but markedly hyperphosphorylated NKCC2 in the TAL
with increases in total NKCC2 levels (27) or without a change in
total NKCC2 levels (28,29). The authors suggested that this was
due to the removal of an inhibitory isoform of SPAK (SPAK2)
and showed that the hypophosphorylation of NCC was accom-
panied by physical reduction in numbers of DCT1 tubular seg-
ments. Similarly, other studies with mouse models of NCC
genetic ablation (47) and knockout of the DCT1-speciﬁc cal-
cium-binding protein, parvalbumin (48), have also shown atro-
phy of the DCT. SPAK has been reported to be directly involved
in the stabilisation of OSR1 at the apical membrane in the DCT
and SPAK knockout results in a signiﬁcant reduction of parvalbu-
min expression (29). However, unlike the knockout models used
in these studies, the SPAK scaffolding functions remain intact in
the point-mutant knock-in SPAKL502A/L502A and SPAKT243A/T243A
mice generated through heterozygous breeding was subjected to PCR to generate a product that encompasses the knock-in mutation region. The resultant PCR products
were ligated into the pCR-Topo 2.1 vector and transformed into E. coli, and clones were sequenced. Thewild-type and knock-in sequences are presented. (B) Expression of
SPAK in tissues (kidney, brain, heart and testis) fromwild-type and knock-in mice. The indicated tissue extracts (40 μg protein) fromwild-type and SPAK502A/502Amice
were subjected to immunoblot analysis with the speciﬁed antibodies. Immunoblots were run in parallel and exposed for the same amount of time to ensure that signal
intensities can be directly compared. Similar results were obtained in three separate experiments. (C and D) Activity of SPAK in wild-type and knock-in mouse tissues.
SPAK was immunoprecipitated from the kidney, testis and brain lysates from wild-type and SPAK502A/502A mice using the SPAK-mouse peptide antibody. The
immunoprecipitates were subjected to activity measurements using the CATCHtide peptide substrate (3). A fraction of the immunoprecipitates was also subjected to
immunoblot assay with the indicated antibodies.
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Figure 3. Reduced phosphorylation of SPAK, NCC, NKCC1, NKCC2 and expression of NCC and NKCC2 in both male and female SPAKL502A/L502A. (A) Expression of WNK1,
WNK4, SPAK, OSR1 and Parvalbumin and phosphorylation of SPAK in wild-type and knock-in male and female mouse kidney. Kidney extract derived from the indicated
mice was subjected to immunoblot analysis with the indicated antibodies. Each sample was derived from a separate littermate animal. Band intensities were quantiﬁed
using Li-Cor Odyssey, and the results are presented relative to the expression of GAPDH. This study has been repeated over three times each with kidney extracts derived
from different animals on each occasion with consistent results. (B) The right panel shows quantiﬁcation of the results of the blots (n = 6, mean ± SEM). *P < 0.05; **P < 0.01;
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mice. Thismay explainwhywe observed no changes in the levels
or staining of parvalbumin (Figs 3A and 4). It is, therefore, pos-
sible to postulate that these remodelling phenomenamay largely
be due to loss of key components of regulatory pathways which
maintain normal tubular structure, rather than a simply loss of
NCC activity.
The altered shape of the arterial pressure waveform in our
SPAKL502A/L502A mice (Fig. 5B) is consistent with increased vascu-
lar compliance and reduced wave reﬂection in the periphery as
compared with the wild-type animals. This may be explained
in part by a diminished cardiac output arising from possible
reductions in cardiac contractility owing to loss of NKCC1
activity in the heart (49) (Fig. 2B) and the lower heart rates of
the SPAKL502A/L502Amice (Fig. 5A), because augmentation is nega-
tively correlated with heart rate in humans (50). It has also been
previously shown that intracranial administration of bumeta-
nide can be used to inhibit the over activity of NKCC1 in the hypo-
thalamic paraventricular nucleus of spontaneously hypertensive
rats. The inhibition of NKCC1 in these hypertensive animals acts
to reduce sympathetic vasomotor tone and lower their heart
rates (51). A similar phenomenon may be occurring in the
SPAKL502A/L502A mice owing to reductions in brain phospho-
NKCC1 (Fig. 2), thus providing a potential neurological explan-
ation for their lower heart rate and reduced vascular tone.
However, SPAK directly affects vascular smooth muscle con-
traction through WNK1 (52) and WNK3 (53) signalling and
NKCC1 (27), the activity of which is necessary for maintaining
vascular smoothmuscle tone (54), so it is likely that reduced aug-
mentation also reﬂects hypophosphorylation of NKCC1 in blood
vessels in a parallel fashion to our ﬁndings in the kidney and
other tissues (Figs 2 and 3). This is further supported by the short-
er τbourgeois found in SPAK
L502A/L502A mice, which implies reduced
vascular resistance consistent with a reduction in vascular con-
tractility. This suggests that targeting the CCT domain of SPAK
may have an additional effect on BP through a direct reduction
in vascular tone. It also suggests a reduced arterial stiffnesswith-
out a change in pulse pressure (Fig. 4), and both are importantly
independent risk factors for cardiovascular mortality (42).
There is increasing interest in targeting the WNK-SPAK/
OSR1-signalling pathway as a new therapeutic strategy to treat
hypertension (16,35). Our ﬁnding that ablation of the CCT do-
main function is sufﬁcient to reduce BP to the same extent as
a kinase ablating knock-in mutation (30) suggests that the CCT
domain of SPAK plays a similarly important role as the kinase
domain in controlling BP. Thus, inhibitors that prevent the
CCT domain-recognising RFXV motifs should be as effective as
compounds that target the protein kinase domain of SPAK in low-
ering BP. Structural analysis reveals that CCT domain recognises
RFXV/I motifs by adopting a unique fold not observed on other
proteins (40). This may indicate that CCT domain inhibitors
might be inherently more speciﬁc than ATP competitive kinase
inhibitors that would have the potential to target other protein
kinases and/or ATP binding enzymes. For the treatment of a
chronic largely asymptomatic condition such as hypertension,
it is particularly important that therapies are as speciﬁc as pos-
sible in order to reduce poorly tolerated off-target side effects.
Owing to the high degree of homology between the CCT do-
main of SPAK and OSR1, it may be impossible to develop drugs
that selectively inhibit SPAK. However, even a drug that partially
inhibited both SPAK and OSR1 isoforms might reduce phosphor-
ylation and expression of NCC and NKCC1/2 enough to lower BP
without signiﬁcant adverse effects. Thus far one CCT domain in-
hibitor termed STOCK 1S-50699 has been reported that has an
IC50 of ∼3 μ, that is capable of inhibitingWNK-SPAK phosphor-
ylating NKCC1 and NCC in mammalian cell lines (11,39). STOCK
1S-50699 is highly hydrophobic, displays poor solubility and can-
not be used in animal models, but the data obtained so far pro-
vide evidence that the development of CCT domain inhibitors
is feasible.
In conclusion, our results establish that the SPAKCCT domain
plays amajor role in regulating BP. Our data suggest that the SPAK
CCT domain regulates BP by promoting SPAK activation by WNK
isoforms that in turn enhance both activity and expression of the
renal sodium co-transporters NCC and NKCC2 with potential
concomitant effects on NKCC1 in the vasculature. The hypoten-
sive phenotype of the SPAKL502A/L502A mice validate the CCT do-
main as a promising new target for future anti-hypertensive
agents. The lack of an overt phenotype in these mice also indi-
cates that CCT domain inhibitors may be well tolerated.
Materials and Methods
Materials
Lumio Green, Colloidal Blue staining kit and precast SDS poly-
acrylamide BisTris gels were from Invitrogen. GL Biochem
synthesized all peptides to a purity of >95%; peptide sequences
were determined by mass spectrometry. Tissue-culture reagents
were from Life Technologies. P81 phosphocellulose paper was
from Whatman, and [γ-32P]-ATP was from PerkinElmer.
***P < 0.001. (C) Analysis of kidney NCC protein levels and phosphorylation inmale and femalewild-type and homozygous knock-inmice following NCC immunoblot and
immunoprecipitation. The upper panel shows that NCC from the indicated kidney extracts was subjected to immunoblot analysis with the total NCC antibody and a
phosphospeciﬁc antibodies recognizing NCC phosphorylated at Thr46, 50, 55, 60 and Ser91 (Thr60 is a key SPAK/OSR1 phosphorylation site in NCC is frequently
detected in Asian patients with Gitelman’s syndrome). The down panel shows that NCC was immunoprecipitated from the indicated kidney extracts and subjected to
immunoblot analysis with the total NCC antibody and a phosphospeciﬁc antibodies recognizing NCC phosphorylated at Thr46, 50, 55 and 60. Band intensities were
quantiﬁed using Li-Cor Odyssey, and the results are presented relative to the expression of GAPDH. This study has been repeated over three times each with kidney
extracts derived from different animals on each occasion with consistent results. (D) The right panel shows quantiﬁcation of the results of the blots (n = 6,
mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001. (E) Analysis of kidney NKCC2 protein levels and phosphorylation in male and female wild-type and homozygous knock-in
mice following NKCC2 immunoprecipitation. NKCC2 was immunoprecipitated from the indicated kidney extracts and subjected to immunoblot analysis with the total
NKCC2 antibody and a phosphospeciﬁc antibodies recognizing NKCC2 phosphorylated at Ser91, Thr100 and Ser130, a major SPAK phosphorylation site. Each sample is
derived from a separate littermate animal. Band intensities were quantiﬁed using Li-Cor Odyssey, and the results are presented relative to the expression of GAPDH. The
study has been repeated over three times each with kidney extracts derived from different animals on each occasion with consistent results. (F) The right panel shows
quantiﬁcation of the results of the blots (n = 6, mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001. (H) Analysis of kidney NKCC1 protein levels and phosphorylation in male and
femalewild-type and homozygous knock-inmice followingNKCC1 immunoblot and immunoprecipitation. The upper panel shows that NKCC1 from the indicated kidney
extracts was subjected to immunoblot analysis with the total NKCC1 antibody and a phosphospeciﬁc antibodies recognizing NKCC1 phosphorylated at Thr203, 207, 212
and 217. The down panel shows that NKCC1 was immunoprecipitated from the indicated kidney extracts and subjected to immunoblot analysis with the total NKCC1
antibody and a phosphospeciﬁc antibodies recognizing NKCC1 phosphorylated at Thr203, 207, 212 and 217. Band intensities were quantiﬁed using Li-Cor Odyssey,
and the results are presented relative to the expression of GAPDH. This study has been repeated over three times each with kidney extracts derived from different
animals on each occasion with consistent results. (I) The right panel shows quantiﬁcation of the results of the blots (n = 6, mean ± SEM). *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 4. Immunolocalisation of NCC and NKCC2 in the renal tubules of SPAKL502A/L502A Mice. Representative pseudocoloured average intensity z projections of
immunoﬂuorescent-stained kidney sections (n = 4 per genotype) showing the distribution of total and phospho proteins in the TAL marked by total NKCC2 (tNKCC2),
early distal convoluted tubule (DCT1) marked by parvalbumin (PVALB) and whole distal convoluted tubule (DCT1/2) marked by total NCC (tNCC). Phospho-NCC T46
(pNCC) and phospho-NKCC2 S91 (pNKCC2) are virtually undetectable in the SPAKL502A/L502A mice. Scale bar = 100 μm.
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Plasmids
C-terminal human SPAK, full length, N-, C-terminalmouse SPAKs
were ampliﬁed employing SuperScript III (Invitrogen) from pla-
centa total RNA (Stratagene) using appropriate oligonucleotides.
The RT–PCR products were ligated into pCR2.1-TOPO vector and
sequenced. The sequence-veriﬁed SPAKs were sub-cloned into
bacterial (pGEX-6P-1) and mammalian (pCMV5) expression vec-
tors using BamHI and NotI. Required amino acid mutations were
introduced into the pCR2.1-TOPO clone using site-directed muta-
genesis by QuikChange method (Stratagene) but substituting the
Taq enzyme with KOD Hot Start DNA polymerase (Novagen). All
DNA plasmids used in this study are listed in Supplementary
Material, Table S1. Oligonucleotides were obtained from Invitro-
gen Life Sciences.DNAsequencingwasperformedbyTheSequen-
cing Service, College of Life Sciences, University of Dundee (www.
dnaseq.co.uk). All recombinant proteins, plasmids and antibodies
generated for the present study are available on request and
are described in additional detail on our website for reagents
(https://mrcppureagents.dundee.ac.uk/).
Expression and puriﬁcation of proteins in Escherichia coli
All pGEX-6P-1 constructs encoding expression of recombinant
with N-terminal Glutathione-S-Transferase (GST) tags were
transformed into BL21 E. coli cells, and 1-l cultures were grown
at 37°C in Luria Broth containing 100 μg/ml ampicillin until the
absorbance at 600 nm was 0.8. Isopropyl ß--thiogalactopyrano-
side (30 μ) was then added, and the cells were cultured for a
further 18 h at 26°C. Cells were isolated by centrifugation, re-
suspended in 40 ml of ice-cold lysis buffer and lysed in one
round of freeze/thawing, followed by sonication (Branson Digital
Soniﬁer; ten 15-s pulses with a setting of 45% amplitude) to frag-
ment DNA. Lysates were centrifuged at 4°C for 15 min at 26 00 g.
The GST-SPAK recombinant proteins were afﬁnity-puriﬁed on
0.5 ml glutathione–Sepharose and eluted in buffer A containing
0.27  sucrose and 20 m glutathione.
Fluorescence polarization
Fluorescence polarization measurements were performed at
25°C with puriﬁed SPAK proteins in 50 m Tris–HCl, pH 7.5,
150 m NaCl and 2 m DTT. The concentration of the SPAK pro-
teins was determined by measuring their absorbance at 280 nm
and calculated using the molar absorption coefﬁcient deter-
mined by the ProtParam Online tool (55). All peptides [SEEGKP
QLVGRFQVTSSK (EP4543) and SEEGKPQLVGAFQVTSSK (EP4544)]
contained an N-terminal linker required for conjugating to the
Lumio Green ﬂuorophore (CCPGCCGGGG) and were initially
resuspended in 50 m ammonium bicarbonate, pH 8. Peptide
labelling was achieved by incubating 10 n of each peptide in a
0.5 ml reaction mixture of 20 μ Lumio Green in 25 m Tris–
HCl, pH 7.5, 200 m NaCl and 5 m 2-mercaptoethanol. Reac-
tions were left to proceed in the dark for 2 h. The peptides were
dialysed for 4 h into 25 m Tris–HCl, pH 7.5, 200 m NaCl and
5 m 2-mercaptoethanol using a Micro DispoDIALYZER with a
100-Da molecular-mass cut-off (Harvard Apparatus) and then
for another 12 h with changed buffer. For ﬂuorescence polariza-
tion, mixtures were set up containing the indicated concentra-
tion of protein, 10 n Lumio-Green-labelled peptide in a ﬁnal
volume of 30 μl. All individual bindings were performed in dupli-
catewith at least 12 data points per curve. Fluorescence polariza-
tion measures were made using a BMG PheraStar plate reader,
with an excitation wavelength of 485 nm and an emission
wavelength of 538 nm, and measurements were corrected to
the ﬂuorescent probe alone. Data analysis and graphing were
then performed in GraphPad Prism6; a one-site-speciﬁc binding
Figure 5. Blood pressure and pressure waveforms of SPAKL502A/L502A mice. (A) Intravascular carotid measurements of systemic systolic blood pressure (SBP) and diastolic
blood pressure (DBP), and heart rate (HR) determined by ECG R-R wave interval inmice under general anaesthesia. (B) Pulsewaveform analysis reveals no change in pulse
pressure (PP) (SBP–DBP) but does show decreased augmentation pressure (AP) (SBP–anacrotic notch [AN] pressure), dicrotic notch (DN) pressure andMAP (1/3 × SBP + 2/3 ×
DBP) in the SPAKL502A/L502Aversuswild type. This hypotensive phenotype is in part owing to changes in vascular contractility in SPAKL502A/L502Amice as evidenced by their
lower augmentation index (AIx) [AP/PP], a marker of arterial stiffness, and is further supported by a decrease in their diastolic pressure decay time constant (τbourgeois)
(1/slope of diastolic pressure decay; measured 30 ms after DN and 20 ms before end DBP), a surrogate marker of decreased vascular resistance. Bars are mean ± SEM,
n = 8–9. Signiﬁcant differences from the SPAK wild type are shown by: *P < 0.02, **P < 0.001.
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model was assumed (Y = Bmax *X/[Kd +X]) and the ﬁtted dissoci-
ation constant computed. All experimental bindings were re-
peated at least twice and comparable results to those shown in
the present study were obtained.
Cell culture and transfections
HEK293 (human embryonic kidney 293) cells were cultured on
10-cm-diameter dishes in DMEM supplemented with 10% (v/v)
foetal bovine serum, 2 m -glutamine, 100 U/ml penicillin and
0.1 mg/ml streptomycin. For transfection experiments, each
dish of adherent HEK293 cells was transfected with 20 μl of
1 mg/ml polyethylenimine (Polysciences) and 5–10 μg of plasmid
DNA as described previously (56). Thirty-six hours post-transfec-
tion, cells were lysed in 0.3 ml of ice-cold lysis buffer/dish, lysates
were clariﬁed by centrifugation at 4°C for 15 min at 26 000g and
the supernatants were frozen in aliquots in liquid nitrogen and
stored at −20°C. Protein concentrations were determined using
the Bradford method.
Buffers
Lysis buffer was 50 m Tris–HCl, pH 7.5, 1 m EGTA, 1 m EDTA,
50 m sodium ﬂuoride, 5 m sodium pyrophosphate, 1 m so-
dium orthovanadate, 1% (w/v) NP-40 or 1% (w/v) Triton X-100,
0.27  sucrose, 0.1% (v/v) 2-mercaptoethanol and protease inhi-
bitors (one tablet per 50 ml). Buffer A was 50 m Tris–HCl, pH
7.5, 0.1 m EGTA and 0.1% (v/v) 2-mercaptoethanol. TBS-Tween
buffer (TTBS) was Tris–HCl, pH 7.5, 0.15  NaCl and 0.2% (v/v)
Tween-20. SDS sample buffer was 1× NuPAGE LDS sample buffer
(Invitrogen), containing 1% (v/v) 2-mercaptoethanol.
Antibodies
The following antibodies were raised in sheep and afﬁnity puri-
ﬁed on the appropriate antigen by the Division of Signal Trans-
duction Therapy Unit at the University of Dundee: WNK1-total
antibody (residues 2360–2382 of human WNK1, S62B), WNK4-
total antibody (residues 1221–1243 of human WNK4, S064B),
Figure 6. Plasma and urine electrolyte levels of SPAKL502A/L502A mice. (A) Plasma electrolytes (n = 12–16 per genotype per electrolyte) and (B) creatinine normalised urinary
electrolytes (n = 16–18 per genotype per electrolyte). (C) Urinary Na+ excretion expressed as mmol Na+/mmol creatinine at various time points after switching from a
3% w/w to a 0.03% w/w salt diet. Inset (C) shows the areas under the two curves (AUC) (n = 16 per genotype). Bars are mean ± SEM. Signiﬁcant differences from the
SPAK wild type are shown by: *P < 0.02, **P < 0.01, ***P < 0.005.
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WNK4 N-terminal antibody (residues 1–14 of mouse WNK4,
S726D), SPAK-mouse antibody (2–76 of mouse SPAK, S668D),
OSR1 mouse antibody (389–408 of mouse OSR1, SAHLPQPAGQ
MPTQPAQVSL, S149C), SPAK/OSR1 (T-loop) phospho-Thr233/
Thr185 antibody (226–238 of human SPAK or residues 178–190
of human OSR1, TRNKVRKpTFVGTP, S204C), SPAK/OSR1
(S-motif ) phospho-Ser373/Ser325 antibody (367–379 of human
SPAK, RRVPGSpSGHLHKT, which is highly similar to residues
319–331 of human OSR1 in which the sequence is RRVPG
SpSGRLHKT, S670B), SPAK phospho-Thr233 antibody (226–238
of human SPAK, TRNKVRKpTFVGTP, S668B), NKCC1 phospho-
Thr203 + Thr207 + Thr212 (residues 198–217 of human NKCC1,
HYYYDpTHTNpTYYLRpTFGHNT, S763B), NKCC1 phospho-Thr
212 + Thr 217 (residues 208–223 of human NKCC1, YYLRpT
FGHNpTMDAVPR, S063D), NKCC1-total antibody (residues 1–260
of shark NKCC1, S841B), NCC phospho-Thr46 + Thr50 + Thr55
antibody (residues 41–60 of human NCC phosphorylated at
Thr46 + Thr50 + Thr55, HPSHLpTHSSpTFCMRpTFGYNT, S908B),
NCC phospho-Thr46 antibody (residues 40–54 of human NCC
phosphorylated at Thr46, SHPSHLpTHSSTFCMRRR, S241C), NCC
phospho-Thr60 antibody (residues 54–66 of human NCC phos-
phorylated at Thr60, RTFGYNpTIDVVPT, S995B), NCC phospho-
Ser91 antibody (residues 85–97 of human NCC phosphorylated
at Ser91, CTLADLHpSFLKQEGRR, S996B), NCC-total antibody (resi-
dues 906–925 ofhumanNCC,CHTKRFEDMIAPFRLNDGFKD, S965B),
NKCC2 phospho-Thr100 (residues 94–106 of human NKCC2,
NTYYLQpTFGHNTM, S431C), NKCC2 phospho-Ser130 (residues
123–137 of human NKCC2, GPKVNRPpSLLEIHEQ, S888C), NKCC2
phospho-Ser91 (residues 86–97 of human NKCC2, RRFHAYD
pSHTNTYYRR, S451C), NKCC2-total antibody (residues 1–174 of
human NKCC2, S838B), GST-total antibody (raised against the
glutathione S-transferase protein, S902A) and ERK1 total anti-
body (full-length human ERK1 protein, S221B). The anti-GAPDH
antibody (ab8245), anti-NCC-total [SLC12A3] (AB95302) and the
anti-parvalbumin antibody (ab11427) were purchased from
Abcam. Anti-PVALB (Parvalbumin PV25) from Swant. Anti-NKCC2-
total (LS-C313275) from LifeSpan BioSciences. The anti-ERK1/2
antibody (9102) was purchased from Cell Signalling Technology.
The anti-FLAG antibody (F1804) was purchased from Sigma–
Aldrich. Secondary antibodies coupled to horseradish peroxidase
used for immunoblotting were obtained from Pierce. Fluoro-
chrome-conjugated secondary antibodies for immunoﬂuores-
cent confocal microscopy were obtained from Life Technologies
and Abcam. Pre-immune IgG used in control immunopreci-
pitation experiments were afﬁnity puriﬁed from pre-immune
serum using protein G-Sepharose.
Immunoprecipitation and assay of SPAK
One milligram of clariﬁed cell lysate was incubated with 5 μg of
the SPAK/OSR1 (total) antibody conjugated to 5 μl of protein
G-Sepharose and incubated for 2 h at 4°C with gentle agitation.
The immunoprecipitates were washed twice with 1 ml of lysis
buffer containing 0.5  NaCl and twice with 1 ml of buffer
A. The SPAK/OSR1 immunoprecipitates were assayed with the
CATCHtide peptide substrate (RRHYYYDTHTNTYYLRTFGHN
TRR) that encompasses the SPAK/OSR1 phosphorylation sites
on NKCC1 (3). Assays were set up in a total volume of 50 μl in buf-
fer A containing 10 m MgCl2, 0.1 m [γ32P]ATP and 300 μ
CATCHtide (37). After incubation for 30 min at 30°C, the reaction
mixture was applied onto P81 phosphocellulose paper, the
papers were washed in phosphoric acid and incorporation of
32P-radioactivity in CATCHtide was quantiﬁed by Cerenkov
counting.
Immunoblotting and total-antibody
immunoprecipitation
Cell lysates (15 μg) in SDS sample buffer were subjected to elec-
trophoresis on polyacrylamide gels and transferred to nitrocellu-
lose membranes. The membranes were incubated for 30 min
with TBS-T containing 5% (w/v) skim milk. The membranes
were then immunoblotted in 5% (w/v) skim milk in TBS-T with
the indicated primary antibodies overnight at 4°C. Sheep anti-
bodies were used at a concentration of 1–2 μg/ml. The incubation
with phospho-speciﬁc sheep antibodies was performed with the
addition of 10 μg/ml of the dephospho-peptide antigen used to
raise the antibody. The blots were then washed six times with
TBS-T and incubated for 1 h at room temperaturewith secondary
HRP-conjugated antibodies diluted 5000-fold in 5% (w/v) skim
milk in TBS-T. After repeating the washing steps, the signal was
detected with enhanced chemiluminescence reagent. Immuno-
blots were developed using a ﬁlm automatic processor (SRX-
101; Konica Minolta Medical), and ﬁlms were scanned with a
600-dpi resolution on a scanner (PowerLook 1000; UMAX). Figures
were generated using Photoshop/Illustrator (Adobe). For total-
antibody immunoprecipitationNCC,NKCC1 andNKCC2were im-
munoprecipitated from indicated kidney extracts. A 2 mg aliquot
of the indicated clariﬁed kidneyextractwere incubatedwith 15 μg
of the indicated total NCC, NKCC1 and NKCC2 antibodies conju-
gated to 15 μl of protein-G–Sepharose. Incubation was for 2 h at
4°C with gentle agitation, and the immunoprecipitates were
washed three times with 1 ml of lysis buffer containing 0.15 
NaCl and twice with 1 ml of buffer A. Bound proteins were eluted
with 1× lithium dodecyl sulphate (LDS) sample buffer.
Generation and genotyping of SPAK knock-in mice
The knock-in mice were generated by TaconicArtemis (http://
www.taconic.com/wmspage.cfm?parm1=1453) as described in
Figure 2A. The knock-in mice were generated and maintained
on an inbred C57BL/6J background. Genotyping was performed
by PCR using genomic DNA isolated from tails or embryonic
membranes. For the SPAK mice, Primer 1 (5′ TCT GTA AGC TCA
TTT ATG TAG TCA CC 3′) and Primer 2 (P2: 5′ CAA GTG AGT
GAG TGA ATA CAG CC 3′) were used to detect the wild-type and
knock-in alleles as described in Figure 2A. The PCR programme
consisted of 2 min at 95°C, 30 s at 95°C, 1 min at 60°C and 1 min
at 72°C: 35 cycles; 10 min at 72°C. DNA sequencingwas performed
by The Sequencing Service, College of Life Sciences, University of
Dundee, UK (www.dnaseq.co.uk).
Mice were maintained under speciﬁc pathogen-free condi-
tions, and all procedures were carried out in accordance with
the regulations set by the Universities of Cambridge and Dundee,
and the United Kingdom Home Ofﬁce.
Sample preparation and immunostaining for imaging
Harvested mouse tissues were immersion ﬁxed in fresh 4% (w/v)
formaldehyde-PBS pH 6.9 for 16 h at 37°C andwashed three times
in PBS and stored at 4°C until parafﬁn embedded. Five-micro-
metre sections were deparafﬁnised in Histoclear (National Diag-
nostics) and rehydrated in graded methanol steps. An antigen
retrieval step was performed with R-Universal buffer in the
2100 antigen retriever for a single heat-pressure cycle (Aptum
Biologics). Sections were permeabilised with 0.05% (v/v) Triton
X-100–PBS for 20 min and blocked for 1 h at 37°C with 2% (v/v)
donkey serum in 0.05% (v/v) Triton X-100–PBS. Primary anti-
bodies were incubated overnight for 16 h at 4°C at the following
concentrations diluted in 1% (v/v) donkey serum in 0.05% (v/v)
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Triton X-100–PBS: 2 μg/ml for pNCC T46, tNCC, pNKCC2 S91,
tNKCC2 and 4 μg/ml for WNK4 N-terminal and 1:2000 for
PVALB. Phospho-speciﬁc antibodies included the addition of
10 μg/ml of the non-phospho peptide used to raise the antibody
per 2 μg/ml of antibody used. Negative controls omitted the pri-
mary antibody and were processed in parallel (Supplementary
Material, Fig. S3). Slides were then washed for 20 min in 0.05%
(v/v) Triton X-100–PBS and incubated in secondary antibody for
1 h at 37°C. Pre-absorbed donkey IgG-conjugated Alexa Fluor
488, 633 and 647 secondary antibodies (Life Technologies/
Abcam) were used at 1:200 diluted in 1% (v/v) donkey serum in
0.05% (v/v) Triton X-100–PBS for immunoﬂuorescent labelling.
Slides were washed as mentioned earlier, counterstained using
Sytox orange nucleic acid stain (S11368—Life Technologies) and
mounted using Prolong gold antifade (P36930—Life Technolo-
gies) and shielded from light.
Image acquisition and processing
Immunoﬂuorescent images were acquired on the Leica TCS SP2
laser-scanning confocal with 488-, 543-, 633-nm laser lines
mounted on an upright Leica DM RXA ﬂuorescent microscope
using an HC PL FLUOTAR 20X/0.5NA objective. Acquisition para-
meterswere as follows: 12-bit, 1024 × 1024 pixels, 2× digital zoom,
800 Hz scan speed, 4-line Kalman ﬁltering, sequential (by line)
channel imaging and 10 slice z-stack of 5 μm.
In FIJI image analysis software, ﬂuorescent z-stacks under-
went background subtraction (1000px radius rolling ball, no
smoothing) and average intensity z-projection. Brightness and
contrast were adjusted by linear histogram stretching to enhance
visibility. Any images to be comparedwith one another were pro-
cessed evenly across thewhole image in parallel, the exception to
this were nuclei images where brightness and contrast were per-
formed on each image independently to ensure the best visibility.
In vivo pulse waveform analysis and BP measurements
Animals were anaesthetized with isoﬂurane on 100% O2 (induc-
tion: 3%,maintenance: 1.75%) and placed on a self-regulating rec-
tal probe-coupled heat mat (TC-1000; CWE) to maintain a body
temperature of 37°C. Heart rate was measured by the R-R wave
interval from ECG Lead II using an animal bio amp (FE136; AD In-
struments) with needle electrodes inserted into fore and hind
limbs (MLA1213; AD Instruments). The right carotid artery was
catheterized with a 1F Mikro-Tip pressure transducer (SPR-1000;
Millar) connected to a bridge amp (FE221; AD Instruments) and
powerlab system (PL3504/P; AD Instruments). When the animals
had stabilized, measurements were taken at 2000 samples/s
using lab chart version 7/8 pro (AD Instruments) to record ECG
and BP pulse waveforms.
Data processing and analysis was performed in Lab chart 8
pro. Using the BP add-on, systolic, diastolic and dicrotic notch
BPs were automatically detected per beat (beats with respira-
tory-induced artefact were gated out of the analysis using the
beats classiﬁer). Mean arterial pressure (MAP) was calculated as
(1/3 systolic pressure + 2/3 diastolic pressure) and pulse pressure
as (systolic pressure− diastolic pressure). Amacrowas scripted to
detect the anacrotic notch, by using the third zero value crossing
the fourth derivative of the pressure (57). The augmentation pres-
sure was calculated as (systolic pressure − anacrotic notch pres-
sure) and augmentation index as (augmentation pressure/pulse
pressure). A macro was scripted to measure the slope of the dia-
stolic pressure decay, 30 ms after the dicrotic notch and 20 ms be-
fore the end diastolic pressure (to avoid perturbations caused by
aortic valve opening/closing). The reciprocal of this slope (ignor-
ing the sign) was calculated from the 20% trimmed mean values
to determine the time decay constant of the diastolic pressure
decay (τbourgeois), which correlates with vascular resistance (41).
Data collection and analysis was carried out in a blinded fashion
throughout.
Plasma and urine electrolyte measurements
Animal were placed on a 3% w/w Na diet for 14 days with urine
andplasma samples collected on betweenDays 7 and 10 for base-
line. On Day 14, mice were switched onto a 0.03% w/w Na diet
with urine samples collected at 0, 3, 6, 12, 24 h after Na-diet
switch. Spot urine was collected from awake mice following
spontaneous micturition on handling over a sheet of Saran®
wrap or Paraﬁlm®. Sampleswere then divided and one sample re-
ceived acidiﬁcation with HNO3 to a ﬁnal concentration of 1% v/v
to prevent precipitation of electrolytes, before bothwere stored at
−80°C. Blood was collected by saphenous venepuncture in awake
restrained animals, and plasma was separated by using Microv-
ette® CB 300 LH (Sarstedt) centrifuged at 2000g for 5 min before
storage at −80°C.
Plasma and urine (non-acidiﬁed) creatinine levels were as-
sayed in the core Core Biochemical Assay Laboratory, Adden-
brooke’s Hospital, Cambridge, UK. Plasma and urine (acidiﬁed)
sampleswere diluted 1:1000 using ultra-pure polishedwater con-
taining 1% v/v HNO3. Cations were then measured using an
inductively coupled plasma—optical emission spectrometry
(Perkin Elmer ICP-OES Analyser) with known standards and
pre-set elemental spectra. Data collection and analysis was car-
ried out in a blinded fashion throughout.
Statistical analysis
Data are presented asmean ± SEM, with n representing the num-
ber of analysed mice. Mean values were compared by the
Student’s t-test for paired or unpaired observationswhere appro-
priate, using SigmaStat Program (Jandel Scientiﬁc, Chicago, IL,
USA) or GraphPad Prism5, or by ANOVA with post hoc testing
using version 15 of SPSS software. A P < 0.05 was considered stat-
istically signiﬁcant.
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Supplementary Material is available at HMG online.
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Supplementary Figure Legends 
Figure S1. Generation and characterisation of specific SPAK antibodies. The N-
SPAK antibody was generated by ligating cDNA corresponding to amino acids 2–74 
of mouse SPAK downstream of the GST open reading frame in the pGEX-6P-1 
vector. The resulting fusion protein was injected into sheep to produce polyclonal 
antibodies. HEK293 cells were transfected with the constructs encoding the full-
length mouse FLAG-tagged SPAK wild type and SPAK L502A. 36 h post 
transfection, the lysates were subjected to immunoblotting with the indicated 
antibodies. The indicated amounts of recombinant mouse full-length GST-SPAK 
protein were subjected to immunoblot analysis on HEK293 cell lysates (A) and 
kidney lysates (B) with the newly generated SPAK and OSR1 mouse antibodies 
described in the Materials and Methods. 
 
Figure S2. Quantitative real-time PCR analysis of sodium ion co-transporter 
expression in the kidney. Total RNA was purified from wild type and 
SPAK
L502A/L502A 
mice kidneys using RNeasy kits (Qiagen) and reverse transcribed 
using iScript (Biorad). mRNA levels of SPAK, OSR1, NKCC1, NKCC2 and NCC 
were assessed by using Sybrgreen-based quantitative real-time PCR according to 
manufacturer’s instructions. The levels were quantified from five separate mice and 
each PCR was performed in triplicate. Results were normalized to 18S rRNA 
expression and levels are presented relative to wild type expression. Primer sequences 
used are shown in Supplementary Table S3. 
 
 
Figure S3. Cardiac ventricular mass. The weight of the Left Ventricle and Septum 
combined (LV+S) are expressed as a % of bodyweight (BW). Bars are mean±SEM 
n=14-16. Significant differences from the SPAK wild type are shown by: * P<0.02. 
 
Figure S4. Representative pseudocoloured average intensity z projections of 
immunofluorescent stained kidney sections. (A) Immunolocalisation of WNK4 in 
the DCT marked by tNCC and TAL marked by NKCC2 (n=4 per genotype. Scale bar 
= 50μm). (B) Primary antibody negative controls for each staining set (Scale bar = 
100μm). 
 
Supplementary Table S1. Breeding of SPAK knock-in mice. Matings for SPAK 
were set up as outlined above and the progeny were genotyped as described in the 
methods. The percentage of each genotype observed is indicated in parenthesis 
followed by its expected Mendelian frequency.  
 
Supplementary Table S2. Summary of the purified proteins used in this study. 
The DSTT DU number, purification system and affinity tags are used in Figure 1 and 
Figure S1.  
 
Supplementary Table S3. Primer sequences used for quantitative PCR 
undertaken in this study. 
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Supplementary Table S1
Cross Genotype  Number 
Born (%) 
Expected 
Mendelian 
Frequency (%) 
SPAK (+/502A) OSR1 (+/+) SPAK (+/+) OSR1 (+/+) 94 (30%) 25 
SPAK (+/502A) OSR1 (+/+) SPAK (+/502A) OSR1 (+/+) 180 (57%) 50 
 SPAK (502A/502A) OSR1 (+/+) 42 (13%) 25 
Kinase/protein DU number Expression 
system 
Affinity tag 
 
GST-SPAK 452 – 545 (end) DU41572 Bacteria GST 
GST-SPAK 452-end L491A DU41619 Bacteria GST 
GST-mSPAK 2-74 DU44920 Bacteria GST 
GST-mSPAK 424-556 DU44891 Bacteria GST 
MBP-mSPAK 2-74 DU48033 Bacteria MBP 
MBP-mSPAK 424-556 DU48034 Bacteria MBP 
FLAG-mSPAK DU48072 HEK293 FLAG 
FLAG-mSPAK Opt L502A DU48455 HEK293 FLAG 
Supplementary Table S2
Supplementary Table S3
Symbol Protein  Use Sense primer (5`-3`) AnƟsense primer (5`-3`) 
SPAK SPAK PCR TCTGTAAGCTCATTTATGTAGTCACC 
P1: STK39 6062_39 
CAAGTGAGTGAGTGAATACAGCC 
P1: STK39 6062_40 
     
SPAK SPAK q-PCR GTCTAGGACATGATGGTATGG CCAACATGGGGTACCAACAAATGC 
OSR1 OSR1 q-PCR CGCTGCAGTCTCCTGTCATCTG CAGAGTGAGGTCTAGGACAGCCAGG 
SLC12A1 NKCC2 q-PCR TTGGATATAACCCACGCCTTTACG GCCATGCCGCTGTTCATCTC 
SLC12A2 NKCC1 q-PCR GCAGATCCTCAGTCAGCCATAC TCCCGAACAACACACGAACC 
SLC12A3 NCC q-PCR CGGGGTTTGTGTCATGAGGATG TTGTATCAATGCCTCTGGGGTTG 
18S 18S rRNA q-PCR GTAACCCGTTGAACCCCATT CCATCCAATCGGTAGTAGCG 
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Sub Augmentation_BP_v2 () 
 startRec = Doc.SelectionStartRecord 
 startOffset = Doc.SelectionStartOffset 
 endRec = Doc.SelectionEndRecord 
 endOffset = Doc.SelectionEndOffset 
 If Not (startRec = kEndRecordIndex) Then 
  Call Doc.SetSelectionRange (startRec, startOffset, startRec, startOffset) 
 End If 
 If (endRec > startRec) Or (endOffset > startOffset) Then 
  Do While (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) 
   ' Begin Find 
   ChannelIndex = 0 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Local minima" 
   FindData = "NoiseThreshold=0.01;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
   ' End Find 
   ' The function below will return true if the last operation failed, 
which will cause the current loop to exit 
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   ' Begin Find 
   ChannelIndex = 9 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Local maxima" 
   FindData = "NoiseThreshold=0.05;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
   ' End Find 
   ' The function below will return true if the last operation failed, 
which will cause the current loop to exit 
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   ' Begin Find 
   ChannelIndex = 9 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Data below" 
   FindData = "Limit=0;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, 
which will cause the current loop to exit
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
' Begin Find
   ChannelIndex = 0 
   SetAction = kSetToPreviousPoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Local maxima" 
   FindData = "NoiseThreshold=0.005;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, 
which will cause the current loop to exit
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.AddToDataPad () 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
  Loop 
 End If 
 If Not (startRec = kEndRecordIndex) Then 
  Call Doc.SetSelectionRange (endRec, endOffset, endRec, endOffset) 
 End If 
End Sub 
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Sub T_Bourgeois_v3 () 
 startRec = Doc.SelectionStartRecord 
 startOffset = Doc.SelectionStartOffset 
 endRec = Doc.SelectionEndRecord 
 endOffset = Doc.SelectionEndOffset 
 If Not (startRec = kEndRecordIndex) Then 
  Call Doc.SetSelectionRange (startRec, startOffset, startRec, startOffset) 
 End If 
 If (endRec > startRec) Or (endOffset > startOffset) Then 
  Do While (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) 
' Begin Find
   ChannelIndex = 10 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Local maxima" 
   FindData = "NoiseThreshold=0.05;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, 
which will cause the current loop to exit
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.SetRightXCompression (5, False, "Chart View") 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.SetRightXCompression (2, False, "Chart View") 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.SetRightXPos (2220892, "Chart View") 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.SetRightXPos (2221024, "Chart View") 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.SetRightXPos (2221156, "Chart View") 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
' Begin Find
   ChannelIndex = 10 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Local minima" 
   FindData = "NoiseThreshold=0.0001;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, 
which will cause the current loop to exit
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
' Begin Find
   ChannelIndex = 10 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Move forward" 
   FindData = "AmountToMove=0.02;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, 
which will cause the current loop to exit
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.AddCommentAtInsertionPoint (10, "start") 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
' Begin Find
   ChannelIndex = 10 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Local minima" 
   FindData = "NoiseThreshold=0.001;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, 
which will cause the current loop to exit
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
' Begin Find
   ChannelIndex = 10 
   SetAction = kSetActivePoint 
   SelectMode = kSelectAround 
   SelectTime = 1 
   DataDisplayMode = kViewDataVisible 
   SelectAll = False 
   Direction = kSearchForward 
   FindType = "Move backward" 
   FindData = "AmountToMove=0.015;" 
   Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, 
which will cause the current loop to exit
   If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
   Call Doc.AddCommentAtInsertionPoint (10, "end") 
   If Not (IsCurrentSelectionWithin (startRec, startOffset, endRec, 
endOffset) = True) Then Exit Do 
  Loop 
 End If 
 If Not (startRec = kEndRecordIndex) Then 
  Call Doc.SetSelectionRange (endRec, endOffset, endRec, endOffset) 
 End If 
' Move the insertion point to the beginning of the file
 Call Doc.SelectChannel(-1, True) 
 Call Doc.SetSelectionTime(0, 0, 0, 0) 
 Do While True 
' Begin Find
  ChannelIndex = 10 
  SetAction = kSetActivePoint 
  SelectMode = kSelectAround 
  SelectTime = 1 
  DataDisplayMode = kViewDataVisible 
  SelectAll = False 
  Direction = kSearchForward 
  FindType = "Search for comment" 
  FindData = "JustThisChannel=0;WhatToLookFor=start;" 
  Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, which 
will cause the current loop to exit
  If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
' Begin Find
  ChannelIndex = 10 
  SetAction = kSetToPreviousPoint 
  SelectMode = kSelectAround 
  SelectTime = 1 
  DataDisplayMode = kViewDataVisible 
  SelectAll = False 
  Direction = kSearchForward 
  FindType = "Search for comment" 
  FindData = "JustThisChannel=0;WhatToLookFor=end;" 
  Call Doc.Find (ChannelIndex, SetAction, SelectMode, SelectTime, 
DataDisplayMode, SelectAll, Direction, FindType, FindData) 
' End Find
' The function below will return true if the last operation failed, which 
will cause the current loop to exit
  If (Services.ShouldExitCurrentRepeat()) Then Exit Do 
  Call Doc.AddToDataPad () 
 Loop 
End Sub 
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